prednisone has been researched along with Lymphoma, Non-Hodgkin in 1697 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
Lymphoma, Non-Hodgkin: Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The antiemetic effect of granisetron on nausea and vomiting induced by cancer chemotherapy (CHOP, VEPA, VEPA-B, massive dose of ETP) was studied in fifty patients with non-Hodgkin's lymphoma." | 9.08 | [Clinical study on the inhibitory effect of a 5-HT3 antagonist, granisetron, for nausea and vomiting induced by chemotherapy (CHOP, VEPA, high-dose ETP) for non-Hodgkin's lymphoma]. ( Fujii, H; Horiike, S; Iwai, T; Kaneko, H; Kashima, K; Misawa, S; Nakagawa, H; Nakao, M; Nakazawa, N; Ookawara, Y; Sasai, Y; Tamura, A; Taniwaki, M; Tsuda, S; Ueda, Y; Yokota, S, 1998) |
| "Two hundred and ninety-eight evaluable patients with non-Hodgkin's lymphoma were stratified according to histology, treated with either BCNU, cyclophosphamide, Oncovin (vincristine), and prednisone (BCOP) or cyclophosphamide, Oncovin (vincristine), and prednisone (COP), and evaluated at 3 months." | 9.04 | BCNU with and without cyclophosphamide, vincristine, and prednisone (COP) and cycle-active therapy in non-Hodgkin's lymphoma. ( Bartolucci, AA; Dorfman, RF; Durant, JR; Gams, RA, 1977) |
| "Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (RCHOP) chemotherapy in non-Hodgkin's lymphoma (NHL) has risk of cardiotoxicity." | 8.31 | Myocardial work-A new tool for early detection of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone chemotherapy induced-cardiotoxicity in hematological patients. ( Balinisteanu, A; Memis, H; Mihaila, S; Mihalcea, D; Vinereanu, D; Vladareanu, AM, 2023) |
| "Recently, the use of targeted synthetic or biological disease-modifying anti-rheumatic drugs (ts/bDMARDs) in addition to conventional synthetic (cs)DMARDs including methotrexate (MTX) for rheumatoid arthritis (RA) has increased." | 8.02 | Outcomes of methotrexate-associated lymphoproliferative disorders in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs. ( Akashi, K; Asaoku, H; Ayano, M; Fujisaki, T; Harada, T; Iwasaki, H; Kato, K; Kohno, K; Mitoma, H; Miyamoto, T; Miyamura, T; Miyoshi, H; Mori, Y; Muta, T; Niiro, H; Ohshima, K; Oryoji, K; Oshiro, Y; Sakamoto, A; Sawabe, T; Takase, K; Takeshita, M; Urata, S; Yamamoto, H; Yoshimoto, G, 2021) |
| "The efficacy of palonosetron in preventing emesis was evaluated in 40 patients." | 7.88 | Efficacy of palonosetron to prevent delayed nausea and vomiting in non-Hodgkin's lymphoma patients undergoing repeated cycles of the CHOP regimen. ( Abe, M; Arai, N; Ariizumi, H; Baba, Y; Fujiwara, S; Harada, H; Hattori, N; Kabasawa, N; Kawaguchi, Y; Murai, S; Nakamaki, T; Nakashima, H; Saito, B; Tsukamoto, H; Uto, Y; Yanagisawa, K, 2018) |
| "In the present study, the antiemetic effect of palonosetron, not combined with dexamethasone and aprepitant, on chemotherapy-induced nausea and vomiting was evaluated in patients with malignant lymphoma receiving first-line rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy, and was compared to that of granisetron." | 7.85 | Comparison between Antiemetic Effects of Palonosetron and Granisetron on Chemotherapy-Induced Nausea and Vomiting in Japanese Patients Treated with R-CHOP. ( Akashi, K; Kadoyama, K; Kamezaki, K; Kato, K; Miyamoto, T; Mori, Y; Nakamura, T; Shiratsuchi, M; Takenaka, K; Uchida, M, 2017) |
| "As patients with B-cell lymphomas suffering from an underlying autoimmune condition undergoing therapy with the CD20 antibody rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) offer the unique possibility of monitoring effects of therapy on various rheumatologic parameters, we have evaluated serologic autoimmune markers and the clinical outcome of patients with autoimmune diseases (ADs) who received lymphoma treatment with R-CHOP during the course of their disease." | 7.74 | Influence of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone on serologic parameters and clinical course in lymphoma patients with autoimmune diseases. ( Gaiger, A; Jaeger, U; Raderer, M; Schett, G; Skrabs, C; Troch, M; Wöhrer, S; Zielinski, CC; Zwerina, J, 2007) |
| "The results of lamivudine therapy in 4 patients with chemotherapy-induced hepatitis B virus (HBV) reactivation are reported." | 7.72 | Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with Lamivudine. ( Ahmed, A; Ahmed, AM; Garcia, G; Keeffe, EB; Nguyen, MH; Simpson, ND; Simpson, PW, 2003) |
| "This article presents a young patient affected with non-Hodgkin lymphoma who developed acute myocardial infarction 7 days after treatment with epirubicin (90 mg/m2, day 1), cyclophosphamide (600 mg/m2, day 1), vincristine (2 mg, day 1), prednisolone (100 mg, days 1-5), and ondansetron (3 x 4 mg/day, days 1-2)." | 7.69 | Acute myocardial infarction in man treated with epirubicin for non-Hodgkin lymphoma. ( Aydiner, A; Buğra, Z; Meriç, M; Topuz, E, 1995) |
| "Nineteen patients with advanced refractory lymphoma and 12 patients with acute leukemia, including seven in blastic crisis of chronic myelogenous leukemia (CML), were treated with vindesine in combination with prednisone." | 7.66 | Combination of vindesine and prednisone in malignant lymphoma and acute leukemia. ( Denning, B; Fontana, JA; Knost, JA; Raich, PC; Rogers, JS; Subramanian, VP; Walker, BK, 1983) |
| " The overall incidence of adverse events was similar between the two treatment groups (p > ." | 6.84 | Efficacy and safety of triple therapy with aprepitant, ondansetron, and prednisone for preventing nausea and vomiting induced by R-CEOP or CEOP chemotherapy regimen for non-Hodgkin lymphoma: a phase 2 open-label, randomized comparative trial. ( Song, Z; Wang, H; Yang, F; Zhang, H; Zhang, M; Zhao, K, 2017) |
| "Dexverapamil was escalated eight dose levels, from 240 to 1,200 mg/m2/d." | 6.68 | Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. ( Bates, SE; Bryant, G; Fojo, A; Herdt, J; Jaffe, ES; Regis, J; Steinberg, SM; Wilson, WH; Wittes, RE; Zhan, Z, 1995) |
| "Lamivudine is a nucleoside analogue that can directly suppress HBV replication." | 5.31 | Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. ( Motta, M; Pelizzari, A; Puoti, M; Rossi, G, 2001) |
| "In the group of high-grade malignant lymphomas there were 39% complete remission, 37% partial remission, and 24% without response." | 5.26 | [Results of chemotherapy with cyclophosphamide, vincristine, methotrexate and prednisone in recurring or disseminated non-Hodgkin lymphomas in the University of Kiel Radiology Clinic]. ( Liffers, R, 1981) |
| "45%, respectively, in Hodgkin's disease, and 85% vs." | 5.25 | Combined cyclophosphamide vincristine, procarbazine, and prednisone (COPP) therapy of malignant lymphoma. Evaluation of 190 patients. ( Barros, CA; Morgenfeld, MC; Palau, M; Pavlovsky, A; Pavlovsky, S; Somoza, N; Suarez, A, 1975) |
| "Present first-line therapy for diffuse large B-cell lymphoma, a subtype of non-Hodgkin lymphoma, is rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)." | 5.19 | Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. ( Amorim, S; Balasubramanian, S; Bandyopadhyay, N; de Vries, R; Flinn, I; Fourneau, N; Friedberg, JW; Hellemans, P; Hivert, B; Morschhauser, F; Oki, Y; Smit, JW; Thieblemont, C; Vermeulen, J; Westin, J; Younes, A, 2014) |
| "The role of rituximab in combination with different CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like chemotherapy regimens in young patients with good-prognosis diffuse large-B-cell lymphoma remains to be defined." | 5.12 | CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. ( Corrado, C; Gill, D; Hansen, M; Imrie, K; Jaeger, U; Kuhnt, E; Kvaloy, S; Lehtinen, T; Loeffler, M; López-Guillermo, A; Ma, D; Mendila, M; Milpied, N; Osterborg, A; Pettengell, R; Pfreundschuh, M; Rashford, M; Scheliga, A; Shpilberg, O; Stahel, R; Trneny, M; Trümper, L; Walewski, J; Zinzani, PL, 2006) |
| "The antiemetic effect of granisetron on nausea and vomiting induced by cancer chemotherapy (CHOP, VEPA, VEPA-B, massive dose of ETP) was studied in fifty patients with non-Hodgkin's lymphoma." | 5.08 | [Clinical study on the inhibitory effect of a 5-HT3 antagonist, granisetron, for nausea and vomiting induced by chemotherapy (CHOP, VEPA, high-dose ETP) for non-Hodgkin's lymphoma]. ( Fujii, H; Horiike, S; Iwai, T; Kaneko, H; Kashima, K; Misawa, S; Nakagawa, H; Nakao, M; Nakazawa, N; Ookawara, Y; Sasai, Y; Tamura, A; Taniwaki, M; Tsuda, S; Ueda, Y; Yokota, S, 1998) |
| "Two triple-drug combinations (cyclophosphamide, vincristine, and prednisone [CVP] and adriamycin, bleomycin, and prednisone [ABP]) were randomly tested in 57 consecutive patients with pathologic stage IV non-Hodgkin's lymphoma." | 5.04 | Non-cross-resistant combinations in stage IV non-Hodgkin's lymphomas. ( Bonadonna, G; Monfardini, S; Villa, E, 1977) |
| "Two hundred and ninety-eight evaluable patients with non-Hodgkin's lymphoma were stratified according to histology, treated with either BCNU, cyclophosphamide, Oncovin (vincristine), and prednisone (BCOP) or cyclophosphamide, Oncovin (vincristine), and prednisone (COP), and evaluated at 3 months." | 5.04 | BCNU with and without cyclophosphamide, vincristine, and prednisone (COP) and cycle-active therapy in non-Hodgkin's lymphoma. ( Bartolucci, AA; Dorfman, RF; Durant, JR; Gams, RA, 1977) |
| "Lenalidomide is an oral non-chemotherapy immunomodulator with direct and indirect effects on non-Hodgkin lymphoma (NHL) cells and with single-agent activity in relapsed/refractory aggressive and indolent B-cell NHL, including mantle cell lymphoma (MCL), diffuse large B-cell lymphoma, and follicular lymphoma." | 4.91 | A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. ( Chiappella, A; Czuczman, MS; Fowler, N; Goy, A; Habermann, TM; Hernandez-Ilizaliturri, FJ; Nowakowski, GS; Vitolo, U; Witzig, TE, 2015) |
| "We reviewed published studies reporting phase II and III clinical trials of dose-dense regimens for breast cancer and NHL, TAC (docetaxel, adriamycin, cyclophosphamide) chemotherapy for breast cancer, and infusional 5-fluorouracil-based regimens for colorectal cancer." | 4.83 | Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. ( Avritscher, EB; Bekele, BN; Cooksley, CD; Elting, LS; Jones, JA; Michelet, M, 2006) |
| "A review of the use of rituximab (Rituxan; Genentech, Inc, South San Francisco, CA, and IDEC Pharmaceuticals, San Diego, CA) in diffuse large B-cell lymphomas is presented, focusing on the recent presentation of the combination of CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) plus rituximab in elderly patients." | 4.81 | Rituximab in the treatment of diffuse large B-cell lymphomas. ( Coiffier, B, 2002) |
| "Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (RCHOP) chemotherapy in non-Hodgkin's lymphoma (NHL) has risk of cardiotoxicity." | 4.31 | Myocardial work-A new tool for early detection of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone chemotherapy induced-cardiotoxicity in hematological patients. ( Balinisteanu, A; Memis, H; Mihaila, S; Mihalcea, D; Vinereanu, D; Vladareanu, AM, 2023) |
| "Recently, the use of targeted synthetic or biological disease-modifying anti-rheumatic drugs (ts/bDMARDs) in addition to conventional synthetic (cs)DMARDs including methotrexate (MTX) for rheumatoid arthritis (RA) has increased." | 4.02 | Outcomes of methotrexate-associated lymphoproliferative disorders in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs. ( Akashi, K; Asaoku, H; Ayano, M; Fujisaki, T; Harada, T; Iwasaki, H; Kato, K; Kohno, K; Mitoma, H; Miyamoto, T; Miyamura, T; Miyoshi, H; Mori, Y; Muta, T; Niiro, H; Ohshima, K; Oryoji, K; Oshiro, Y; Sakamoto, A; Sawabe, T; Takase, K; Takeshita, M; Urata, S; Yamamoto, H; Yoshimoto, G, 2021) |
| "CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) represents standard chemotherapy in non-Hodgkin's lymphoma (NHL) with risk of cardiotoxicity." | 3.96 | 3D echocardiography, arterial stiffness, and biomarkers in early diagnosis and prediction of CHOP-induced cardiotoxicity in non-Hodgkin's lymphoma. ( Bruja, R; Florescu, M; Mihalcea, D; Patrascu, N; Vinereanu, D; Vladareanu, AM, 2020) |
| "The efficacy of palonosetron in preventing emesis was evaluated in 40 patients." | 3.88 | Efficacy of palonosetron to prevent delayed nausea and vomiting in non-Hodgkin's lymphoma patients undergoing repeated cycles of the CHOP regimen. ( Abe, M; Arai, N; Ariizumi, H; Baba, Y; Fujiwara, S; Harada, H; Hattori, N; Kabasawa, N; Kawaguchi, Y; Murai, S; Nakamaki, T; Nakashima, H; Saito, B; Tsukamoto, H; Uto, Y; Yanagisawa, K, 2018) |
| "In the present study, the antiemetic effect of palonosetron, not combined with dexamethasone and aprepitant, on chemotherapy-induced nausea and vomiting was evaluated in patients with malignant lymphoma receiving first-line rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy, and was compared to that of granisetron." | 3.85 | Comparison between Antiemetic Effects of Palonosetron and Granisetron on Chemotherapy-Induced Nausea and Vomiting in Japanese Patients Treated with R-CHOP. ( Akashi, K; Kadoyama, K; Kamezaki, K; Kato, K; Miyamoto, T; Mori, Y; Nakamura, T; Shiratsuchi, M; Takenaka, K; Uchida, M, 2017) |
| " Here, we hypothesize that including a selective human CAR activator with the CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) regimen can improve the efficacy without exacerbating off-target toxicity of this regimen in non-Hodgkin lymphoma treatment." | 3.83 | Activation of the Constitutive Androstane Receptor Increases the Therapeutic Index of CHOP in Lymphoma Treatment. ( Baer, MR; Hassan, HE; Hedrich, WD; Heyward, S; Wang, H; Xiao, J; Zhang, J; Zhang, Y, 2016) |
| " The prognostic factors of congestive heart failure (CHF) were investigated, including the impact of empirical cardioprotection by dexrazoxane." | 3.80 | Incidence and risk-factors of CHOP/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin's lymphoma. ( Brion, A; Cahn, JY; Daguindau, E; Deconinck, E; Limat, S; Nerich, V; Perrin, S; Woronoff-Lemsi, MC, 2014) |
| "Six courses of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) or cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone (CHOEP) chemotherapy were recommended for first-line therapy of patients with nodal, intestinal or hepatosplenic T-cell lymphomas (evidence: low; recommendation: do, weak)." | 3.80 | SIE-SIES-GITMO guidelines for the management of adult peripheral T- and NK-cell lymphomas, excluding mature T-cell leukaemias. ( Barosi, G; Billio, A; Corradini, P; Gallamini, A; Marchetti, M; Pileri, S; Pimpinelli, N; Rossi, G; Tura, S; Zinzani, PL, 2014) |
| "For patients with follicular lymphoma, these figures were 72% and 80%, respectively." | 3.80 | Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma. ( Ayala, A; Cabanillas, F; Cox, JD; Fuller, LM; Ha, CS; Hagemeister, FB; Hess, M; Manning, JT; McLaughlin, P; Pro, B; Rodriguez, MA; Romaguera, J; Seymour, JF; Smith, TL, 2003) |
| " Using the redox scanner that collects the fluorescence signals from both the oxidized flavoproteins (Fp) and the reduced form of nicotinamide adenine dinucleotide (NADH) in snap-frozen tumor tissues, we investigated the effects of chemotherapy on mouse xenografts of a human diffuse large B-cell lymphoma cell line (DLCL2)." | 3.79 | Mapping the redox state of CHOP-treated non-Hodgkin's lymphoma xenografts in mice. ( Choe, R; Farhad, N; Feng, M; Glickson, JD; Lee, SC; Li, LZ; Mir, TA; Xu, HN, 2013) |
| "Treatment of non-Hodgkin lymphoma (NHL) with cyclophosphamide, vincristine, doxorubicin and prednisone (CHOP) is known to be associated with a significant risk of febrile neutropenia (FN) of up to 50% [Osby et al." | 3.79 | Primary prophylaxis with granulocyte colony-stimulating factor (GCSF) reduces the incidence of febrile neutropenia in patients with non-Hodgkin lymphoma (NHL) receiving CHOP chemotherapy treatment without adversely affecting their quality of life: cost-be ( Blacklock, H; Coomarasamy, C; Issa, S; Knox, A; Lee, S; Zeng, IS, 2013) |
| "The authors present the first case report of a patient with lymphoma who developed disseminated cryptococcal osteomyelitis and meningitis while being treated with the PEP-C (prednisone, etoposide, procarbazine and cyclophosphamide) chemotherapy regimen." | 3.78 | Cryptococcal osteomyelitis and meningitis in a patient with non-hodgkin's lymphoma treated with PEP-C. ( Brown, JM; Fan, AC; Felsher, DW; Fischbein, NJ; Howard, W; Hsieh, RW; McClellan, JS; To, CA, 2012) |
| " Paraneoplastic pemphigus was diagnosed based on these findings; treatment was started with cyclophosphamide, doxorubicin, vincristin and prednisone." | 3.74 | Paraneoplastic pemphigus associated with non-Hodgkin lymphoma. ( Batista, MD; de Almeida, FA; Enokihara, MM; Lopes, RD; Michalany, NS; Takano, D, 2008) |
| "As patients with B-cell lymphomas suffering from an underlying autoimmune condition undergoing therapy with the CD20 antibody rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) offer the unique possibility of monitoring effects of therapy on various rheumatologic parameters, we have evaluated serologic autoimmune markers and the clinical outcome of patients with autoimmune diseases (ADs) who received lymphoma treatment with R-CHOP during the course of their disease." | 3.74 | Influence of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone on serologic parameters and clinical course in lymphoma patients with autoimmune diseases. ( Gaiger, A; Jaeger, U; Raderer, M; Schett, G; Skrabs, C; Troch, M; Wöhrer, S; Zielinski, CC; Zwerina, J, 2007) |
| " Hypercalcemia and high serum level of calcitriol were found." | 3.74 | [Hypercalcaemia and malignant lymphoma. One case report]. ( Berrut, G; Foussard, C; Frein, D; Josselin, N; Lavigne, C; Moles, MP; Sivova, N, 2007) |
| "In the histiocytic lymphomas, BCNU added to CVP increases the percentage of CRs but it does so at the expense of considerable toxicity." | 3.74 | Chemotherapy of non-Hodgkin's lymphomas: Eastern Cooperative Oncology Group experience. ( Bennett, JM; Carbone, PP; Ezdinli, E; Johnson, GJ; Lenhard, RE; Pocock, SJ, 1977) |
| "The results of lamivudine therapy in 4 patients with chemotherapy-induced hepatitis B virus (HBV) reactivation are reported." | 3.72 | Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with Lamivudine. ( Ahmed, A; Ahmed, AM; Garcia, G; Keeffe, EB; Nguyen, MH; Simpson, ND; Simpson, PW, 2003) |
| "The purpose of this historical case series study was to evaluate the association of age on delivered dose intensity of initial CHOP (cyclophosphamide/doxorubicin/ vincristine/prednisone) chemotherapy and the occurrence of hospitalizations for febrile neutropenia for patients with intermediate-grade non-Hodgkin's lymphoma (NHL)." | 3.71 | The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. ( Caggiano, V; Carter, WB; Delgado, D; Dickman, E; Ford, J; Fridman, M; Kerr, R; Lawless, G; Lee, M; Morrison, VA; Picozzi, V; Pohlman, B; Scott, S, 2001) |
| " Three groups of patients were prospectively evaluated: Group I: 15 patients with Wegener's granulomatosis and 4 patients with severe scleritis received a single dose cyclophosphamide (15 mg/kg bw/day) and 250 mg prednisone i." | 3.70 | Unique alterations of thyroid function parameters after i.v. administration of alkylating drugs (cyclophosphamide and ifosfamide). ( Jockenhövel, F; Kummer, G; Mann, K; Philipp, T; Reinhardt, W; Reinwein, D; Sauter, V; Uppenkamp, M; Witzke, O, 1999) |
| "This article presents a young patient affected with non-Hodgkin lymphoma who developed acute myocardial infarction 7 days after treatment with epirubicin (90 mg/m2, day 1), cyclophosphamide (600 mg/m2, day 1), vincristine (2 mg, day 1), prednisolone (100 mg, days 1-5), and ondansetron (3 x 4 mg/day, days 1-2)." | 3.69 | Acute myocardial infarction in man treated with epirubicin for non-Hodgkin lymphoma. ( Aydiner, A; Buğra, Z; Meriç, M; Topuz, E, 1995) |
| "Chemotherapy programs using either bolus or infusional delivery were selected representing standard or commonplace regimens for the treatment of patients with breast cancer (cyclophosphamide, methotrexate, fluorouracil [CMF] or CA); colon cancer (5-fluorouracil[5-FU] infusion vs." | 3.69 | Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors--Part one. Model projections for cost based on charges. ( Anderson, NR; Lokich, JJ; Moore, CL, 1996) |
| "The incidence of concurrent NHL and the incidence of future NHL after oral prednisone, radiotherapy, or no treatment were retrospectively evaluated in 33 cases of lymphoid hyperplasia (22 benign lymphoid hyperplasias, BLH, and 11 atypical lymphoid hyperplasias, ALH), after follow-up of 2-13 years." | 3.69 | Prognosis of orbital lymphoid hyperplasia. ( Leccisotti, A; Polito, E, 1996) |
| "We report the first case of Epstein Barr virus (EBV) positive non-Hodgkin's lymphoma occurring 20 years after continuous phenytoin therapy for idiopathic epilepsy." | 3.69 | EBV-positive non-Hodgkin's lymphoma developing after phenytoin therapy. ( Del Campo, F; Dominguez-Franjo, P; Garcia-Suarez, J; Herrero, B; Munoz, MA; Pardo, A; Piris, MA, 1996) |
| "Nineteen patients with advanced refractory lymphoma and 12 patients with acute leukemia, including seven in blastic crisis of chronic myelogenous leukemia (CML), were treated with vindesine in combination with prednisone." | 3.66 | Combination of vindesine and prednisone in malignant lymphoma and acute leukemia. ( Denning, B; Fontana, JA; Knost, JA; Raich, PC; Rogers, JS; Subramanian, VP; Walker, BK, 1983) |
| " During lymphoma chemotherapy with cyclophosphamide, vincristine and prednisone (VCP) he developed tachycardia and syncope accompanied by severe hypertension." | 3.66 | Malignant pheochromocytoma. Severe clinical exacerbation and release of stored catecholamines during lymphoma chemotherapy. ( Georges, LP; Osburne, RC; Sode, J; Taub, MA, 1982) |
| "Two hundred and fifty-two patients with advanced stages of favorable non-Hodgkin's lymphoma (NHL) subtypes (nodular histiocytic (NH), and diffuse well-differentiated lymphocytic (DLWD)) were analyzed for response and survival to moderate (cyclophosphamide-prednisone (CP)) vs." | 3.66 | Moderate versus intensive chemotherapy of prognostically favorable non-Hodgkin's lymphoma: a progress report. ( Berard, C; Costello, WG; Ezdinli, EZ; Hartsock, RJ; Silverstein, MN; Sokal, JE, 1980) |
| "The results of a chemotherapy regimen utilizing adriamycin in combination with vincristine, prednisone plus or minus cyclophosphamide (CHOP-HOP) for the treatment of non-Hodgkin lymphoma are compared to those of a non-adriamycin containing combination (COP)." | 3.66 | Improvement in complete response rate, duration of response and survival with adriamycin combination chemotherapy for non-Hodgkin lymphoma: a prognostic factor comparison of two regimens. ( Cabanillas, F; Freireich, EJ; Rodriguez, V, 1978) |
| "Combination chemotherapy with CHOP (cyclophosphamide, Adriamycin, vincristine, and prednisone) and HOP (Adrimycin, vincristine, and prednisone, was used as treatment for patients with pathologically staged, advanced non-Hodgkin's lymphoma." | 3.65 | Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. ( Coltman, C; Gamble, JF; Gottlieb, JA; Grozea, PN; Gutterman, J; Haut, A; Jones, SE; Lane, M; McKelvey, EM; Moon, TE; Stephens, R; Talley, RW; Wilson, HE, 1976) |
| "Intersitial pneumonia and pulmonary fibrosis developed in a 72-year-old man during therapy with cyclophosphamide, vincristine, and prednisone." | 3.65 | Cyclophosphamide therapy and interstitial pulmonary fibrosis. ( Patel, AR; Rao, KP; Rhee, HL; Sassoon, H; Shah, PC, 1976) |
| " The overall incidence of adverse events was similar between the two treatment groups (p > ." | 2.84 | Efficacy and safety of triple therapy with aprepitant, ondansetron, and prednisone for preventing nausea and vomiting induced by R-CEOP or CEOP chemotherapy regimen for non-Hodgkin lymphoma: a phase 2 open-label, randomized comparative trial. ( Song, Z; Wang, H; Yang, F; Zhang, H; Zhang, M; Zhao, K, 2017) |
| "Reduced dosage of G-CSF allows dose-dense chemotherapy scheduling, limits exposure to G-CSF and also represents an opportunity for cost savings." | 2.79 | Feasibility and safety of a reduced duration of therapy of colony-stimulating factor in a dose-dense regimen. ( Bonizzoni, E; Bosi, A; Fabbri, E; Kovalchuk, S; Perrone, T; Puccini, B; Rigacci, L, 2014) |
| "Disability after treatment due to pathological fracture was not seen." | 2.76 | Limited chemotherapy and shrinking field radiotherapy for Osteolymphoma (primary bone lymphoma): results from the trans-Tasman Radiation Oncology Group 99.04 and Australasian Leukaemia and Lymphoma Group LY02 prospective trial. ( Barton, M; Christie, D; Dear, K; Le, T; Porter, D; Pratt, G; Roos, D; Wirth, A, 2011) |
| "Of the 57 patients in this phase I trial, 55 participated in 1 of 2 dosing schedules that included rituximab (375 mg/m(2)) and cyclophosphamide (750 or 1,000 mg/m(2)) administered on day 1 of each 21-day cycle and prednisone (100 mg orally) days 2 to 6." | 2.76 | Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma. ( Dumitrescu, O; Gerecitano, J; Hamlin, P; Horanlli, E; Iasonos, A; Mo, Q; Moskowitz, CH; Noy, A; O'Connor, OA; Pappanicholaou, J; Portlock, C; Rojas, CN; Sarasohn, D; Schulman, P; Straus, D; Zelenetz, AD; Zhang, Z, 2011) |
| "Pixantrone is a potentially more effective, less cardiotoxic alternative to doxorubicin for patients with aggressive non-Hodgkin lymphoma (aNHL)." | 2.76 | Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphoma. ( Borchmann, P; Cernohous, P; Engert, A; Herbrecht, R; Hess, G; Morschhauser, F; Singer, JW; Veals, SA; Wilhelm, M, 2011) |
| "Dexrazoxane has in vitro antioxidant capacity." | 2.75 | In vitro and in vivo study on the antioxidant activity of dexrazoxane. ( Antonelli, A; Carpi, A; Cervetti, G; Fallahi, P; Franzoni, F; Galetta, F; Petrini, M; Regoli, F; Santoro, G; Tocchini, L, 2010) |
| "The estimated 2-year incidence of CNS disease was 6." | 2.74 | CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). ( Boehme, V; Loeffler, M; Pfreundschuh, M; Schmitz, N; Zeynalova, S, 2009) |
| "Late-onset ones were cataract and dry eye (5) (13." | 2.74 | [Role of modified radiotherapy in the combined treatment of orbital non-Hodgkin lymphoma]. ( Bochkareva, TN; Cherviakov, AM; Il'in, NV; Leenman, EE; Vinogradova, IuN, 2009) |
| "Treatment with etoposide also evolved as a prognostic factor because the risk of CNS failure was significantly reduced after CHOEP (P=0." | 2.73 | Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). ( Boehme, V; Kaiser, U; Kloess, M; Loeffler, M; Pfreundschuh, M; Schmitz, N; Zeynalova, S, 2007) |
| "Myelosuppression and infections were dose limiting whereas posttreatment complications, including fatalities, resulted from infections." | 2.73 | The multicenter trial SAKK 37/95 of cladribine, cyclophosphamide and prednisone in the treatment of chronic lymphocytic leukemias and low-grade non-Hodgkin's lymphomas. ( Ballabeni, P; Cerny, T; Fey, M; Hess, U; Laurencet, F; Luthi, JM; Plancherel, C; Rufener, B; Zulian, GB, 2007) |
| " It is concluded that sodium selenite administration at the dosage and duration chosen acts as a down regulator of Bcl-2 and improves clinical outcome." | 2.73 | The impact of high-dose sodium selenite therapy on Bcl-2 expression in adult non-Hodgkin's lymphoma patients: correlation with response and survival. ( Asfour, IA; El-Desoky, H; Fayek, M; Hegab, HM; Moussa, MA; Raouf, S; Saleh, R; Soliman, M, 2007) |
| "A total of 164 patients with follicular lymphoma (grade 1/2), mantle cell lymphoma or lymphoplasmacytic lymphoma (immunocytoma) was randomised to treatment with vincristine 2 mg (day 1) and prednisone 100 mg/m2 (days 1-5) + bendamustine 60 mg/m2 (days 1-5) or + cyclophosphamide 400 mg/m2 (days 1-5) for a total of eight 21-day cycles." | 2.72 | Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). ( Arzberger, H; Boewer, C; Bremer, K; Dachselt, K; Franke, A; Freund, M; Fricke, HJ; Hahnfeld, S; Herold, M; Ismer, B; Klinkenstein, C; Müller, C; Niederwieser, D; Pasold, R; Richter, P; Schirmer, V; Schulze, A; Schulze, M; Schwarzer, A; Weniger, J; Winkelmann, C, 2006) |
| " However, the optimal dose of granulocyte colony-stimulating factor (G-CSF) for PBSC mobilization in combination with chemotherapy for autograft remains unknown." | 2.71 | A dose-finding study of glycosylated G-CSF (Lenograstim) combined with CHOP therapy for stem cell mobilization in patients with non-Hodgkin's lymphoma. ( Chou, T; Kasai, M; Kawano, F; Kiyama, Y; Masaki, Y; Mitsuya, H; Morishima, Y; Ogura, M; Ohnishi, K; Sasaki, T; Takeyama, K; Tobinai, K; Yokozawa, T, 2003) |
| "Advanced follicular lymphoma is incurable with conventional chemotherapy and radiotherapy." | 2.71 | A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. ( Braziel, RM; Fisher, RI; Gaynor, ER; LeBlanc, M; Maloney, DG; Miller, TP; Press, OW; Rivkin, SE; Unger, JM, 2003) |
| "Mitoxantrone is an anthracenedione, which is active in NHL and its toxicity profile may be more favorable than doxorubicin with respect to alopecia, mucositis and cardiotoxicity." | 2.71 | A randomized trial comparing intensified CNOP vs. CHOP in patients with aggressive non-Hodgkin's lymphoma. ( Angelopoulou, MK; Bourantas, KL; Christopoulos, G; Grigorakis, V; Kalmantis, T; Kokkinis, G; Korantzis, J; Michalis, E; Mihalakeas, I; Pangalis, GA; Papayiannis, A; Repousis, P; Roussou, P; Siakantaris, MP; Stamatellou, M; Stefanoudakis, E; Symeonidis, A; Vassilakopoulos, TP; Vrakidou, E, 2003) |
| "CHOP-14 with the addition of rhG-CSF is safe and practicable in a large multicentre setting in patients aged 18-75 years." | 2.71 | Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). ( Bittner, S; Kloess, M; Loeffler, M; Pfreundschuh, M; Reiser, M; Rudolph, C; Schmalenberg, H; Schmits, R; Truemper, L; Wunderlich, A, 2003) |
| "Complete pharmacokinetics and pharmacodynamic analysis was determined in 19 patients during 38 cycles of chemotherapy: 19 cycles with CHOP and 19 CHOP + HAART in a crossover-designed study." | 2.71 | Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma. ( Boiocchi, M; Cattarossi, G; Corona, G; Di Gennaro, G; Tirelli, U; Toffoli, G; Vaccher, E, 2004) |
| " In this multicenter study, THP (pirarubicin)-COP (cyclophosphamide, vincristine, and prednisolone) was compared to two thirds dosage of full CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) regimen with regard to both adverse events and efficacy." | 2.71 | Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin's lymphoma. ( Harada, M; Hotta, T; Kitamura, K; Masaoka, T; Masuda, M; Matsuda, T; Miura, AB; Miyazaki, T; Mizoguchi, H; Mori, M; Niho, Y; Saito, H; Shibata, A; Takaku, F, 2005) |
| "Since these regimens may cause premature ovarian failure (POF), the ovarian function was studied in 13 consecutive women aged < or =40 years, treated with four cycles of intensified CHOP (cyclophosphamide 2000-3000 mg/m2 per cycle doxorubicin 50 mg/m2, vincristine 1." | 2.71 | Fertility and ovarian function are preserved in women treated with an intensified regimen of cyclophosphamide, adriamycin, vincristine and prednisone (Mega-CHOP) for non-Hodgkin lymphoma. ( Avivi, I; Ben Shahar, M; Blumenfeld, Z; Dann, EJ; Epelbaum, R; Haim, N; Rowe, JM, 2005) |
| "Three patients had grade 3 infections." | 2.71 | Gemcitabine, vinorelbine and prednisone for refractory or relapsed aggressive lymphoma, results of a phase II single center study. ( Dührsen, U; Kasper, C; Müller-Beissenhirtz, H; Nückel, H, 2005) |
| "Idarubicin is a 4-demethoxy-anthracycline analogue of daunorubicin that has proven activity in non-Hodgkin lymphoma, and has been reported to cause less cardiotoxicity." | 2.71 | Comparison of CHOP versus CIOP in good prognosis younger patients with histologically aggressive non-Hodgkin lymphoma. ( Burton, C; Cunningham, D; Hancock, B; Hoskin, P; Linch, D; Qian, W; Smith, P; Vaughan-Hudson, G, 2005) |
| "The present study aimed to determine the long-term safety and efficacy of chimeric anti-CD 20 antibody rituxan (rituximab, Biogen IDEC, San Diego, CA, USA; Genentech, South San Francisco, CA, USA) in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy in previously untreated patients with aggressive non-Hodgkin's lymphoma (NHL)." | 2.71 | Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. ( Czuczman, M; Fisher, RI; Grillo-Lopez, A; Grossbard, ML; Link, BK; Vose, JM, 2005) |
| "Thirty-three patients with previously untreated advanced aggressive B-cell NHL received six infusions of Rituxan (375 mg/m2 per dose) on day 1 of each cycle in combination with six doses of CHOP chemotherapy given on day 3 of each cycle." | 2.70 | Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. ( Czuczman, M; Fisher, RI; Gilman, P; Grillo-Lopez, A; Grossbard, ML; Kunkel, LA; Link, BK; Lowe, A; Vose, JM, 2001) |
| " In addition, the effects on viral load, CD4 counts, and opportunistic infections were examined with the use of combination chemotherapy combined with HAART." | 2.70 | Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. ( Ambinder, R; Flexner, C; Grochow, L; Hamzeh, F; Harrington, W; Herndier, B; Kaplan, L; Lee, J; Levine, A; Ratner, L; Redden, D; Scadden, D; Straus, D; Tan, B; Tang, S, 2001) |
| " One patient died after the first CHOP administration because of anthracycline-related acute cardiomyopathy (corresponding to a toxic death rate of 2." | 2.70 | Influence of amifostine on toxicity of CHOP in elderly patients with aggressive non-Hodgkin's lymphoma--a phase II study. ( Budach, V; Eucker, J; Genvresse, I; Krüger, L; Lange, C; Possinger, K; Schweigert, M; Sezer, O; Späth-Schwalbe, E, 2002) |
| "Twenty-one patients (ALL:10, NHL:8, ATLL:2, ATL:1) were assessable for response and toxicity." | 2.69 | [EPOCH therapy for relapsed/refractory lymphoid malignancies]. ( Asai, O; Dobashi, N; Kato, A; Katori, M; Kobayashi, T; Kuraishi, Y; Nagamine, M; Tajima, N; Usui, N; Watanabe, H; Yamazaki, H; Yano, S, 1998) |
| " No toxic deaths have occurred." | 2.69 | Etoposide, mitoxantrone and prednisone: a salvage regimen with low toxicity for refractory or relapsed non-Hodgkin's lymphoma. ( Budel, L; Doorduijn, JK; Löwenberg, B; Sonneveld, P; Spruit, P; van Der Holt, B; van't Veer, M, 2000) |
| " The mobilization kinetics of circulating progenitor cells in patients with aggressive NHL is dependent on the dosage and schedule of CHOP." | 2.69 | Randomized comparison of mobilization kinetics of circulating CD34+ cells between biweekly CHOP and dose-escalated CHOP with the prophylactic use of lenograstim (glycosylated rHuG-CSF) in aggressive non-Hodgkin's lymphoma. The lenograstim/Lymphoma Study G ( Chou, T; Ikeda, S; Itoh, K; Kasai, M; Mizorogi, F; Morishima, Y; Ogura, M; Ohno, T; Ohtsu, T; Sai, T; Sasaki, Y; Taniwaki, M; Tobinai, K; Uike, N; Yoshida, K, 2000) |
| "The clinical efficacy of COP-BLAM chemotherapy combined with human recombinant granulocyte colony-stimulating factor (G-CSF) was evaluated in 104 previously untreated patients with non-Hodgkin's lymphoma (NHL)." | 2.68 | COP-BLAM regimen combined with granulocyte colony-stimulating factor and high-grade non-Hodgkin's lymphoma. ( Niitsu, N; Umeda, M, 1995) |
| "Dexverapamil was escalated eight dose levels, from 240 to 1,200 mg/m2/d." | 2.68 | Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. ( Bates, SE; Bryant, G; Fojo, A; Herdt, J; Jaffe, ES; Regis, J; Steinberg, SM; Wilson, WH; Wittes, RE; Zhan, Z, 1995) |
| "Disease progression, which includes recurrence at the primary tumor site, is a major cause of treatment failure in patients with mediastinal presentations." | 2.68 | Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: a Childrens Cancer Group study. ( Kadin, M; Kersey, JH; King, D; Krailo, MD; Meadows, AT; Morse, M; Rosenstock, J; Steinherz, PG; Tubergen, DG, 1995) |
| "Six patients (4 with Hodgkin's disease) achieved a complete response (CR) (35%; 95% CI: 14-62%)." | 2.68 | Infusional chemotherapy (EPOCH) in patients with refractory or relapsed lymphoma. ( Carrión, JR; García Arroyo, FR; Salinas, P, 1995) |
| "Patients with undifferentiated non-Burkitt's lymphoma had a longer survival than those with undifferentiated Burkitt's." | 2.68 | Aggressive chemotherapy in the treatment of Burkitt's and non-Burkitt's undifferentiated lymphoma. ( Andersen, JW; Hines, JD; Mann, R; Mazza, JJ; Neiman, RS; O'Connell, MJ; Oken, MM, 1995) |
| "The pharmacokinetics and the pharmacodynamic profile of subcutaneously administered recombinant human non-glycosylated interleukin-3 (rhIL-3) was studied in lymphoma patients after standard CHOP chemotherapy." | 2.68 | Pharmacokinetic and pharmacodynamic studies of subcutaneously administered recombinant human interleukin-3 following chemotherapy for non-Hodgkin's lymphoma. ( Hovgaard, DJ; Mortensen, BT; Nissen, NI, 1995) |
| "We evaluated the efficacy and adverse effects of biweekly COP-BLAM (cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin and procarbazine) therapy combined with granulocyte colony-stimulating factor (G-CSF) for treating non-Hodgkin's lymphoma (NHL)." | 2.68 | Biweekly COP-BLAM (cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin and procarbazine) regimen combined with granulocyte colony stimulating factor (G-CSF) for intermediate-grade non-Hodgkin's lymphoma. ( Niitsu, N; Umeda, M, 1996) |
| "Twenty eligible patients with NHL and chronic lymphatic leukemia (CLL), resistant to or relapsed after previous protocols of polychemotherapy were treated with oral etoposide at a dosage of 50 mg/m2/day for 21 days in a 28-day cycle." | 2.68 | Severe myelotoxicity of oral etoposide in heavily pretreated patients with non-Hodgkin's lymphoma or chronic lymphatic leukemia. ( Bairey, O; Blickstein, D; Hadar, H; Lahav, M; Prokocimer, M; Shaklai, M; Shaklai, S; Sulkes, J, 1996) |
| " rhGM-CSF was administered at a dosage of 5 micrograms/kg for 10 days or until neutrophils were > 1/nl following chemotherapy." | 2.68 | Recombinant human granulocyte-macrophage colony-stimulating factor after combined chemotherapy in high-grade non-Hodgkin's lymphoma--a randomised pilot study. ( Bergmann, L; Hoelzer, D; Karakas, T; Knuth, A; Lautenschläger, G; Mitrou, PS, 1995) |
| "Treatment of both Hodgkin's disease (HD) and high-grade non-Hodgkin's lymphoma (HG-NHL) with bulky presentation at diagnosis frequently results in residual masses detected radiologically." | 2.68 | Monitoring bulky mediastinal disease with gallium-67, CT-scan and magnetic resonance imaging in Hodgkin's disease and high-grade non-Hodgkin's lymphoma. ( Babini, L; Barbieri, E; Battista, G; Bendandi, M; Canini, R; Fanti, S; Frezza, G; Gherlinzoni, F; Gozzetti, A; Merla, E; Monetti, N; Pisi, P; Rimondi, MR; Tura, S; Zinzani, PL; Zompatori, M, 1996) |
| "DNA aneuploidy was shown in 57% of cases, but was not predictive of clinical outcome." | 2.68 | Prognostic implications of ploidy and proliferative activity in the diffuse, aggressive non-Hodgkin's lymphomas. ( Andersen, J; Bauer, KD; Fisher, RI; Gordon, LI; Jiang, S; Neiman, RS; Oken, MM; Variakojis, D; Winter, JN, 1996) |
| "Fourteen had Hodgkin's and four non-Hodgkin's lymphoma." | 2.68 | Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. ( Avivi, I; Ben-Shahar, M; Blumenfeld, Z; Epelbaum, R; Haim, N; Linn, S, 1996) |
| " In summary, G-CSF (filgrastim) will facilitate the shortening of the dosage interval between cycles of CHOP chemotherapy due to accelerated hematological recovery." | 2.68 | A phase I trial to assess the value of recombinant human granulocyte colony stimulating factor (R-MeTHuG-CSF, filgrastim) in accelerating the dose rate of chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma (NHL). The Central Lymphoma Grou ( Bailey, NP; Barnard, D; Child, JA; Cullen, MH; Earl, H; Fletcher, J; Smith, GM; Woodruffe, CM, 1996) |
| " Prognostic factors other than age should be taken into account, particularly when doses and dosing intervals are determined." | 2.68 | Prognostic factors in elderly patients with non-Hodgkin's lymphoma treated with cyclophosphamide, vincristine, prednisone, bleomycin, Adriamycin, procarbazine (COP-BLAM) therapy. ( Niitsu, N, 1997) |
| "One hundred and sixty seven patients with non-Hodgkin's lymphoma were randomly divided into two groups, the treatment group, which consisted of 112 cases using Chinese herbs combined with chemotherapy and 55 cases of control group were treated by chemotherapy only." | 2.68 | [Clinical observation on 112 cases with non-Hodgkin's lymphoma treated by Chinese herbs combined with chemotherapy]. ( Guo, XM; Li, JX; Yang, XF, 1997) |
| "Oral prednisone was administered daily during the entire treatment period." | 2.67 | P-VABEC: a prospective study of a new weekly chemotherapy regimen for elderly aggressive non-Hodgkin's lymphoma. ( Amadori, S; Avvisati, G; Coluzzi, S; Giovannini, M; Guglielmi, C; Mandelli, F; Martelli, M; Torromeo, C, 1993) |
| "The patients were randomly assigned to a regimen of cyclophosphamide, vincristine, prednisone, and doxorubicin or to this regimen combined with recombinant interferon alfa." | 2.67 | Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. ( Andersen, JW; Bhide, V; Borden, EC; Hawkins, MJ; O'Connell, MJ; Oken, MM; Smalley, RV, 1992) |
| "58% of the non-Hodgkin's lymphomas occurred in patients with marked immunodeficiency, 85% were high grade malignancies and 47% had primary extranodal disease." | 2.67 | [Malignant lymphoma associated with HIV infection]. ( Becker, K; Clemens, MR; Fischer, T; Helm, EB; Knauf, W; Mitrou, PS; Pohl, C; Schrappe-Bächer, M; Serke, M; Westerhausen, M, 1991) |
| "Patients treated for non-Hodgkin lymphoma are at risk of cardiovascular adverse events, with the risk of heart failure being particularly high." | 2.66 | Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis. ( Asselbergs, FW; Bosman, LP; Cramer, MJ; Doevendans, PA; Kamphuis, JAM; Linschoten, M; Teske, AJ; van Rhenen, A, 2020) |
| " In addition, increasing the dosage of epirubicin did not result in an increase in the haematologic toxicity or percent of CR." | 2.66 | Comparison of CHOP-B vs CEOP-B in 'poor prognosis' non-Hodgkin's lymphomas. A randomized trial. ( Brandi, M; Calabrese, P; De Lena, M; Lorusso, V; Maiello, E; Marzullo, F; Mazzei, A; Romito, S, 1989) |
| "Epirubicin is an effective agent when used in combination chemotherapy in both low grade and high grade lymphoma with less toxicity than doxorubicin." | 2.66 | Combination chemotherapy including epirubicin for the management of non-Hodgkin's lymphoma. ( Al-Ismail, SA; Gough, J; Whittaker, JA, 1987) |
| " The frequency of infection was significantly lower among the patients on the PEPA program, and dosage escalation of the chemotherapeutic agents was accomplished more often among these patients." | 2.65 | Protected environment-prophylactic antibiotic program for malignant lymphoma. Randomized trial during chemotherapy to induce remission. ( Bodey, GP; Cabanillas, F; Freireich, EJ; Rodriguez, V, 1979) |
| "The response rate and survival in diffuse histiocytic lymphoma have improved since the first study." | 2.64 | Chemotherapy of non-Hodgkin's lymphoma: 10 years' experience in the Southwest Oncology Group. ( Coltman, CA; Jones, SE; Luce, JK; McKelvey, EM; Moon, TE, 1977) |
| "In patients with diffuse lymphoma a complete remission rate of 50% was obtained with both regimens." | 2.64 | Combination versus successive single agent chemotherapy in lymphocytic lymphoma. ( Bloomfield, CD; Kennedy, BJ; Kiang, DT; Peterson, BA; Theologides, A; Vosika, G, 1978) |
| "Following testing, a pituitary adenoma and mediastinal non-Hodgkin's lymphoma were diagnosed." | 2.58 | Growth hormone-secreting pituitary macroadenoma presenting concurrently with non-Hodgkin's lymphoma and responding to doxorubicin treatment: case report and review of the literature. ( Balena, R; Barkhoudarian, G; Barnard, ZR; Batra, A; Lekovic, GP; Palejwala, S; Wilkinson, EP, 2018) |
| " This review summarizes its efficacy and toxicity, and focuses on the pharmacokinetic features of vincristine that affect clinical outcomes." | 2.50 | Pharmacokinetic evaluation of vincristine for the treatment of lymphoid malignancies. ( Said, R; Tsimberidou, AM, 2014) |
| "Limited comparative data exist for the treatment of HIV-associated non-Hodgkin lymphoma." | 2.49 | Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. ( Barta, SK; Boue, F; Dunleavy, K; Galicier, L; Garcia, O; Kaplan, LD; Lee, JY; Little, RF; Morgades, M; Mounier, N; Navarro, JT; Noy, A; Oriol, A; Ratner, L; Remick, SC; Ribera, JM; Sparano, JA; Spina, M; Tamari, R; Tirelli, U; Wang, D; Weiss, R; Wilson, WH; Wyen, C; Xue, X, 2013) |
| "Then we performed a Pubmed search for "systemic sclerosis & non-Hodgkin's lymphoma," limited to the English language." | 2.46 | Non-Hodgkin's lymphoma in systemic sclerosis: case and literature review. ( Ilardi, G; Mascolo, M; Staibano, S; Valentini, G; Vettori, S, 2010) |
| "Late-onset neutropenia is intriguing biologically and while its pathogenesis and mechanism are not completely understood, many interesting hypotheses have been proposed to explain its occurrence." | 2.46 | Rituximab-associated neutropenia. ( Dunleavy, K; Tay, K; Wilson, WH, 2010) |
| "Mitoxantrone has a broad anti-tumour activity including lymphoma with potentially less cardiotoxicity than doxorubicin, which may be of particular importance in elderly patients." | 2.44 | CNOP (mitoxantrone) chemotherapy is inferior to CHOP (doxorubicin) in the treatment of patients with aggressive non-Hodgkin lymphoma (meta-analysis). ( Ahlbom, A; Anders, A; Andersson, T; Björkholm, M; Eva, O; Magnus, B; Ösby, E; Tomas, A, 2008) |
| "Erythema nodosum is the most frequent clinicopathological variant of the panniculitides." | 2.42 | [Erythema nodosum association with malignant lymphoma]. ( Griniūte, R; Pileckyte, M, 2003) |
| "Pretreatment with oblimersen followed by cyclophosphamide (Cytoxan, Neosar) markedly improved survival relative to single-agent cyclophosphamide in a murine xenograft model." | 2.42 | Targeting the proapoptotic factor Bcl-2 in non-Hodgkin's lymphoma. ( Klasa, RJ, 2004) |
| " Particularly in patients aged over 80 years, to avoid side effects it is essential to adjust dosage and route of administration of chemotherapy." | 2.42 | [Malignant lymphoma, multiple myeloma and myeloproliferative diseases in the elderly]. ( Umeda, M, 2004) |
| "Sixteen textbooks and chemotherapy reference books reviewed quoted only one prednisone dosage as part of the standard CHOP regimen; the prednisone dosages quoted as standard varied between publications." | 2.41 | The prednisone dosage in the CHOP chemotherapy regimen for non-Hodgkin's lymphomas (NHL): is there a standard? ( Colon-Otero, G; Moreno, A; Solberg, LA, 2000) |
| "Low-grade and follicular lymphomas account for approximately 40% of the incidences of NHL in the United States." | 2.41 | Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. ( Benyunes, M; Bernstein, SH; Bernstein, ZP; Brown, K; Czuczman, MS; Fallon, A; Grillo-López, AJ; Klippenstein, D; Loud, P; McCarthy, P; Miller, K; Mohr, A; Rock, MK; Skipper, M; Stewart, C; Wentling, D, 2002) |
| "In gastric MALT lymphoma, Helicobacter pylori might provide the antigenic stimulus for its growth." | 2.40 | [Recent progress in the management of malignant lymphoma]. ( Ohnishi, K, 1997) |
| "A 47 year old woman with a MALT lymphoma affecting the breast exclusively is reported." | 2.40 | [Primary MALT-type lymphoma of the breast]. ( Campo, E; Cervantes, F; Esteve, J; Montserrat, E; Rafel, M; Serra, A; Velasco, M, 1998) |
| "A patient who developed Hodgkin's disease after an 11-year remission of marginal zone B-cell (MZB) lymphoma (low grade B-cell lymphoma of mucosa-associated lymphoid tissue type) is presented." | 2.40 | Hodgkin's disease following extranodal marginal zone B-cell lymphoma in remission. ( Hara, K; Shimizu, K; Yatabe, Y, 1999) |
| "Four patients had a prior AIDS diagnosis." | 2.39 | Intensive treatment of AIDS-related non-Hodgkin's lymphomas with the MACOP-B protocol. ( Grünewald, T; Jautzke, G; Pohle, HD; Ruf, B; Schürmann, D; Weiss, R, 1995) |
| "Malignant lymphoma is classified into the following five major categories: aggressive lymphoma, indolent B-lymphoma, Hodgkin's disease, T-lymphoblastic lymphoma and adult T-cell leukemia-lymphoma (ATL)." | 2.39 | [Recent progress in the chemotherapy of malignant lymphoma]. ( Tobinai, K, 1995) |
| "Treatment with prednisone (2 mg/kg daily for 8 weeks) and vincristine (1 mg/m2 once weekly for 4 weeks) brought about partial remission of the angioimmunoblastic lymphadenopathy with normalization of the clinical and laboratory findings, the splenohepatomegaly regressed, and there was only a small amount of ascites." | 2.39 | [Reversible myelofibrosis in angioimmunoblastic lymphadenopathy]. ( Mayet, WJ; Meyer zum Büschenfelde, KH; Orth, T; Störkel, S; Treichel, U, 1994) |
| "Five cases occurred in association with ANLL, 2 cases as sites of ANLL relapse, and 1 case in association with myelodysplasia." | 2.39 | Primary extramedullary leukemia of the prostate: case report and review of the literature. ( Kidd, P; Quien, ET; Saidi, P; Sandhaus, L; Strair, R; Wallach, B, 1996) |
| "Thoracic and abdominal irradiation for Hodgkin's disease was performed concomitantly with chemotherapy for the non-Hodgkin's lymphoma." | 2.38 | Cerebral non-Hodgkin's lymphoma discovered when treating Hodgkin's disease. ( Bergeron, C; Chatel, M; Darcel, F; Edan, C; Faivre, J; Jouan, H; Le Moine, P; Le Prise-Fleury, E; Patte, C; Tass, P, 1993) |
| "As salvage therapy in non-Hodgkin's lymphoma (NHL), IMV-Bleo (ifosfamide, methotrexate, etoposide, bleomycin) produced a complete remission (CR) rate of 41% and seemed to be particularly effective in patients with suboptimal response to first-line treatment." | 2.38 | European experience with ifosfamide in lymphomas. ( Diehl, V; Schaadt, M; von Kalle, AK, 1989) |
| "Chemotherapy of malignant lymphomas has accomplished a significant progress during the two decades." | 2.38 | [Current status of chemotherapy in the treatment of malignant lymphomas]. ( Hayashi, K; Kimura, I; Mizuta, J; Murashima, M; Ohnoshi, T; Tada, A; Tagawa, S; Ueno, K, 1989) |
| "Grade 3/4 neutropenia was observed in 26% of cycles and in 65% of patients." | 1.56 | Modified EPOCH for high-risk non-Hodgkin lymphoma in sub-Saharan Africa. ( Chikasema, M; Chimzimu, F; Chiyoyola, S; Ellis, GK; Fedoriw, G; Gopal, S; Kaimila, B; Kampani, C; Kasonkanji, E; Mhango, W; Montgomery, ND; Mtangwanika, A; Mulenga, M; Nicholas, S; Nyasosela, R; Nyirenda, R; Painschab, MS; Randall, C; Tewete, B; Tomoka, T; Westmoreland, KD; Zuze, T, 2020) |
| "Proximal renal tubular acidosis (RTA) complicated with anemiawas confirmed after admission." | 1.56 | [The 475th case: renal tubular acidosis, renal failure, anemia, and lactic acidosis]. ( Chen, G; Li, MX; Wu, D, 2020) |
| "Severe fatigue was defined as MFI-20 scores ≥60 on dimension scales scored from 0 to 100." | 1.51 | Long-term fatigue in survivors of non-Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross-sectional study. ( Anthony, S; Broussais-Guillaumot, F; Busson, R; Casasnovas, RO; Damaj, G; Delarue, R; Feugier, P; Haioun, C; Henry-Amar, M; Jais, JP; Laborde, L; Morschhauser, F; Mounier, N; Nerich, V; Ribrag, V; Salles, G; Sebban, C; Thieblemont, C; Tilly, H; Ysebaert, L, 2019) |
| " Efficacy assessment was based on incidence of FN and serious neutropenia (neutrophil count <500/μL), hospitalization days and chemotherapy dosage level." | 1.51 | [Comparison of Pegfilgrastim and Filgrastim for the Primary Prophylactic Effect for Preventing Febrile Neutropenia in Patients Undergoing Rituximab with Dose-adjusted EPOCH Chemotherapy]. ( Izumitani, S; Kataoka, T; Matsuo, H; Murase, T; Nishigakiuchi, R; Saeki, Y; Sakurashita, H; Taogoshi, T, 2019) |
| "Incidence and severity of interstitial pneumonitis were compared among the four groups." | 1.48 | Incidence of interstitial pneumonitis in non-Hodgkin's lymphoma patients receiving immunochemotherapy with pegylated liposomal doxorubicin and rituximab. ( Chao, T; Huang, L; Jiang, Y; Peng, H; Shen, Q; Thapa, S; Yang, K; Yu, S; Zhang, L; Zhou, T, 2018) |
| "We conclude that hyperglycemia is common during first-line NHL treatment with R-CHOP or DA-EPOCH-R, even in the absence of known diabetes and is associated with alterations of chemotherapy." | 1.48 | Hyperglycemia during first-line R-CHOP or dose adjusted R-EPOCH chemotherapy for non-Hodgkin lymphoma is prevalent and associated with chemotherapy alteration - a retrospective study. ( Dothard, A; Hurd, D; Isom, S; Kennedy, L; Lamar, ZS; Lesser, G; McClain, D; Robinson, M; Vaidya, R, 2018) |
| "Differentiated thyroid cancer is the most common endocrine malignancy with concomitant hematological malignancy in 7%." | 1.48 | Synchronous papillary thyroid cancer and non-Hodgkin lymphoma: Case report. ( Bochev, P; Cirocchi, R; Hristoskova, R; Mutafchiyski, VM; Philipov, A; Popivanov, GI; Tabakov, M, 2018) |
| "Early recognition of secondary achalasia is important as its treatment involves management of underlying malignancy, while treatment of primary achalasia mainly involves lowering the lower oesophageal sphincter pressure with pneumatic dilatation or Heller's myotomy." | 1.48 | Uncommon cause of dysphagia: paraneoplastic achalasia. ( Bhansali, S; Choudhary, NS; Nasa, M; Sud, R, 2018) |
| "Advances in anti-lymphoma therapy prolong overall survival, making late adverse effects, like doxorubicin-related cardiotoxicity, an even more important clinical issue." | 1.48 | Primary Cardioprotection Reduces Mortality in Lymphoma Patients with Increased Risk of Anthracycline Cardiotoxicity, Treated by R-CHOP Regimen. ( Długosz-Danecka, M; Gruszka, AM; Jaroszyński, A; Jurczak, W; Krawczyk, K; Ogórka, T; Olszanecka, A; Skotnicki, AB; Sobociński, M; Szmit, S, 2018) |
| " Incidence of PIs, radiological features, patients' characteristics, underlying NHL type, rituximab/chemotherapy dosing schedules, and symptoms were recorded." | 1.46 | 18F-FDG-PET/CT Pulmonary Infiltrates in Non-Hodgkin Lymphoma Patients Treated with Combined Immunochemotherapy: Incidence and Clinical Characteristics. ( Bairey, O; Berger, T; Cohen, YC; Eshel, L; Raanani, P; Shpilberg, O; Stern, D, 2017) |
| " In both animal models the anti-lymphoma activity of selinexor is enhanced through combination with DEX or EVER." | 1.43 | Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone. ( Aboukameel, A; Azmi, AS; Baloglu, E; Bhutani, D; Carlson, R; Elloul, S; Kauffman, M; Mohammad, RM; Muqbil, I; Senapedis, W; Shacham, S; Zonder, J, 2016) |
| "Initial spinal cord compression (ISCC) in B-cell non-Hodgkin lymphoma (NHL) is rarely present at diagnosis." | 1.42 | Management and prognosis of 66 patients with B-cell non-Hodgkin lymphoma presenting with initial spinal cord compression: a French retrospective multicenter study. ( Amorim, S; Brice, P; Brière, J; Coiffier, B; de Kerviler, E; Dupuis, J; Filliatre, L; Fleury, I; Mazari, MA; Mounier, N; Thieblemont, C; Tilly, H, 2015) |
| "Patients with chronic lymphocytic leukemia or non-Hodgkin’s lymphoma are at risk of infectious diseases of respiratory system because of immunodeficiency." | 1.42 | Organizing pneumonia appearing in B-cell chronic leukemia malignancy progression - a case report. ( Maksymiuk, B; Opoka, L; Polaczek, MM; Roszkowski-Sliż, K; Zych, J, 2015) |
| " This study aimed to assess the efficacy and toxicity of dose-adjusted CHOP alone or in combination with rituximab (R-CHOP) by examining the stem cell mobilization in NHL patients." | 1.42 | Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin's lymphoma. ( Gui, L; Han, X; He, X; Liu, P; Qin, Y; Shi, Y; Yang, J; Yang, S; Yao, J; Zhang, C; Zhang, S; Zhao, L; Zhou, P; Zhou, S, 2015) |
| "It only gives 5% of the testicular tumors, 2% of extranodal lymphomas, and barely 1% of all non-Hodgkin diseases." | 1.40 | [Diagnosis and treatment of primary testicular non-Hodgkin lymphoma]. ( Demeter, J; Nyirády, P; Romics, I; Romics, M, 2014) |
| "GLS combined with cTnT may provide a reliable and non-invasive method to predict cardiac dysfunction in patients receiving anthracycline-based chemotherapy." | 1.40 | Two-dimensional speckle tracking echocardiography combined with high-sensitive cardiac troponin T in early detection and prediction of cardiotoxicity during epirubicine-based chemotherapy. ( Chen, H; Cheng, L; Kang, Y; Li, L; Pan, C; Shu, X; Sun, M; Xu, X, 2014) |
| "Seventy-five Hodgkin lymphoma and non-Hodgkin lymphoma patients and a control group of 257 fertile men." | 1.40 | Impact of lymphoma treatments on spermatogenesis and sperm deoxyribonucleic acid: a multicenter prospective study from the CECOS network. ( Auger, J; Berthaut, I; Brugnon, F; Bujan, L; Daudin, M; Hennebicq, S; Moinard, N; Rives, N; Saias, J; Szerman, E; Walschaerts, M, 2014) |
| "Fatigue was assessed again after 10 and 21 days." | 1.39 | The relationship between learned resourcefulness and cancer-related fatigue in patients with non-Hodgkin lymphoma. ( Bar-Tal, Y; Barnoy, S; Menshadi, N, 2013) |
| "CT abdomen confirmed the diagnosis of typhlitis, demonstrating characteristic terminal ileum, caecal and right-sided colon involvement." | 1.39 | Concomitant typhlitis and Clostridium difficile colitis developed after first R-CHOP chemotherapy in a non-Hodgkin lymphoma patient. ( Buppajarntham, S; Junpaparp, P; Madueno, FV; Varadi, G, 2013) |
| "Radiation therapy of follicular lymphoma has showed consistent results, which demonstrated by 100% of 5-year tumor-specific survival in the whole group, 100% disease-free survival in patients with stage II, the lack of recurrence in the irradiation fields." | 1.39 | [Current technologies in radiotherapy for non-Hodgkin lymphomas]. ( Vinogradova, IuN, 2013) |
| " Primary therapies were divided into four groups: radiotherapy alone, moderately dosed COPP/ABVD-like chemotherapies for intermediate and advanced stages and BEACOPP escalated." | 1.37 | Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis. ( Diehl, V; Engert, A; Franklin, J; Hasenclever, D; Josting, A; Loeffler, M; Scholz, M, 2011) |
| "Orbital lymphoma is a very rare type of primary Non-Hodgkin lymphoma." | 1.37 | Treatment of a patient with adnexal lymphoma with Rituximab. ( Bilgir, F; Bilgir, O; Calan, M; Oztekin, O; Sari, F; Yuksel, A, 2011) |
| "Hepatic T-cell lymphosarcoma with involvement of regional lymph nodes and concurrent schistosomiasis were diagnosed in an 11-year-old male neutered mixed-breed dog with a history of chronic weight loss, inappetence, vomiting, and diarrhea." | 1.37 | Lymphosarcoma associated with Heterobilharzia americana infection in a dog. ( Ambrose, D; Brown, CA; Frontera-Acevedo, K; Moorhead, AR; Saba, CF; Stone, RH, 2011) |
| "Pirarubicin is an analog of doxorubicin." | 1.36 | Long-term results of pirarubicin versus doxorubicin in combination chemotherapy for aggressive non-Hodgkin's lymphoma: single center, 15-year experience. ( Cao, Y; Fu, X; Guan, Z; Guo, C; Huang, H; Huang, J; Lin, T; Xiao, J; Zhai, L, 2010) |
| "The severe pulmonary adverse events tended to occur more frequently with R-CHOP (18." | 1.36 | Severe pulmonary adverse effects in lymphoma patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus rituximab. ( Bang, SM; Kang, YA; Kim, JH; Lee, CT; Lee, JH; Lee, JS; Lee, KW; Lim, KH; Yoon, HI, 2010) |
| " The elimination half-life at steady state of rituximab in all patients was estimated to be 19." | 1.36 | Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies. ( Aarden, L; Baars, JW; Beijnen, JH; Huitema, AD; Tran, L, 2010) |
| "Drug-induced pneumonitis is a serious and an unpredictable side effect of chemotherapy in patients with malignant lymphoma." | 1.35 | Drug-induced pneumonitis detected earlier by 18F-FDG-PET than by high-resolution CT: a case report with non-Hodgkin's lymphoma. ( Daimaru, O; Fukaya, N; Imai, T; Ito, S; Nagata, T; Uchida, H; Yamane, T; Yoshiya, K, 2008) |
| "Prednisone and acyclovir were administered empirically during the course of the diagnostic evaluation." | 1.35 | Neurolymphomatosis mimicking chemotherapy-induced ototoxicity. ( Hansen, MR; Hong, RS; Woodson, EA, 2009) |
| "In humans and dogs, paraneoplastic peripheral neuropathies have been documented with different neoplastic processes including lymphoproliferative disorders." | 1.35 | Peripheral neuropathy in a cat with renal lymphoma. ( Capucchio, MT; Catalano, D; Cavana, P; Farca, AM; Sammartano, F; Valazza, A, 2009) |
| "Prednisone 50 mg was administered every other day orally for thirty days and then tapered over the next thirty days." | 1.35 | Accelerated R-COP: a pilot study for the treatment of advanced low grade lymphomas that has a high complete response rate. ( Bertino, JR; Gharibo, M; Levitt, MJ; Rubin, A; Schaar, D; Strair, R, 2009) |
| "Rituximab has dramatically improved the survival of patients with non-Hodgkin's lymphomas (NHL), but the dosing regimen currently used should be optimized." | 1.35 | Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma. ( Cartron, G; Girard, P; Hénin, E; Paintaud, G; Ternant, D; Tod, M, 2009) |
| " Though lack of difference may be attributed to the small sample size, suboptimal supportive care for intensive treatment would increase risk of toxic deaths." | 1.35 | Outcome and haemato-toxicity of two chemotherapy regimens for childhood non-Hodgkin's lymphoma in a Kenyan hospital. ( Macharia, WM, 2009) |
| "Toxic leukoencephalopathy syndromes are rare disorders of cerebral injury characterized by changes in the white matter and accompanying neurologic dysfunction." | 1.35 | Necrotizing leukoencephalopathy following CHOP chemotherapy. ( Blaes, AH; Hui, SK; Lee, CK; Peterson, BA; Santa-Cruz, KS, 2008) |
| "We would like to add IgM monoclonal gammopathy and non-Hodgkin's lymphoma as one of the diseases associated with erythema elevatum diutinum considering that the activity of erythema elevatum diutinum and non-Hodgkin's lymphoma fluctuated in parallel in the present case." | 1.35 | Erythema elevatum diutinum with rare distribution as a first clinical sign of non-Hodgkin's lymphoma: a novel association? ( Apostolopoulou, M; Hatzitolios, A; Kaiafa, G; Papadopoulos, A; Psomas, E; Savopoulos, C; Tzalokostas, V; Tzellos, TG, 2008) |
| "In 1999 she was diagnosed with systemic lupus erythematosus (SLE) based on her symptoms of malar rash, polyarthritis, leukopenia, autoimmune hemolytic anemia and positive anti-DNA antibody test." | 1.34 | Successful rituximab-CHOP treatment of systemic lupus erythematosus associated with diffuse large B-cell non-Hodgkin lymphoma. ( Gergely, L; Illes, A; Kiss, E; Ress, Z; Simon, Z; Tarr, T, 2007) |
| "Histological, we mainly notified follicular lymphoma constituted of small cells 50%, followed by mixed follicular and large cells lymphomas with respectively 27." | 1.34 | [Therapeutic results and evolution of Black African patients with follicular lymphoma: Ivory Coast experience]. ( Koffi, G; Kouakou, B; Ndathz, E; Ndiaye, FS; Sangare, A; Sanogo, I, 2007) |
| " Seven patients received indinavir at a dosage of 800 mg three times daily and three patients received nelfinavir at a dosage of 750 mg three times daily." | 1.33 | Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients. ( Bassetti, D; Bassetti, M; Cinelli, R; Cruciani, M; Di Gennaro, G; Gatti, G; Tirelli, U; Vaccher, E, 2005) |
| "Of the 13 cases, 5 were Hodgkin's disease (HD), and 8 were non-Hodgkin's lymphoma (NHL)." | 1.33 | [Clinical analysis of reactive thymic hyperplasia following chemotherapy for childhood malignant lymphoma]. ( Ling, JY; Sun, XF; Wang, ZH; Xia, Y; Zhen, ZJ, 2006) |
| " The accentuated neutropenia may be related to the specific chemotherapy regimen or drug, eg, cyclophosphamate since same day Pf was safe with regimens in which a non alkylating agent (taxane, gemcitabine, navelbine, cisplatin) was used with a weekly chemotherapy dosing schema and did not generate accentuated neutropenia." | 1.33 | Same day Pegfilgrastim and CHOP chemotherapy for non-Hodgkin lymphoma. ( Lokich, JJ, 2006) |
| "Only young patients have a high risk of second cancer during follow-up beyond 10 years." | 1.33 | Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study. ( Baars, JW; Carde, P; Kluin-Nelemans, HC; Meerwaldt, JH; Moser, EC; Noordijk, EM; Thomas, J; van Glabbeke, M; van Leeuwen, FE, 2006) |
| " There was also no difference in the survival between radiotherapy dosage | 1.32 | [Clinical analysis of 75 patients with nasopharyngeal non-Hodgkin's lymphoma]. ( Guan, ZZ; He, YJ; Huang, HQ; Jiang, WQ; Li, YH; Lin, TY; Xia, ZJ; Xu, RH, 2003) |
| "Grade 3-4 leukopenia was observed in 61% of patients with 11% of febrile neutropenia." | 1.32 | ACOD, a modified CHOP regimen for elderly patients with aggressive non-Hodgkin's lymphoma. ( Cavalli, F; Cocorocchio, E; Conconi, A; De Luzio, K; Ferrucci, PF; Martinelli, G; Mazzetta, C; Mingrone, W; Peccatori, FA; Santoro, P; Zucca, E, 2003) |
| "The in-field and out of field recurrence rates were 18 and 31%, respectively, for the entire group and 22 and 44%, respectively, for the palliative group." | 1.32 | Abdominal irradiation after chemotherapy in non-Hodgkin's lymphoma: review of 32 patients. ( Akoum, R; Brihi, E; Chahine, G; Saade, M, 2003) |
| " In addition, before the modification, patients with Stage IV disease received a cumulative dose of 15,600 mg/m(2) of cyclophosphamide for 3 years; after 1980, these patients received the same dosage as the other patients (i." | 1.32 | Lymphoblastic lymphoma of childhood and the LSA2-L2 protocol: the 30-year experience at Memorial-Sloan-Kettering Cancer Center. ( Filippa, DA; Mora, J; Qin, J; Wollner, N, 2003) |
| "Considering all tumors, no excess of second cancer was observed." | 1.32 | Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. ( André, M; Bosly, A; Brice, P; Coiffier, B; Gaulard, P; Gisselbrecht, C; Haioun, C; Henry-Amar, M; Leleu, X; Morel, P; Mounier, N; Reyes, F; Sonet, A; Tilly, H, 2004) |
| " The safety of pegfilgrastim in this patient population was determined by reports of adverse events." | 1.32 | Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma. ( Case, D; George, S; Hackett, J; Liang, BC; Meza, LA; Neumann, TA; Shogan, JE; Yang, BB; Yunus, F, 2003) |
| "Twenty-two patients presented with breast cancer (BC) in complete remission after CHOP for NHL." | 1.32 | Breast cancer after curative chemotherapy in non-Hodgkin's lymphoma: examination of the role of drug resistance and retrospective comparison to the outcome of de novo breast cancer. ( Davaris, P; Dimitrakopoulos, A; Kosmas, C; Lazaris, A; Pangalis, GA; Papalambros, E; Rokana, S; Siakantaris, MP; Tsavaris, N; Vadiaka, M; Zorzos, H, 2004) |
| "Lymphoma is a malign disease of the lymphoid system." | 1.32 | Cyclooxygenase-2 (Cox-2) expression in lymphomas. ( Erdoğan, S; Ergin, M; Hakverdi, S; Hazar, B; Seyrek, E; Tuncer, I, 2004) |
| "Primary adrenal insufficiency was confirmed on cortisol dynamics (very low basal and peak cortisol) after insulin-induced hypoglycemia." | 1.32 | Adrenal insufficiency due to primary bilateral adrenal non-Hodgkin's lymphoma. ( Aejaz Aziz, S; Ahmad Laway, B; Ahmad, M; Alam Bhat, K; Hamid Zargar, A; Hayat Bhat, M; Iftikhar Bashir, M; Iqbal Wani, A; Shah, A, 2004) |
| "Prednisone was taken orally on D1-5 at a dose of 60 mg/m(2)." | 1.31 | [Gemcitabine in the treatment of relapsed or refractory non-Hodgkin's lymphoma]. ( Li, A; Luo, R; Ma, S; Sheng, X, 2002) |
| "DNA aneuploidy was statistically significant (P < 0." | 1.31 | DNA flow cytometry of non-Hodgkin's lymphomas: correlation with cytologic grade and clinical relapse. ( Dey, P; Gupta, SK; Saikia, UN; Vohra, H, 2000) |
| "We describe a case of an acute myelogenous leukemia (AML) associated with t(1;11) (q23;p15), which is a novel simple variant translocation of t(7;11)(p15;p15)." | 1.31 | Translocation (1;11)(q23;p15), a novel simple variant of translocation (7;11)(p15;p15), in a patient with AML (M2) accompanied by non-Hodgkin lymphoma and gastric cancer. ( Hatano, Y; Kume, M; Miura, AB; Miura, I, 2000) |
| "We followed-up 33 patients with non-Hodgkin's lymphoma or with Hodgkin's disease during the years 1987-1997 who were referred for semen cryopreservation." | 1.31 | Follow-up of sperm concentration and motility in patients with lymphoma. ( Botchan, A; Hauser, R; Paz, G; Tal, R; Yavetz, H; Yogev, L, 2000) |
| "Transient hypotension was the most common side effect occurring in association with amifostine." | 1.31 | Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study. ( Genvresse, I; Harder, H; Lange, C; Possinger, K; Schanz, J; Schweigert, M; Späth-Schwalbe, E, 2001) |
| "Lamivudine is a nucleoside analogue that can directly suppress HBV replication." | 1.31 | Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. ( Motta, M; Pelizzari, A; Puoti, M; Rossi, G, 2001) |
| "Peripheral facial palsy has been considered as a possible neurological complication of the early stage of HIV infection but the number of reported cases in the literature is limited." | 1.31 | Bilateral peripheral facial palsy secondary to lymphoma in a patient with HIV/AIDS: a case report and literature review. ( de Almeida, SM; Leite, AG; Leite, PG; Sasaki, Md, 2002) |
| "Patients treated for Hodgkin's disease and non-Hodgkin lymphomas were followed for 5 years after start of therapy." | 1.30 | Five-year follow-up of saliva in patients treated for lymphomas. ( Keinànen, S; Laine, P; Lindqvist, C; Meurman, JH; Pyrhönen, S; Teerenhovi, L, 1997) |
| "Acute respiratory failure and a massive pleural effusion developed, and mechanical ventilation was begun." | 1.30 | [Tumor lysis syndrome after treatment for mediastinal non-Hodgkin's lymphoma]. ( Hachiya, T; Harada, T; Hayano, T; Honda, T; Kaneki, T; Kawashima, A; Koizumi, T; Kubo, K; Maruyama, Y; Sekiguchi, M, 1997) |
| " Data were collected at each treatment cycle via a 75-item self-report questionnaire, with severity of each side effect graded on a 5-point scale." | 1.30 | Side effects of CHOP in the treatment of non-hodgkin's lymphoma. ( North, C; Sitzia, J; Stanley, J; Winterberg, N, 1997) |
| "Leukoencephalopathy syndromes encompass a variety of neurologic abnormalities that affect cerebral white matter." | 1.30 | Fatal leukoencephalopathy in a patient with non-Hodgkin's lymphoma treated with CHOP chemotherapy and high-dose steroids. ( Burton, GV; Cain, MS; Holcombe, RF, 1998) |
| "We report a case of fulminant myelofibrosis after administration of fludarabine in a patient diagnosed as having refractory low-grade lymphoma, progressing fatally." | 1.30 | Fatal myelofibrosis following fludarabine administration in a patient with indolent lymphoma. ( Azaceta, G; Gutierrez, M; Palomera, L; Soria, J; Varo, MJ, 1998) |
| "By FIGO cervical cancer, staging system, there were 8/10 stage I b, 1/10 stage II b and 1/10 stage IV." | 1.30 | [Ten-case report on primary cervical lymphoma]. ( Cao, J; Sun, M; Zhang, G, 1997) |
| "Chylothorax is an accumulation of thoracic lymph or chyle in the pleural cavity." | 1.29 | Intrapleural bleomycin in the treatment of chylothorax. ( Aasebø, U; Norum, J, 1994) |
| "The occurrence of HIV associated non-Hodgkin's lymphoma (NHL) is a well recognized event." | 1.29 | Hodgkin's disease and non-Hodgkin's lymphoma in an HIV positive patient. ( Brody, J; Goh, JC; Kaplan, MH; Koduru, P; Lichtman, SM; Susin, M, 1993) |
| "In November 1991, recurrence was found in the peripheral lymph node and the colon." | 1.29 | [Successful oral administration of etoposide therapy for refractory malignant lymphoma treated with frequent combination chemotherapy]. ( Ashida, T; Ayabe, T; Maekawa, I; Namiki, M; Shibata, Y; Taruishi, M, 1993) |
| "There has been only one isolated CNS recurrence." | 1.29 | Combination chemotherapy for intermediate and high grade non-Hodgkin's lymphoma. ( Barnett, MJ; Dhaliwal, HS; Gallagher, CJ; Ganesan, TS; Gregory, W; Johnson, PW; Matthews, J; Richards, MA; Rohatiner, AZ; Whelan, JS, 1993) |
| "More than 50% of patients with non Hodgkin's lymphomas (NHL) are long-term survivors." | 1.29 | [Semen preservation and gonadal toxicity in the treatment of non Hodgkin lymphoma. Experience at the Gustave-Roussy Institute from 1980 to 1993]. ( Auger, J; Bendahmane, B; Decaudin, D; Koscielny, S; Munck, JN; Naccache, P, 1996) |
| "Epidural hematoma is a rare cause of spinal cord compression, which usually provokes severe neurological deficits." | 1.29 | Cervical spontaneous epidural hematoma as a complication of non-Hodgkin's lymphoma. ( Carletti, S; Frondizi, D; Maira, G; Mastronardi, L; Spera, C, 1996) |
| " Two patients developed exacerbation of hepatitis when the dosage of prednisolone was reduced after they had ten weeks of high dose prednisolone." | 1.29 | Exacerbation of hepatitis in hepatitis B carriers following chemotherapy for haematological malignancies. ( Chong, R; Goh, YT; Lee, LH; Ng, HS; Tan, P; Wong, GC, 1996) |
| "Information about elderly patients with acute lymphoblastic leukemia is scarce." | 1.28 | [Treatment of elderly patients with hematological malignancies]. ( Mizoguchi, H; Saito, H, 1992) |
| "5 micrograms/kg/day, sc), which significantly shortened the duration of neutropenia and decreased the number of days with episodes of fever when compared with those not given rhG-CSF, consequently facilitating the treatment without prolonging the dosing intervals." | 1.28 | [The COP-BLAM III therapy of non-Hodgkin's lymphoma]. ( Arai, N; Hara, A; Shirai, T; Umeda, M, 1991) |
| "In a random HIV-seropositive population, malignant lymphomas were diagnosed in 31 patients, of whom 24 (77%) had non-Hodgkin lymphoma (NHL) and 7 (23%) Hodgkin lymphoma (HL)." | 1.28 | Malignant lymphomas in HIV-seropositive patients. Frequency, features, and prognosis. Report on 31 cases. ( Cervos-Navarro, J; Dienemann, D; Jautzke, G; Langford, A; Pohle, HD; Ruf, B; Schürmann, D; Stein, H, 1991) |
| "Forty-seven cases of adult non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD) seen at the University of Benin Teaching Hospital between 1975 and 1987 have been analysed with respect to the presenting features, management and survival." | 1.28 | The malignant lymphomas in Benin City, Nigeria. ( Adedeji, MO, 1989) |
| "The effectiveness of treatment of lymphosarcoma of lymph nodes with cyclophosphamide, vincristin (oncovin) and prednisolone (scheme COP) was found to depend on the cytomorphological type of tumor, stage and previous therapy, with duration of remission being in direct correlationship with its degree." | 1.27 | [Results of combined chemotherapy of lymphosarcoma with cyclophosphamide, vincristine and prednisolone]. ( Abdyldaev, RA; Kruglova, GV, 1983) |
| "Seven patients with autoimmune hemolytic anemia (AIHA) associated with an underlying lymphoproliferative disorder were treated with intravenous immunoglobulin." | 1.27 | Rapid transient reversal of anemia and long-term effects of maintenance intravenous immunoglobulin for autoimmune hemolytic anemia in patients with lymphoproliferative disorders. ( Besa, EC, 1988) |
| "Seemingly, dogs with uncomplicated lymphosarcoma rarely have renal dysfunction or clinically important alterations in uric acid or phosphorus excretion secondary to rapid tumor lysis." | 1.27 | Uric acid and phosphorus excretion in dogs with lymphosarcoma. ( Leifer, CE; Matus, RE; Page, RL, 1986) |
| "Low median survival of patients with brain metastases (5." | 1.27 | [Clinical picture, diagnosis and treatment of the brain lesions in lymphosarcomas]. ( Kruglova, GV; Setdikov, RA, 1986) |
| "Twelve dogs with lymphosarcoma and hypercalcemia were treated over a period of 36 months." | 1.26 | Chemotherapeutic responses in dogs with lymphosarcoma and hypercalcemia. ( Madewell, BR; Theilen, GH; Weller, RE, 1982) |
| "Of the 13 patients without initial CNS disease, 4 have relapsed, 3 with primary CNS relapse and 1 with a recurrent abdominal mass." | 1.26 | Lymphoblastic lymphoma in adults: results of a pilot protocol. ( Burke, JS; Cohen, JR; Coleman, CN; Rosenberg, SA, 1981) |
| "In the group of high-grade malignant lymphomas there were 39% complete remission, 37% partial remission, and 24% without response." | 1.26 | [Results of chemotherapy with cyclophosphamide, vincristine, methotrexate and prednisone in recurring or disseminated non-Hodgkin lymphomas in the University of Kiel Radiology Clinic]. ( Liffers, R, 1981) |
| "15 patients with malignant lymphomas (stage III B or IV) who had become resistant to previous combination chemotherapy were treated with DTIC." | 1.26 | Imidazole carboxamide (DTIC) in the treatment of advanced lymphomas. Efficacy of DTIC in cases which fail to respond to conventional chemotherupetic combinations. ( Donner, L; Klener, P, 1977) |
| "Low-grade malignant lymphomas are treated best with conventional doses of an alkylating agent." | 1.26 | [Chemotherapy in non-Hodgkin's lymphomas (author's transl)]. ( Schmidt, CG, 1977) |
| "The response rates for lymphocytic and histiocytic lymphomas were 82 and 86%." | 1.26 | Combination of cyclophosphamide, vincristine, and prednisone, followed by maintenance chemotherapy, with and without radiotherapy, in the management of patients with non-Hodgkin's lymphomas. ( David, R; Duhamel, G; Gorin, NC; Najman, A; Stachowiak, J, 1977) |
| "Secondary glaucoma was found to be associated with intraocular reticulum cell sarcoma in approximately two-thirds of the reported cases, and neovascular glaucoma in about one-quarter of these cases." | 1.26 | Intraocular reticulum cell sarcoma: its dramatic response to systemic chemotherapy and its angiogenic potential. ( Dallow, RI; Sullivan, SF, 1977) |
| "Pooled allogeneic lymphosarcoma cells used in treatment together with other allogeneic lymphosarcoma cells and autochthonous tumour cells were employed as antigens." | 1.26 | Leukocyte migration inhibition responses in canine lymphosarcoma. ( Bostock, DE; Onions, DE; Owen, LN, 1978) |
| "The response rates for lymphocytic and histiocytic lymphomas were 80 and 86%." | 1.26 | [Cyclophosphamide-vincristine-prednisone combination in the treatment of lympho- and reticulosarcomas in adults (60 cases)]. ( David, R; Duhamel, G; Gorin, NC; Najman, A; Stachowiak, J, 1976) |
| "The survival was longer for nodular lymphosarcoma patients (25% are alive at 7 years for Stages III and IV) than for diffuse lymphosarcomata and reticulosarcomata (10%)." | 1.25 | Non-Hodgkin's malignant lymphomata in adults: chemo-radiotherapy in stages III and IV. ( Amiel, JL; Hayat, M; Mathé, G; Pouillart, P; Schwarzenberg, L; Tubiana, M, 1975) |
| "Patients with diffuse histiocytic lymphoma who achieved a histologically proven complete remission after 6 months of treatment without maintenance have remained disease-free whereas those with nodular poorly differentiated lymphocytic and diffuse well-differentiated lymphocytic lymphomas have demonstrated a pattern of continuous late recurrence." | 1.25 | Non-Hodgkin's lymphoma: patterns of relapse from complete remission after combination chemotherapy. ( Canellos, GP; Chabner, BA; DeVita, VT; Schein, PS; Young, RC, 1975) |
| "45%, respectively, in Hodgkin's disease, and 85% vs." | 1.25 | Combined cyclophosphamide vincristine, procarbazine, and prednisone (COPP) therapy of malignant lymphoma. Evaluation of 190 patients. ( Barros, CA; Morgenfeld, MC; Palau, M; Pavlovsky, A; Pavlovsky, S; Somoza, N; Suarez, A, 1975) |
| "Patients with diffuse histiocytic lymphoma who achieved a complete remission after 6 months of treatment without maintenance have remained disease-free, whereas those with nodular poorly differentiated lymphocytic and diffuse well differentiated lymphocytic lymphomata demonstrate a pattern of continuous late recurrence." | 1.25 | Results of combination chemotherapy of non-Hodgkin's lymphoma. ( Berard, C; Canellos, GP; Chabner, BA; DeVita, VT; Schein, PS; Young, RD, 1975) |
| "A patient had metastatic lymphosarcoma involving the right atrium and tricuspid valve in which functional tricuspid valve obstruction was relieved by chemotherapy." | 1.25 | Lymphosarcoma of the right atrium. Angiographic and hemodynamic documentation of response to chemotherapy. ( Garfein, OB, 1975) |
| "Necropsy revealed a reticulum cell sarcoma-microglioma of the brain." | 1.25 | Cerebral reticulum cell sarcoma after multiple renal transplants. ( Barnett, LB; Schwartz, E, 1974) |
| "Two patients developed reticulum cell sarcomata after they had been treated with azathioprine and prednisone in the course of cadaveric renal transplantation." | 1.25 | Reticulum cell sarcoma after renal homotransplantation and azathioprine and prednisone therapy. ( Doak, PB; Montgomerie, JZ; North, JD; Smith, F, 1968) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 353 (20.80) | 18.7374 |
| 1990's | 568 (33.47) | 18.2507 |
| 2000's | 484 (28.52) | 29.6817 |
| 2010's | 245 (14.44) | 24.3611 |
| 2020's | 47 (2.77) | 2.80 |
| Authors | Studies |
|---|---|
| Tekinalp, A | 1 |
| Kars, TU | 1 |
| Dikici, HZ | 1 |
| Yılmaz, PD | 1 |
| Demircioğlu, S | 1 |
| Çeneli, Ö | 1 |
| Leslie, LA | 1 |
| Reiss, SN | 1 |
| Yerram, P | 1 |
| Modelevsky, L | 1 |
| Grommes, C | 1 |
| Fleming, M | 1 |
| Huang, Y | 1 |
| Dotson, E | 1 |
| Bond, DA | 1 |
| Reneau, J | 1 |
| Epperla, N | 2 |
| Alinari, L | 4 |
| Brammer, J | 1 |
| Christian, BA | 2 |
| Baiocchi, RA | 2 |
| Maddocks, K | 1 |
| Sawalha, Y | 1 |
| Wang, Y | 1 |
| Xue, H | 1 |
| Song, W | 1 |
| Xiao, S | 1 |
| Jing, F | 1 |
| Dong, T | 1 |
| Wang, L | 3 |
| Pavlovsky, M | 1 |
| Cubero, D | 1 |
| Agreda-Vásquez, GP | 1 |
| Enrico, A | 1 |
| Mela-Osorio, MJ | 1 |
| San Sebastián, JA | 1 |
| Fogliatto, L | 1 |
| Ovilla, R | 1 |
| Avendano, O | 1 |
| Machnicki, G | 1 |
| Barreyro, P | 1 |
| Trufelli, D | 1 |
| Villanova, P | 1 |
| Baech, J | 1 |
| Severinsen, MT | 1 |
| Øvlisen, AK | 1 |
| Frederiksen, H | 1 |
| Vestergaard, P | 1 |
| Torp-Pedersen, C | 1 |
| Jørgensen, J | 1 |
| Clausen, MR | 1 |
| Poulsen, CB | 1 |
| Brown, P | 1 |
| Gang, AO | 1 |
| Pedersen, RS | 1 |
| Ekström Smedby, K | 1 |
| Eloranta, S | 1 |
| Jakobsen, LH | 1 |
| El-Galaly, TC | 1 |
| Nassereldine, H | 1 |
| Mohty, R | 1 |
| Awada, H | 1 |
| Abou Dalle, I | 1 |
| El-Cheikh, J | 1 |
| Bazarbachi, A | 1 |
| Edina, BC | 1 |
| Rinaldi, I | 1 |
| Zduniak, A | 1 |
| Lévêque, E | 1 |
| Perdrix, A | 1 |
| Etancelin, P | 1 |
| Ménard, AL | 1 |
| Lenain, P | 1 |
| Contentin, N | 1 |
| Pépin, LF | 1 |
| Leprêtre, S | 1 |
| Lemasle, E | 1 |
| Lanic, H | 1 |
| Stamatoullas-Bastard, A | 1 |
| Kammoun-Quique, L | 1 |
| Tilly, H | 13 |
| Bauer, F | 1 |
| Jardin, F | 3 |
| Camus, V | 1 |
| Seifert, R | 1 |
| Kersting, D | 1 |
| Rischpler, C | 1 |
| Sandach, P | 1 |
| Ferdinandus, J | 1 |
| Fendler, WP | 1 |
| Rahbar, K | 1 |
| Weckesser, M | 2 |
| Umutlu, L | 1 |
| Hanoun, C | 1 |
| Hüttmann, A | 3 |
| Reinhardt, HC | 1 |
| von Tresckow, B | 1 |
| Herrmann, K | 2 |
| Dührsen, U | 4 |
| Schäfers, M | 1 |
| Mihalcea, D | 2 |
| Memis, H | 1 |
| Balinisteanu, A | 1 |
| Vladareanu, AM | 2 |
| Mihaila, S | 1 |
| Vinereanu, D | 2 |
| Huang, YM | 1 |
| Hsieh, CH | 1 |
| Wang, SY | 1 |
| Tsao, CH | 1 |
| Lee, JC | 1 |
| Chen, YJ | 1 |
| Santiago-Sanabria, L | 1 |
| Garza-Arrieta, J | 1 |
| Porras-Ibarra, GD | 1 |
| Malfavón-Farias, M | 1 |
| Zimmerman, K | 1 |
| Walsh, KA | 1 |
| Ferrari, JT | 1 |
| Keuler, NS | 1 |
| Atherton, MJ | 1 |
| Lenz, JA | 1 |
| Burack, WR | 1 |
| Li, H | 1 |
| Adlowitz, D | 1 |
| Spence, JM | 1 |
| Rimsza, LM | 2 |
| Shadman, M | 1 |
| Spier, CM | 3 |
| Kaminski, MS | 3 |
| Leonard, JP | 2 |
| Leblanc, ML | 2 |
| Smith, SM | 1 |
| Friedberg, JW | 4 |
| Kumar, A | 2 |
| Abutalib, SA | 1 |
| Awan, FT | 1 |
| Chen, YB | 2 |
| Gopal, AK | 1 |
| Holter-Chakrabarty, J | 1 |
| Kekre, N | 1 |
| Lee, CJ | 1 |
| Lekakis, L | 1 |
| Lin, Y | 2 |
| Mei, M | 1 |
| Nathan, S | 1 |
| Nastoupil, L | 1 |
| Oluwole, O | 1 |
| Phillips, AA | 1 |
| Reid, E | 1 |
| Rezvani, AR | 1 |
| Trotman, J | 2 |
| Zurko, J | 1 |
| Kharfan-Dabaja, MA | 1 |
| Sauter, CS | 1 |
| Perales, MA | 1 |
| Locke, FL | 1 |
| Carpenter, PA | 1 |
| Hamadani, M | 1 |
| Kiamos, A | 1 |
| Boldig, K | 1 |
| Gagadam, V | 1 |
| Gujarathi, R | 1 |
| Suleman, A | 1 |
| Aktar, SJ | 1 |
| Ante, Z | 1 |
| Liu, N | 1 |
| Chan, KKW | 1 |
| Cheung, MC | 2 |
| Prica, A | 1 |
| Turdo, A | 1 |
| Gaggianesi, M | 1 |
| D'Accardo, C | 1 |
| Porcelli, G | 1 |
| Bella, SD | 1 |
| Cricchio, D | 1 |
| Pillitteri, I | 1 |
| Porcasi, R | 1 |
| Lo Iacono, M | 1 |
| Verona, F | 1 |
| Modica, C | 1 |
| Roozafzay, N | 1 |
| Florena, AM | 1 |
| Stassi, G | 1 |
| Mancuso, S | 1 |
| Todaro, M | 1 |
| Li, J | 3 |
| Yao, C | 1 |
| Xu, Y | 3 |
| Ping, P | 1 |
| Yin, H | 1 |
| Sun, Y | 2 |
| Zuze, T | 1 |
| Ellis, GK | 1 |
| Kasonkanji, E | 2 |
| Kaimila, B | 2 |
| Nyasosela, R | 2 |
| Nyirenda, R | 1 |
| Tomoka, T | 2 |
| Mulenga, M | 1 |
| Chikasema, M | 2 |
| Tewete, B | 1 |
| Mtangwanika, A | 1 |
| Chiyoyola, S | 1 |
| Chimzimu, F | 2 |
| Kampani, C | 2 |
| Mhango, W | 1 |
| Nicholas, S | 1 |
| Randall, C | 1 |
| Montgomery, ND | 2 |
| Fedoriw, G | 1 |
| Westmoreland, KD | 1 |
| Painschab, MS | 1 |
| Gopal, S | 2 |
| Parissenti, AM | 1 |
| Pritzker, LB | 1 |
| Guo, B | 1 |
| Narendrula, R | 1 |
| Wang, SX | 1 |
| Lin, LL | 1 |
| Pei, J | 1 |
| Skowronski, K | 1 |
| Bienzle, D | 1 |
| Woods, JP | 1 |
| Pritzker, KPH | 1 |
| Coomber, BL | 1 |
| Chen, G | 1 |
| Wu, D | 1 |
| Li, MX | 1 |
| Sparano, JA | 6 |
| Lee, JY | 6 |
| Kaplan, LD | 6 |
| Ramos, JC | 2 |
| Ambinder, RF | 5 |
| Wachsman, W | 1 |
| Aboulafia, D | 2 |
| Noy, A | 5 |
| Henry, DH | 1 |
| Ratner, L | 4 |
| Cesarman, E | 3 |
| Chadburn, A | 4 |
| Mitsuyasu, R | 3 |
| Jurczak, W | 3 |
| Długosz-Danecka, M | 3 |
| Szmit, S | 3 |
| Linschoten, M | 2 |
| Kamphuis, JAM | 1 |
| van Rhenen, A | 1 |
| Bosman, LP | 1 |
| Cramer, MJ | 1 |
| Doevendans, PA | 1 |
| Teske, AJ | 1 |
| Asselbergs, FW | 2 |
| Bartlett, NL | 2 |
| Suzuki, T | 4 |
| Tetsuka, S | 1 |
| Ogawa, T | 2 |
| Hashimoto, R | 1 |
| Okada, S | 2 |
| Kato, H | 2 |
| Reid, EG | 1 |
| Siegel, ER | 1 |
| Moore, PC | 1 |
| Rubinstein, PG | 1 |
| Durand, CM | 1 |
| Baiocchi, R | 1 |
| Kaplan, L | 2 |
| Capoferri, AA | 1 |
| Ikeda, T | 3 |
| Fujiwara, SI | 1 |
| Nakajima, H | 2 |
| Kawaguchi, SI | 1 |
| Toda, Y | 1 |
| Ito, S | 4 |
| Ochi, S | 1 |
| Nagayama, T | 1 |
| Mashima, K | 1 |
| Umino, K | 1 |
| Minakata, D | 1 |
| Nakano, H | 2 |
| Morita, K | 2 |
| Yamasaki, R | 2 |
| Kawasaki, Y | 1 |
| Ashizawa, M | 2 |
| Yamamoto, C | 1 |
| Hatano, K | 1 |
| Sato, K | 2 |
| Oh, I | 1 |
| Ohmine, K | 2 |
| Muroi, K | 5 |
| Kanda, Y | 2 |
| Vujosevic, S | 1 |
| Toma, C | 1 |
| Muraca, A | 1 |
| Alkabes, M | 1 |
| Villani, E | 1 |
| Nucci, P | 1 |
| De Cilla, S | 1 |
| Tedjaseputra, A | 1 |
| Gilbertson, M | 1 |
| Low, M | 1 |
| Fedele, PL | 1 |
| Kumar, B | 1 |
| Simpson, I | 1 |
| Grigoriadis, G | 1 |
| Shortt, J | 1 |
| Opat, S | 1 |
| Gregory, GP | 1 |
| Kumar, R | 2 |
| Hujairi, N | 1 |
| Mohammed, K | 1 |
| Attygalle, A | 1 |
| Alexander, E | 1 |
| Chau, I | 1 |
| Cunningham, D | 5 |
| Iyengar, S | 1 |
| El-Sharkawi, D | 1 |
| Sharma, B | 1 |
| Jayaraj, R | 1 |
| Kumarasamy, C | 1 |
| Raymond, G | 1 |
| Shaw, P | 1 |
| Kamphuis, JA | 1 |
| Ma, C | 1 |
| Yu, B | 1 |
| Zhang, H | 2 |
| Yang, B | 1 |
| Li, D | 1 |
| Li, R | 1 |
| Lu, X | 1 |
| Florescu, M | 1 |
| Bruja, R | 1 |
| Patrascu, N | 1 |
| Roder, L | 1 |
| Konrardy, K | 1 |
| Grauer, D | 1 |
| Hoffmann, M | 1 |
| Huang, LW | 1 |
| Sun, D | 1 |
| Link, TM | 1 |
| Lang, T | 1 |
| Ai, W | 1 |
| Steinman, MA | 1 |
| Andreadis, C | 1 |
| Seymour, EK | 1 |
| Khan, HY | 1 |
| Li, Y | 2 |
| Chaker, M | 1 |
| Muqbil, I | 2 |
| Aboukameel, A | 2 |
| Ramchandren, R | 1 |
| Houde, C | 1 |
| Sterbis, G | 1 |
| Yang, J | 2 |
| Bhutani, D | 2 |
| Pregja, S | 1 |
| Reichel, K | 1 |
| Huddlestun, A | 1 |
| Neveux, C | 1 |
| Corona, K | 1 |
| Landesman, Y | 1 |
| Shah, J | 1 |
| Kauffman, M | 2 |
| Shacham, S | 2 |
| Mohammad, RM | 2 |
| Azmi, AS | 2 |
| Zonder, JA | 1 |
| Harada, T | 2 |
| Iwasaki, H | 2 |
| Muta, T | 1 |
| Urata, S | 1 |
| Sakamoto, A | 1 |
| Kohno, K | 1 |
| Takase, K | 1 |
| Miyamura, T | 1 |
| Sawabe, T | 1 |
| Asaoku, H | 3 |
| Oryoji, K | 1 |
| Fujisaki, T | 1 |
| Mori, Y | 2 |
| Yoshimoto, G | 1 |
| Ayano, M | 1 |
| Mitoma, H | 1 |
| Miyamoto, T | 2 |
| Niiro, H | 1 |
| Yamamoto, H | 1 |
| Oshiro, Y | 1 |
| Miyoshi, H | 1 |
| Ohshima, K | 1 |
| Takeshita, M | 1 |
| Akashi, K | 2 |
| Kato, K | 3 |
| Yokoyama, M | 3 |
| Kusano, Y | 2 |
| Inoue, N | 2 |
| Nishimura, N | 2 |
| Mishima, Y | 3 |
| Nukada, T | 2 |
| Hatake, K | 6 |
| Terui, Y | 4 |
| Cao, YJ | 1 |
| Duan, J | 1 |
| Liu, LF | 1 |
| Wei, X | 1 |
| Ren, L | 1 |
| Zhang, LN | 1 |
| Zhang, W | 2 |
| Yasuda, H | 1 |
| Yasuda, M | 1 |
| Komatsu, N | 3 |
| McBride, A | 1 |
| MacDonald, K | 1 |
| Abraham, I | 1 |
| Maruyama, D | 2 |
| Ohmachi, K | 2 |
| Kim, YR | 1 |
| Kim, SJ | 3 |
| Park, Y | 1 |
| Oh, SY | 2 |
| Yun, HJ | 1 |
| Mun, YC | 1 |
| Kim, JS | 2 |
| Minotti, G | 1 |
| Menna, P | 1 |
| Salvatorelli, E | 1 |
| Ram, N | 1 |
| Rashid, O | 1 |
| Farooq, S | 1 |
| Ulhaq, I | 1 |
| Islam, N | 1 |
| Wilson-Robles, H | 1 |
| Budke, CM | 1 |
| Miller, T | 2 |
| Dervisis, N | 1 |
| Novosad, A | 1 |
| Wright, Z | 1 |
| Thamm, DH | 4 |
| Vickery, K | 1 |
| Burgess, K | 1 |
| Childress, M | 1 |
| Lori, J | 1 |
| Saba, C | 1 |
| Rau, S | 1 |
| Silver, M | 1 |
| Post, G | 1 |
| Reeds, K | 1 |
| Gillings, S | 1 |
| Schleis, S | 1 |
| Stein, T | 1 |
| Brugmann, B | 1 |
| DeRegis, C | 1 |
| Smrkovski, O | 1 |
| Lawrence, J | 1 |
| Laver, T | 1 |
| Hayashi, H | 1 |
| Suzuki, A | 1 |
| Ohata, K | 1 |
| Ishihara, M | 1 |
| Kubota, Y | 1 |
| Kobayashi, R | 1 |
| Shibata, Y | 2 |
| Nakamura, H | 2 |
| Nakamura, N | 3 |
| Kitagawa, J | 1 |
| Tsurumi, H | 4 |
| Shimizu, M | 2 |
| Itoh, Y | 2 |
| Takahashi, A | 1 |
| Ueda, K | 1 |
| Nomura, T | 2 |
| Cohen, YC | 1 |
| Berger, T | 1 |
| Eshel, L | 1 |
| Stern, D | 1 |
| Bairey, O | 3 |
| Raanani, P | 4 |
| Shpilberg, O | 6 |
| Malecek, MK | 1 |
| Petrich, AM | 3 |
| Rozell, S | 1 |
| Chu, B | 1 |
| Trifilio, S | 1 |
| Galanina, N | 1 |
| Maurer, M | 1 |
| Farooq, U | 1 |
| Link, BK | 4 |
| Nowakowski, GS | 2 |
| Nabhan, C | 2 |
| Ayed, AO | 1 |
| Saito, B | 1 |
| Nakashima, H | 1 |
| Abe, M | 1 |
| Murai, S | 1 |
| Baba, Y | 1 |
| Arai, N | 6 |
| Kawaguchi, Y | 1 |
| Fujiwara, S | 1 |
| Kabasawa, N | 1 |
| Tsukamoto, H | 1 |
| Uto, Y | 1 |
| Ariizumi, H | 1 |
| Yanagisawa, K | 1 |
| Hattori, N | 1 |
| Harada, H | 1 |
| Nakamaki, T | 1 |
| Uchida, M | 1 |
| Nakamura, T | 1 |
| Kamezaki, K | 1 |
| Takenaka, K | 2 |
| Shiratsuchi, M | 1 |
| Kadoyama, K | 1 |
| Khelfa, Y | 1 |
| Lebowicz, Y | 1 |
| Jamil, MO | 1 |
| Wang, H | 3 |
| Wang, M | 1 |
| Wei, J | 1 |
| Mao, L | 1 |
| Jin, J | 3 |
| Zhou, T | 1 |
| Shen, Q | 1 |
| Peng, H | 1 |
| Chao, T | 1 |
| Zhang, L | 4 |
| Huang, L | 1 |
| Yang, K | 1 |
| Thapa, S | 1 |
| Yu, S | 1 |
| Jiang, Y | 1 |
| de Souza, KJ | 1 |
| Ferro, RS | 1 |
| Prestes-Carneiro, LE | 1 |
| Carrilho, PAM | 1 |
| Vasconcelos, DM | 1 |
| Adams, HJA | 1 |
| Kwee, TC | 1 |
| Lamar, ZS | 2 |
| Dothard, A | 1 |
| Kennedy, L | 2 |
| Isom, S | 1 |
| Robinson, M | 1 |
| Vaidya, R | 2 |
| Hurd, D | 2 |
| McClain, D | 1 |
| Lesser, G | 1 |
| Jeon, SY | 1 |
| Yhim, HY | 2 |
| Kim, HS | 1 |
| Kim, JA | 2 |
| Yang, DH | 2 |
| Kwak, JY | 1 |
| Bhatia, S | 1 |
| Anavekar, NS | 1 |
| Bascuas, T | 1 |
| Moreno, M | 2 |
| Grille, S | 1 |
| Chabalgoity, JA | 1 |
| Popivanov, GI | 1 |
| Bochev, P | 1 |
| Hristoskova, R | 1 |
| Mutafchiyski, VM | 1 |
| Tabakov, M | 1 |
| Philipov, A | 1 |
| Cirocchi, R | 1 |
| Mărginean, CO | 1 |
| Meliţ, LE | 1 |
| Horvath, E | 1 |
| Gozar, H | 1 |
| Chinceşan, MI | 1 |
| Nasa, M | 1 |
| Bhansali, S | 1 |
| Choudhary, NS | 1 |
| Sud, R | 1 |
| Kriegsmann, K | 1 |
| Rieger, M | 1 |
| Schwarzbich, MA | 1 |
| Sitter, S | 1 |
| Kriegsmann, M | 1 |
| Bruckner, T | 1 |
| Hensel, M | 2 |
| Ho, AD | 6 |
| Witzens-Harig, M | 2 |
| Wuchter, P | 1 |
| Müller, S | 2 |
| Hertenstein, B | 1 |
| Thomssen, H | 1 |
| Kotzerke, J | 1 |
| Mesters, R | 1 |
| Berdel, WE | 1 |
| Franzius, C | 1 |
| Kroschinsky, F | 1 |
| Kofahl-Krause, D | 1 |
| Bengel, FM | 1 |
| Dürig, J | 1 |
| Matschke, J | 1 |
| Schmitz, C | 1 |
| Pöppel, T | 1 |
| Ose, C | 1 |
| Brinkmann, M | 1 |
| La Rosée, P | 1 |
| Freesmeyer, M | 1 |
| Hertel, A | 1 |
| Höffkes, HG | 1 |
| Behringer, D | 1 |
| Prange-Krex, G | 1 |
| Wilop, S | 1 |
| Krohn, T | 1 |
| Holzinger, J | 1 |
| Griesshammer, M | 1 |
| Giagounidis, A | 1 |
| Raghavachar, A | 1 |
| Maschmeyer, G | 1 |
| Brink, I | 1 |
| Bernhard, H | 1 |
| Haberkorn, U | 1 |
| Gaska, T | 1 |
| Kurch, L | 1 |
| van Assema, DME | 1 |
| Klapper, W | 1 |
| Hoelzer, D | 4 |
| Geworski, L | 1 |
| Jöckel, KH | 2 |
| Scherag, A | 1 |
| Bockisch, A | 1 |
| Rekowski, J | 1 |
| Lu, L | 1 |
| Shi, HZ | 1 |
| Xiao, ZJ | 1 |
| Wang, D | 2 |
| Li, CL | 1 |
| Hakkou, F | 1 |
| Chbicheb, S | 1 |
| El Wady, W | 1 |
| Milligan, MG | 1 |
| Bigger, E | 1 |
| Abramson, JS | 2 |
| Sohani, AR | 2 |
| Zola, M | 1 |
| Kayembe, MKA | 1 |
| Medhin, H | 1 |
| Suneja, G | 1 |
| Lockman, S | 1 |
| Chabner, BA | 10 |
| Dryden-Peterson, SL | 1 |
| David, RJ | 1 |
| Baran, A | 1 |
| Loh, KP | 1 |
| Casulo, C | 2 |
| Barr, PM | 1 |
| Reagan, PM | 1 |
| Lekovic, GP | 1 |
| Batra, A | 1 |
| Barnard, ZR | 1 |
| Wilkinson, EP | 1 |
| Balena, R | 1 |
| Palejwala, S | 1 |
| Barkhoudarian, G | 1 |
| Avilés, A | 11 |
| Nambo, MJ | 5 |
| Neri, N | 4 |
| Gruszka, AM | 1 |
| Olszanecka, A | 1 |
| Ogórka, T | 1 |
| Sobociński, M | 1 |
| Jaroszyński, A | 1 |
| Krawczyk, K | 1 |
| Skotnicki, AB | 1 |
| DeWeerdt, S | 1 |
| Marquardt, TM | 1 |
| Lindley, SES | 1 |
| Smith, AN | 2 |
| Cannon, CM | 1 |
| Rodriguez, CO | 2 |
| Childress, MO | 1 |
| Northrup, NC | 1 |
| Flinn, IW | 4 |
| van der Jagt, R | 2 |
| Kahl, B | 1 |
| Wood, P | 3 |
| Hawkins, T | 1 |
| MacDonald, D | 3 |
| Simpson, D | 3 |
| Kolibaba, K | 3 |
| Issa, S | 5 |
| Chang, J | 1 |
| Hallman, D | 1 |
| Chen, L | 2 |
| Burke, JM | 3 |
| Zelenetz, AD | 3 |
| Salles, G | 5 |
| Mason, KD | 1 |
| Le Gouill, S | 1 |
| Sehn, LH | 2 |
| Cartron, G | 4 |
| Chamuleau, MED | 1 |
| Goy, A | 2 |
| Tam, CS | 1 |
| Lugtenburg, PJ | 1 |
| Sinha, A | 1 |
| Samineni, D | 1 |
| Herter, S | 1 |
| Ingalla, E | 1 |
| Szafer-Glusman, E | 1 |
| Klein, C | 1 |
| Sampath, D | 1 |
| Kornacker, M | 1 |
| Mobasher, M | 1 |
| Morschhauser, F | 5 |
| Pirozzi, A | 1 |
| Cartenì, G | 1 |
| Scagliarini, S | 1 |
| Fusco, M | 1 |
| Riccardi, F | 1 |
| Mounier, N | 7 |
| Anthony, S | 1 |
| Busson, R | 1 |
| Thieblemont, C | 3 |
| Ribrag, V | 5 |
| Haioun, C | 6 |
| Casasnovas, RO | 1 |
| Feugier, P | 1 |
| Delarue, R | 2 |
| Ysebaert, L | 1 |
| Sebban, C | 4 |
| Broussais-Guillaumot, F | 1 |
| Damaj, G | 1 |
| Nerich, V | 2 |
| Jais, JP | 1 |
| Laborde, L | 1 |
| Henry-Amar, M | 3 |
| Kataoka, T | 1 |
| Sakurashita, H | 1 |
| Taogoshi, T | 1 |
| Nishigakiuchi, R | 1 |
| Murase, T | 1 |
| Izumitani, S | 1 |
| Saeki, Y | 1 |
| Matsuo, H | 1 |
| Moleti, ML | 1 |
| Al-Jadiry, MF | 1 |
| Shateh, WA | 1 |
| Al-Darraji, AF | 1 |
| Mohamed, S | 1 |
| Uccini, S | 1 |
| Piciocchi, A | 1 |
| Foà, R | 2 |
| Testi, AM | 1 |
| Al-Hadad, S | 1 |
| Bhagat, N | 1 |
| Kalkur, P | 1 |
| Kalkur, S | 1 |
| Liang, JH | 1 |
| Zhu, HY | 1 |
| Qian, J | 1 |
| Liao, H | 1 |
| Wu, JZ | 1 |
| Xia, Y | 3 |
| Wu, W | 1 |
| Cao, L | 1 |
| Fan, L | 1 |
| Li, JY | 1 |
| Xu, W | 1 |
| Aránguiz, N | 1 |
| Vega, J | 1 |
| Gurdogan, M | 1 |
| Ozkan, U | 1 |
| Stardelova, KG | 1 |
| Stojanovik, A | 1 |
| Jovanovska, RP | 1 |
| Stavrik, S | 1 |
| Dimitrova, M | 1 |
| Kostova, NM | 1 |
| Serafimoski, V | 1 |
| Kesavan, M | 1 |
| Eyre, TA | 1 |
| Collins, GP | 1 |
| Messori, A | 2 |
| Fadda, V | 1 |
| Maratea, D | 1 |
| Trippoli, S | 2 |
| Menshadi, N | 1 |
| Bar-Tal, Y | 1 |
| Barnoy, S | 1 |
| Czuczman, MS | 5 |
| Junpaparp, P | 1 |
| Buppajarntham, S | 1 |
| Madueno, FV | 1 |
| Varadi, G | 1 |
| Emir, S | 1 |
| Vezir, E | 1 |
| Azkur, D | 1 |
| Demir, HA | 1 |
| Metin, A | 1 |
| Chaabouni, S | 1 |
| Ben Salah Lahiani, H | 1 |
| Ghorbel, L | 1 |
| Abdelmoula, M | 1 |
| Elloumi, M | 3 |
| Daoud, J | 4 |
| Mohamed, M | 1 |
| Brain, T | 1 |
| Sharma, S | 1 |
| Seccia, V | 1 |
| Pietrini, M | 1 |
| Briganti, T | 1 |
| Buda, G | 1 |
| Mironova, NL | 1 |
| Petrushanko, IY | 1 |
| Patutina, OA | 1 |
| Sen'kova, AV | 1 |
| Simonenko, OV | 1 |
| Mitkevich, VA | 1 |
| Markov, OV | 1 |
| Zenkova, MA | 1 |
| Makarov, AA | 1 |
| Zhang, Y | 2 |
| Chen, MB | 1 |
| Zhou, XY | 1 |
| Hong, XN | 4 |
| Xu, HN | 1 |
| Mir, TA | 1 |
| Lee, SC | 1 |
| Feng, M | 1 |
| Farhad, N | 1 |
| Choe, R | 1 |
| Glickson, JD | 1 |
| Li, LZ | 1 |
| Rancea, M | 2 |
| Will, A | 2 |
| Borchmann, P | 3 |
| Monsef, I | 3 |
| Engert, A | 7 |
| Skoetz, N | 2 |
| Wan, N | 1 |
| Jiao, Y | 1 |
| Huang, S | 1 |
| Zheng, ZX | 1 |
| Xu, Q | 1 |
| Yuan, XH | 1 |
| Hong, J | 2 |
| Yoon, HH | 1 |
| Ahn, HK | 1 |
| Sym, SJ | 1 |
| Park, J | 2 |
| Park, PW | 1 |
| Ahn, JY | 2 |
| Park, S | 2 |
| Cho, EK | 2 |
| Shin, DB | 2 |
| Lee, JH | 4 |
| Barta, SK | 2 |
| Xue, X | 1 |
| Tamari, R | 1 |
| Ribera, JM | 5 |
| Spina, M | 6 |
| Tirelli, U | 17 |
| Weiss, R | 3 |
| Galicier, L | 1 |
| Boue, F | 1 |
| Wilson, WH | 6 |
| Wyen, C | 1 |
| Oriol, A | 2 |
| Navarro, JT | 3 |
| Dunleavy, K | 2 |
| Little, RF | 2 |
| Garcia, O | 2 |
| Morgades, M | 1 |
| Remick, SC | 1 |
| Vinogradova, IuN | 2 |
| Galardy, PJ | 1 |
| Hochberg, J | 1 |
| Perkins, SL | 1 |
| Harrison, L | 1 |
| Goldman, S | 1 |
| Cairo, MS | 2 |
| Iványi, JL | 2 |
| Marton, E | 2 |
| Plander, M | 2 |
| Engert, ZV | 1 |
| Tóth, C | 2 |
| Hyun, SY | 1 |
| Cheong, JW | 1 |
| Min, YH | 1 |
| Ahn, JS | 1 |
| Lee, WS | 1 |
| Ryoo, HM | 1 |
| Do, YR | 1 |
| Lee, HS | 1 |
| Suh, C | 3 |
| Stiff, PJ | 1 |
| Unger, JM | 4 |
| Cook, JR | 1 |
| Constine, LS | 1 |
| Couban, S | 1 |
| Stewart, DA | 2 |
| Shea, TC | 2 |
| Porcu, P | 2 |
| Winter, JN | 4 |
| Kahl, BS | 3 |
| Miller, TP | 18 |
| Tubbs, RR | 1 |
| Marcellus, D | 1 |
| Barton, KP | 1 |
| Mills, GM | 2 |
| LeBlanc, M | 5 |
| Forman, SJ | 1 |
| Fisher, RI | 29 |
| Milpied, N | 8 |
| Levine, AM | 4 |
| Dewilde, S | 1 |
| Woods, B | 1 |
| Castaigne, JG | 1 |
| Parker, C | 1 |
| Dunlop, W | 1 |
| Ben Salah, H | 1 |
| Fourati, N | 1 |
| Boudawara, T | 1 |
| Frikha, M | 1 |
| Mahfoud, T | 1 |
| Tanz, R | 1 |
| Mesmoudi, M | 1 |
| Khmamouche, MR | 1 |
| El Khannoussi, B | 1 |
| Ichou, M | 1 |
| Errihani, H | 3 |
| Limat, S | 3 |
| Daguindau, E | 1 |
| Cahn, JY | 3 |
| Brion, A | 2 |
| Perrin, S | 1 |
| Woronoff-Lemsi, MC | 3 |
| Deconinck, E | 7 |
| Romics, M | 1 |
| Demeter, J | 1 |
| Romics, I | 1 |
| Nyirády, P | 1 |
| Guirguis, HR | 1 |
| Piliotis, E | 1 |
| Spaner, D | 1 |
| Berinstein, NL | 2 |
| Imrie, K | 2 |
| Buckstein, R | 1 |
| Elgendy, IY | 1 |
| Lo, MC | 1 |
| Kang, Y | 1 |
| Xu, X | 1 |
| Cheng, L | 1 |
| Li, L | 2 |
| Sun, M | 2 |
| Chen, H | 1 |
| Pan, C | 1 |
| Shu, X | 1 |
| Hertzberg, M | 3 |
| Matthews, JP | 2 |
| Stone, JM | 2 |
| Dubosq, MC | 1 |
| Grigg, A | 3 |
| Ellis, D | 1 |
| Benson, W | 1 |
| Browett, P | 1 |
| Horvath, N | 2 |
| Januszewicz, H | 1 |
| Abdi, E | 1 |
| Green, M | 1 |
| Bonaventura, A | 1 |
| Marlton, P | 2 |
| Cannell, P | 1 |
| Wolf, M | 4 |
| Said, R | 1 |
| Tsimberidou, AM | 2 |
| Masarone, M | 1 |
| De Renzo, A | 5 |
| La Mura, V | 1 |
| Sasso, FC | 1 |
| Romano, M | 1 |
| Signoriello, G | 1 |
| Rosato, V | 1 |
| Perna, F | 1 |
| Pane, F | 1 |
| Persico, M | 1 |
| Schwartzberg, LS | 1 |
| Saleh, M | 2 |
| Whittaker, S | 1 |
| Abella, E | 3 |
| Cohen, JB | 2 |
| Geyer, SM | 1 |
| Lozanski, G | 1 |
| Zhao, W | 1 |
| Heerema, NA | 1 |
| Hall, NC | 1 |
| Nagar, VA | 1 |
| Hemminger, JA | 1 |
| Jones, JA | 2 |
| Maddocks, KJ | 1 |
| Flynn, JM | 1 |
| Devine, SM | 1 |
| Blum, KA | 1 |
| Hawkins, TE | 2 |
| Kwan, YL | 2 |
| Craig, M | 2 |
| Clementi, R | 1 |
| Hallman, DM | 1 |
| Munteanu, M | 2 |
| Langeberg, WJ | 1 |
| Siozon, CC | 1 |
| Page, JH | 1 |
| Morrow, PK | 1 |
| Chia, VM | 1 |
| Baldini, S | 1 |
| Carrai, V | 1 |
| Puccini, B | 2 |
| Rigacci, L | 4 |
| Alterini, R | 2 |
| Bosi, A | 2 |
| Corradini, P | 1 |
| Marchetti, M | 1 |
| Barosi, G | 1 |
| Billio, A | 1 |
| Gallamini, A | 2 |
| Pileri, S | 5 |
| Pimpinelli, N | 1 |
| Rossi, G | 6 |
| Zinzani, PL | 23 |
| Tura, S | 16 |
| Zimmer, P | 1 |
| Mierau, A | 1 |
| Bloch, W | 1 |
| Strüder, HK | 1 |
| Hülsdünker, T | 1 |
| Schenk, A | 1 |
| Fiebig, L | 1 |
| Baumann, FT | 1 |
| Hahn, M | 1 |
| Reinart, N | 1 |
| Hallek, M | 3 |
| Elter, T | 2 |
| Kovalchuk, S | 1 |
| Fabbri, E | 1 |
| Bonizzoni, E | 1 |
| Perrone, T | 1 |
| Guerrero, MD | 1 |
| Swenson, KK | 1 |
| Koga, Y | 1 |
| Takada, H | 1 |
| Suminoe, A | 1 |
| Ohga, S | 2 |
| Hara, T | 4 |
| Aaldriks, AA | 1 |
| Giltay, EJ | 1 |
| Nortier, JW | 1 |
| van der Geest, LG | 1 |
| Tanis, BC | 1 |
| Ypma, P | 1 |
| le Cessie, S | 1 |
| Maartense, E | 1 |
| Hohloch, K | 1 |
| Zeynalova, S | 5 |
| Held, G | 1 |
| Ziepert, M | 4 |
| Loeffler, M | 12 |
| Wulf, G | 1 |
| Schmitz, N | 6 |
| Pfreundschuh, M | 14 |
| Trümper, L | 10 |
| Ahmad, AK | 1 |
| Hui, P | 1 |
| Litkouhi, B | 1 |
| Azodi, M | 1 |
| Rutherford, T | 1 |
| McCarthy, S | 1 |
| Xu, ML | 1 |
| Schwartz, PE | 1 |
| Ratner, E | 1 |
| Younes, A | 5 |
| Flinn, I | 1 |
| Amorim, S | 2 |
| Hivert, B | 1 |
| Westin, J | 1 |
| Vermeulen, J | 1 |
| Bandyopadhyay, N | 1 |
| de Vries, R | 1 |
| Balasubramanian, S | 1 |
| Hellemans, P | 1 |
| Smit, JW | 1 |
| Fourneau, N | 1 |
| Oki, Y | 1 |
| Bujan, L | 1 |
| Walschaerts, M | 1 |
| Brugnon, F | 1 |
| Daudin, M | 1 |
| Berthaut, I | 1 |
| Auger, J | 2 |
| Saias, J | 1 |
| Szerman, E | 1 |
| Moinard, N | 1 |
| Rives, N | 1 |
| Hennebicq, S | 1 |
| Ancochea, Á | 1 |
| Salar, A | 2 |
| García-Pallarols, F | 2 |
| Gimeno, E | 2 |
| Fernández-Rodriguez, C | 1 |
| Sánchez-González, B | 2 |
| Sun, Z | 1 |
| Li, X | 1 |
| Wu, X | 2 |
| Fu, X | 2 |
| Chang, Y | 1 |
| Zhang, M | 3 |
| Mertsoylu, H | 1 |
| Muallaoglu, S | 1 |
| Besen, AA | 1 |
| Erdogdu, S | 1 |
| Sezer, A | 1 |
| Sedef, AM | 1 |
| Kose, F | 1 |
| Arican, A | 2 |
| Ozyilkan, O | 1 |
| Kikuchi, M | 4 |
| Nakasone, H | 1 |
| Akahoshi, Y | 1 |
| Ugai, T | 1 |
| Wada, H | 1 |
| Sakamoto, K | 1 |
| Kawamura, K | 1 |
| Ishihara, Y | 1 |
| Sato, M | 1 |
| Terasako-Saito, K | 1 |
| Kimura, S | 1 |
| Yamazaki, R | 1 |
| Kako, S | 1 |
| Kanda, J | 1 |
| Nishida, J | 1 |
| Sekiguchi, N | 1 |
| Noto, S | 1 |
| Kida, M | 1 |
| Hangaishi, A | 1 |
| Usuki, K | 1 |
| Fleury, I | 1 |
| Coiffier, B | 19 |
| Dupuis, J | 1 |
| Mazari, MA | 1 |
| Filliatre, L | 1 |
| Brière, J | 4 |
| Brice, P | 7 |
| de Kerviler, E | 1 |
| Balducci, L | 1 |
| Mo, M | 1 |
| Saven, A | 2 |
| Salmasi, G | 1 |
| Li, M | 1 |
| Sivabalasundaram, V | 1 |
| Panzarella, T | 1 |
| Tsang, R | 1 |
| Kukreti, V | 1 |
| Crump, M | 4 |
| Kuruvilla, J | 1 |
| Zaucha, JM | 1 |
| Drozd-Sokołowska, J | 1 |
| Spychałowicz, W | 1 |
| Joks, M | 1 |
| Torbicki, A | 1 |
| Felli, V | 1 |
| Di Sibio, A | 1 |
| Anselmi, M | 1 |
| Gennarelli, A | 1 |
| Sucapane, P | 1 |
| Splendiani, A | 1 |
| Catalucci, A | 1 |
| Marini, C | 1 |
| Gallucci, M | 1 |
| Knutson, SK | 1 |
| Warholic, NM | 1 |
| Johnston, LD | 1 |
| Klaus, CR | 1 |
| Wigle, TJ | 1 |
| Iwanowicz, D | 1 |
| Littlefield, BA | 1 |
| Porter-Scott, M | 1 |
| Smith, JJ | 1 |
| Moyer, MP | 1 |
| Copeland, RA | 1 |
| Pollock, RM | 1 |
| Kuntz, KW | 1 |
| Raimondi, A | 1 |
| Keilhack, H | 1 |
| Ji, D | 1 |
| Hong, X | 1 |
| Guo, Y | 2 |
| Xue, K | 1 |
| Zhang, Q | 1 |
| Shen, W | 1 |
| Cao, J | 2 |
| Jordheim, LP | 1 |
| Ghesquieres, H | 1 |
| Pallardy, S | 1 |
| Demangel, D | 1 |
| Salles, GA | 1 |
| Dumontet, C | 2 |
| Witzig, TE | 2 |
| Habermann, TM | 5 |
| Hernandez-Ilizaliturri, FJ | 1 |
| Chiappella, A | 1 |
| Vitolo, U | 6 |
| Fowler, N | 1 |
| Shin, SY | 1 |
| Lee, ST | 1 |
| Kim, HJ | 1 |
| Ki, CS | 1 |
| Jung, CW | 1 |
| Kim, JW | 1 |
| Kim, SH | 2 |
| Anyfanti, P | 1 |
| Gouridou, E | 1 |
| Tsinaridis, A | 1 |
| Bekiaropoulos, D | 1 |
| Argyropoulos, E | 1 |
| Sousos, N | 1 |
| Petrou, I | 1 |
| Papathanasiou, M | 1 |
| Morichovitou, A | 1 |
| Damianidis, G | 1 |
| Bakatselos, S | 1 |
| Ratkal, V | 1 |
| Chawla, A | 1 |
| Mishra, DK | 1 |
| Monappa, V | 1 |
| Tseng, YD | 1 |
| Chen, YH | 1 |
| Catalano, PJ | 2 |
| Ng, A | 1 |
| Hazarika, M | 1 |
| Iqbal, A | 1 |
| Krishnatreya, M | 1 |
| Sharma, JD | 1 |
| Bhuyan, C | 1 |
| Saikia, BJ | 1 |
| Roy, PS | 1 |
| Das, R | 1 |
| Nandy, P | 1 |
| Kataki, AC | 1 |
| Ouafki, I | 1 |
| Sghiri, T | 1 |
| Lkhoyaali, S | 1 |
| Mrabti, H | 1 |
| Polaczek, MM | 1 |
| Zych, J | 1 |
| Opoka, L | 1 |
| Maksymiuk, B | 1 |
| Roszkowski-Sliż, K | 1 |
| Vidal, L | 1 |
| Gurion, R | 1 |
| Ram, R | 1 |
| Gafter-Gvili, A | 1 |
| Collette, SA | 1 |
| Allstadt, SD | 1 |
| Chon, EM | 1 |
| Vernau, W | 1 |
| Garrett, LD | 1 |
| Choy, K | 1 |
| Rebhun, RB | 1 |
| Skorupski, KA | 1 |
| Ganovska, A | 1 |
| Kovachev, S | 1 |
| Switchenko, JM | 1 |
| Koff, JL | 1 |
| Sinha, R | 1 |
| Kaufman, JL | 1 |
| Khoury, HJ | 1 |
| Bumpers, N | 1 |
| Colbert, A | 1 |
| Hutchison-Rzepka, A | 1 |
| Nastoupil, LJ | 1 |
| Heffner, LT | 1 |
| Langston, AA | 1 |
| Lechowicz, MJ | 1 |
| Lonial, S | 1 |
| Flowers, CR | 1 |
| Curran, K | 1 |
| Shi, Y | 1 |
| Zhou, P | 1 |
| Han, X | 1 |
| He, X | 2 |
| Zhou, S | 1 |
| Liu, P | 1 |
| Zhang, C | 1 |
| Gui, L | 1 |
| Qin, Y | 2 |
| Yang, S | 2 |
| Zhao, L | 1 |
| Yao, J | 1 |
| Zhang, S | 1 |
| Epeldegui, M | 1 |
| Martínez, AC | 1 |
| Widney, DP | 1 |
| Magpantay, LI | 1 |
| Regidor, D | 1 |
| Martínez-Maza, O | 1 |
| Giridhar, P | 1 |
| Mallick, S | 1 |
| Bhasker, S | 1 |
| Pathy, S | 1 |
| Mohanti, BK | 1 |
| Biswas, A | 1 |
| Sharma, A | 1 |
| Hwang, I | 1 |
| Cho, EY | 1 |
| Khan-Kheil, AM | 1 |
| Mustafa, HM | 1 |
| Anand, DV | 1 |
| Banerjee, P | 1 |
| De Angelis, F | 1 |
| Tosti, ME | 1 |
| Capria, S | 1 |
| Russo, E | 1 |
| D'Elia, GM | 1 |
| Annechini, G | 1 |
| Stefanizzi, C | 1 |
| Pulsoni, A | 1 |
| Landsburg, DJ | 1 |
| Press, O | 1 |
| Cassaday, R | 1 |
| Chavez, JC | 1 |
| Song, K | 1 |
| Gandhi, M | 1 |
| Shah, N | 1 |
| Fenske, TS | 1 |
| Jaso, J | 1 |
| Medeiros, LJ | 3 |
| Yang, DT | 1 |
| Samura, B | 1 |
| Ma, XR | 1 |
| Wang, J | 1 |
| Zhang, WG | 1 |
| Chen, YX | 1 |
| Cao, XM | 1 |
| He, AL | 1 |
| Liu, J | 1 |
| Wang, JL | 1 |
| Zhao, WH | 1 |
| Yang, Y | 2 |
| Lei, B | 1 |
| Zhang, PY | 1 |
| Wang, FX | 1 |
| Gu, LF | 1 |
| Fino, N | 1 |
| Palmer, J | 1 |
| Gruber, L | 1 |
| Morris, BB | 1 |
| Raetskaya-Solntseva, O | 1 |
| Zamkoff, K | 1 |
| Hedrich, WD | 1 |
| Xiao, J | 2 |
| Heyward, S | 1 |
| Zhang, J | 1 |
| Baer, MR | 1 |
| Hassan, HE | 1 |
| Sreenivas, J | 1 |
| Mallya, A | 1 |
| Karthikeyan, VS | 1 |
| Amirtham, U | 1 |
| Wang, XJ | 1 |
| Tang, T | 1 |
| Farid, M | 1 |
| Quek, R | 1 |
| Tao, M | 1 |
| Lim, ST | 1 |
| Wee, HL | 1 |
| Chan, A | 1 |
| van der Jagt, RH | 1 |
| Victor, TW | 1 |
| Fedoriw, Y | 1 |
| Moses, A | 1 |
| Mzumara, S | 1 |
| Varela, C | 1 |
| Makwakwa, V | 1 |
| Itimu, S | 1 |
| Kamiza, S | 1 |
| Dhungel, BM | 1 |
| Krysiak, R | 1 |
| Richards, KL | 1 |
| Liomba, NG | 1 |
| Chan, H | 1 |
| Jackson, S | 1 |
| McLay, J | 1 |
| Knox, A | 2 |
| Lee, J | 2 |
| Wang, S | 1 |
| Campione, E | 1 |
| Di Prete, M | 1 |
| Del Principe, I | 1 |
| Diluvio, L | 1 |
| Citarella, L | 1 |
| Orlandi, A | 1 |
| Chimenti, S | 1 |
| Bianchi, L | 1 |
| Payandeh, M | 1 |
| Najafi, S | 1 |
| Shojaiyan, FZ | 1 |
| Sadeghi, M | 1 |
| Annibali, O | 1 |
| Chiodi, F | 1 |
| Cenfra, N | 1 |
| Sarlo, C | 1 |
| Mega, S | 1 |
| Cavallari, I | 1 |
| Rago, A | 1 |
| Tomassini, S | 1 |
| Mecarocci, S | 1 |
| Cimino, G | 2 |
| Avvisati, G | 2 |
| Fukushima, R | 1 |
| Kobayashi, Y | 2 |
| Fukuhara, S | 1 |
| Miyamoto, K | 1 |
| Munakata, W | 1 |
| Kim, SW | 3 |
| Watanabe, T | 2 |
| Taniguchi, H | 1 |
| Maeshima, A | 1 |
| Tobinai, K | 11 |
| Mondello, P | 1 |
| Steiner, N | 1 |
| Willenbacher, W | 1 |
| Wasle, I | 1 |
| Zaja, F | 5 |
| Zambello, R | 1 |
| Visentin, A | 1 |
| Mauro, E | 1 |
| Ferrero, S | 1 |
| Ghione, P | 1 |
| Pitini, V | 2 |
| Cuzzocrea, S | 1 |
| Mian, M | 1 |
| Takahashi, T | 4 |
| Kumanomidou, S | 1 |
| Takami, S | 1 |
| Okada, T | 2 |
| Adachi, K | 1 |
| Jo, Y | 1 |
| Ikejiri, F | 1 |
| Onishi, C | 1 |
| Kawakami, K | 1 |
| Miyake, T | 1 |
| Inoue, M | 1 |
| Moriyama, I | 1 |
| Suzuki, R | 1 |
| Suzumiya, J | 1 |
| Sundararajan, S | 1 |
| Puvvada, S | 1 |
| Persky, DO | 1 |
| Evans, SS | 1 |
| Gandhi, AS | 1 |
| Clemmons, AB | 1 |
| DeRemer, DL | 1 |
| Huang, HW | 1 |
| Jiang, YB | 1 |
| Fu, TW | 1 |
| Xu, T | 1 |
| Chen, XC | 1 |
| Jin, ZM | 1 |
| Wu, DP | 2 |
| Song, Z | 1 |
| Zhao, K | 1 |
| Yang, F | 1 |
| Zeng, J | 2 |
| Yang, L | 1 |
| Huang, F | 1 |
| Hong, T | 1 |
| He, Z | 1 |
| Lei, J | 1 |
| Sun, H | 1 |
| Lu, Y | 1 |
| Hao, X | 1 |
| Amioka, M | 1 |
| Sairaku, A | 1 |
| Ochi, T | 1 |
| Kyo, T | 1 |
| Kihara, Y | 1 |
| Cabanillas, F | 18 |
| Rivera, N | 1 |
| Pardo, WI | 1 |
| Elloul, S | 1 |
| Carlson, R | 1 |
| Senapedis, W | 1 |
| Baloglu, E | 1 |
| Zonder, J | 1 |
| Grisariu, S | 1 |
| Vaxman, I | 1 |
| Gatt, M | 1 |
| Elias, S | 1 |
| Avni, B | 1 |
| Arad, A | 1 |
| Pasvolsky, O | 1 |
| Paltiel, O | 1 |
| Tu, S | 1 |
| Zhong, D | 1 |
| Song, C | 1 |
| Ekhzaimy, A | 1 |
| Mujamammi, A | 1 |
| Al-Rawi, NH | 1 |
| Short, NJ | 1 |
| Kantarjian, HM | 1 |
| Ko, H | 1 |
| Khoury, JD | 1 |
| Ravandi, F | 1 |
| Thomas, DA | 1 |
| Garcia-Manero, G | 1 |
| Khouri, M | 1 |
| Cortes, JE | 1 |
| Wierda, WG | 1 |
| Verstovsek, S | 1 |
| Estrov, Z | 1 |
| Ferrajoli, A | 1 |
| Thompson, PA | 1 |
| Pierce, S | 1 |
| O'Brien, SM | 1 |
| Jabbour, E | 2 |
| Zucca, E | 3 |
| Moser, BK | 1 |
| McCann, MH | 1 |
| Lahiani Ben Salah, H | 1 |
| Zwick, C | 1 |
| Birkmann, J | 2 |
| Peter, N | 2 |
| Bodenstein, H | 1 |
| Fuchs, R | 3 |
| Hänel, M | 1 |
| Reiser, M | 2 |
| Clemens, M | 1 |
| Masuda, A | 1 |
| Isobe, Y | 1 |
| Sugimoto, K | 1 |
| Ando, J | 1 |
| Oshimi, K | 1 |
| Michallet, AS | 1 |
| Taslipinar, A | 1 |
| Bolu, E | 1 |
| Kebapcilar, L | 1 |
| Sahin, M | 1 |
| Uckaya, G | 1 |
| Kutlu, M | 1 |
| Akutsu, M | 2 |
| Tsunoda, S | 2 |
| Izumi, T | 4 |
| Tanaka, M | 2 |
| Katano, S | 1 |
| Inoue, K | 2 |
| Igarashi, S | 1 |
| Hirabayashi, K | 1 |
| Furukawa, Y | 2 |
| Kobayashi, H | 1 |
| Ozawa, K | 2 |
| Kirito, K | 1 |
| Nagashima, T | 1 |
| Teramukai, S | 1 |
| Fukushima, M | 1 |
| Kano, Y | 1 |
| Daruwalla, ZJ | 1 |
| Razak, AR | 1 |
| Duke, D | 1 |
| Grogan, L | 2 |
| Batista, MD | 1 |
| Takano, D | 1 |
| Lopes, RD | 1 |
| Enokihara, MM | 1 |
| Michalany, NS | 1 |
| de Almeida, FA | 1 |
| Guo, HY | 1 |
| Zhao, XM | 1 |
| Cao, JN | 2 |
| Hu, XC | 1 |
| Yin, JL | 1 |
| Castelino, FV | 1 |
| Wasfy, JH | 1 |
| Collier, D | 1 |
| Han, HS | 1 |
| Escalón, MP | 1 |
| Hsiao, B | 1 |
| Serafini, A | 1 |
| Lossos, IS | 3 |
| Yamane, T | 4 |
| Daimaru, O | 1 |
| Nagata, T | 1 |
| Yoshiya, K | 1 |
| Fukaya, N | 1 |
| Imai, T | 1 |
| Uchida, H | 1 |
| Laffosse, JM | 1 |
| Gomez-Brouchet, A | 1 |
| Molinier, F | 1 |
| Chiron, P | 1 |
| Roché, H | 1 |
| Puget, J | 1 |
| Cheson, BD | 4 |
| Jonathan, F | 1 |
| Nishio, M | 1 |
| Endo, T | 2 |
| Fujimoto, K | 1 |
| Yamamoto, S | 2 |
| Obara, M | 1 |
| Yamaguchi, K | 1 |
| Takeda, Y | 1 |
| Goto, H | 4 |
| Kasahara, I | 1 |
| Sato, N | 3 |
| Koike, T | 3 |
| Pettengell, R | 4 |
| Bosly, A | 6 |
| Szucs, TD | 1 |
| Jackisch, C | 1 |
| Leonard, R | 1 |
| Paridaens, R | 1 |
| Constenla, M | 1 |
| Schwenkglenks, M | 3 |
| Chung, CS | 1 |
| Liao, WC | 1 |
| Wang, HP | 1 |
| Shabbat, S | 1 |
| Aharoni, J | 1 |
| Sarid, L | 1 |
| Ben-Harush, M | 1 |
| Kapelushnik, J | 1 |
| Boehme, V | 2 |
| Sénéchal, C | 1 |
| Saint, F | 1 |
| Petit, T | 1 |
| Petit, J | 1 |
| Hong, RS | 1 |
| Woodson, EA | 1 |
| Hansen, MR | 1 |
| Il'in, NV | 1 |
| Bochkareva, TN | 1 |
| Cherviakov, AM | 1 |
| Leenman, EE | 2 |
| Sharma, R | 1 |
| Smith, P | 3 |
| Robertson, G | 1 |
| Dent, O | 1 |
| Clarke, SJ | 1 |
| Cavana, P | 1 |
| Sammartano, F | 1 |
| Capucchio, MT | 1 |
| Catalano, D | 1 |
| Valazza, A | 1 |
| Farca, AM | 1 |
| Osborne, RF | 1 |
| Hamilton, JS | 1 |
| Avitia, S | 1 |
| Hainsworth, JD | 7 |
| Spigel, DR | 1 |
| Markus, TM | 1 |
| Shipley, D | 1 |
| Thompson, D | 1 |
| Rotman, R | 1 |
| Dannaher, C | 1 |
| Greco, FA | 7 |
| Cabras, MG | 2 |
| Mamusa, AM | 1 |
| Freilone R, R | 1 |
| Dessalvi, P | 1 |
| Orsucci, L | 3 |
| Tonso, A | 1 |
| Levis, A | 3 |
| Liberati, M | 1 |
| Lay, G | 1 |
| Angelucci, E | 1 |
| Levitt, MJ | 1 |
| Gharibo, M | 1 |
| Strair, R | 2 |
| Schaar, D | 1 |
| Rubin, A | 1 |
| Bertino, JR | 1 |
| Quero, L | 1 |
| Hennequin, C | 1 |
| Provencio, M | 2 |
| Sanchez, A | 1 |
| Maximiano, C | 1 |
| Cantos, B | 1 |
| Méndez, M | 1 |
| Bonilla, F | 2 |
| Anoop, P | 1 |
| Ravindranathan, G | 1 |
| Osuji, N | 1 |
| Dearden, CE | 1 |
| Wotherspoon, A | 1 |
| Bain, BJ | 1 |
| Matutes, E | 2 |
| Vettori, S | 1 |
| Staibano, S | 1 |
| Mascolo, M | 1 |
| Ilardi, G | 1 |
| Valentini, G | 1 |
| Gyánó, G | 1 |
| Czumbil, L | 1 |
| Ternant, D | 1 |
| Hénin, E | 1 |
| Tod, M | 1 |
| Paintaud, G | 1 |
| Girard, P | 1 |
| Tempescul, A | 1 |
| Querellou, S | 1 |
| Ianotto, JC | 1 |
| Boisramé, S | 1 |
| Valette, G | 1 |
| Berthou, C | 3 |
| Azim, HA | 3 |
| Santoro, L | 1 |
| Bociek, RG | 1 |
| Gandini, S | 1 |
| Malek, RA | 1 |
| Grover, RK | 1 |
| Stites, PC | 1 |
| Helm, TN | 1 |
| Hashimoto, T | 1 |
| Beutner, EH | 1 |
| Sancho, JM | 1 |
| Gardella, S | 1 |
| Coll, R | 1 |
| Gallardo, D | 1 |
| Ustaalioglu, BB | 1 |
| Bilici, A | 1 |
| Seker, M | 1 |
| Canpolat, N | 1 |
| Ozdemir, N | 1 |
| Salepci, T | 2 |
| Gumus, M | 1 |
| Galetta, F | 1 |
| Franzoni, F | 1 |
| Cervetti, G | 2 |
| Regoli, F | 1 |
| Fallahi, P | 1 |
| Tocchini, L | 1 |
| Carpi, A | 1 |
| Antonelli, A | 1 |
| Petrini, M | 5 |
| Santoro, G | 1 |
| Yun, J | 1 |
| Kong, JH | 1 |
| Lee, SH | 1 |
| Kim, K | 1 |
| Ko, YH | 1 |
| Kim, WS | 1 |
| Aksu, K | 1 |
| Cagirgan, S | 2 |
| Ozsan, N | 1 |
| Keser, G | 1 |
| Sahin, F | 1 |
| Kwon, SI | 1 |
| Chung, YS | 1 |
| Kim, YJ | 1 |
| Zhai, L | 1 |
| Guo, C | 1 |
| Cao, Y | 1 |
| Huang, J | 1 |
| Huang, H | 1 |
| Guan, Z | 1 |
| Lin, T | 1 |
| Mannina, D | 2 |
| Luminari, S | 4 |
| Dondi, A | 1 |
| Polimeno, G | 2 |
| Baldini, L | 5 |
| Stelitano, C | 4 |
| Merli, F | 3 |
| Dell'Olio, M | 1 |
| Gobbi, PG | 5 |
| Giglio, G | 2 |
| Barbolini, E | 1 |
| Brugiatelli, M | 4 |
| Federico, M | 9 |
| Bishop, MR | 2 |
| Dean, RM | 1 |
| Steinberg, SM | 6 |
| Odom, J | 1 |
| Pollack, SM | 1 |
| Pavletic, SZ | 1 |
| Sportes, C | 1 |
| Gress, RE | 1 |
| Fowler, DH | 1 |
| Zhu, J | 3 |
| Song, YQ | 1 |
| Delbès, G | 1 |
| Vaisheva, F | 1 |
| Luu, T | 1 |
| Marcon, L | 1 |
| Hales, BF | 1 |
| Robaire, B | 1 |
| Qiao, W | 1 |
| Zhao, J | 1 |
| Wang, C | 2 |
| Wang, T | 1 |
| Xing, Y | 1 |
| Pan, ZL | 1 |
| Ji, XY | 1 |
| Shi, YM | 1 |
| Zhou, J | 1 |
| He, E | 1 |
| Skog, S | 1 |
| Ross, E | 1 |
| Lim, KH | 1 |
| Yoon, HI | 1 |
| Kang, YA | 1 |
| Lee, KW | 1 |
| Kim, JH | 1 |
| Bang, SM | 1 |
| Lee, CT | 1 |
| Lee, JS | 1 |
| Tay, K | 1 |
| Laatiri, MA | 1 |
| Ali, ZB | 1 |
| Ben Othmen, T | 1 |
| Msadek, F | 1 |
| Toumi, N | 2 |
| Bouaouina, N | 1 |
| Maalej, M | 1 |
| Ghannem, H | 1 |
| Meddeb, B | 1 |
| Kriwalsky, MS | 1 |
| Schroers, R | 1 |
| Stricker, I | 1 |
| Hollstein, S | 1 |
| Kunkel, M | 1 |
| Martin, P | 1 |
| Goldsmith, SJ | 1 |
| Coleman, M | 3 |
| Machado, AS | 1 |
| Da Silva Robaina, MC | 1 |
| Magalhães De Rezende, LM | 1 |
| Apa, AG | 1 |
| Amoêdo, ND | 1 |
| Bacchi, CE | 1 |
| Klumb, CE | 1 |
| Zhao, XY | 1 |
| Leaw, SJ | 1 |
| Li, ZT | 1 |
| Chang, JH | 1 |
| Jones, K | 1 |
| Gandhi, MK | 1 |
| Tran, L | 1 |
| Baars, JW | 4 |
| Aarden, L | 1 |
| Beijnen, JH | 1 |
| Huitema, AD | 1 |
| Goussetis, E | 1 |
| Peristeri, I | 1 |
| Kitra, V | 1 |
| Traeger-Synodinos, J | 1 |
| Theodosaki, M | 1 |
| Psarra, K | 1 |
| Kanariou, M | 1 |
| Tzortzatou-Stathopoulou, F | 1 |
| Petrakou, E | 1 |
| Fylaktou, I | 1 |
| Kanavakis, E | 1 |
| Graphakos, S | 1 |
| Brunello, A | 1 |
| Kapoor, R | 1 |
| Extermann, M | 1 |
| Shamsian, BS | 1 |
| Goudarzipour, K | 1 |
| Alavi, S | 1 |
| Jadali, F | 1 |
| Gharib, A | 1 |
| Aghakhani, R | 1 |
| Arzanian, MT | 1 |
| Rezaei, N | 1 |
| Christie, D | 1 |
| Dear, K | 1 |
| Le, T | 1 |
| Barton, M | 1 |
| Wirth, A | 1 |
| Porter, D | 1 |
| Roos, D | 1 |
| Pratt, G | 1 |
| Nickelsen, M | 1 |
| Metzner, B | 1 |
| Rosenwald, A | 1 |
| Canova, F | 1 |
| Marino, D | 2 |
| Trentin, C | 1 |
| Soldà, C | 1 |
| Ghiotto, C | 1 |
| Aversa, SM | 4 |
| Alvarez-Larrán, A | 1 |
| Pedro, C | 1 |
| Comín, J | 1 |
| Saumell, S | 1 |
| Gómez, M | 1 |
| Besses, C | 2 |
| Scholz, M | 2 |
| Franklin, J | 1 |
| Josting, A | 1 |
| Diehl, V | 3 |
| Hasenclever, D | 1 |
| Soliman, MA | 1 |
| Fathy, AA | 1 |
| Alkilani, A | 1 |
| Abd El-Bary, N | 1 |
| El-Bassal, F | 1 |
| Buric, N | 1 |
| Jovanovic, G | 1 |
| Radovanovic, Z | 1 |
| Buric, M | 1 |
| Tijanic, M | 1 |
| Gandolfi, L | 1 |
| Broccoli, A | 1 |
| Argnani, L | 1 |
| Fanti, S | 2 |
| Pellegrini, C | 1 |
| Stefoni, V | 5 |
| Derenzini, E | 1 |
| Quirini, F | 1 |
| Baccarani, M | 5 |
| Ainoda, Y | 1 |
| Hirai, Y | 1 |
| Shoji, T | 1 |
| Totsuka, K | 1 |
| Hannawa, IS | 1 |
| Bestul, DJ | 1 |
| Kurokawa, T | 1 |
| Kaya, H | 1 |
| Yoshida, T | 1 |
| Itoh, K | 5 |
| Nakata, M | 1 |
| Shibata, T | 1 |
| Morishima, Y | 4 |
| Ogura, M | 8 |
| Ueda, R | 1 |
| Aikawa, K | 1 |
| Nakamura, S | 3 |
| Fukuda, H | 2 |
| Shimoyama, M | 5 |
| Hotta, T | 6 |
| Wang, YY | 1 |
| Zhang, JL | 1 |
| Wang, X | 1 |
| Liang, H | 1 |
| Li, JM | 1 |
| Shen, ZX | 1 |
| Pérez-Crespo, M | 1 |
| Moragón, M | 1 |
| Onrubia, J | 1 |
| Sevila, A | 1 |
| Alfonso, R | 1 |
| Miralles, J | 1 |
| Requena, L | 1 |
| Perry, JA | 1 |
| Eickhoff, J | 1 |
| Avery, AC | 1 |
| Dow, SW | 1 |
| Bilgir, O | 1 |
| Bilgir, F | 1 |
| Calan, M | 1 |
| Yuksel, A | 1 |
| Sari, F | 1 |
| Oztekin, O | 1 |
| Gerecitano, J | 1 |
| Portlock, C | 2 |
| Hamlin, P | 1 |
| Moskowitz, CH | 1 |
| Straus, D | 3 |
| Schulman, P | 2 |
| Dumitrescu, O | 1 |
| Sarasohn, D | 1 |
| Pappanicholaou, J | 1 |
| Iasonos, A | 1 |
| Zhang, Z | 1 |
| Mo, Q | 1 |
| Horanlli, E | 1 |
| Rojas, CN | 1 |
| O'Connor, OA | 1 |
| Herbrecht, R | 4 |
| Wilhelm, M | 1 |
| Hess, G | 1 |
| Cernohous, P | 1 |
| Veals, SA | 1 |
| Singer, JW | 1 |
| Shikama, N | 2 |
| Oguchi, M | 3 |
| Isobe, K | 2 |
| Nakamura, K | 5 |
| Tamaki, Y | 1 |
| Hasegawa, M | 3 |
| Kodaira, T | 1 |
| Sasaki, S | 2 |
| Kagami, Y | 3 |
| Mihaljevic, BS | 1 |
| Todorovic, MR | 1 |
| Andjelic, BM | 1 |
| Antic, DA | 1 |
| Perunicic Jovanovic, MD | 1 |
| Macharia, WM | 1 |
| Dai, W | 1 |
| Dharamsi, JW | 1 |
| Soliman, S | 1 |
| Ricotti, C | 1 |
| Gander, R | 1 |
| Bergstresser, P | 1 |
| Chan, J | 1 |
| Hou, S | 1 |
| Yang, W | 1 |
| Reagan, JL | 1 |
| Rosmarin, A | 1 |
| Butera, JN | 1 |
| Nadeem, A | 1 |
| Schiffman, FJ | 1 |
| Sikov, WM | 1 |
| Winer, E | 1 |
| Mega, AE | 1 |
| Tanaka, T | 2 |
| Shimada, K | 1 |
| Yamamoto, K | 1 |
| Hirooka, Y | 1 |
| Niwa, Y | 1 |
| Sugiura, I | 1 |
| Kitamura, K | 2 |
| Kosugi, H | 1 |
| Kinoshita, T | 2 |
| Schmitt, CJ | 1 |
| Dietrich, S | 1 |
| Stone, RH | 1 |
| Frontera-Acevedo, K | 1 |
| Saba, CF | 1 |
| Ambrose, D | 1 |
| Moorhead, AR | 1 |
| Brown, CA | 1 |
| Glass, B | 2 |
| Kaiser, U | 4 |
| Cavallin-Stahl, E | 3 |
| Haenel, M | 1 |
| Truemper, L | 2 |
| Farina, P | 1 |
| Jirillo, A | 1 |
| De Franchis, G | 1 |
| Simonetto, M | 1 |
| Tsukasaki, K | 2 |
| Simonelli, S | 1 |
| Gianazza, E | 1 |
| Mombelli, G | 1 |
| Bondioli, A | 1 |
| Ferraro, G | 1 |
| Penco, S | 1 |
| Sirtori, CR | 1 |
| Franceschini, G | 1 |
| Calabresi, L | 1 |
| Madana, J | 1 |
| Yolmo, D | 1 |
| Saxena, SK | 1 |
| Gopalakrishnan, S | 1 |
| Varmavuo, V | 1 |
| Mäntymaa, P | 1 |
| Kuittinen, T | 1 |
| Nousiainen, T | 4 |
| Jantunen, E | 3 |
| Castillo, JJ | 1 |
| Echenique, IA | 1 |
| Jiang, L | 1 |
| Xie, JL | 1 |
| Zhou, XG | 1 |
| O'Connor, CM | 1 |
| Sheppard, S | 1 |
| Hartline, CA | 1 |
| Huls, H | 1 |
| Johnson, M | 1 |
| Palla, SL | 1 |
| Maiti, S | 1 |
| Ma, W | 1 |
| Davis, RE | 1 |
| Craig, S | 1 |
| Lee, DA | 1 |
| Champlin, R | 1 |
| Wilson, H | 1 |
| Cooper, LJ | 1 |
| Yamashita, H | 2 |
| Asazuma, N | 1 |
| Igarashi, H | 1 |
| Machinami, R | 1 |
| Ogata, I | 1 |
| Cotto, M | 1 |
| Liboy, I | 1 |
| Rivera, E | 1 |
| Pavia, OA | 1 |
| Bruno, M | 1 |
| Ouarssani, A | 1 |
| Atoini, F | 1 |
| Lhou, FA | 1 |
| Rguibi, MI | 1 |
| Halasz, LM | 1 |
| Jacene, HA | 1 |
| Van den Abbeele, AD | 2 |
| Lacasce, A | 1 |
| Mauch, PM | 1 |
| Ng, AK | 1 |
| Rujirojindakul, P | 1 |
| Lekhakula, A | 2 |
| Mukai, K | 1 |
| Chou, T | 3 |
| Mikuni, C | 1 |
| Fukushima, N | 1 |
| Kiyama, Y | 2 |
| Sasaki, T | 3 |
| Watanabe, Y | 1 |
| Stefos, T | 1 |
| Michos, GM | 1 |
| Papadopoulos, G | 1 |
| Navrozoglou, I | 1 |
| Dousias, V | 1 |
| Rullo, R | 1 |
| Addabbo, F | 1 |
| Festa, VM | 1 |
| Revannasiddaiah, S | 1 |
| Bhattacharyya, T | 1 |
| Wijaya, I | 1 |
| Sanityoso, A | 1 |
| Lesmana, LA | 1 |
| Stallone, G | 1 |
| Infante, B | 1 |
| Tartaglia, L | 1 |
| Bruno, F | 1 |
| Gesualdo, L | 1 |
| Grandaliano, G | 1 |
| To, CA | 1 |
| Hsieh, RW | 1 |
| McClellan, JS | 1 |
| Howard, W | 1 |
| Fischbein, NJ | 1 |
| Brown, JM | 1 |
| Felsher, DW | 1 |
| Fan, AC | 1 |
| Lee, S | 1 |
| Zeng, IS | 1 |
| Coomarasamy, C | 1 |
| Blacklock, H | 1 |
| Alvarez Burneo, LE | 1 |
| Mercedes, LK | 1 |
| Arce-Álvarez, A | 1 |
| Kim, T | 1 |
| Choi, SH | 1 |
| Jeong, JY | 1 |
| Woo, JH | 1 |
| Kim, YS | 1 |
| Sung, H | 1 |
| Kim, MN | 1 |
| Yoon, DH | 1 |
| Lee, SO | 1 |
| Gómez, HL | 1 |
| Samanéz, C | 1 |
| Campana, F | 1 |
| Neciosup, SP | 1 |
| Vera, L | 1 |
| Casanova, L | 3 |
| Leon, J | 1 |
| Flores, C | 1 |
| de Mendoza, FH | 1 |
| Casteñeda, CA | 1 |
| Pinto, JA | 1 |
| Vallejos, CS | 1 |
| Yoon, JH | 1 |
| Kang, HJ | 1 |
| Kim, H | 1 |
| Lee, JW | 1 |
| Park, JD | 1 |
| Park, KD | 1 |
| Shin, HY | 1 |
| Ahn, HS | 1 |
| Bassi, A | 1 |
| Scarfi, F | 1 |
| Galeone, M | 1 |
| Arunachalam, M | 1 |
| Difonzo, E | 1 |
| Strum, SB | 1 |
| Adalsteinsson, O | 1 |
| Black, RR | 1 |
| Segal, D | 1 |
| Peress, NL | 1 |
| Waldenfels, J | 1 |
| Shikata, H | 1 |
| Yakushijin, Y | 1 |
| Yamanouchi, J | 1 |
| Azuma, T | 1 |
| Yasukawa, M | 1 |
| Sekkate, S | 1 |
| Kairouani, M | 1 |
| Mellas, N | 1 |
| El Kabbaj, H | 1 |
| M'rabti, H | 1 |
| Guldrís, EM | 1 |
| Vázquez, P | 1 |
| Fernández, A | 1 |
| Wilder, RB | 5 |
| Rodriguez, MA | 12 |
| Tucker, SL | 6 |
| Ha, CS | 6 |
| Romaguera, JE | 5 |
| Pro, B | 2 |
| Hess, MA | 5 |
| Cox, JD | 6 |
| Toyota, S | 1 |
| Dan, K | 2 |
| Schmitt, B | 1 |
| Wendtner, CM | 1 |
| Bergmann, M | 1 |
| Busch, R | 1 |
| Franke, A | 2 |
| Pasold, R | 2 |
| Schlag, R | 1 |
| Hopfinger, G | 1 |
| Hiddemann, W | 7 |
| Emmerich, B | 2 |
| Jones, EA | 1 |
| Pringle, JH | 1 |
| Angel, CA | 1 |
| Rees, RC | 1 |
| Gotlib, V | 1 |
| Singareddy, S | 1 |
| Gergis, U | 1 |
| Vakios, J | 1 |
| Guevara, E | 1 |
| Yavorkovsky, LL | 1 |
| Patel, A | 1 |
| Butt, A | 1 |
| Nayak, A | 1 |
| Vose, JM | 7 |
| Weisenburger, DD | 6 |
| Lynch, JC | 1 |
| Bierman, PJ | 5 |
| Chan, JC | 1 |
| Bast, M | 3 |
| Aoun, P | 1 |
| Bociek, G | 1 |
| Greiner, T | 1 |
| Armitage, JO | 12 |
| Paccalin, M | 1 |
| Lacotte-Thierry, L | 1 |
| Delwail, V | 4 |
| Morrow, TJ | 1 |
| Volpe, S | 1 |
| Gupta, S | 2 |
| Tannous, RE | 1 |
| Fridman, M | 4 |
| Zsáry, A | 2 |
| Szücs, S | 2 |
| Schneider, T | 3 |
| Rosta, A | 2 |
| Sármán, P | 2 |
| Fenyvesi, T | 2 |
| Karádi, I | 2 |
| Gherlinzoni, F | 13 |
| Storti, S | 6 |
| Zaccaria, A | 2 |
| Pavone, E | 4 |
| Moretti, L | 4 |
| Gentilini, P | 4 |
| Guardigni, L | 4 |
| Fattori, PP | 3 |
| Falini, B | 5 |
| Lauta, VM | 6 |
| Mazza, P | 7 |
| Volpe, E | 2 |
| Lauria, F | 4 |
| Aitini, E | 5 |
| Ciccone, F | 1 |
| Tani, M | 3 |
| Büchler, T | 1 |
| Ferra, C | 1 |
| Virgili, N | 1 |
| Montanya, E | 1 |
| Grañena, A | 2 |
| Sawada, M | 3 |
| Yamada, T | 3 |
| Fukuno, K | 2 |
| Kasahara, S | 2 |
| Yoshikawa, T | 1 |
| Kanemura, N | 2 |
| Oyama, M | 2 |
| Takami, T | 2 |
| Moriwaki, H | 3 |
| Theodossiou, C | 1 |
| Schwarzenberger, P | 1 |
| McLaughlin, P | 9 |
| Hagemeister, FB | 9 |
| Sarris, A | 2 |
| Romaguera, J | 4 |
| Hess, M | 4 |
| Smith, TL | 2 |
| Ayala, A | 2 |
| Preti, A | 1 |
| Lee, MS | 2 |
| Gan, H | 1 |
| Zhang, F | 1 |
| Veneri, D | 2 |
| Zanetti, F | 1 |
| Franchini, M | 1 |
| Krampera, M | 1 |
| Pizzolo, G | 4 |
| Iwuagwu, OC | 1 |
| Kober, R | 1 |
| Klasa, RJ | 2 |
| Meyer, RM | 6 |
| Shustik, C | 1 |
| Sawka, CA | 3 |
| Smith, A | 1 |
| Guévin, R | 1 |
| Maksymiuk, A | 1 |
| Rubinger, M | 2 |
| Samosh, M | 1 |
| Laplante, S | 1 |
| Grenier, JF | 1 |
| Plowman, PN | 1 |
| Taylor, A | 1 |
| Jackson, AS | 1 |
| Lightman, S | 1 |
| Pavesio, C | 1 |
| Linassier, C | 1 |
| Desablens, B | 4 |
| Lefrancq, T | 1 |
| Le Prise, PY | 2 |
| Harousseau, JL | 2 |
| Jacob, C | 1 |
| Gandhour, C | 1 |
| Haillot, O | 1 |
| Lucas, V | 1 |
| Leloup, R | 1 |
| Escoffre, M | 1 |
| Colombat, P | 7 |
| Tabuteau, S | 1 |
| Alekseeva, IuA | 2 |
| Zaritskiĭ, AIu | 2 |
| Medvedeva, NV | 2 |
| Mikhaĭlova, NB | 2 |
| Zubarovskaia, LS | 2 |
| Afanas'ev, BV | 2 |
| Yamazaki, T | 3 |
| Sawada, U | 7 |
| Kura, Y | 4 |
| Ito, T | 1 |
| Kaneita, Y | 2 |
| Yasukawa, K | 2 |
| Horie, T | 3 |
| Gill, S | 1 |
| Melosky, B | 1 |
| Haley, L | 1 |
| ChanYan, C | 1 |
| Numbenjapon, T | 2 |
| Sriswasdi, C | 1 |
| Mongkonsritragoon, W | 1 |
| Leelasiri, A | 1 |
| Prayoonwiwat, W | 3 |
| Mottl, H | 1 |
| Bajciova, V | 1 |
| Nemec, J | 1 |
| Al Shemmari, S | 1 |
| Al Awadi, S | 1 |
| Bessell, EM | 1 |
| Burton, A | 1 |
| Haynes, AP | 1 |
| Glaholm, J | 1 |
| Child, JA | 2 |
| Cullen, MH | 2 |
| Davies, JM | 1 |
| Smith, GM | 2 |
| Ellis, IO | 1 |
| Jack, A | 2 |
| Jones, EL | 1 |
| Demesmay, K | 1 |
| Voillat, L | 3 |
| Bernard, Y | 1 |
| Sabbah, A | 1 |
| Takeyama, K | 1 |
| Kasai, M | 2 |
| Ohnishi, K | 3 |
| Mitsuya, H | 1 |
| Kawano, F | 1 |
| Masaki, Y | 1 |
| Yokozawa, T | 1 |
| Boye, J | 1 |
| Martelli, M | 12 |
| De Vivo, A | 1 |
| Cantonetti, M | 2 |
| Meloni, G | 2 |
| Rizzo, M | 1 |
| Molinari, AL | 1 |
| Pescarmona, E | 1 |
| Pileri, SA | 1 |
| Mandelli, F | 12 |
| Zanssen, S | 1 |
| Buse, G | 1 |
| Ma, S | 1 |
| Sheng, X | 1 |
| Luo, R | 1 |
| Li, A | 1 |
| Baehring, JM | 1 |
| Longtine, J | 1 |
| Hochberg, FH | 2 |
| Barbón García, JJ | 1 |
| Viña Escalar, C | 1 |
| Menéndez Fernández, CL | 1 |
| Fernández Alvarez, C | 1 |
| Carballo Fernández, C | 1 |
| Villarreal Renedo, PM | 1 |
| Lombardo, M | 4 |
| Morabito, F | 2 |
| Molica, S | 2 |
| Cavanna, L | 4 |
| Sacchi, S | 1 |
| Broglia, C | 2 |
| Angrilli, F | 1 |
| Ilariucci, F | 1 |
| Luisi, D | 1 |
| Bertè, R | 2 |
| Szánthó, A | 1 |
| Bálega J, Já | 1 |
| Csapó, Z | 1 |
| Sréter L, Lí | 1 |
| Matolcsy, A | 1 |
| Papp, Z | 1 |
| Yuan, ZY | 3 |
| Xu, RH | 5 |
| He, YJ | 4 |
| Guan, ZZ | 6 |
| Huang, HQ | 6 |
| Jiang, WQ | 7 |
| Wang, W | 1 |
| Zhou, ZM | 1 |
| Xia, ZJ | 5 |
| Lin, XB | 4 |
| Li, YH | 6 |
| Xu, GC | 1 |
| Sun, XF | 4 |
| Liu, DG | 1 |
| Lin, TY | 5 |
| Belcadhi, M | 1 |
| el Omri, H | 1 |
| Gnaba, K | 1 |
| Mani, R | 1 |
| Abdelkefi, M | 1 |
| Bouzouita, K | 1 |
| Ennabli, S | 1 |
| Bouzouita, H | 1 |
| Stahel, R | 2 |
| Vose, J | 2 |
| Press, OW | 1 |
| Braziel, RM | 1 |
| Maloney, DG | 1 |
| Gaynor, ER | 8 |
| Rivkin, SE | 1 |
| Oh, KC | 1 |
| Zang, DY | 1 |
| Pangalis, GA | 3 |
| Vassilakopoulos, TP | 1 |
| Michalis, E | 1 |
| Roussou, P | 1 |
| Vrakidou, E | 1 |
| Repousis, P | 1 |
| Angelopoulou, MK | 2 |
| Siakantaris, MP | 3 |
| Korantzis, J | 1 |
| Symeonidis, A | 1 |
| Grigorakis, V | 1 |
| Stefanoudakis, E | 1 |
| Stamatellou, M | 1 |
| Bourantas, KL | 1 |
| Kalmantis, T | 1 |
| Christopoulos, G | 1 |
| Kokkinis, G | 1 |
| Mihalakeas, I | 1 |
| Papayiannis, A | 1 |
| Paschal, BR | 1 |
| Seymour, JF | 2 |
| Fuller, LM | 5 |
| Manning, JT | 1 |
| Pileckyte, M | 1 |
| Griniūte, R | 1 |
| Wunderlich, A | 1 |
| Kloess, M | 3 |
| Rudolph, C | 1 |
| Bittner, S | 1 |
| Schmalenberg, H | 1 |
| Schmits, R | 3 |
| Martinelli, G | 2 |
| Ferrucci, PF | 1 |
| Mingrone, W | 1 |
| Cocorocchio, E | 2 |
| Conconi, A | 1 |
| Peccatori, FA | 1 |
| De Luzio, K | 1 |
| Santoro, P | 1 |
| Mazzetta, C | 1 |
| Cavalli, F | 2 |
| Last, KW | 1 |
| Cornelius, V | 1 |
| Delves, T | 1 |
| Sieniawska, C | 1 |
| Fitzgibbon, J | 1 |
| Norton, A | 1 |
| Amess, J | 1 |
| Wilson, A | 1 |
| Rohatiner, AZ | 2 |
| Lister, TA | 1 |
| Ohmoto, K | 1 |
| Tsuduki, M | 1 |
| Simpson, ND | 1 |
| Simpson, PW | 1 |
| Ahmed, AM | 1 |
| Nguyen, MH | 1 |
| Garcia, G | 1 |
| Keeffe, EB | 1 |
| Ahmed, A | 1 |
| Blayney, DW | 2 |
| Grogan, T | 1 |
| Chapman, RA | 1 |
| Spiridonidis, CH | 1 |
| Taylor, SA | 1 |
| Bearman, SI | 1 |
| Alliot, C | 2 |
| Márquez Moreno, AJ | 1 |
| Mañas Uxó, J | 1 |
| Amores Ramírez, F | 1 |
| Aguilar Cuevas, R | 1 |
| Ortega Jiménez, MV | 1 |
| Leiva Vera, C | 1 |
| Pérez Rodríguez, D | 1 |
| Brihi, E | 1 |
| Akoum, R | 1 |
| Saade, M | 1 |
| Chahine, G | 1 |
| Litchy, S | 1 |
| Lamb, MR | 1 |
| Rodriguez, GI | 1 |
| Scroggin, C | 1 |
| Pan, D | 1 |
| Qin, J | 2 |
| Farber, C | 1 |
| O'Brien, J | 1 |
| Filippa, D | 2 |
| Portlock, CS | 4 |
| Smyth, EF | 1 |
| Bartlett, RJ | 1 |
| Shields, ML | 1 |
| White, TJ | 1 |
| Wengraf, C | 1 |
| Malliti, M | 1 |
| Junot, H | 1 |
| Fievet, MH | 1 |
| Gabarre, J | 1 |
| Taright, N | 1 |
| Vernant, JP | 1 |
| Thuillier, A | 1 |
| Doorduijn, JK | 5 |
| van der Holt, B | 5 |
| van Imhoff, GW | 4 |
| van der Hem, KG | 1 |
| Kramer, MH | 4 |
| van Oers, MH | 1 |
| Ossenkoppele, GJ | 8 |
| Schaafsma, MR | 2 |
| Verdonck, LF | 7 |
| Verhoef, GE | 3 |
| Steijaert, MM | 2 |
| Buijt, I | 4 |
| Uyl-de Groot, CA | 6 |
| van Agthoven, M | 4 |
| Mulder, AH | 3 |
| Sonneveld, P | 11 |
| Lepage, E | 9 |
| Blanc, M | 3 |
| Attal, M | 1 |
| Fillet, G | 3 |
| Guettier, C | 1 |
| Molina, TJ | 2 |
| Gisselbrecht, C | 8 |
| Reyes, F | 7 |
| Simonelli, C | 4 |
| Zanussi, S | 2 |
| Cinelli, R | 3 |
| Dal Maso, L | 1 |
| Di Gennaro, G | 4 |
| D'Andrea, M | 2 |
| Nasti, G | 2 |
| Vaccher, E | 6 |
| De Paoli, P | 2 |
| Mead, G | 1 |
| Woodcock, J | 1 |
| Young, C | 1 |
| Mora, J | 2 |
| Filippa, DA | 1 |
| Wollner, N | 4 |
| MONTORSI, W | 1 |
| COSTE, F | 1 |
| CAYLA, J | 1 |
| DUBOIS-FERRIERE, H | 2 |
| GORSUCH, GE | 1 |
| SCHOYER, NH | 1 |
| Jäger, U | 2 |
| SCHNEIDER, H | 1 |
| SIEDE, W | 1 |
| KYLE, RA | 1 |
| McPARLAND, CE | 1 |
| DAMESHEK, W | 1 |
| GUPTA, NN | 1 |
| MITTAL, SP | 1 |
| HARTAI, F | 1 |
| BURNINGHAM, RA | 1 |
| RESTREPO, A | 1 |
| PUGH, RP | 1 |
| BROWN, EB | 1 |
| SCHLOSSMAN, SF | 1 |
| KHURI, PD | 1 |
| LESSNER, HE | 1 |
| HARRINGTON, WJ | 1 |
| IRVINE, RA | 1 |
| ROBERTSON, WB | 1 |
| BOOTSMA, BK | 1 |
| KARNOFSKY, DA | 1 |
| DEBLASIIS, M | 1 |
| DIETZSCH, HJ | 1 |
| LIBERTI, R | 1 |
| WATKIN, DM | 1 |
| STEINFELD, JL | 1 |
| EAKINS, D | 1 |
| FULTON, T | 1 |
| HADDEN, DR | 1 |
| D ANGIO, GJ | 1 |
| MIUS, A | 1 |
| EVANS, AE | 1 |
| Dai, MS | 1 |
| Chao, TY | 1 |
| Yu, CY | 1 |
| Schouten, HC | 7 |
| Qian, W | 3 |
| Kvaloy, S | 3 |
| Porcellini, A | 6 |
| Hagberg, H | 3 |
| Johnsen, HE | 3 |
| Sydes, MR | 1 |
| Kvalheim, G | 1 |
| Gregory, SA | 3 |
| Case, DC | 2 |
| Bosserman, L | 1 |
| Litwak, DL | 1 |
| Berry, WR | 1 |
| Kalman, LA | 2 |
| Belt, RJ | 1 |
| Al-Shemmari, SH | 1 |
| Sajnani, KP | 1 |
| Ameen, RM | 1 |
| Ragheb, AM | 1 |
| Solal-Celigny, P | 3 |
| Hoskin, P | 3 |
| Taylor, K | 1 |
| McMillan, A | 1 |
| Forstpointner, R | 1 |
| Bacon, P | 1 |
| Renwick, J | 1 |
| Korolenko, VO | 2 |
| Gershanovich, ML | 2 |
| Tikhonova, VV | 2 |
| André, M | 1 |
| Leleu, X | 1 |
| Sonet, A | 1 |
| Morel, P | 4 |
| Gaulard, P | 5 |
| Talamini, R | 3 |
| Tedeschi, R | 1 |
| Gloghini, A | 1 |
| Carbone, A | 5 |
| Lambert, JF | 1 |
| Elfenbein, GJ | 1 |
| Ogawa, M | 3 |
| Nagasaki, E | 1 |
| Furuta, N | 1 |
| Shinozaki, E | 1 |
| Tokutome, N | 1 |
| Chin, K | 1 |
| Mizunuma, N | 1 |
| Takahashi, S | 2 |
| Usui, N | 4 |
| Tokuchi, Y | 1 |
| Kamachi, M | 1 |
| Harada, M | 2 |
| Mishina, T | 1 |
| Yamashiro, K | 1 |
| Suzuki, H | 3 |
| Isobe, H | 1 |
| Zijlstra, JM | 1 |
| Hoekstra, OS | 2 |
| Raijmakers, PG | 1 |
| Comans, EF | 1 |
| van der Hoeven, JJ | 1 |
| Teule, GJ | 2 |
| Jonkhoff, AR | 1 |
| v Tinteren, H | 1 |
| Lammertsma, AA | 1 |
| Huijgens, PC | 4 |
| Lyman, GH | 2 |
| Delgado, DJ | 2 |
| Mandigers, CM | 1 |
| Meijerink, JP | 1 |
| Dekker, AW | 2 |
| Schattenberg, AV | 1 |
| Raemaekers, JM | 5 |
| Kojima, Y | 1 |
| Saio, M | 1 |
| Chen, SP | 1 |
| Wu, DS | 1 |
| Zhao, XL | 1 |
| Cocconi, G | 1 |
| Franciosi, V | 1 |
| Dodero, A | 1 |
| Bologna, A | 1 |
| Vasini, G | 1 |
| De Lisi, V | 1 |
| Di Blasio, B | 1 |
| Ceci, G | 1 |
| Camisa, R | 1 |
| Cascinu, S | 1 |
| Hagenbeek, A | 11 |
| Seriakov, AP | 1 |
| Ushakov, II | 1 |
| Ardashev, VN | 1 |
| Mazurov, VI | 1 |
| Korotkiĭ, AN | 1 |
| George, S | 1 |
| Yunus, F | 1 |
| Case, D | 1 |
| Yang, BB | 1 |
| Hackett, J | 1 |
| Shogan, JE | 1 |
| Meza, LA | 1 |
| Neumann, TA | 1 |
| Liang, BC | 1 |
| Hehn, ST | 1 |
| Tulpule, A | 2 |
| Espina, BM | 2 |
| Pedro Santabarbara, AB | 1 |
| Palmer, M | 1 |
| Schiflett, J | 1 |
| Boswell, W | 1 |
| Smith, S | 2 |
| Rossini, F | 1 |
| Terruzzi, E | 1 |
| Perego, D | 1 |
| Miccolis, I | 1 |
| Rivolta, F | 1 |
| Manca, E | 1 |
| Pogliani, EM | 1 |
| Todeschini, G | 4 |
| Secchi, S | 1 |
| Morra, E | 2 |
| Orlandi, E | 3 |
| Pasini, F | 2 |
| Gallo, E | 1 |
| Ambrosetti, A | 4 |
| Tecchio, C | 1 |
| Tarella, C | 3 |
| Gabbas, A | 1 |
| Gargantini, L | 1 |
| Pizzuti, M | 3 |
| Fioritoni, G | 1 |
| Gottin, L | 1 |
| Lazzarino, M | 2 |
| Menestrina, F | 2 |
| Paulli, M | 1 |
| Palestro, M | 1 |
| Di Vito, F | 2 |
| Wittebol, S | 1 |
| Budel, LM | 1 |
| Costello, RT | 2 |
| Zerazhi, H | 1 |
| Charbonnier, A | 1 |
| de Colella, JM | 2 |
| Alzieu, C | 1 |
| Poizot-Martin, I | 1 |
| Cohen, R | 1 |
| Bardou, VJ | 2 |
| Xerri, L | 2 |
| Olive, D | 1 |
| Nezri, M | 1 |
| Lepeu, G | 2 |
| Gastaut, JA | 2 |
| Moser, EC | 3 |
| Noordijk, EM | 10 |
| van Glabbeke, M | 9 |
| Teodorovic, I | 7 |
| de Wolf-Peeters, C | 6 |
| Carde, P | 11 |
| Kluin-Nelemans, JC | 6 |
| Tsavaris, N | 1 |
| Kosmas, C | 2 |
| Zorzos, H | 1 |
| Lazaris, A | 1 |
| Vadiaka, M | 1 |
| Dimitrakopoulos, A | 1 |
| Rokana, S | 1 |
| Papalambros, E | 1 |
| Davaris, P | 1 |
| Rezgui-Marhoul, L | 1 |
| Bouslama, K | 1 |
| Bouchriha, M | 1 |
| Harmel, A | 1 |
| Mzabi-Rgaya, S | 1 |
| Hendaoui, L | 1 |
| Ben Dridi, M | 1 |
| Narayan, D | 1 |
| DaSilva, D | 1 |
| Doshi, M | 1 |
| Sayarlioglu, M | 1 |
| Bayram, I | 1 |
| Sayarlioglu, H | 1 |
| Erkoc, R | 1 |
| Gergely, L | 2 |
| Aleksza, M | 1 |
| Váróczy, L | 1 |
| Ponyi, A | 1 |
| Sipka, S | 1 |
| Illés, A | 2 |
| Szegedi, G | 1 |
| Santini, G | 6 |
| De Souza, C | 3 |
| Aversa, S | 1 |
| Patti, C | 1 |
| Tedeschi, L | 2 |
| Candela, M | 1 |
| Olivieri, A | 3 |
| Chisesi, T | 7 |
| Rubagotti, A | 4 |
| Centurioni, R | 2 |
| Nardi, V | 1 |
| Congiu, M | 1 |
| Gennaro, M | 1 |
| Truini, M | 2 |
| Toliusis, V | 1 |
| Pamerneckas, A | 1 |
| Petrulis, A | 1 |
| Tamulaitis, G | 1 |
| Pilipavicius, G | 1 |
| Pijadin, A | 1 |
| Musuraca, G | 1 |
| Gabriele, A | 1 |
| Marchi, E | 1 |
| Jullien, V | 1 |
| Perrin, C | 1 |
| Peyrade, F | 3 |
| Lemoigne, F | 1 |
| Chichmanian, RM | 1 |
| Blaive, B | 1 |
| Osby, E | 5 |
| Askling, J | 1 |
| Landgren, O | 1 |
| Dickman, PW | 1 |
| Ekbom, A | 1 |
| Björkholm, M | 6 |
| Hu, Y | 1 |
| Feng, FY | 2 |
| Shi, YK | 2 |
| Zhou, LQ | 3 |
| Gu, DZ | 2 |
| Wang, QL | 4 |
| Nie, DH | 1 |
| Hu, WH | 1 |
| Gao, YH | 2 |
| Wu, Y | 1 |
| Zhang, SP | 1 |
| Bertz, H | 1 |
| Zeiser, R | 1 |
| Lange, W | 1 |
| Fetscher, S | 1 |
| Waller, CF | 1 |
| Finke, J | 1 |
| Bertini, M | 3 |
| Mozzana, R | 1 |
| Trottini, M | 1 |
| Botto, B | 3 |
| Quintana, G | 1 |
| De Paoli, A | 2 |
| Li, YX | 3 |
| Zhao, LJ | 1 |
| Liu, XF | 3 |
| Qian, TN | 1 |
| Yu, ZH | 3 |
| Hazar, B | 1 |
| Ergin, M | 1 |
| Seyrek, E | 1 |
| Erdoğan, S | 1 |
| Tuncer, I | 1 |
| Hakverdi, S | 1 |
| Chalhoub, B | 1 |
| Suzan, F | 1 |
| Aloulou, S | 1 |
| Cainap, C | 1 |
| Fermé, C | 3 |
| Safwat, A | 1 |
| Bayoumi, Y | 1 |
| Akkoush, H | 1 |
| Mahmoud, HK | 1 |
| Hamid Zargar, A | 1 |
| Ahmad Laway, B | 1 |
| Alam Bhat, K | 1 |
| Shah, A | 1 |
| Ahmad, M | 1 |
| Aejaz Aziz, S | 1 |
| Iftikhar Bashir, M | 1 |
| Iqbal Wani, A | 1 |
| Hayat Bhat, M | 1 |
| Dale, DC | 1 |
| Friedberg, J | 1 |
| Crawford, J | 1 |
| Acquatella, G | 1 |
| Insausti, CL | 1 |
| García, R | 1 |
| Gómez, R | 1 |
| Hernández, M | 1 |
| Carneiro, M | 1 |
| Santos, S | 1 |
| Nouel, A | 1 |
| Nishioka, T | 1 |
| Tsuchiya, K | 1 |
| Nishioka, S | 1 |
| Kitahara, T | 1 |
| Ohmori, K | 1 |
| Homma, A | 1 |
| Aoyma, H | 1 |
| Shindoh, M | 1 |
| Shirato, H | 1 |
| Pruthi, S | 1 |
| Stafyla, VK | 1 |
| Phillips, SW | 1 |
| Porrata, LF | 1 |
| Reynolds, CA | 1 |
| Toffoli, G | 1 |
| Corona, G | 1 |
| Cattarossi, G | 1 |
| Boiocchi, M | 1 |
| Zhang, CQ | 1 |
| Zhen, ZJ | 2 |
| Wang, ZH | 2 |
| Wang, ZQ | 1 |
| Zheng, W | 2 |
| Yong, WB | 1 |
| Zhang, YT | 2 |
| Wang, XP | 1 |
| Xie, Y | 1 |
| Katahira, T | 1 |
| Takayama, T | 3 |
| Miyanishi, K | 1 |
| Hayashi, T | 3 |
| Takahashi, Y | 1 |
| Takimoto, R | 1 |
| Matsunaga, T | 1 |
| Kato, J | 2 |
| Niitsu, Y | 2 |
| Ozdemir, F | 1 |
| Aydin, F | 2 |
| Yilmaz, M | 1 |
| Kavgaci, H | 1 |
| Bektas, O | 1 |
| Yavuz, MN | 1 |
| Yavuz, AA | 1 |
| Luo, ZG | 1 |
| Zhang, P | 2 |
| Wang, XY | 1 |
| Kim, JG | 1 |
| Sohn, SK | 1 |
| Kim, DH | 1 |
| Baek, JH | 1 |
| Park, TI | 1 |
| Lee, KB | 1 |
| Lenz, G | 1 |
| Dreyling, M | 1 |
| Schiegnitz, E | 1 |
| Haferlach, T | 2 |
| Hasford, J | 1 |
| Unterhalt, M | 3 |
| Rahman, S | 1 |
| Rahman, W | 1 |
| Rahman, F | 1 |
| Zell, JA | 1 |
| Yoon, EJ | 1 |
| Ignatius Ou, SH | 1 |
| Hoefs, JC | 1 |
| Chang, JC | 1 |
| Visani, G | 1 |
| Guiducci, B | 1 |
| D'Adamo, F | 1 |
| Mele, A | 1 |
| Nicolini, G | 1 |
| Leopardi, G | 1 |
| Sparaventi, G | 1 |
| Barulli, S | 1 |
| Malerba, L | 1 |
| Isidori, A | 1 |
| Malagola, M | 1 |
| Piccaluga, PP | 1 |
| Umeda, M | 19 |
| Ishii, K | 1 |
| Yamamoto, Y | 2 |
| Shigeki, T | 1 |
| Kitayama, H | 1 |
| Hayashi, K | 4 |
| Hirose, A | 1 |
| Ohta, T | 1 |
| Mugitani, A | 2 |
| Fujino, H | 1 |
| Yagi, T | 1 |
| Hirai, M | 1 |
| Teshima, H | 1 |
| Katsurada, T | 1 |
| Urase, F | 1 |
| Kitajima, H | 1 |
| Yamamoto, R | 1 |
| Hashiguchi, K | 1 |
| Iwai, A | 1 |
| Satoh, S | 2 |
| Hanaoka, N | 1 |
| Okudaira, K | 1 |
| Inoue, T | 2 |
| Miyazaki, J | 1 |
| Matsuzaki, K | 1 |
| Tsuzuki, Y | 1 |
| Kawaguchi, A | 1 |
| Nagao, S | 1 |
| Miura, S | 1 |
| Hatano, B | 1 |
| Foussard, C | 4 |
| Maisonneuve, H | 2 |
| Gressin, R | 3 |
| Rousselet, MC | 1 |
| Rachieru, P | 2 |
| Pignon, B | 1 |
| Mahé, B | 2 |
| Ghandour, C | 2 |
| Casassus, P | 1 |
| Lamy, T | 3 |
| McGuire, BW | 1 |
| Cruickshank, SE | 1 |
| Johnson, DH | 5 |
| Ricca, I | 2 |
| Compagno, M | 1 |
| Ladetto, M | 2 |
| Rocci, A | 1 |
| Dell'Aquila, M | 1 |
| Omedè, P | 1 |
| De Marco, F | 1 |
| D'Antico, S | 1 |
| Caracciolo, D | 2 |
| Ferrero, D | 1 |
| Carlo-Stella, C | 1 |
| Cruciani, M | 1 |
| Gatti, G | 1 |
| Bassetti, M | 1 |
| Bassetti, D | 1 |
| Wessels, G | 1 |
| Bernard Hesseling, P | 1 |
| Ganem, G | 1 |
| Lederlin, P | 3 |
| Laurent, G | 1 |
| Garavaglia, E | 1 |
| Taccagni, G | 1 |
| Montoli, S | 1 |
| Panacci, N | 1 |
| Ponzoni, M | 1 |
| Frigerio, L | 1 |
| Mangili, G | 1 |
| Heredia, F | 1 |
| Bravo, M | 1 |
| Pierotic, M | 1 |
| Majlis, A | 1 |
| Carmona, L | 1 |
| Rao, PS | 1 |
| Mackenzie, MA | 2 |
| Van't Veer, MB | 1 |
| Wijermans, PW | 3 |
| Kluin, PM | 3 |
| Kluin-Nelemans, HC | 5 |
| Mori, M | 5 |
| Masuda, M | 1 |
| Miyazaki, T | 2 |
| Miura, AB | 2 |
| Mizoguchi, H | 2 |
| Shibata, A | 2 |
| Saito, H | 2 |
| Matsuda, T | 1 |
| Masaoka, T | 2 |
| Niho, Y | 1 |
| Takaku, F | 3 |
| Astudillo, L | 1 |
| Peron, JM | 1 |
| Sailler, L | 1 |
| Danjoux, M | 1 |
| Rigal-Huguet, F | 1 |
| Arlet-Suau, E | 1 |
| Dann, EJ | 2 |
| Epelbaum, R | 7 |
| Avivi, I | 2 |
| Ben Shahar, M | 1 |
| Haim, N | 8 |
| Rowe, JM | 1 |
| Blumenfeld, Z | 4 |
| He, YF | 2 |
| Li, ZM | 1 |
| Wang, FH | 2 |
| Wang, SS | 2 |
| Pedersen, LM | 1 |
| Klausen, TW | 1 |
| Davidsen, UH | 1 |
| Keltai, K | 1 |
| Pásztor, E | 1 |
| Jánoskuti, L | 1 |
| Monfardini, S | 6 |
| Zoli, V | 1 |
| Salvagno, L | 8 |
| Bianco, A | 3 |
| Bordonaro, R | 1 |
| Benevolo, G | 1 |
| Crugnola, M | 1 |
| Crivellari, G | 1 |
| Vivaldi, P | 1 |
| Basso, U | 1 |
| Torri, V | 1 |
| Vardar, E | 1 |
| Ozkok, G | 1 |
| Cetinel, M | 1 |
| Postaci, H | 1 |
| Basaran, G | 1 |
| Basaran, M | 1 |
| Onat, H | 2 |
| Scadden, DT | 1 |
| Shioyama, Y | 1 |
| Urashima, Y | 1 |
| Terashima, H | 1 |
| Honda, H | 1 |
| Tanvetyanon, T | 1 |
| Hoecht, S | 1 |
| Hinkelbein, W | 1 |
| Adli, M | 1 |
| Sevinc, A | 1 |
| Kalender, ME | 1 |
| Bernard, M | 1 |
| LeMevel, A | 1 |
| Branger, B | 1 |
| Le Maignan, C | 2 |
| Cassasus, P | 1 |
| Celigny, PS | 1 |
| Guyotat, D | 1 |
| Fleisch, F | 1 |
| Reinhart, WH | 1 |
| Brand, B | 1 |
| Berger, C | 1 |
| El Cheikh, J | 1 |
| Vacher-Copponat, H | 1 |
| Moal, V | 1 |
| Yano, S | 2 |
| Asai, O | 2 |
| Dobashi, N | 4 |
| Osawa, H | 1 |
| Takei, Y | 1 |
| Sugiyama, K | 1 |
| Takahara, S | 1 |
| Otubo, H | 1 |
| Saito, T | 1 |
| Okawa, Y | 1 |
| Hagino, T | 1 |
| Kaito, K | 1 |
| Kobayashi, M | 3 |
| Doorduijn, J | 1 |
| Holt, B | 1 |
| Steijaert, M | 1 |
| Uyl-de Groot, C | 1 |
| Belgaumi, AF | 1 |
| Shalaby, L | 1 |
| Al-Kofide, A | 1 |
| Chaudhary, MA | 1 |
| Alviedo, C | 1 |
| Sabbah, R | 1 |
| Müller-Beissenhirtz, H | 1 |
| Kasper, C | 1 |
| Nückel, H | 1 |
| Zhang, DS | 1 |
| Ding, Y | 1 |
| Wang, B | 1 |
| Zhang, XS | 1 |
| Liang, HZ | 1 |
| Chamorey, E | 1 |
| Rossi, JF | 1 |
| Harrousseau, JL | 1 |
| Fabbro, M | 1 |
| Richard, B | 1 |
| Vilque, JP | 1 |
| Thyss, A | 2 |
| Herold, M | 1 |
| Schulze, A | 1 |
| Niederwieser, D | 1 |
| Fricke, HJ | 1 |
| Richter, P | 2 |
| Freund, M | 2 |
| Ismer, B | 1 |
| Dachselt, K | 1 |
| Boewer, C | 1 |
| Schirmer, V | 1 |
| Weniger, J | 1 |
| Winkelmann, C | 1 |
| Klinkenstein, C | 1 |
| Schulze, M | 1 |
| Arzberger, H | 1 |
| Bremer, K | 1 |
| Hahnfeld, S | 1 |
| Schwarzer, A | 1 |
| Müller, C | 2 |
| Burton, C | 2 |
| Vaughan-Hudson, G | 1 |
| Hancock, B | 2 |
| Linch, D | 2 |
| Italiano, A | 1 |
| Saudes, L | 1 |
| Enschede, SH | 1 |
| Porter, C | 1 |
| Venugopal, P | 2 |
| Chakravarti, A | 1 |
| Leslie, WT | 1 |
| Burkhardt, B | 1 |
| Zimmermann, M | 1 |
| Oschlies, I | 1 |
| Niggli, F | 1 |
| Mann, G | 1 |
| Parwaresch, R | 5 |
| Riehm, H | 1 |
| Schrappe, M | 1 |
| Reiter, A | 1 |
| Dzhumabaeva, BT | 1 |
| Kremenetskaia, AM | 2 |
| Gotman, LN | 1 |
| Shavlokhov, VS | 1 |
| Kaplanskaia, IB | 3 |
| Kravchenko, SK | 2 |
| Vishnevskaia, ES | 1 |
| Gemdzhian, EG | 1 |
| Frank, GA | 1 |
| Shepherd, FA | 2 |
| Franssen, E | 2 |
| Brandwein, J | 2 |
| Dotten, DA | 1 |
| Routy, JP | 1 |
| Walker, IR | 1 |
| St-Louis, J | 1 |
| Taylor, M | 1 |
| Arts, K | 1 |
| Foote, M | 1 |
| Thomas, J | 11 |
| Bron, D | 5 |
| Meerwaldt, JH | 7 |
| Grossbard, ML | 2 |
| Czuczman, M | 2 |
| Grillo-Lopez, A | 2 |
| Nakamae, H | 2 |
| Tsumura, K | 1 |
| Terada, Y | 1 |
| Nakane, T | 1 |
| Nakamae, M | 1 |
| Ohta, K | 3 |
| Hino, M | 3 |
| Trümper, LH | 1 |
| Balzarotti, M | 2 |
| Uziel, L | 1 |
| Ferreri, AJ | 3 |
| Santoro, A | 2 |
| Comella, P | 2 |
| Abate, G | 3 |
| Fiore, M | 1 |
| Di Finizio, G | 1 |
| Zarrilli, D | 2 |
| Konopka, L | 2 |
| Pawelski, S | 2 |
| Bibb, J | 1 |
| Hromas, R | 1 |
| Rabinowitz, I | 1 |
| Ambulkar, I | 1 |
| Kulkarni, B | 1 |
| Borges, A | 1 |
| Jagannath, P | 1 |
| Advani, SH | 5 |
| Morillas, P | 1 |
| Quiles, J | 1 |
| Nuñez, D | 1 |
| Senent, C | 1 |
| Martínez, S | 1 |
| Fernández, JA | 1 |
| Bertomeu, V | 1 |
| Di Renzo, N | 3 |
| Montanini, A | 1 |
| Vigliotti, ML | 1 |
| Liberati, AM | 1 |
| Spedini, P | 1 |
| Baldissera, RC | 1 |
| Nucci, M | 1 |
| Vigorito, AC | 1 |
| Maiolino, A | 1 |
| Simões, BP | 1 |
| Lorand-Metze, I | 1 |
| Aranha, FJ | 1 |
| Miranda, EC | 1 |
| Pagnano, KB | 1 |
| Ruiz, MA | 1 |
| Moraes, AA | 1 |
| De Souza, CA | 1 |
| Bahlis, N | 1 |
| Valentine, K | 1 |
| Balogh, A | 1 |
| Savoie, L | 1 |
| Morris, DG | 1 |
| Jones, A | 1 |
| Brown, C | 1 |
| Russell, JA | 1 |
| Engel, C | 1 |
| Mitrou, P | 1 |
| Arasteh, K | 1 |
| Schuermann, D | 1 |
| Hentrich, M | 1 |
| Duehrsen, U | 1 |
| Sudeck, H | 1 |
| Schmidt-Wolf, IG | 1 |
| Anagnostopoulos, I | 1 |
| Huhn, D | 7 |
| Milligan, D | 1 |
| Dyer, MJ | 2 |
| Mouncey, P | 1 |
| MacLennan, K | 2 |
| Webb, A | 1 |
| Epure, C | 1 |
| Ionascu, L | 1 |
| Hagima, N | 1 |
| Nan, S | 1 |
| Stefaniu, I | 1 |
| Eghbali, H | 1 |
| Hoskin, PJ | 2 |
| Staab-Renner, E | 1 |
| Kalmus, J | 1 |
| Schott, A | 1 |
| Negrouk, A | 1 |
| Marcus, R | 2 |
| Elbl, L | 3 |
| Vasova, I | 3 |
| Tomaskova, I | 3 |
| Jedlicka, F | 3 |
| Navratil, M | 3 |
| Pospisil, Z | 1 |
| Vorlicek, J | 3 |
| Avritscher, EB | 1 |
| Cooksley, CD | 1 |
| Michelet, M | 1 |
| Bekele, BN | 1 |
| Elting, LS | 1 |
| Ling, JY | 1 |
| Yao, B | 2 |
| Fang, H | 1 |
| He, XH | 1 |
| Yang, JL | 1 |
| Yu, YX | 1 |
| Li, B | 1 |
| Bu, Q | 2 |
| Peng, YL | 1 |
| Pan, ZH | 2 |
| Komoto, D | 1 |
| Nishiyama, Y | 1 |
| Monden, T | 1 |
| Sasakawa, Y | 1 |
| Toyama, Y | 1 |
| Satoh, K | 1 |
| Ohno, M | 1 |
| Kanenishi, K | 1 |
| Ohkawa, M | 1 |
| Kober, T | 1 |
| Hülsewede, H | 1 |
| Bohlius, J | 1 |
| Fassina, A | 1 |
| Boscolo Berto, R | 1 |
| El Mazloum, R | 1 |
| Gottardo, F | 1 |
| Artibani, W | 1 |
| Osterborg, A | 1 |
| Trneny, M | 1 |
| Ma, D | 1 |
| Gill, D | 1 |
| Walewski, J | 1 |
| Jaeger, U | 2 |
| Hansen, M | 1 |
| Lehtinen, T | 1 |
| López-Guillermo, A | 4 |
| Corrado, C | 3 |
| Scheliga, A | 1 |
| Mendila, M | 1 |
| Rashford, M | 1 |
| Kuhnt, E | 1 |
| Horsman, JM | 1 |
| Hough, R | 1 |
| Hancock, BW | 2 |
| Elis, A | 1 |
| Tevet, A | 1 |
| Yerushalmi, R | 1 |
| Blickstein, D | 3 |
| Bairy, O | 1 |
| Abraham, A | 1 |
| Manor, Y | 1 |
| Lishner, M | 2 |
| Izutsu, K | 1 |
| Shiraishi, K | 1 |
| Chiba, S | 2 |
| Kurokawa, M | 1 |
| Tago, M | 1 |
| Igaki, H | 1 |
| Ohtomo, K | 1 |
| Nakagawa, K | 1 |
| Huerta-Guzman, J | 2 |
| Cleto, S | 2 |
| Krejcí, M | 1 |
| Chaloupka, V | 2 |
| Mayer, J | 1 |
| Shipp, M | 1 |
| Wahie, S | 1 |
| Alexandroff, A | 1 |
| Reynolds, NJ | 1 |
| Meggit, SJ | 1 |
| Song, YW | 1 |
| Liu, YP | 1 |
| Wang, WH | 1 |
| Wang, SL | 1 |
| Sun, YT | 1 |
| Bai, CM | 1 |
| Yang, T | 1 |
| Liu, XL | 1 |
| Zhu, YL | 1 |
| Chen, SC | 1 |
| Shen, T | 1 |
| Ford, CD | 1 |
| Gabor, F | 1 |
| Morgan, R | 1 |
| Dabbas, B | 1 |
| Hariprasad, R | 1 |
| Kumar, L | 2 |
| Bhatla, DM | 1 |
| Kukreja, M | 1 |
| Papaiah, S | 1 |
| Wang, WL | 1 |
| Wen, XP | 1 |
| Han, L | 1 |
| Berman, N | 1 |
| Buchanan, LH | 1 |
| Smith, DL | 1 |
| Sherrod, A | 1 |
| Dharmapala, D | 1 |
| Gee, C | 1 |
| Boswell, WD | 1 |
| Nathwani, BN | 3 |
| Welles, L | 1 |
| Stern, CJ | 1 |
| Decker, M | 1 |
| Rothermundt, C | 1 |
| Holländer, G | 1 |
| Tichelli, A | 1 |
| Rochlitz, C | 1 |
| Betticher, DC | 2 |
| Radford, JA | 2 |
| Kaufmann, M | 1 |
| Aulitzky, WE | 1 |
| Beck, J | 1 |
| von Rohr, A | 1 |
| Kovascovics, T | 1 |
| Cogliatti, SB | 1 |
| Cina, S | 1 |
| Maibach, R | 1 |
| Cerny, T | 2 |
| Linch, DC | 3 |
| Lokich, JJ | 3 |
| Babu Rao, V | 1 |
| Kerketta, L | 1 |
| Madkaikar, M | 1 |
| Farah, J | 1 |
| Ghosh, K | 1 |
| Intragumtornchai, T | 4 |
| Bunworasate, U | 1 |
| Nakorn, TN | 1 |
| Rojnuckarin, P | 1 |
| Daponte, A | 1 |
| Ioannou, M | 1 |
| Gioti, C | 1 |
| Kallitsaris, A | 1 |
| Dalekos, GN | 1 |
| Messinis, IE | 1 |
| Park, SH | 1 |
| Kim, S | 1 |
| Ko, OB | 1 |
| Koo, JE | 1 |
| Lee, D | 1 |
| Jeong, YP | 1 |
| Huh, J | 1 |
| Kim, SB | 1 |
| Lee, JL | 1 |
| Rimsza, L | 1 |
| van Leeuwen, FE | 1 |
| Signorelli, M | 1 |
| Maneo, A | 1 |
| Cammarota, S | 1 |
| Isimbaldi, G | 1 |
| Garcia Parra, R | 1 |
| Perego, P | 1 |
| Maria Pogliani, E | 1 |
| Mangioni, C | 1 |
| Sawicka-Zukowska, M | 1 |
| Kajdas, L | 1 |
| Muszynska-Roslan, K | 1 |
| Krawczuk-Rybak, M | 1 |
| Sonta-Jakimczyk, D | 2 |
| Szczepanski, T | 1 |
| Laurencet, F | 1 |
| Ballabeni, P | 1 |
| Rufener, B | 1 |
| Hess, U | 1 |
| Fey, M | 1 |
| Luthi, JM | 1 |
| Plancherel, C | 1 |
| Zulian, GB | 3 |
| Cummins, DL | 1 |
| Mimouni, D | 1 |
| Tzu, J | 1 |
| Owens, N | 1 |
| Anhalt, GJ | 3 |
| Meyerle, JH | 1 |
| Connors, JM | 8 |
| Bentley, M | 1 |
| Lewis, ID | 1 |
| Spencer, A | 1 |
| Herrmann, R | 3 |
| Arthur, C | 1 |
| Durrant, S | 1 |
| van Kerkhoven, M | 1 |
| MacMillan, J | 1 |
| Mrongovius, R | 1 |
| Notenboom, A | 1 |
| de Jong, DD | 1 |
| Zhang, YJ | 2 |
| Xia, YF | 2 |
| Lu, TX | 2 |
| Xian, CG | 1 |
| Zou, GR | 1 |
| Xie, FY | 1 |
| Li, HX | 1 |
| Ruggiero, A | 1 |
| Maurizi, P | 1 |
| Larocca, LM | 1 |
| Arlotta, A | 1 |
| Riccardi, R | 1 |
| Parvez, T | 1 |
| Behani, A | 1 |
| Ali, A | 1 |
| Omoti, AE | 1 |
| Omoti, CE | 1 |
| Wöhrer, S | 1 |
| Troch, M | 1 |
| Zwerina, J | 1 |
| Schett, G | 1 |
| Skrabs, C | 1 |
| Gaiger, A | 1 |
| Zielinski, CC | 1 |
| Raderer, M | 1 |
| Sugimoto, T | 1 |
| Matano, S | 1 |
| Nishijima, H | 1 |
| Kakuta, K | 1 |
| Inamura, K | 1 |
| Okamura, T | 1 |
| Munemoto, S | 1 |
| Hishizawa, M | 1 |
| Okamoto, K | 1 |
| Chonabayashi, K | 1 |
| Kaneko, H | 5 |
| Watanabe, M | 1 |
| Tsudo, M | 1 |
| Bouabdallah, K | 1 |
| Ramírez V, P | 1 |
| Ocqueteau T, M | 1 |
| Alvarez Z, M | 1 |
| Bertín C-M, P | 1 |
| Lira V, P | 1 |
| Bustos C, M | 1 |
| Besa de C, P | 1 |
| Northup, JK | 1 |
| Gadre, SA | 1 |
| Ge, Y | 1 |
| Lockhart, LH | 1 |
| Velagaleti, GV | 1 |
| Collins-Burow, B | 1 |
| Santos, ES | 1 |
| Holte, H | 2 |
| Teerenhovi, L | 4 |
| Anderson, H | 1 |
| Myhre, J | 1 |
| Pertovaara, H | 1 |
| Ost, A | 1 |
| Nilsson, B | 1 |
| Nair, R | 2 |
| Prabhash, K | 1 |
| Sengar, M | 1 |
| Bakshi, A | 1 |
| Gujral, S | 1 |
| Parikh, P | 1 |
| Di Mario, A | 1 |
| Garzia, M | 1 |
| d'Alò, F | 1 |
| Rumi, C | 1 |
| Massini, G | 1 |
| Bellesi, S | 1 |
| Zini, G | 1 |
| Soliman, KB | 1 |
| Abbas, MM | 1 |
| Seksaka, MA | 1 |
| Wafa, S | 1 |
| Balah, AS | 1 |
| Gołkowski, F | 1 |
| Buziak-Bereza, M | 1 |
| Barczyński, M | 1 |
| Stefańska, A | 1 |
| Wierzchowski, W | 1 |
| Huszno, B | 1 |
| Cichoń, S | 1 |
| Peterson, BA | 7 |
| Johnson, J | 1 |
| Shipp, MA | 4 |
| Barcos, M | 7 |
| Gockerman, JP | 2 |
| Canellos, GP | 14 |
| Rahemtullah, A | 1 |
| Hochberg, E | 1 |
| Safi, S | 1 |
| Kassmaoui, H | 1 |
| Hassikou, H | 1 |
| Alami, M | 1 |
| Homadi, A | 1 |
| Tabache, F | 1 |
| Baaj, M | 1 |
| Hadri, L | 1 |
| Inoue, Y | 1 |
| Tamaki, H | 1 |
| Yamagami, T | 2 |
| Nakatsuka, S | 1 |
| Soma, T | 2 |
| Frein, D | 1 |
| Lavigne, C | 1 |
| Josselin, N | 1 |
| Sivova, N | 1 |
| Moles, MP | 1 |
| Berrut, G | 1 |
| Desch, CE | 1 |
| Vongkovit, P | 1 |
| Mena, RR | 1 |
| Allen, B | 1 |
| Terenghi, F | 1 |
| Ardolino, G | 1 |
| Nobile-Orazio, E | 1 |
| Wieder, HA | 1 |
| Buck, AK | 1 |
| Schöffel, M | 1 |
| Krause, BJ | 1 |
| Fend, F | 1 |
| Schuster, T | 1 |
| Meyer zum Büschenfelde, C | 1 |
| Wester, HJ | 1 |
| Duyster, J | 1 |
| Peschel, C | 1 |
| Schwaiger, M | 1 |
| Dechow, T | 1 |
| Reilly, TB | 1 |
| Schuster, DM | 1 |
| Starsiak, MD | 1 |
| Kost, CB | 1 |
| Halkar, RK | 1 |
| Damiani, D | 2 |
| Grimaz, S | 1 |
| Sperotto, A | 2 |
| Geromin, A | 2 |
| Skert, C | 1 |
| Cerno, M | 2 |
| Rinaldi, C | 2 |
| Fanin, R | 3 |
| Gemici, C | 1 |
| Kochi, M | 1 |
| Fujii, M | 2 |
| Kanamori, N | 1 |
| Kaiga, T | 1 |
| Schultz, A | 1 |
| Maruschke, M | 1 |
| Leithäuser, M | 1 |
| Seiter, H | 1 |
| Castañeda, C | 1 |
| Vanel, D | 1 |
| Leboulleux, S | 1 |
| Lumbroso, J | 1 |
| Couanet, D | 1 |
| Bonniaud, G | 1 |
| Aupérin, A | 1 |
| Masson, F | 1 |
| Bosq, J | 2 |
| Edeline, V | 1 |
| Pigneur, F | 1 |
| Schlumberger, M | 1 |
| Swaneveld, FH | 1 |
| van Vugt, RM | 1 |
| de Boer, JP | 1 |
| Dijkmans, BA | 1 |
| Lems, WF | 1 |
| Simon, Z | 1 |
| Tarr, T | 1 |
| Ress, Z | 1 |
| Kiss, E | 1 |
| Faganello, G | 1 |
| Belham, M | 1 |
| Thaman, R | 1 |
| Blundell, J | 1 |
| Eller, T | 1 |
| Wilde, P | 1 |
| Magomedova, AU | 1 |
| Zybunova, EE | 1 |
| Samoĭlova, RS | 1 |
| Vorob'ev, IA | 1 |
| Obukhova, TN | 1 |
| Ryzhko, VV | 1 |
| Zvonkov, EE | 1 |
| Vorob'ev, AI | 1 |
| Gao, Y | 1 |
| Wang, BF | 1 |
| Cai, QQ | 1 |
| Asfour, IA | 1 |
| Fayek, M | 1 |
| Raouf, S | 1 |
| Soliman, M | 1 |
| Hegab, HM | 1 |
| El-Desoky, H | 1 |
| Saleh, R | 1 |
| Moussa, MA | 1 |
| Morrison, VA | 3 |
| Koffi, G | 1 |
| Kouakou, B | 1 |
| Ndiaye, FS | 1 |
| Ndathz, E | 1 |
| Sanogo, I | 1 |
| Sangare, A | 1 |
| Yu, H | 1 |
| Peng, LP | 1 |
| Ye, L | 1 |
| Vural, F | 1 |
| Saydam, G | 1 |
| Hekimgil, M | 1 |
| Soyer, NA | 1 |
| Tombuloglu, M | 1 |
| Jhamb, R | 1 |
| Gupta, N | 1 |
| Garg, S | 1 |
| Kumar, S | 1 |
| Gulati, S | 1 |
| Mishra, D | 1 |
| Beniwal, P | 1 |
| Lorusso, D | 1 |
| Ferrandina, G | 1 |
| Pagano, L | 1 |
| Gagliardi, ML | 1 |
| Scambia, G | 1 |
| Moulin-Romsee, G | 1 |
| Spaepen, K | 1 |
| Stroobants, S | 1 |
| Mortelmans, L | 1 |
| Fayad, LE | 1 |
| Carbone, J | 1 |
| Perez-Fernandez, R | 1 |
| Muñoz, A | 1 |
| Sabin, P | 1 |
| Carreño, L | 1 |
| Fernandez-Cruz, E | 1 |
| Liu, L | 1 |
| Zou, P | 1 |
| Magnus, B | 1 |
| Andersson, T | 1 |
| Tomas, A | 1 |
| Ahlbom, A | 1 |
| Anders, A | 1 |
| Eva, O | 1 |
| Li, QC | 1 |
| Yuan, XL | 1 |
| Wang, YF | 1 |
| Zou, DH | 1 |
| Zhao, YZ | 1 |
| Qiu, LG | 1 |
| Blaes, AH | 1 |
| Santa-Cruz, KS | 1 |
| Lee, CK | 2 |
| Hui, SK | 1 |
| Deaver, D | 1 |
| Kilickap, S | 1 |
| Yavuz, B | 1 |
| Aksoy, S | 1 |
| Sahiner, L | 1 |
| Dincer, M | 1 |
| Harputluoglu, H | 1 |
| Erman, M | 1 |
| Aytemir, K | 1 |
| Tokgozoglu, L | 1 |
| Barista, I | 2 |
| Vercambre-Darras, S | 1 |
| Mortier, L | 1 |
| Lambert, M | 1 |
| Delattre, C | 1 |
| Gaxotte, V | 1 |
| Morell-Dubois, S | 1 |
| Paccou, J | 1 |
| Terriou, L | 1 |
| Piette, F | 1 |
| Hatzitolios, A | 1 |
| Tzellos, TG | 1 |
| Savopoulos, C | 1 |
| Tzalokostas, V | 1 |
| Kaiafa, G | 1 |
| Psomas, E | 1 |
| Apostolopoulou, M | 1 |
| Papadopoulos, A | 2 |
| Errante, D | 2 |
| Aversa, SML | 1 |
| Han, T | 3 |
| Ezdinli, EZ | 5 |
| Sokal, JE | 2 |
| Caldwell, IW | 1 |
| Montgomery, PR | 1 |
| Peachey, RD | 1 |
| Nuss, DD | 1 |
| Rassiga, AL | 1 |
| Klastersky, J | 1 |
| Focan, C | 2 |
| Cryns-Lenain, E | 1 |
| Bouhy, F | 1 |
| Lapière, CM | 1 |
| Giustolisi, R | 1 |
| Guglielmo, P | 1 |
| Di Raimondo, F | 1 |
| Milone, G | 2 |
| Cacciola, E | 1 |
| Haller, DG | 1 |
| Silber, R | 1 |
| Balentine, L | 1 |
| Skikne, BS | 1 |
| Park, CH | 1 |
| Lynch, SR | 1 |
| Anderson, JR | 7 |
| Wilson, JF | 2 |
| Jenkin, DT | 1 |
| Meadows, AT | 7 |
| Kersey, J | 1 |
| Chilcote, RR | 4 |
| Coccia, P | 1 |
| Exelby, P | 2 |
| Kushner, J | 1 |
| Siegel, S | 2 |
| Hammond, D | 1 |
| Jacquillat, C | 3 |
| Khayat, D | 1 |
| Desprez-Curely, JP | 1 |
| Weil, M | 3 |
| Brocheriou, C | 1 |
| Auclerc, G | 1 |
| Chamseddine, N | 1 |
| Bernard, J | 2 |
| Abdullaev, RA | 1 |
| Poddubnaia, IV | 3 |
| Shramko, AF | 1 |
| Coyne, J | 1 |
| Dervan, P | 1 |
| Soffer, T | 1 |
| Chan, WC | 2 |
| Brynes, RK | 1 |
| Vogler, WR | 1 |
| O'Neal, S | 1 |
| Raich, PC | 1 |
| Walker, BK | 1 |
| Rogers, JS | 1 |
| Subramanian, VP | 1 |
| Fontana, JA | 1 |
| Knost, JA | 1 |
| Denning, B | 1 |
| Berliner, S | 1 |
| Shoenfeld, Y | 1 |
| Sidi, Y | 1 |
| Santo, M | 1 |
| Weinberger, A | 1 |
| Luria, D | 1 |
| Hazaz, B | 1 |
| Pecht, M | 1 |
| Zaizov, R | 1 |
| Pinkhas, J | 3 |
| Abdyldaev, RA | 1 |
| Kruglova, GV | 3 |
| Weinstein, HJ | 2 |
| Cassady, JR | 3 |
| Levey, R | 1 |
| Kueh, YK | 1 |
| Tan, YO | 1 |
| Sng, I | 2 |
| Rauff, A | 1 |
| van der Meulen, N | 1 |
| Prindull, G | 1 |
| Lipp, K | 1 |
| Winge, JF | 1 |
| Amaro, A | 1 |
| Beristain, C | 1 |
| Cárdenas, JL | 1 |
| Mancera, VJ | 1 |
| Ramírez, G | 1 |
| Taub, MA | 1 |
| Osburne, RC | 1 |
| Georges, LP | 1 |
| Sode, J | 1 |
| Weller, RE | 1 |
| Theilen, GH | 1 |
| Madewell, BR | 1 |
| Büchi, G | 1 |
| Mazza, U | 1 |
| Camaschella, C | 1 |
| Saglio, G | 1 |
| Cambrin, GR | 1 |
| Termine, G | 1 |
| Enrico, E | 1 |
| Autino, R | 1 |
| Zappala, C | 1 |
| Volpe, R | 2 |
| Veronesi, A | 1 |
| Galligioni, E | 1 |
| Trovo, MG | 2 |
| Grigoletto, E | 1 |
| Misset, JL | 2 |
| De Vassal, F | 3 |
| Delgado, M | 1 |
| Ribaud, P | 1 |
| Musset, M | 2 |
| Dorval, T | 1 |
| Machover, D | 1 |
| Jasmin, C | 3 |
| Hayat, M | 9 |
| Schwarzenberg, L | 5 |
| Mathe, G | 5 |
| Coleman, CN | 1 |
| Cohen, JR | 1 |
| Burke, JS | 1 |
| Rosenberg, SA | 3 |
| Vicente, J | 1 |
| Rivas, C | 1 |
| Holgado, J | 1 |
| Murias, A | 1 |
| Oliva, H | 1 |
| Costello, WG | 1 |
| Silverstein, MN | 3 |
| Berard, C | 5 |
| Hartsock, RJ | 2 |
| Liffers, R | 1 |
| Deonarine, L | 1 |
| Weinerman, BH | 2 |
| MacDougall, BK | 1 |
| Kemel, S | 1 |
| Dinçol, D | 1 |
| Içli, F | 2 |
| Karaoğuz, H | 1 |
| Cay, F | 1 |
| Demirkazik, A | 1 |
| Akbulut, H | 1 |
| Nimer, SD | 1 |
| Zelenetz, A | 1 |
| Guglielmi, C | 7 |
| Coluzzi, S | 2 |
| Amadori, S | 8 |
| Giovannini, M | 1 |
| Torromeo, C | 1 |
| Fujiyama, Y | 1 |
| Kitoh, K | 1 |
| Niwakawa, M | 1 |
| Andoh, A | 1 |
| Hodohara, K | 1 |
| Bamba, T | 1 |
| Hosoda, S | 1 |
| Leonard, RC | 4 |
| Prescott, RJ | 2 |
| Mao, JH | 1 |
| White, JM | 1 |
| Anglin, P | 1 |
| Strauss, BA | 1 |
| Brandwein, JM | 1 |
| Soysal, T | 1 |
| Ferhanoğlu, B | 2 |
| Bilir, M | 1 |
| Akman, N | 1 |
| Sabbioni, R | 1 |
| Santo, A | 1 |
| Meneghini, V | 2 |
| Perona, G | 3 |
| Cetto, GL | 2 |
| Velasquez, WS | 3 |
| Allen, PK | 1 |
| Swan, F | 4 |
| Cabanillas, FF | 4 |
| Engelhard, M | 8 |
| Gerhartz, H | 3 |
| Brittinger, G | 8 |
| Geiseler, B | 1 |
| Gerhartz, D | 1 |
| Haunauske, AR | 1 |
| Hartlapp, HJ | 1 |
| Zagonel, V | 5 |
| Babare, R | 1 |
| Merola, MC | 1 |
| Lazzarini, R | 1 |
| Sweetenham, JW | 2 |
| Proctor, SJ | 2 |
| Blaise, D | 2 |
| De Laurenzi, A | 1 |
| Pearce, R | 1 |
| Taghipour, G | 1 |
| Goldstone, AH | 2 |
| Laurenzi A [corrected to De Laurenzi, A] | 1 |
| Corbally, N | 2 |
| Dervan, PA | 1 |
| Byrne, A | 1 |
| Carney, DN | 1 |
| Kimby, E | 2 |
| Gahrton, G | 1 |
| Glimelius, B | 1 |
| Johansson, B | 2 |
| Johansson, H | 2 |
| Juliusson, G | 1 |
| Järnmark, M | 1 |
| Löfvenberg, E | 1 |
| Pate, O | 1 |
| Dahlberg, S | 11 |
| Oken, MM | 6 |
| Grogan, TM | 5 |
| Mize, EM | 2 |
| Glick, JH | 5 |
| Coltman, CA | 7 |
| Somers, R | 8 |
| Keuning, JJ | 1 |
| Delmer, A | 1 |
| de Bock, R | 2 |
| Keunig, JJ | 1 |
| O'Riordan, JM | 1 |
| Molloy, K | 1 |
| O'Briain, DS | 1 |
| Devaney, D | 1 |
| McShane, D | 1 |
| Considine, N | 1 |
| McCann, SR | 1 |
| Sertoli, MR | 3 |
| Congiu, AM | 4 |
| Contu, A | 6 |
| Coser, P | 4 |
| Vespignani, M | 2 |
| Ben-Dayan, D | 1 |
| Mittelman, M | 1 |
| Floru, S | 1 |
| Djaldetti, M | 1 |
| Cassi, E | 1 |
| Butti, C | 1 |
| Pisoni, GB | 1 |
| Ceriani, A | 1 |
| Confalonieri, C | 1 |
| Scandolaro, L | 1 |
| Lombardi, F | 2 |
| Montalbetti, L | 1 |
| Slingerland, J | 1 |
| Theresa, C | 1 |
| Sutcliffe, SB | 1 |
| Costa, MA | 1 |
| Rabinowits, M | 1 |
| Froimtchuk, MJ | 1 |
| Olivatto, LO | 1 |
| Allan, SE | 1 |
| Gil, RA | 1 |
| Andrade, CA | 1 |
| Martino, JL | 1 |
| Dobbin, JA | 1 |
| Carriço, MK | 1 |
| Weisenburger, D | 2 |
| Niitsu, N | 20 |
| Longo, DL | 5 |
| Duffey, PL | 2 |
| Jaffe, ES | 7 |
| Raffeld, M | 1 |
| Hubbard, SM | 3 |
| Wittes, RE | 3 |
| DeVita, VT | 16 |
| Young, RC | 12 |
| Lei, KI | 2 |
| Leung, WT | 1 |
| Johnson, PJ | 1 |
| Shiff, J | 1 |
| Chetrit, A | 2 |
| Ramot, B | 3 |
| Ben-Bassat, I | 2 |
| Asano, S | 4 |
| Siegert, W | 4 |
| Nerl, C | 1 |
| Tiemann, M | 4 |
| Heinz, R | 5 |
| Gerhartz, HH | 4 |
| Schlimok, G | 2 |
| Thiel, E | 4 |
| Huber, C | 1 |
| Schadek, C | 1 |
| Brandmaier, R | 1 |
| Stern, AC | 1 |
| Gordon, LI | 5 |
| Andersen, J | 4 |
| Colgan, J | 2 |
| Glick, J | 4 |
| Resnick, GD | 2 |
| O'Connell, M | 1 |
| Cassileth, PA | 2 |
| Molnár, Z | 1 |
| Várady, E | 1 |
| Ringwald, G | 1 |
| Fleischmann, T | 1 |
| Page, FJ | 1 |
| Laidlaw, CR | 1 |
| Cooper, I | 1 |
| Tekuzman, G | 1 |
| Firat, D | 2 |
| Baltali, E | 1 |
| Kansu, E | 1 |
| Kars, A | 1 |
| Ozisik, Y | 1 |
| Ruacan, S | 1 |
| Uzunalimoğlu, B | 1 |
| Karaağaoğlu, E | 1 |
| Díaz-Maqueo, JC | 5 |
| Talavera, A | 5 |
| García, EL | 4 |
| Gopal, R | 3 |
| Saikia, TK | 2 |
| Soman, CS | 1 |
| Dinshaw, KA | 3 |
| Freilone, R | 2 |
| Gavarotti, P | 2 |
| Pini, M | 2 |
| Schürmann, D | 2 |
| Grünewald, T | 1 |
| Jautzke, G | 2 |
| Pohle, HD | 2 |
| Ruf, B | 2 |
| Norum, J | 1 |
| Aasebø, U | 1 |
| Shiramizu, B | 1 |
| Herndier, B | 2 |
| Hahn, J | 1 |
| Meeker, TC | 1 |
| Ng, V | 1 |
| Volberding, PA | 1 |
| McGrath, MS | 1 |
| De Lena, M | 4 |
| Ditonno, P | 1 |
| Lorusso, V | 3 |
| Brandi, M | 2 |
| Timurian, A | 1 |
| Marzullo, F | 3 |
| Ventrella, V | 1 |
| Pellecchia, A | 1 |
| Silvestri, F | 2 |
| Velisig, M | 1 |
| Virgolini, L | 1 |
| Barillari, G | 1 |
| Fiacchini, M | 3 |
| Bocchia, M | 6 |
| Martelli, MF | 2 |
| Papa, G | 9 |
| Kuni-Eda, Y | 1 |
| Okabe, M | 2 |
| Kurosawa, M | 1 |
| Maekawa, I | 3 |
| Higuchi, M | 2 |
| Kawamura, M | 2 |
| Morioka, M | 2 |
| Suzuki, S | 2 |
| Ohmura, T | 2 |
| Fujimoto, N | 1 |
| Aydiner, A | 1 |
| Buğra, Z | 1 |
| Topuz, E | 1 |
| Meriç, M | 1 |
| Dreger, P | 1 |
| Klöss, M | 2 |
| Petersen, B | 1 |
| Löffler, H | 2 |
| Peacock, JE | 1 |
| Greven, CM | 1 |
| Cruz, JM | 2 |
| Hurd, DD | 1 |
| Bendandi, M | 8 |
| de Ridder, M | 1 |
| van der Lelie, H | 1 |
| Nieuwenhuis, K | 2 |
| Schouten, H | 1 |
| Mulder, A | 1 |
| van Reijswoud, I | 1 |
| Hop, W | 2 |
| Lowenberg, B | 4 |
| Pittaluga, S | 2 |
| Bijnens, L | 3 |
| Peeters, CD | 1 |
| Ugar, DA | 1 |
| Türker, M | 1 |
| Memis, L | 1 |
| Soesan, M | 1 |
| Bates, SE | 2 |
| Fojo, A | 3 |
| Bryant, G | 2 |
| Zhan, Z | 2 |
| Regis, J | 2 |
| Herdt, J | 2 |
| Burke, HB | 1 |
| Mross, K | 1 |
| Fielding, AK | 1 |
| Pearce, RM | 1 |
| Bezwoda, W | 1 |
| Rastogi, RB | 1 |
| Erazo Valla, A | 1 |
| Pavlovsky, S | 4 |
| Morioka, H | 1 |
| Resegotti, L | 2 |
| Rueckle, H | 1 |
| Somoza, N | 4 |
| Moreno-Nogueira, JA | 1 |
| Séroussi, B | 1 |
| Morice, V | 1 |
| Dreyfus, F | 1 |
| Boisvieux, JF | 1 |
| Browman, GP | 1 |
| Samosh, ML | 1 |
| Benger, AM | 1 |
| Bryant-Lukosius, D | 1 |
| Wilson, WE | 1 |
| Frank, GL | 1 |
| Leber, BF | 1 |
| Sternbach, MS | 1 |
| Foster, GA | 1 |
| Satoh, Y | 1 |
| Irie, T | 2 |
| Tsuboi, I | 2 |
| Hryniuk, W | 1 |
| Dudgeon, DJ | 1 |
| Brower, M | 1 |
| Taylor, S | 1 |
| Redman, JR | 1 |
| Gutterman, JU | 1 |
| Ohnoshi, T | 3 |
| Mizuta, J | 2 |
| Tagawa, S | 3 |
| Matsutomo, S | 3 |
| Saito, S | 2 |
| Kawashima, K | 2 |
| Akagi, T | 1 |
| Kimura, I | 3 |
| Feigal, EG | 1 |
| Herranz, MT | 1 |
| Corrales, A | 1 |
| Molina, MA | 1 |
| Redondo, E | 1 |
| Almagro, M | 1 |
| Martí, J | 1 |
| Waits, TM | 2 |
| Greer, JP | 5 |
| Wolff, SN | 4 |
| Stein, RS | 3 |
| McMaster, ML | 4 |
| Cuthbert, RJ | 1 |
| Craig, JI | 1 |
| Ludlam, CA | 1 |
| Wu, GQ | 1 |
| Bates, S | 1 |
| Kohler, DR | 1 |
| Ngan, HY | 1 |
| Liang, RH | 1 |
| Lam, WK | 1 |
| Chan, TK | 2 |
| Lichtman, SM | 3 |
| Brody, J | 1 |
| Kaplan, MH | 1 |
| Susin, M | 1 |
| Koduru, P | 1 |
| Goh, JC | 1 |
| Müller, U | 1 |
| Stahel, RA | 2 |
| Hara, A | 6 |
| Shirai, T | 8 |
| Meusers, P | 4 |
| Wilmanns, W | 2 |
| Mueller, P | 1 |
| Musch, R | 1 |
| Quirt, IC | 1 |
| Skillings, JR | 1 |
| Cripps, MC | 1 |
| Bramwell, VH | 1 |
| Gospodarowicz, MK | 2 |
| Burns, BF | 1 |
| Sargeant, AM | 1 |
| Shepherd, LE | 1 |
| Kawaguchi, N | 1 |
| Yashima, M | 1 |
| Tei, H | 1 |
| Hayakawa, H | 1 |
| Hovgaard, DJ | 2 |
| Nissen, NI | 7 |
| Mounedji-Boudiaf, L | 1 |
| Culine, S | 1 |
| Devoldère, G | 1 |
| Terrier-Lacombe, MJ | 1 |
| Kattan, J | 1 |
| Cazier, A | 1 |
| Farhat, F | 1 |
| Bekradda, M | 1 |
| Droz, JP | 1 |
| Imrie, KR | 1 |
| Kutas, G | 1 |
| Warner, E | 1 |
| Burkes, R | 4 |
| Quirt, I | 1 |
| McGeer, A | 1 |
| Touroutoglou, N | 1 |
| Dimopoulos, MA | 2 |
| Pugh, W | 1 |
| Cox, J | 1 |
| Sarris, AH | 2 |
| Tubergen, DG | 1 |
| Krailo, MD | 2 |
| Rosenstock, J | 2 |
| Kadin, M | 1 |
| Morse, M | 2 |
| King, D | 1 |
| Steinherz, PG | 2 |
| Kersey, JH | 2 |
| Juan, MT | 1 |
| Sheu, LF | 1 |
| Chang, JY | 1 |
| Hwang, WS | 1 |
| Johnson, F | 1 |
| Hunt, S | 1 |
| Llanos, M | 1 |
| Tabernero, J | 1 |
| Brunet, J | 1 |
| Amenedo, M | 1 |
| Pallares, C | 1 |
| de Andres, L | 1 |
| Lopez, JJ | 1 |
| Carrión, JR | 2 |
| García Arroyo, FR | 1 |
| Salinas, P | 1 |
| Banks, PM | 1 |
| Katou, H | 1 |
| Miyaguchi, M | 1 |
| Sakai, S | 1 |
| Yamauchi, A | 1 |
| Kuwabara, H | 1 |
| Sakamoto, H | 1 |
| Leviov, M | 2 |
| Ben-Shahar, M | 7 |
| Ben-Arie, Y | 2 |
| Dror, Y | 1 |
| Faraggi, D | 2 |
| van Putten, WL | 1 |
| van Oers, RH | 1 |
| Haak, HL | 2 |
| Walker, AM | 1 |
| Makarewicz, R | 1 |
| Swirska, M | 1 |
| Terlikiewicz, J | 1 |
| Joensuu, H | 3 |
| Ristamäki, R | 2 |
| Söderström, KO | 1 |
| Jalkanen, S | 2 |
| Finlay, JL | 3 |
| Cecalupo, AJ | 1 |
| Hutchinson, RJ | 1 |
| Kadin, ME | 2 |
| Kjeldsberg, CR | 2 |
| Provisor, AJ | 1 |
| Woods, WG | 1 |
| Kessinger, A | 2 |
| White, LM | 1 |
| Gray, BG | 1 |
| Ichise, M | 1 |
| Kirsh, JC | 1 |
| Obrist, R | 1 |
| Battista, C | 1 |
| Panza, N | 1 |
| Chiurazzi, B | 1 |
| Iodice, G | 1 |
| Esposito, G | 1 |
| Bevilacqua, N | 1 |
| Pacilio, G | 1 |
| Jurcic, JG | 1 |
| Koll, B | 1 |
| Brown, AE | 1 |
| Crown, JP | 1 |
| Yahalom, J | 2 |
| Gulati, SC | 1 |
| Ruijs, CD | 1 |
| van Kempen-Harteveld, ML | 1 |
| van Baarlen, J | 1 |
| Hordijk, GJ | 1 |
| Karth, GD | 1 |
| Knapp, S | 1 |
| Tueni, C | 1 |
| Zighelboim, J | 1 |
| Larson, MV | 1 |
| Goss, PE | 1 |
| Rudinskas, L | 2 |
| King, M | 2 |
| Chow, W | 2 |
| Myers, R | 2 |
| Davidson, M | 2 |
| Poldre, P | 2 |
| Sutton, D | 2 |
| Koch, P | 3 |
| Nahler, M | 1 |
| Michiels, JJ | 3 |
| Blijham, G | 1 |
| van de Lelie, J | 1 |
| Raemakers, JW | 1 |
| van der Heul, C | 1 |
| Baxter, JD | 1 |
| DiNubile, MJ | 1 |
| Maluf, PT | 1 |
| Odone Filho, V | 1 |
| Cristofani, LM | 1 |
| Britto, JL | 1 |
| Almeida, MT | 1 |
| Pontes, E | 1 |
| Maksoud, JG | 1 |
| Manissadjian, A | 1 |
| Bokemeyer, C | 1 |
| Schmoll, HJ | 1 |
| van Rhee, J | 1 |
| Kuczyk, M | 1 |
| Schuppert, F | 1 |
| Poliwoda, H | 1 |
| O'Day, SJ | 1 |
| Rabinowe, SN | 2 |
| Neuberg, D | 7 |
| Freedman, AS | 4 |
| Soiffer, RJ | 3 |
| Spector, NA | 1 |
| Robertson, MJ | 2 |
| Anderson, K | 1 |
| Whelan, M | 1 |
| Pesek, K | 1 |
| Köppler, H | 4 |
| Pflüger, KH | 4 |
| Eschenbach, I | 4 |
| Pfab, R | 4 |
| Zeller, W | 2 |
| Holle, R | 1 |
| Steinhauer, UE | 1 |
| Gropp, C | 2 |
| Oehl, S | 2 |
| Orth, T | 1 |
| Treichel, U | 1 |
| Mayet, WJ | 1 |
| Störkel, S | 1 |
| Meyer zum Büschenfelde, KH | 1 |
| Andersen, JW | 3 |
| Smalley, RV | 2 |
| Tucci, L | 1 |
| Levato, D | 1 |
| Levato, L | 1 |
| Manfredi, L | 1 |
| Rolski, J | 1 |
| Koralewski, P | 1 |
| Pawlicki, M | 1 |
| Takagi, T | 8 |
| Sakai, C | 4 |
| Oguro, M | 3 |
| Gryn, J | 1 |
| Gordon, R | 1 |
| Bapat, A | 1 |
| Goldman, N | 1 |
| Goldberg, J | 2 |
| Uematsu, M | 3 |
| Kondo, M | 5 |
| Hiramatsu, H | 2 |
| Ikeda, Y | 1 |
| Mikata, S | 1 |
| Katayama, M | 1 |
| Ito, H | 3 |
| Kusano, S | 1 |
| Kubo, A | 1 |
| Kaku, K | 1 |
| Takahashi, M | 1 |
| Moriyama, Y | 1 |
| Nakahata, T | 1 |
| Yoshida, Y | 2 |
| Kaneko, T | 1 |
| Miwa, S | 1 |
| Lobo-Sanahuja, F | 2 |
| García, I | 2 |
| Barrantes, JC | 1 |
| Barrantes, M | 1 |
| Jiménez, R | 2 |
| Argüello, A | 1 |
| Mitsuhashi, S | 1 |
| Ninomiya, H | 1 |
| Shibuya, A | 1 |
| Kojima, H | 4 |
| Nagasawa, T | 1 |
| Ohsaka, A | 2 |
| Kawachi, S | 1 |
| Watanabe, N | 1 |
| Ishida, H | 1 |
| van Lingen, A | 1 |
| Golding, R | 1 |
| Gerrits, WB | 1 |
| Kerkhofs, H | 1 |
| Buda, F | 1 |
| Buda, C | 1 |
| La Torre, F | 1 |
| Simon, G | 1 |
| Binotto, F | 1 |
| Bellomo, R | 1 |
| Russo, F | 1 |
| Croatto, T | 1 |
| Duchi, M | 1 |
| Mandoliti, G | 1 |
| Broekmans, FJ | 1 |
| Swartjes, JM | 1 |
| Van der Valk, P | 2 |
| Schutter, EM | 1 |
| Salloum, E | 1 |
| Levin, M | 1 |
| Ayabe, T | 1 |
| Ashida, T | 1 |
| Taruishi, M | 1 |
| Namiki, M | 1 |
| Postma, TJ | 1 |
| Benard, BA | 1 |
| Heimans, JJ | 1 |
| Dhaliwal, HS | 1 |
| Gregory, W | 1 |
| Richards, MA | 1 |
| Johnson, PW | 1 |
| Whelan, JS | 1 |
| Gallagher, CJ | 1 |
| Matthews, J | 1 |
| Ganesan, TS | 1 |
| Barnett, MJ | 1 |
| Berg, WA | 1 |
| Fishman, EK | 1 |
| Dorigo, A | 1 |
| Mansberg, R | 1 |
| Ansell, SM | 1 |
| Falkson, G | 3 |
| Varsos, G | 1 |
| Fuks, Z | 1 |
| Myers, J | 1 |
| Clarkson, BD | 2 |
| Straus, DJ | 2 |
| Bergeron, C | 2 |
| Le Moine, P | 1 |
| Le Prise-Fleury, E | 1 |
| Jouan, H | 1 |
| Tass, P | 1 |
| Darcel, F | 1 |
| Chatel, M | 1 |
| Edan, C | 1 |
| Patte, C | 4 |
| Faivre, J | 1 |
| Magnasco, H | 2 |
| Cerutti, I | 1 |
| Saslavsky, J | 1 |
| Fernández, I | 1 |
| Bruno, S | 1 |
| Sampi, K | 3 |
| Dana, BW | 4 |
| Chase, E | 2 |
| Coltman, C | 2 |
| Tondini, C | 1 |
| Zanini, M | 1 |
| Bengala, C | 1 |
| Rocca, A | 1 |
| Giardini, R | 1 |
| Buzzoni, R | 2 |
| Valagussa, P | 3 |
| Bonadonna, G | 5 |
| Cajozzo, A | 3 |
| Leone, G | 5 |
| Takvorian, T | 1 |
| Mauch, P | 2 |
| Anderson, KC | 2 |
| Spector, N | 1 |
| Grossbard, M | 2 |
| Lindsley, KL | 1 |
| Lieberman, P | 1 |
| Heller, G | 1 |
| Ohtaka, A | 1 |
| Hoshino, M | 1 |
| Miwa, A | 1 |
| Sakata, Y | 1 |
| Sakamoto, S | 1 |
| Miura, Y | 3 |
| Shinohara, N | 1 |
| Kuraishi, Y | 3 |
| Kobayashi, T | 3 |
| Hirano, A | 1 |
| Isogai, Y | 1 |
| Takagi, K | 1 |
| Zrunek, M | 2 |
| Kürsten, R | 1 |
| Erlacher, L | 2 |
| Wagner, A | 2 |
| Knoflach, B | 1 |
| Chott, A | 2 |
| Luger, A | 2 |
| Radaszkiewicz, T | 3 |
| Jenkin, RD | 2 |
| Sposto, R | 4 |
| Coccia, PF | 2 |
| Exelby, PR | 1 |
| Janicek, M | 2 |
| Shulman, LN | 3 |
| Zdziarska, B | 3 |
| Nowacki, P | 2 |
| Millo, B | 1 |
| Kaźmierczak, M | 1 |
| Komarnicki, M | 1 |
| Kroll, R | 1 |
| Plewicka, M | 1 |
| Szelc, S | 1 |
| Smok-Ragankiewicz, A | 1 |
| Wojcieszek, A | 1 |
| Szkita, D | 1 |
| Mazza, JJ | 1 |
| Hines, JD | 1 |
| Neiman, RS | 4 |
| Mann, R | 2 |
| O'Connell, MJ | 6 |
| Flecknoe-Brown, S | 1 |
| Musso, M | 1 |
| Iannitto, E | 1 |
| Perrotti, A | 1 |
| Rutten, FF | 1 |
| Mortensen, BT | 1 |
| Hermine, O | 1 |
| d'Agay, MF | 1 |
| Lavignac, C | 1 |
| Marolleau, JP | 1 |
| Diebold, J | 2 |
| Reyas, F | 1 |
| Diviné, M | 4 |
| Pautier, P | 1 |
| Dupriez, B | 2 |
| Mineur, P | 1 |
| Audhuy, B | 1 |
| Reni, M | 2 |
| Bolognesi, A | 1 |
| Verusio, C | 1 |
| Villa, E | 3 |
| Cheng, AL | 1 |
| Rodriguez, JM | 1 |
| Haggag, M | 2 |
| Silingardi, V | 4 |
| Avanzini, P | 5 |
| Carotenuto, M | 3 |
| Frassoldati, A | 1 |
| Pieresca, C | 2 |
| Vallisa, D | 2 |
| Ben-Arieh, Y | 1 |
| Freidin, N | 1 |
| Reshef, R | 1 |
| Goss, P | 1 |
| Moses, AE | 1 |
| Rahav, G | 1 |
| Bloom, AI | 1 |
| Okon, E | 1 |
| Polliack, A | 3 |
| Maayan, S | 1 |
| Zimmerman, J | 1 |
| Singer, JM | 1 |
| Mijovic, A | 1 |
| Pettingale, KW | 1 |
| Nethersell, A | 1 |
| Dobbs, HJ | 1 |
| Samaratunga, IR | 1 |
| Lakhani, A | 1 |
| Mufti, GJ | 2 |
| Hansen, PB | 2 |
| Ralfkiaer, E | 1 |
| Jensen, L | 1 |
| Gaarsdal, E | 1 |
| Hansen, NE | 1 |
| Nishi, K | 1 |
| Itaya, T | 1 |
| Fuzimoto, N | 1 |
| Siekierska-Hellmann, M | 1 |
| Sworczak, K | 1 |
| Boj, E | 1 |
| Magrath, I | 1 |
| Adde, M | 1 |
| Shad, A | 1 |
| Venzon, D | 1 |
| Seibel, N | 1 |
| Gootenberg, J | 1 |
| Neely, J | 1 |
| Arndt, C | 1 |
| Nieder, M | 1 |
| Jaffe, E | 1 |
| Wittes, RA | 1 |
| Horak, ID | 1 |
| Bezwoda, WR | 1 |
| Dansey, R | 1 |
| Shaklai, S | 1 |
| Prokocimer, M | 2 |
| Hadar, H | 1 |
| Lahav, M | 1 |
| Sulkes, J | 1 |
| Shaklai, M | 2 |
| Vignetti, M | 1 |
| De Sanctis, V | 1 |
| Calabresi, F | 1 |
| Hoshino, Y | 1 |
| Ohtsuki, T | 2 |
| Yamada, M | 2 |
| Tomizuka, H | 1 |
| Furusawa, S | 4 |
| Vail, DM | 1 |
| Kisseberth, WC | 1 |
| Obradovich, JE | 1 |
| Moore, FM | 1 |
| London, CA | 1 |
| MacEwen, EG | 1 |
| Ritter, MA | 1 |
| Anderson, J | 2 |
| Schilder, RJ | 1 |
| Cassileth, P | 2 |
| Bergmann, L | 3 |
| Karakas, T | 3 |
| Knuth, A | 3 |
| Lautenschläger, G | 2 |
| Mitrou, PS | 4 |
| Moore, CL | 2 |
| Anderson, NR | 2 |
| Naccache, P | 1 |
| Decaudin, D | 3 |
| Koscielny, S | 2 |
| Bendahmane, B | 1 |
| Munck, JN | 2 |
| Vaughan Hudson, B | 2 |
| Cunningham, DC | 1 |
| Newland, AC | 1 |
| Milligan, DW | 1 |
| Stevenson, PA | 1 |
| Wood, JK | 1 |
| MacLennan, KA | 1 |
| Anderson, L | 2 |
| Gregory, WM | 2 |
| Vaughan Hudson, G | 2 |
| Hoederath, A | 1 |
| Sack, H | 1 |
| Stuschke, M | 2 |
| Lampka, E | 1 |
| Steiner, M | 1 |
| Windchy, A | 1 |
| Gould, AR | 1 |
| Kushner, GM | 1 |
| Weber, R | 1 |
| Polito, E | 1 |
| Leccisotti, A | 1 |
| Zompatori, M | 1 |
| Battista, G | 1 |
| Barbieri, E | 2 |
| Rimondi, MR | 1 |
| Frezza, G | 1 |
| Pisi, P | 1 |
| Merla, E | 2 |
| Gozzetti, A | 1 |
| Canini, R | 1 |
| Monetti, N | 1 |
| Babini, L | 1 |
| Shchepotin, IB | 1 |
| Evans, SR | 1 |
| Shabahang, M | 1 |
| Chorny, V | 1 |
| Buras, RR | 1 |
| Korobko, V | 1 |
| Zadorozhny, A | 1 |
| Nauta, RJ | 1 |
| Delgado, S | 1 |
| Ruiz, H | 1 |
| de la Torre, A | 1 |
| Guzman, R | 4 |
| Jager, E | 2 |
| Breda, E | 1 |
| Pauselli, F | 1 |
| Temperilli, L | 1 |
| Sawada, KI | 1 |
| Kohno, M | 1 |
| Hannda, H | 1 |
| Yasukouchi, T | 1 |
| Tanngo, M | 1 |
| Hirayama, A | 2 |
| Gómez-Espuch, J | 1 |
| Feliu, E | 2 |
| Tanosaki, R | 1 |
| Okamoto, S | 1 |
| Ohya, K | 1 |
| Ogawa, Y | 1 |
| Yoshida, M | 2 |
| Imagawa, S | 1 |
| Kuriki, K | 1 |
| Saito, K | 1 |
| Fojo, AT | 1 |
| Alvarez, M | 1 |
| Robey, R | 1 |
| Hose, C | 1 |
| Monks, A | 1 |
| Kang, YK | 1 |
| Chabner, B | 1 |
| Burney, IA | 1 |
| Malik, IA | 1 |
| Bellesi, G | 1 |
| Bernardi, F | 1 |
| Stefanacci, S | 1 |
| Innocenti, F | 1 |
| Fusco, II | 1 |
| Longo, G | 2 |
| Di Lollo, S | 1 |
| Ferrini, PR | 1 |
| Macia, J | 1 |
| Gomez, X | 1 |
| Esquerda, A | 1 |
| Perez, B | 1 |
| Callao, V | 1 |
| Marzo, C | 1 |
| Duque, G | 1 |
| Li, Q | 1 |
| Ang, PT | 2 |
| Hattori, M | 4 |
| Motomura, S | 3 |
| Tomita, N | 3 |
| Taguchi, J | 2 |
| Tanabe, J | 3 |
| Sakai, R | 2 |
| Fujisawa, S | 2 |
| Fukawa, H | 3 |
| Kanamori, H | 3 |
| Mouri, H | 1 |
| Maruta, A | 2 |
| Kodama, F | 3 |
| Okubo, T | 1 |
| Ibrahim, EM | 3 |
| Bunyan, RF | 1 |
| al-Mulhim, FA | 2 |
| al-Nabhan, AA | 1 |
| Ibrahim, RE | 1 |
| Ciotti, R | 1 |
| Cinieri, S | 1 |
| Di Nota, A | 1 |
| Rota-Scalabrini, D | 1 |
| Mastronardi, L | 1 |
| Carletti, S | 1 |
| Frondizi, D | 1 |
| Spera, C | 1 |
| Maira, G | 1 |
| Wong, GC | 1 |
| Tan, P | 1 |
| Goh, YT | 1 |
| Ng, HS | 1 |
| Chong, R | 1 |
| Lee, LH | 1 |
| Garcia-Suarez, J | 1 |
| Dominguez-Franjo, P | 1 |
| Del Campo, F | 1 |
| Herrero, B | 1 |
| Munoz, MA | 1 |
| Piris, MA | 1 |
| Pardo, A | 1 |
| Variakojis, D | 1 |
| Jiang, S | 1 |
| Bauer, KD | 1 |
| Linn, S | 1 |
| Quien, ET | 1 |
| Wallach, B | 1 |
| Sandhaus, L | 1 |
| Kidd, P | 1 |
| Saidi, P | 1 |
| Laurencet, FM | 2 |
| Dietrich, PY | 1 |
| Anchisi, S | 1 |
| Mermillod, B | 1 |
| Alberto, P | 2 |
| Comar, M | 1 |
| Bidoli, E | 1 |
| Giacca, M | 1 |
| Haanen, JB | 1 |
| Bieger, R | 2 |
| van't Wout, JW | 1 |
| Nel, JS | 1 |
| Falkson, CI | 2 |
| Falk, S | 1 |
| Walther, F | 1 |
| Denk, R | 1 |
| Montserrat, E | 4 |
| García-Conde, J | 2 |
| Viñolas, N | 1 |
| Hernández-Nieto, L | 1 |
| Zubizarreta, A | 3 |
| Maldonado, J | 2 |
| Alcalá, A | 2 |
| Faura, MV | 1 |
| Llorente, A | 1 |
| Bladé, J | 2 |
| Fontanillas, M | 2 |
| Estapé, J | 1 |
| Dhermain, F | 1 |
| Girinsky, T | 2 |
| Juliéron, M | 1 |
| Cosset, JM | 5 |
| Grau, E | 2 |
| Perella, M | 2 |
| Gómez, A | 2 |
| Pastor, E | 2 |
| Mirabet, MD | 1 |
| García, F | 1 |
| Ibáñez, JL | 1 |
| Aguiló, J | 1 |
| Stutte, HJ | 1 |
| Weidmann, E | 1 |
| Izuno, I | 1 |
| Takei, K | 1 |
| Gomi, K | 1 |
| Sone, S | 1 |
| Albrecht, H | 1 |
| Stellbrink, HJ | 1 |
| Greten, H | 1 |
| Guffanti, A | 1 |
| Gobbi, P | 1 |
| Colombi, M | 1 |
| Maiolo, AT | 1 |
| Rehn, SM | 1 |
| Rodriguez, M | 1 |
| Bergström, SR | 1 |
| Nyman, RS | 1 |
| Glimelius, BL | 2 |
| Kiene, J | 1 |
| Sezer, O | 2 |
| Rasche, H | 1 |
| Klempa, I | 1 |
| Papadopoulos, AJ | 1 |
| Pambakian, H | 1 |
| Tiptaft, R | 1 |
| Devaja, O | 1 |
| Raju, KS | 1 |
| Drénou, B | 1 |
| Amiot, L | 1 |
| Fardel, O | 1 |
| Caulet-Maugendre, S | 1 |
| Sasportes, M | 1 |
| Fauchet, R | 1 |
| Brockmeyer, NH | 1 |
| Pohl, G | 1 |
| Mertins, L | 1 |
| Ezzat, AA | 2 |
| Raja, MA | 1 |
| Berry, J | 2 |
| Abd El-Warith, A | 1 |
| Khan, BA | 1 |
| Rhydderch, DC | 1 |
| Meurman, JH | 2 |
| Laine, P | 2 |
| Keinànen, S | 1 |
| Pyrhönen, S | 2 |
| Lindqvist, C | 2 |
| Erdoğan, G | 1 |
| Güllü, S | 1 |
| Colak, T | 1 |
| Kamel, AN | 1 |
| Başkal, N | 1 |
| Ekinci, C | 1 |
| Caracciolo, F | 3 |
| Capochiani, E | 3 |
| Papineschi, F | 3 |
| Swierz, J | 1 |
| Zieliński, H | 1 |
| Dabek, A | 1 |
| Barai, U | 1 |
| Teoh, N | 1 |
| Stoppa, AM | 1 |
| Bouabdallah, R | 2 |
| Chabannon, C | 1 |
| Novakovitch, G | 1 |
| Vey, N | 1 |
| Camerlo, J | 1 |
| Resbeut, M | 1 |
| Di Stefano, D | 1 |
| Maraninchi, D | 1 |
| Lee, AY | 1 |
| Klimo, P | 6 |
| O'Reilly, SE | 1 |
| Gascoyne, RD | 2 |
| Gobbi, M | 4 |
| Magagnoli, M | 5 |
| Venturi, S | 1 |
| Tabanelli, M | 3 |
| Liso, V | 1 |
| Uehara, S | 1 |
| Omagari, J | 1 |
| Kunitake, N | 1 |
| Jingu, K | 2 |
| Masuda, K | 2 |
| Mihara, M | 1 |
| Shimizu, H | 1 |
| Tsukuda, H | 1 |
| Adachi, M | 1 |
| Hinoda, Y | 2 |
| Aoki, S | 1 |
| Tsujisaki, M | 1 |
| Imai, K | 1 |
| Takano, H | 1 |
| Sawada, K | 1 |
| Natoya, A | 1 |
| Tarumi, T | 1 |
| Hirayama, S | 1 |
| Koizumi, K | 1 |
| Takahashi, TA | 1 |
| Sekiguchi, S | 1 |
| Stone, J | 1 |
| Cooper, IA | 1 |
| Robertson, TI | 2 |
| Fox, RM | 1 |
| Fierro, MT | 1 |
| Doveil, GC | 1 |
| Quaglino, P | 1 |
| Savoia, P | 1 |
| Verrone, A | 1 |
| Bernengo, MG | 1 |
| Kaplan, W | 1 |
| Kamieńska, E | 1 |
| Kaneki, T | 1 |
| Hachiya, T | 1 |
| Hayano, T | 1 |
| Koizumi, T | 1 |
| Kubo, K | 1 |
| Kawashima, A | 1 |
| Sekiguchi, M | 1 |
| Honda, T | 1 |
| Maruyama, Y | 1 |
| Shehab, TM | 1 |
| Lok, AS | 1 |
| Bastion, Y | 1 |
| Blay, JY | 1 |
| Bordessoule, D | 2 |
| Salles, B | 1 |
| Obrador, GT | 1 |
| Price, B | 1 |
| O'Meara, Y | 1 |
| Salant, DJ | 1 |
| Corti, C | 1 |
| Theodore, C | 1 |
| Bayle, C | 2 |
| Rougier, P | 1 |
| Nasr, F | 1 |
| Bailey, NP | 1 |
| Woodruffe, CM | 1 |
| Fletcher, J | 1 |
| Earl, H | 1 |
| Barnard, D | 1 |
| Fuse, H | 1 |
| Hirano, S | 1 |
| Masuda, S | 1 |
| Takeshima, M | 1 |
| Maymind, M | 1 |
| Mergelas, JE | 1 |
| Seibert, DG | 1 |
| Hostetter, RB | 1 |
| Chang, WW | 1 |
| Mac Manus, MP | 1 |
| Hoppe, RT | 2 |
| Link, MP | 2 |
| Shuster, JJ | 2 |
| Donaldson, SS | 1 |
| Berard, CW | 7 |
| Murphy, SB | 1 |
| Sato, T | 3 |
| Kawanishi, J | 1 |
| Kogawa, K | 1 |
| Ohya, M | 1 |
| Sakamaki, S | 1 |
| Schenkein, DP | 1 |
| Roitman, D | 1 |
| Miller, KB | 1 |
| Morelli, J | 1 |
| Stadtmauer, E | 1 |
| Pecora, AL | 1 |
| Fernandez, H | 1 |
| Cooper, BW | 1 |
| Kutteh, L | 1 |
| Lazarus, HM | 1 |
| Kuma, K | 1 |
| Matsuzuka, F | 1 |
| Real, E | 1 |
| Escandon, J | 1 |
| Cario, E | 1 |
| Rünzi, M | 1 |
| Metz, K | 1 |
| Layer, P | 1 |
| Goebell, H | 1 |
| Feng, F | 1 |
| Zhou, L | 1 |
| Pinotti, G | 1 |
| Roggero, E | 1 |
| Pascarella, A | 1 |
| Bertoni, F | 1 |
| Savio, A | 1 |
| Savio, E | 1 |
| Capella, C | 1 |
| Pedrinis, E | 1 |
| Saletti, P | 1 |
| Morandi, E | 1 |
| Santandrea, G | 1 |
| Möhler, M | 1 |
| Gutzler, F | 1 |
| Kallinowski, B | 1 |
| Goeser, T | 1 |
| Stremmel, W | 1 |
| Villikka, K | 1 |
| Muhonen, T | 1 |
| Sitzia, J | 1 |
| North, C | 1 |
| Stanley, J | 1 |
| Winterberg, N | 1 |
| Díaz Maqueo, JC | 2 |
| Gribben, JG | 2 |
| Fisher, DC | 1 |
| Andersen, N | 1 |
| Schlossman, R | 1 |
| Kroon, M | 1 |
| Ritz, J | 1 |
| Aster, J | 1 |
| Nadler, LM | 2 |
| Rosti, G | 1 |
| van Hoof, A | 1 |
| Ritter, M | 1 |
| Shen-Orr, Z | 1 |
| Shariki, K | 1 |
| McNeil, C | 1 |
| Infanti, L | 1 |
| Stocchi, R | 1 |
| Savignano, C | 1 |
| Ulusoy, S | 1 |
| Ovali, E | 1 |
| Goto, S | 1 |
| Nakaseko, C | 1 |
| Kumagai, K | 1 |
| Camoriano, JK | 1 |
| Schroeder, G | 1 |
| Kurtin, PJ | 1 |
| Cazals, D | 1 |
| Verola, O | 1 |
| Neidhart-Berard, AM | 1 |
| Remenieras, L | 1 |
| Doyen, C | 1 |
| Hamelsand, J | 1 |
| Molina, T | 1 |
| Moulonguet, I | 1 |
| Cain, MS | 1 |
| Burton, GV | 1 |
| Holcombe, RF | 1 |
| Sonnen, R | 1 |
| Kuse, R | 1 |
| Taguchi, H | 1 |
| Shishido, T | 1 |
| Hiraoka, A | 1 |
| Kageyama, T | 1 |
| Kanamaru, A | 1 |
| Zippel, K | 1 |
| Agnes, A | 1 |
| Zieren, HU | 1 |
| Chapman, R | 1 |
| Szer, J | 1 |
| Buzzi, M | 1 |
| Sabattini, E | 1 |
| Ascani, S | 1 |
| Albertini, P | 2 |
| Sasai, Y | 1 |
| Misawa, S | 1 |
| Iwai, T | 1 |
| Tamura, A | 1 |
| Nakazawa, N | 1 |
| Ueda, Y | 1 |
| Horiike, S | 1 |
| Yokota, S | 1 |
| Taniwaki, M | 2 |
| Kashima, K | 1 |
| Tsuda, S | 1 |
| Ookawara, Y | 1 |
| Nakao, M | 1 |
| Nakagawa, H | 1 |
| Fujii, H | 2 |
| Warzocha, K | 1 |
| Ribeiro, P | 1 |
| Bienvenu, J | 1 |
| Roy, P | 1 |
| Charlot, C | 1 |
| Rigal, D | 1 |
| Arranz, R | 1 |
| García-Alfonso, P | 1 |
| Sobrino, P | 1 |
| Zamora, P | 1 |
| Carrión, R | 1 |
| García-Laraña, J | 1 |
| Pérez, G | 1 |
| López, J | 1 |
| Lavilla, E | 1 |
| Lozano, M | 1 |
| Rayón, C | 2 |
| Colomer, R | 3 |
| Barón, MG | 1 |
| Flores, E | 2 |
| Pérez-Manga, G | 1 |
| Fernández-Rañada, JM | 1 |
| Nowrousian, MR | 2 |
| Wöltjen, HH | 1 |
| Kreuser, ED | 1 |
| Reuss-Borst, M | 1 |
| Terhardt-Kasten, E | 1 |
| Busch, M | 1 |
| Neubauer, A | 2 |
| Hanrath, RD | 1 |
| Middeke, H | 1 |
| Helm, G | 1 |
| Stein, H | 2 |
| Donisi, A | 1 |
| Casari, S | 1 |
| Re, A | 1 |
| Stellini, R | 1 |
| Cadeo, G | 1 |
| Carosi, G | 1 |
| Yamazaki, H | 1 |
| Kato, A | 1 |
| Watanabe, H | 1 |
| Nagamine, M | 1 |
| Katori, M | 1 |
| Tajima, N | 1 |
| Gabbay, U | 1 |
| Stark, P | 1 |
| Epstein, O | 1 |
| Lahav, J | 1 |
| Ten Harkel, AD | 1 |
| Kist-Van Holthe, JE | 1 |
| Van Weel, M | 1 |
| Van der Vorst, MM | 1 |
| Gómez, H | 3 |
| Hidalgo, M | 1 |
| Pen, DL | 2 |
| Otero, J | 2 |
| Rodríguez, W | 2 |
| Carracedo, C | 2 |
| Cortés-Funes, H | 1 |
| Vallejos, C | 2 |
| Navaratnam, S | 1 |
| Williams, GJ | 1 |
| Pettigrew, NM | 1 |
| Mowat, MR | 1 |
| Begleiter, A | 1 |
| Johnston, JB | 1 |
| Ogawa, H | 1 |
| Sugiyama, H | 1 |
| Tani, Y | 1 |
| Tatekawa, T | 1 |
| Oji, Y | 1 |
| Kubota, T | 1 |
| Kimura, T | 1 |
| Nakagawa, M | 1 |
| Sasaki, K | 1 |
| Matsunashi, T | 1 |
| Miyake, S | 1 |
| Kishimoto, T | 1 |
| Urasiński, I | 2 |
| Wichert, K | 1 |
| Zuk, E | 1 |
| Bogomolski-Yahalom, V | 1 |
| Okun, E | 1 |
| Sherman, Y | 1 |
| Lossos, A | 1 |
| Adelstein, DJ | 1 |
| Carlin, S | 1 |
| Yokose, N | 1 |
| Ogata, K | 1 |
| Tamura, H | 1 |
| An, E | 1 |
| Kamikubo, K | 1 |
| Kudoh, S | 1 |
| Rodriguez-Diaz Pavón, J | 1 |
| Dong, K | 1 |
| Moon, T | 1 |
| Alvarez-Carmona, AM | 1 |
| León, P | 1 |
| Sancho-Tello, R | 1 |
| Carbonell, F | 1 |
| Contreras, E | 1 |
| Hernando, A | 1 |
| Hirokawa, N | 1 |
| Hareyama, M | 1 |
| Akiba, H | 1 |
| Satoh, M | 1 |
| Oouchi, A | 1 |
| Tamakawa, M | 1 |
| Sakata, K | 1 |
| Nagakura, H | 1 |
| Koito, K | 1 |
| Harabuchi, Y | 1 |
| Kataura, A | 1 |
| Mas, L | 1 |
| Santillana, S | 1 |
| Valdivia, S | 1 |
| Moreau, P | 1 |
| Rapp, MJ | 1 |
| Moreau, A | 1 |
| Dupas, B | 1 |
| Bulabois, CE | 1 |
| Juge-Morineau, N | 1 |
| Sternberg, AJ | 1 |
| Killick, S | 1 |
| Wotherspoon, AC | 1 |
| Catovsky, D | 1 |
| Airoldi, M | 1 |
| Pecchio, F | 1 |
| Albanese, F | 1 |
| Mastromatteo, V | 1 |
| Gariboldi, A | 1 |
| Negri, L | 1 |
| Fazio, M | 1 |
| Leoni, P | 2 |
| Nati, S | 2 |
| Soracco, M | 1 |
| Guarnaccia, C | 1 |
| Pescosta, N | 1 |
| Majolino, I | 2 |
| Spriano, M | 1 |
| Vimercati, R | 1 |
| Rossi, E | 1 |
| Zambaldi, G | 3 |
| Mangoni, L | 1 |
| Rizzoli, V | 4 |
| Gyger, M | 1 |
| Langley, R | 1 |
| Lespérance, B | 1 |
| Caplan, SN | 1 |
| Wiernik, PH | 4 |
| Moore, DF | 1 |
| Bennett, JM | 3 |
| Vogl, SE | 1 |
| Harris, JE | 1 |
| Luger, S | 1 |
| Nakao, A | 1 |
| Kamada, K | 1 |
| Imamura, M | 1 |
| Sakagami, K | 1 |
| Uda, M | 1 |
| Mitsuoka, S | 1 |
| Yamazaki, J | 1 |
| Nakayama, M | 1 |
| Gandarillas, MA | 1 |
| Conde, E | 1 |
| Mazorra, F | 1 |
| Cuadrado, MA | 1 |
| Baro, J | 1 |
| Garijo, J | 1 |
| Recio, M | 1 |
| Richard, C | 1 |
| Iriondo, A | 1 |
| Rafel, M | 1 |
| Esteve, J | 1 |
| Cervantes, F | 3 |
| Velasco, M | 1 |
| Serra, A | 1 |
| Campo, E | 1 |
| Ohyama, S | 1 |
| Bando, K | 1 |
| Hasegawa, Y | 1 |
| Taniguti, M | 1 |
| Shirayma, H | 1 |
| Pronzato, P | 1 |
| Lionetto, R | 1 |
| Botto, F | 1 |
| Pensa, F | 1 |
| Tognoni, A | 1 |
| Kameoka, J | 1 |
| Ichinohasama, R | 1 |
| Miura, I | 2 |
| Tomiya, Y | 1 |
| Ishikawa, I | 1 |
| Kadowaki, I | 1 |
| Sasaki, O | 1 |
| Kimura, J | 1 |
| Meguro, K | 1 |
| Ooya, K | 1 |
| Renou, P | 1 |
| Krulik, M | 1 |
| Dreiher, J | 1 |
| Raamami, P | 1 |
| Clò, V | 1 |
| Dini, D | 1 |
| Marotta, G | 1 |
| Bigazzi, C | 1 |
| Forconi, F | 1 |
| Taha, HM | 1 |
| Narasihman, P | 1 |
| Venkatesh, L | 1 |
| Cawley, M | 1 |
| Kaplan, B | 1 |
| Machida, U | 1 |
| Kami, M | 1 |
| Hirai, H | 1 |
| Malamos, NA | 1 |
| Antonopoulos, MJ | 1 |
| Nobuoka, A | 1 |
| Ishigaki, S | 1 |
| Takada, K | 1 |
| Celsing, F | 1 |
| Widell, S | 1 |
| Merk, K | 2 |
| Bernell, P | 1 |
| Grimfors, G | 1 |
| Hedlund, A | 1 |
| Liliemark, J | 1 |
| Svedmyr, E | 1 |
| Guo, XM | 1 |
| Li, JX | 1 |
| Yang, XF | 1 |
| Palomera, L | 1 |
| Azaceta, G | 1 |
| Varo, MJ | 1 |
| Soria, J | 1 |
| Gutierrez, M | 3 |
| Ohno, R | 1 |
| Enzenauer, RW | 1 |
| Brozetti, JJ | 1 |
| Dragoo, RA | 1 |
| van der Waal, RI | 1 |
| Pas, HH | 1 |
| Schulten, EA | 1 |
| Jonkman, MF | 1 |
| Nieboer, C | 1 |
| Tsai, DE | 1 |
| Stadtmauer, EA | 1 |
| Canaday, DJ | 1 |
| Vaughn, DJ | 1 |
| Vivanco Martínez, JL | 1 |
| López Pérez, J | 1 |
| Melero Moreno, C | 1 |
| Torres Valdivieso, MJ | 1 |
| Palacios López, ME | 1 |
| Contra Gómez, T | 1 |
| Martín Ramos, N | 1 |
| Bernacer Borja, M | 1 |
| Gil López, C | 1 |
| Valverde Moreno, F | 1 |
| Acar, H | 1 |
| Ecirli, S | 1 |
| Gündoğan, F | 1 |
| Bulay, O | 1 |
| Acar, A | 1 |
| Sato, Y | 1 |
| Mochimaru, J | 1 |
| Hanai, M | 1 |
| Shimizu, K | 4 |
| Hara, K | 2 |
| Yatabe, Y | 1 |
| Yazici, H | 1 |
| Yalcinkaya, L | 1 |
| Inanc, S | 1 |
| Saip, P | 1 |
| Dalay, N | 1 |
| O'Neill, BP | 2 |
| Wang, CH | 2 |
| O'Fallon, JR | 2 |
| Colgan, JD | 1 |
| Earle, JD | 4 |
| Krigel, RL | 2 |
| Brown, LD | 2 |
| McGinnis, WL | 1 |
| Ben-Yehuda, D | 1 |
| Bremnes, RM | 1 |
| Bremnes, Y | 1 |
| Dønnem, T | 1 |
| Rodriguez, J | 1 |
| Fayad, L | 1 |
| Santiago, M | 1 |
| Halcox, JP | 1 |
| Guetty-Alberto, M | 1 |
| Iten, PA | 1 |
| Jamieson, KA | 1 |
| Beggs, I | 1 |
| Robb, JE | 1 |
| el-Hakim, H | 1 |
| Nunez, DA | 1 |
| Del Forno, A | 1 |
| Del Borgo, C | 1 |
| Turriziani, A | 1 |
| Ottaviani, F | 1 |
| Antinori, A | 1 |
| Fantoni, M | 1 |
| Peters, FP | 3 |
| Ten Haaft, MA | 1 |
| Okumura, H | 1 |
| Murai, Y | 1 |
| Suzuki, K | 3 |
| Nonaka, Y | 1 |
| Sato, H | 1 |
| Tomiyama, J | 2 |
| Muto, Y | 1 |
| Kashimura, M | 1 |
| Chim, CS | 1 |
| Kwong, YL | 1 |
| Lie, AK | 1 |
| Liang, R | 2 |
| Macpherson, N | 1 |
| Lesack, D | 1 |
| Klasa, R | 1 |
| Horsman, D | 1 |
| Barnett, M | 1 |
| Shinohara, K | 1 |
| Takeda, K | 2 |
| Kameda, N | 1 |
| Katsuki, K | 1 |
| Ariyoshi, K | 1 |
| Kamei, T | 1 |
| Akiyama, J | 1 |
| Hayashi, S | 1 |
| Masaki, N | 1 |
| Fukushima, K | 1 |
| Matsukawa, M | 1 |
| Yamato, S | 1 |
| Shoda, R | 1 |
| Muraoka, R | 1 |
| Shimojo, E | 1 |
| Umeda, N | 1 |
| Togawa, A | 1 |
| Kamath, SS | 1 |
| Marcus, RB | 1 |
| Lynch, JW | 1 |
| Mendenhall, NP | 1 |
| Merlo, EM | 1 |
| Maiolo, A | 1 |
| Brocchieri, A | 1 |
| Tua, A | 1 |
| Grignani, G | 1 |
| Reinhardt, W | 1 |
| Sauter, V | 1 |
| Jockenhövel, F | 1 |
| Kummer, G | 1 |
| Uppenkamp, M | 1 |
| Witzke, O | 1 |
| Philipp, T | 1 |
| Reinwein, D | 1 |
| Mann, K | 1 |
| Tomita, T | 1 |
| Imanishi, Y | 1 |
| Kanke, M | 1 |
| Kanzaki, J | 1 |
| Ohno, Y | 1 |
| Tokumaru, Y | 1 |
| Inuyama, Y | 1 |
| Grillo-López, AJ | 2 |
| White, CA | 1 |
| Gordon, L | 1 |
| LoBuglio, AF | 2 |
| Jonas, C | 1 |
| Klippenstein, D | 2 |
| Dallaire, B | 1 |
| Varns, C | 1 |
| Ember, I | 1 |
| Kiss, I | 1 |
| Raposa, T | 1 |
| Castagna, L | 1 |
| Campbell, C | 1 |
| Sawka, C | 1 |
| Stroszczynski, C | 1 |
| Hosten, N | 1 |
| Oellinger, J | 1 |
| Spahn, G | 1 |
| Amthauer, H | 1 |
| Bittner, RC | 1 |
| Hierholzer, J | 1 |
| Ludwig, WD | 1 |
| Felix, R | 1 |
| Young, M | 1 |
| Weller, E | 1 |
| Ghosh, C | 1 |
| Flynn, P | 1 |
| Ronconi, F | 1 |
| Scaramucci, L | 1 |
| Palombi, F | 1 |
| Anticoli Borza, P | 1 |
| Cellini, C | 1 |
| Dubey, SP | 1 |
| Sengupta, SK | 1 |
| Kaleh, LK | 1 |
| Morewaya, JT | 1 |
| Palmieri, G | 1 |
| Bianco, AR | 1 |
| Catalano, G | 1 |
| De Vita, F | 1 |
| Dammacco, F | 1 |
| Lucarelli, G | 1 |
| Mantovani, G | 1 |
| D'Aprile, M | 1 |
| Heyning, FH | 1 |
| Hogendoorn, PC | 1 |
| Hermans, J | 2 |
| Khaled, HM | 1 |
| Zekri, ZK | 1 |
| Mokhtar, N | 1 |
| Ali, NM | 1 |
| Darwish, T | 1 |
| Elattar, I | 1 |
| Gaafar, R | 1 |
| Moawad, MS | 1 |
| Inoue, R | 1 |
| Natazuka, T | 1 |
| Tamekane, A | 1 |
| Kajimoto, Y | 1 |
| Iwata, N | 1 |
| Matsuoka, H | 1 |
| Chihara, K | 1 |
| Matsui, T | 3 |
| Hernández-Boluda, JC | 1 |
| Alvarez, A | 1 |
| Saikia, UN | 1 |
| Dey, P | 1 |
| Vohra, H | 1 |
| Gupta, SK | 1 |
| Marino, G | 1 |
| Frohlich, DE | 1 |
| Chen, JL | 1 |
| Kehoe, KM | 1 |
| Matsuda, M | 1 |
| Hattori, T | 1 |
| Tabata, K | 1 |
| Seki, S | 1 |
| Yoshimura, K | 1 |
| Tajika, M | 1 |
| Murakami, N | 1 |
| Hatano, Y | 1 |
| Kume, M | 1 |
| Ghirardelli, ML | 1 |
| Quarta, G | 1 |
| Loni, C | 1 |
| Ascari, E | 1 |
| Willich, NA | 2 |
| Reinartz, G | 2 |
| Horst, EJ | 1 |
| Delker, G | 1 |
| Reers, B | 2 |
| Grothaus-Pinke, B | 2 |
| Kocik, J | 2 |
| Stuart, RK | 1 |
| Ajarim, D | 1 |
| Bazarbashi, S | 1 |
| El-Foudeh, MO | 1 |
| Rahal, M | 1 |
| Al-Sayed, A | 1 |
| Okada, Y | 1 |
| Ando, M | 1 |
| Kato, T | 2 |
| Taji, H | 1 |
| Wróbel, G | 1 |
| Bogusławska-Jaworska, J | 1 |
| Kazanowska, B | 1 |
| Armata, J | 6 |
| Bubała, H | 1 |
| Dłuzniewska, A | 1 |
| Kołecki, P | 1 |
| Kowalczyk, J | 1 |
| Rokicka-Milewska, R | 1 |
| Sopyło, B | 1 |
| Stefaniak, MJ | 1 |
| Stefańska, K | 1 |
| Matysiak, M | 1 |
| Stańczak, E | 1 |
| Sutheesophon, J | 1 |
| Sutcharitchan, P | 1 |
| Swasdikul, D | 2 |
| Liow, K | 1 |
| Asmar, P | 1 |
| Liow, M | 1 |
| Spanaki, M | 1 |
| Townsend, JJ | 1 |
| Buys, S | 1 |
| Baringer, JR | 1 |
| Osborn, A | 1 |
| Kjeldsberg, C | 2 |
| Forman, JD | 1 |
| Balcerzak, SP | 3 |
| Roy, V | 1 |
| Gururangan, S | 1 |
| Chen, CI | 1 |
| Skingley, P | 1 |
| Koharasawa, H | 1 |
| Fujita, H | 1 |
| Harano, H | 2 |
| Miyashita, H | 1 |
| Matsuzaki, M | 1 |
| Ogawa, K | 2 |
| Ishigatsubo, Y | 2 |
| Várkonyi, J | 1 |
| Zalatnai, A | 1 |
| Timár, J | 1 |
| Matolcsi, A | 1 |
| Falus, A | 1 |
| Bencsáth, M | 1 |
| László, V | 1 |
| Pócsik, E | 1 |
| Kotlán, B | 1 |
| Császár, A | 1 |
| Cole, BF | 1 |
| Marit, G | 1 |
| Ravoet, C | 1 |
| Moreno, A | 1 |
| Colon-Otero, G | 1 |
| Solberg, LA | 1 |
| Penkowa, M | 1 |
| Kirk, O | 1 |
| Skinhøj, P | 1 |
| Pedersen, C | 1 |
| Lisse, I | 1 |
| Kiss, K | 1 |
| Zhou, X | 1 |
| Hamilton-Dutoit, SJ | 1 |
| Zhang, G | 1 |
| Chen, J | 1 |
| Wang, Z | 2 |
| Yong, W | 1 |
| Wei, Y | 1 |
| Wang, A | 1 |
| Luo, Y | 1 |
| Aboud, W | 1 |
| Marshall, R | 1 |
| Berkelhammer, C | 1 |
| Ikeda, H | 2 |
| Hirota, S | 1 |
| Sasai, K | 2 |
| Hayabuchi, N | 2 |
| Voso, MT | 1 |
| Pantel, G | 1 |
| Weis, M | 1 |
| Schmidt, P | 1 |
| Martin, S | 1 |
| Moos, M | 1 |
| Haas, R | 1 |
| Hohaus, S | 1 |
| Takubo, T | 2 |
| Kumura, T | 1 |
| Nishiki, S | 1 |
| Kinoshita, Y | 1 |
| Koh, K | 1 |
| Kamitani, T | 2 |
| Tatsumi, N | 2 |
| Goodman, SN | 1 |
| Post, L | 1 |
| Jamison, J | 1 |
| Miller, CB | 1 |
| Gore, S | 1 |
| Diehl, L | 1 |
| Willis, C | 1 |
| Byr, JC | 1 |
| Hildebrandt, G | 1 |
| Holler, E | 1 |
| Woenkhaus, M | 1 |
| Quarch, G | 1 |
| Reichle, A | 1 |
| Schalke, B | 1 |
| Andreesen, R | 1 |
| Spruit, P | 1 |
| van't Veer, M | 1 |
| Budel, L | 1 |
| Ohtsu, T | 2 |
| Sasaki, Y | 2 |
| Yoshida, K | 1 |
| Ohno, T | 1 |
| Mizorogi, F | 2 |
| Uike, N | 1 |
| Sai, T | 1 |
| Ikeda, S | 1 |
| Tal, R | 1 |
| Botchan, A | 1 |
| Hauser, R | 1 |
| Yogev, L | 1 |
| Paz, G | 1 |
| Yavetz, H | 1 |
| Oksenhendler, E | 1 |
| Gerard, L | 1 |
| Dubreuil, ML | 1 |
| Levy, Y | 1 |
| Matheron, S | 1 |
| Cazals-Hatem, D | 1 |
| Chevret, S | 1 |
| Clauvel, JP | 1 |
| Medvedev, PV | 1 |
| Nikitin, EA | 1 |
| Pivnik, AV | 2 |
| Mead, GM | 2 |
| Bleehen, NM | 1 |
| Gregor, A | 1 |
| Bullimore, J | 1 |
| Shirley, D | 1 |
| Rampling, RP | 1 |
| Trevor, J | 1 |
| Glaser, MG | 1 |
| Lantos, P | 1 |
| Ironside, JW | 1 |
| Moss, TH | 1 |
| Brada, M | 1 |
| Whaley, JB | 1 |
| Stenning, SP | 1 |
| Koh, KR | 1 |
| Aoyama, Y | 1 |
| Ota, T | 1 |
| Kishida, T | 1 |
| Sannomiya, Y | 1 |
| Takemura, S | 1 |
| Yamazaki, E | 1 |
| Pearson, D | 1 |
| Niedzwiecki, D | 1 |
| Carlisle, TL | 1 |
| Cooper, MR | 1 |
| Johnson, JL | 3 |
| Schlembach, PJ | 1 |
| Corato, A | 1 |
| Rossi, B | 1 |
| Vincenzi, C | 1 |
| Lambiase, A | 1 |
| de Wynter, E | 1 |
| Nadali, G | 1 |
| Chartrin, I | 1 |
| Ifrah, N | 1 |
| Arveux, P | 1 |
| Cornillet, P | 1 |
| Tourani, JM | 1 |
| Gardembas, M | 1 |
| Delain, M | 1 |
| Abgrall, JF | 1 |
| Kootz, C | 1 |
| Wakita, H | 1 |
| Igarashi, T | 1 |
| Ishizawa, K | 1 |
| Onozawa, Y | 1 |
| Minami, H | 1 |
| Anastasopoulou, A | 1 |
| Roozendaal, KJ | 1 |
| Musson, H | 1 |
| Maes, B | 1 |
| Brousse, C | 1 |
| Baumelou, E | 1 |
| Schioppa, O | 1 |
| Vultaggio, G | 1 |
| White, LA | 1 |
| Varterasian, M | 1 |
| Vaiani, M | 1 |
| Jerkeman, M | 2 |
| Iijima, K | 2 |
| Chizuka, A | 1 |
| Gilman, P | 1 |
| Lowe, A | 1 |
| Kunkel, LA | 1 |
| Silfen, ME | 1 |
| Garvin, JH | 1 |
| Hays, AP | 1 |
| Starkman, HS | 1 |
| Aranoff, GS | 1 |
| Levine, LS | 1 |
| Feldstein, NA | 1 |
| Wong, B | 1 |
| Oberfield, SE | 1 |
| Krol, AD | 1 |
| Berenschot, HW | 1 |
| Doekharan, D | 1 |
| Henzen-Logmans, S | 1 |
| van 't Veer, MB | 1 |
| Davis, JW | 1 |
| Moriarty, RP | 1 |
| Schlossberg, SM | 1 |
| Schellhammer, PF | 1 |
| Vigna, E | 1 |
| Azzarà, A | 1 |
| Carulli, G | 1 |
| Rizzuti-Gullaci, A | 1 |
| Vaquero, M | 1 |
| Romeu, J | 1 |
| Batlle, M | 1 |
| Flores, A | 2 |
| Millá, F | 2 |
| Tang, S | 1 |
| Redden, D | 1 |
| Hamzeh, F | 1 |
| Scadden, D | 1 |
| Ambinder, R | 1 |
| Levine, A | 1 |
| Harrington, W | 1 |
| Grochow, L | 1 |
| Flexner, C | 1 |
| Tan, B | 1 |
| Pau, A | 1 |
| Horne, M | 1 |
| Wilson, W | 1 |
| Verity, DH | 1 |
| Graham, EM | 1 |
| Carr, R | 1 |
| van der Walt, JD | 1 |
| Stanford, MR | 1 |
| Mikhaeel, NG | 1 |
| Spittle, MF | 1 |
| Lalisang, RI | 1 |
| Fickers, MM | 2 |
| Erdkamp, FL | 2 |
| Wils, JA | 2 |
| Houben, SG | 1 |
| Wals, J | 2 |
| Genvresse, I | 2 |
| Lange, C | 2 |
| Schanz, J | 1 |
| Schweigert, M | 2 |
| Harder, H | 1 |
| Possinger, K | 2 |
| Späth-Schwalbe, E | 2 |
| Trenhaile, TR | 1 |
| Killackey, MA | 1 |
| Polistena, P | 1 |
| Indrizzi, L | 1 |
| Jourdan, E | 1 |
| Topart, D | 1 |
| Pinzani, V | 1 |
| Jourdan, J | 1 |
| Matsue, T | 1 |
| Nakagawa, Y | 1 |
| Okamoto, R | 1 |
| Klepfish, A | 1 |
| Sarid, R | 1 |
| Shtalrid, M | 1 |
| Shvidel, L | 1 |
| Berrebi, A | 1 |
| Schattner, A | 1 |
| Mandel, L | 1 |
| Surattanont, F | 1 |
| Dourmas, M | 1 |
| Basu, S | 1 |
| Selvachandran, SN | 1 |
| Cade, D | 1 |
| Ribeiro, RC | 1 |
| Fletcher, BD | 1 |
| Kennedy, W | 1 |
| Harrison, PL | 1 |
| Neel, MD | 1 |
| Kaste, SC | 1 |
| Sandlund, JT | 1 |
| Rubnitz, JE | 1 |
| Razzouk, BI | 1 |
| Relling, MV | 1 |
| Pui, CH | 1 |
| Dugay, J | 1 |
| Maakaroun, A | 1 |
| De Muret, A | 1 |
| Mitropoulos, FA | 1 |
| Rassidakis, G | 1 |
| Vayiopoulos, GA | 1 |
| Papalampros, E | 1 |
| Kalovidouris, A | 1 |
| Giles, FJ | 1 |
| Shan, J | 1 |
| Akan, H | 1 |
| Aydogdu, I | 1 |
| Aziz, Z | 1 |
| Bapsy, PP | 1 |
| Buyukkececi, F | 1 |
| Chaimongkol, B | 1 |
| Chen, PM | 2 |
| Cheong, SK | 1 |
| Hamza, R | 1 |
| Khalid, HM | 1 |
| Kim, SY | 1 |
| Koc, H | 1 |
| Muthalib, A | 1 |
| Patel, M | 1 |
| Poovalingam, VP | 1 |
| Rana, F | 1 |
| Reksodiputro, AH | 1 |
| Ruff, P | 1 |
| Sagar, TG | 1 |
| Schwarer, AP | 1 |
| Song, HS | 1 |
| Suh, CW | 1 |
| Suharti, C | 1 |
| Supindiman, I | 1 |
| Tee, GY | 1 |
| Thamprasit, T | 1 |
| Villalon, AH | 1 |
| Wickham, NR | 1 |
| Wong, JE | 1 |
| Yalcin, A | 1 |
| Jootar, S | 1 |
| Petroni, GR | 2 |
| Parker, BA | 1 |
| Wagner, ND | 1 |
| Omura, GA | 1 |
| Robert, M | 1 |
| Kolitz, J | 1 |
| Budman, DR | 1 |
| Vinciguerra, V | 1 |
| Hoffman, M | 1 |
| Mittelman, A | 1 |
| Allen, SL | 1 |
| Fusco, D | 1 |
| Hayes, FA | 1 |
| Yamabe, H | 1 |
| Dodo, Y | 1 |
| Kashii, S | 1 |
| Nagata, Y | 1 |
| Hiraoka, M | 1 |
| Dobson, JM | 1 |
| Blackwood, LB | 1 |
| McInnes, EF | 1 |
| Bostock, DE | 2 |
| Nicholls, P | 1 |
| Hoather, TM | 1 |
| Tom, BD | 1 |
| Colgan, JP | 1 |
| McGinnis, WJ | 1 |
| Kirchner, EM | 1 |
| Ebsen, M | 1 |
| Kirchner, J | 1 |
| Theegarten, D | 1 |
| Voigtmann, R | 1 |
| Lee, EJ | 1 |
| Schiffer, CA | 1 |
| Freter, CE | 1 |
| Frizzera, G | 1 |
| Bloomfield, CD | 5 |
| Tari, A | 1 |
| Tani, H | 1 |
| Kashiwado, K | 1 |
| Kurihara, K | 1 |
| Fujihara, M | 1 |
| Yoshino, T | 2 |
| Mermershtain, W | 1 |
| Benharroch, D | 1 |
| Lavrenkov, K | 1 |
| Geffen, DB | 1 |
| German, I | 1 |
| Cohen, Y | 4 |
| Egerer, G | 1 |
| Sauerland, K | 1 |
| Katayama, H | 1 |
| Takeuchi, M | 1 |
| Munemasa, M | 1 |
| Tada, A | 2 |
| Soda, R | 1 |
| Takahashi, K | 1 |
| Picozzi, VJ | 1 |
| Pohlman, BL | 1 |
| Lawless, GD | 1 |
| Lee, MW | 1 |
| Kerr, RO | 1 |
| Ford, JM | 1 |
| Carter, WB | 2 |
| Jacobson, JO | 1 |
| Assawametha, N | 1 |
| O'Charoen, R | 1 |
| Wilder, DD | 1 |
| Ogden, JL | 1 |
| Jain, VK | 1 |
| Visco, C | 1 |
| Mesina, OM | 1 |
| Picozzi, V | 1 |
| Scott, S | 1 |
| Pohlman, B | 1 |
| Dickman, E | 1 |
| Lee, M | 1 |
| Lawless, G | 1 |
| Kerr, R | 1 |
| Caggiano, V | 1 |
| Delgado, D | 1 |
| Ford, J | 1 |
| Maung, K | 1 |
| D'Orazio, AI | 1 |
| Pelizzari, A | 1 |
| Motta, M | 1 |
| Puoti, M | 1 |
| Vanninen, E | 2 |
| Remes, J | 1 |
| Ritanen, E | 1 |
| Vuolteenaho, O | 1 |
| Hartikainen, J | 2 |
| Termuhlen, AM | 1 |
| Siegel, SE | 3 |
| Tabatabai, G | 1 |
| Cuttica, A | 1 |
| Zallio, F | 1 |
| Bergui, L | 1 |
| Marinone, C | 1 |
| Pagano, M | 1 |
| de Crescenzo, A | 1 |
| Salomone, A | 1 |
| Boccadoro, M | 1 |
| Pileri, A | 1 |
| Wessendorf, S | 1 |
| Lichter, P | 1 |
| Schwänen, C | 1 |
| Fritz, B | 1 |
| Baudis, M | 1 |
| Walenta, K | 1 |
| Döhner, H | 1 |
| Bentz, M | 1 |
| Tsang, RW | 1 |
| Rübe, C | 1 |
| Nguyen, TP | 1 |
| Pfreunschuh, M | 1 |
| Kouroukis, CT | 1 |
| Kaasa, S | 1 |
| Hjermstad, M | 1 |
| Kvaløy, S | 1 |
| Laplanche, A | 1 |
| Bertozzi, AI | 1 |
| Baruchel, A | 1 |
| Frappaz, D | 1 |
| Schmitt, C | 1 |
| Mechinaud, F | 1 |
| Nelken, B | 1 |
| Boutard, P | 1 |
| Michon, J | 1 |
| Fallon, A | 1 |
| Mohr, A | 1 |
| Stewart, C | 1 |
| Bernstein, ZP | 1 |
| McCarthy, P | 1 |
| Skipper, M | 1 |
| Brown, K | 1 |
| Miller, K | 1 |
| Wentling, D | 1 |
| Loud, P | 1 |
| Rock, MK | 1 |
| Benyunes, M | 1 |
| Bernstein, SH | 1 |
| Kato, Y | 1 |
| Akiba, J | 1 |
| Tajima, K | 1 |
| Yoshino, M | 1 |
| Singh, VP | 1 |
| Khanna, A | 1 |
| Rai, M | 1 |
| Sundar, S | 1 |
| Shukla, PK | 1 |
| Naresh, T | 1 |
| Shukla, J | 1 |
| Bhama, JK | 1 |
| Azad, NS | 1 |
| Fisher, WE | 1 |
| el Omari-Alaoui, H | 1 |
| Kebdani, T | 1 |
| Benjaafar, N | 1 |
| el Ghazi, E | 1 |
| Erriahni, H | 1 |
| el Gueddari, BK | 1 |
| Nouvel, C | 1 |
| Deconninck, E | 1 |
| Galimberti, S | 1 |
| Marasca, R | 1 |
| Fazzi, R | 1 |
| Benedetti, E | 1 |
| Guerrini, F | 1 |
| Oliva, E | 1 |
| Torelli, G | 1 |
| Sasaki, Md | 1 |
| Leite, PG | 1 |
| Leite, AG | 1 |
| de Almeida, SM | 1 |
| Krüger, L | 1 |
| Eucker, J | 1 |
| Budach, V | 1 |
| Ericsson, SM | 1 |
| Larsson, RL | 1 |
| Nygren, HP | 1 |
| Sundström, C | 1 |
| Singhal, D | 1 |
| Witham, TF | 1 |
| Germanwala, A | 1 |
| Flickinger, JC | 1 |
| Schiff, D | 1 |
| Kondziolka, D | 1 |
| Porcaro, AB | 1 |
| D'Amico, A | 1 |
| Novella, G | 1 |
| Curti, P | 1 |
| Ficarra, V | 1 |
| Antoniolli, SZ | 1 |
| Martignoni, G | 1 |
| Matteo, B | 1 |
| Malossini, G | 1 |
| Economopoulos, T | 1 |
| Mellou, S | 1 |
| Pavlidis, N | 1 |
| Samantas, E | 1 |
| Nicolaides, C | 1 |
| Tsatalas, C | 1 |
| Papageogriou, E | 1 |
| Papasavvas, P | 1 |
| Fountzilas, G | 1 |
| Paira, S | 1 |
| Graf, C | 1 |
| Roverano, S | 1 |
| Rossini, J | 1 |
| Creager, AJ | 1 |
| Geisinger, KR | 1 |
| Bergman, S | 1 |
| Ansari, MS | 1 |
| Nabi, G | 1 |
| Singh, I | 1 |
| Hemal, AK | 1 |
| Pandey, G | 1 |
| Lattuada, A | 2 |
| Milani, F | 1 |
| Beretta, G | 1 |
| Pouillart, P | 3 |
| Amiel, JL | 5 |
| Tubiana, M | 2 |
| Zajaçzkowski, J | 1 |
| Halikowski, B | 1 |
| Pituch, A | 1 |
| Legutko, L | 2 |
| Pajdak, E | 1 |
| Tancini, G | 1 |
| DeLena, M | 1 |
| Klener, P | 2 |
| Donner, L | 2 |
| Schmidt, CG | 3 |
| Anderson, T | 1 |
| Bender, RA | 1 |
| Norton, L | 3 |
| Luce, JK | 2 |
| McKelvey, EM | 2 |
| Jones, SE | 4 |
| Moon, TE | 2 |
| Lenhard, RE | 4 |
| Ezdinli, E | 3 |
| Johnson, GJ | 3 |
| Carbone, PP | 6 |
| Pocock, SJ | 1 |
| Pajak, T | 1 |
| Glidewell, O | 4 |
| Blom, H | 1 |
| Flaherty, M | 1 |
| Hayes, D | 1 |
| McIntyre, R | 1 |
| Holland, JF | 7 |
| Gamble, JF | 4 |
| Butler, JJ | 2 |
| Sinkovics, JG | 1 |
| Wallace, S | 1 |
| Martin, RG | 1 |
| Gehan, EA | 2 |
| Shullenberger, CC | 2 |
| Bodey, GP | 1 |
| Rodriguez, V | 2 |
| Freireich, EJ | 2 |
| Menefee, MG | 1 |
| Zellner, DC | 1 |
| Wright, RC | 1 |
| Ishino, H | 1 |
| Yokoyama, S | 1 |
| Mii, T | 1 |
| Gorin, NC | 2 |
| David, R | 2 |
| Stachowiak, J | 2 |
| Najman, A | 2 |
| Duhamel, G | 2 |
| Sullivan, SF | 1 |
| Dallow, RI | 1 |
| Davey, FR | 1 |
| Gottlieb, AJ | 3 |
| Durant, JR | 1 |
| Gams, RA | 1 |
| Bartolucci, AA | 1 |
| Dorfman, RF | 1 |
| Chaffey, JT | 1 |
| Hellman, S | 1 |
| Rosenthal, DS | 1 |
| Moloney, WC | 2 |
| Johnson, RE | 3 |
| Brereton, HD | 1 |
| Laurens, A | 1 |
| Thevenot, J | 1 |
| Charron, D | 1 |
| Jorry, F | 1 |
| Dumonchel, P | 1 |
| Martola, R | 1 |
| Rubio-Félix, D | 1 |
| Maicas, M | 1 |
| Rubio-Vitaller, A | 1 |
| Gil, JL | 1 |
| Giralt, M | 1 |
| Raichs, A | 1 |
| Brecher, ML | 1 |
| Sinks, LF | 1 |
| Thomas, RR | 1 |
| Freeman, AI | 1 |
| Harrison, DT | 1 |
| Neiman, PE | 1 |
| Sullivan, K | 1 |
| Hafermann, M | 1 |
| Rudolph, RH | 1 |
| Einstein, AB | 1 |
| Forcier, RJ | 2 |
| McIntyre, OR | 1 |
| Pajak, TF | 2 |
| Hayes, DM | 2 |
| Rege, V | 1 |
| Spurr, CL | 4 |
| Silver, RT | 4 |
| Harley, JB | 2 |
| Cuttner, J | 2 |
| Papp, GM | 1 |
| Walden, PA | 1 |
| Philalithis, PE | 1 |
| Joekes, AM | 1 |
| Bagshawe, KD | 1 |
| Kennedy, BJ | 2 |
| Kiang, DT | 1 |
| Vosika, G | 1 |
| Theologides, A | 1 |
| Jones, WB | 1 |
| Rhamy, RK | 1 |
| Faber, RB | 1 |
| Flexner, JM | 2 |
| Molin, JA | 1 |
| Onions, DE | 1 |
| Owen, LN | 1 |
| Costello, W | 1 |
| Vance, ZB | 1 |
| Jaffe, N | 2 |
| Buell, D | 1 |
| Nathan, DG | 1 |
| Leimert, JT | 1 |
| Corder, MP | 1 |
| Tewfik, HH | 1 |
| Guthrie, R | 1 |
| Maguire, LC | 1 |
| Gingrich, RD | 1 |
| Belpomme, D | 1 |
| Albahary, C | 1 |
| Depierre, R | 1 |
| Glatstein, E | 3 |
| Kaplan, HS | 1 |
| Young, CW | 1 |
| Prentice, RL | 1 |
| Owens, AH | 2 |
| Bakemeier, R | 2 |
| Horton, JH | 1 |
| Shnider, BI | 1 |
| Stolbach, L | 2 |
| Klein, HO | 2 |
| Gottlieb, JA | 1 |
| Wilson, HE | 2 |
| Haut, A | 1 |
| Talley, RW | 1 |
| Stephens, R | 1 |
| Lane, M | 1 |
| Grozea, PN | 2 |
| Gutterman, J | 1 |
| Bar-Meir, S | 1 |
| Golan, A | 1 |
| Vries, A | 1 |
| Kaufman, JH | 1 |
| Aungst, CW | 4 |
| Stutzman, L | 3 |
| Pocock, S | 1 |
| Silverstein, M | 1 |
| Horton, J | 1 |
| Bennett, J | 1 |
| Perlia, C | 1 |
| Brunk, SF | 1 |
| Klaassen, DJ | 1 |
| Carbone, P | 1 |
| Smets, LA | 1 |
| Mulder, E | 1 |
| de Waal, FC | 1 |
| Cleton, FJ | 1 |
| Blok, J | 1 |
| Benjamin, RS | 1 |
| Chang, P | 1 |
| Sutherland, JC | 3 |
| Rosenfeld, C | 1 |
| Patel, AR | 1 |
| Shah, PC | 1 |
| Rhee, HL | 1 |
| Sassoon, H | 1 |
| Rao, KP | 1 |
| Jochimsen, PR | 1 |
| Pearlman, NW | 1 |
| Lawton, RL | 1 |
| Schein, PS | 4 |
| Davis, JA | 1 |
| Kantrowitz, PA | 1 |
| Chandler, HL | 1 |
| Schatzki, SC | 1 |
| Morgenfeld, MC | 1 |
| Pavlovsky, A | 1 |
| Suarez, A | 1 |
| Palau, M | 1 |
| Barros, CA | 1 |
| Reis, HE | 1 |
| Passek, S | 1 |
| Bruntsch, U | 2 |
| Teske, HJ | 1 |
| Becker, G | 1 |
| Höffken, K | 2 |
| Young, RD | 1 |
| Bergsagel, DE | 1 |
| Brown, TC | 1 |
| Reid, J | 1 |
| Slater, A | 1 |
| Whittaker, JA | 2 |
| Fisher, DJ | 1 |
| Lewis, RA | 1 |
| Clark, RB | 1 |
| Padilla, F | 1 |
| Hall, WH | 1 |
| Boyd, CM | 1 |
| Thompson, BW | 1 |
| Lopez-Majano, V | 1 |
| Sion, A | 1 |
| Friedell, MT | 1 |
| Abraira, C | 1 |
| Chefec, G | 1 |
| Garfein, OB | 1 |
| Galen, MA | 1 |
| Lazarus, JM | 1 |
| Lowrie, EG | 1 |
| Hampers, CL | 1 |
| Crookston, JH | 1 |
| Bleeker, GM | 1 |
| Wagenaar, SS | 1 |
| Peeters, HJ | 1 |
| Humans, W | 1 |
| Oushoorn, HH | 1 |
| van Slooten, EA | 1 |
| Pichert, G | 1 |
| Peters, J | 1 |
| Dommann, C | 1 |
| Joss, R | 1 |
| Gebbers, JO | 1 |
| Kroner, T | 1 |
| Sulser, H | 1 |
| Honegger, HP | 1 |
| Maurer, R | 1 |
| Bianconcini, G | 1 |
| Mazzali, F | 1 |
| Candini, R | 1 |
| Dallasta, A | 1 |
| Gobbi, F | 1 |
| Putterman, C | 1 |
| Gilon, D | 1 |
| Uretzki, G | 1 |
| Bar-Ziv, J | 1 |
| Dolińska, D | 1 |
| Stankiewicz, J | 1 |
| Grzelec, H | 1 |
| Oyama, A | 4 |
| Ariyoshi, Y | 1 |
| Tenovuo, J | 1 |
| Murtomaa, H | 1 |
| Sinisalo, M | 1 |
| Oksanen, K | 1 |
| Koivisto, V | 1 |
| Vikberg, V | 1 |
| Endrizzi, L | 1 |
| Schintu, GM | 1 |
| Olmeo, N | 1 |
| Chiarion-Sileni, V | 1 |
| Sorarù, M | 1 |
| Fiorentino, MV | 1 |
| Shiigai, T | 1 |
| Platanias, LC | 1 |
| Putterman, AM | 1 |
| Vijayakumar, S | 1 |
| Recant, W | 1 |
| Weichselbaum, RR | 1 |
| Bitran, JD | 1 |
| Salles, MT | 1 |
| Neyra, O | 1 |
| Taja, L | 1 |
| Cervantes, G | 2 |
| Gagnière, M | 1 |
| Cerrillo, M | 1 |
| Mohar, A | 1 |
| Osornio, A | 1 |
| Reynoso, E | 1 |
| Gorodezky, G | 1 |
| Taillan, B | 1 |
| Ferrari, E | 1 |
| Garnier, G | 1 |
| Fuzibet, JG | 1 |
| Vinti, H | 1 |
| Dujardin, P | 1 |
| Steinke, B | 3 |
| Bross, K | 2 |
| Reinold, HM | 2 |
| Heim, ME | 4 |
| Schalk, KP | 1 |
| Heidemann, E | 2 |
| Josten, K | 2 |
| Arnold, H | 2 |
| Manegold, C | 1 |
| Hoffman, I | 1 |
| Nakano, M | 1 |
| Kawanishi, Y | 1 |
| Kuge, S | 1 |
| Kuriyama, Y | 1 |
| Kuwabara, S | 1 |
| Yaguchi, M | 1 |
| Toyama, K | 1 |
| Tsukada, K | 1 |
| Arima, K | 1 |
| Ohosone, Y | 1 |
| Hanada, T | 1 |
| Mita, S | 1 |
| Harada, K | 1 |
| Matsuoka, Y | 1 |
| Irimajiti, S | 1 |
| Fukuda, J | 1 |
| Dodwell, DJ | 1 |
| de Campos, ES | 1 |
| Soh, LT | 1 |
| Chua, EJ | 1 |
| Ong, YW | 1 |
| Ashiya, M | 1 |
| Satou, Y | 1 |
| Hirano, H | 1 |
| Sakuma, A | 1 |
| Kouda, K | 1 |
| Harrington, D | 1 |
| Neiman, R | 1 |
| Gottlieb, A | 1 |
| Sumimura, J | 1 |
| Miyata, M | 1 |
| Nakao, K | 1 |
| Kamiike, W | 1 |
| Yamaguchi, T | 1 |
| Matsuda, H | 1 |
| Hawkins, MJ | 1 |
| Bhide, V | 1 |
| Borden, EC | 1 |
| Tacik, J | 1 |
| Skoczeń, S | 1 |
| Balwierz, W | 1 |
| Demina, EA | 1 |
| Evtushenko, VV | 1 |
| Sotnikov, VM | 2 |
| Pan'shin, GA | 2 |
| Grigor'eva, MA | 1 |
| White, L | 1 |
| Quah, TC | 1 |
| Zeymer, U | 1 |
| Hirschmann, WD | 1 |
| Neuhaus, KL | 1 |
| Jakić-Razumović, J | 1 |
| Uzarević, B | 1 |
| Petrovecki, M | 1 |
| Marusić, M | 1 |
| Radman, I | 1 |
| Labar, B | 1 |
| Hovgaard, D | 1 |
| Thun-Hohenstein, L | 1 |
| Frisch, H | 1 |
| Schuster, E | 1 |
| Hanamura, A | 1 |
| Maeda, H | 1 |
| Kuwayama, W | 1 |
| Takano, Y | 1 |
| Coma, A | 1 |
| Jonte, F | 1 |
| Zanabili, Y | 1 |
| Soto, I | 1 |
| Fanjul, F | 1 |
| Carrera, D | 1 |
| Luño, E | 1 |
| Jalón, S | 1 |
| Pinto, V | 1 |
| Medolago, G | 1 |
| Virotta, G | 1 |
| Pitì, A | 1 |
| Tespili, M | 1 |
| D'Adda, F | 1 |
| Rottoli, MR | 1 |
| Comotti, B | 1 |
| Motta, T | 1 |
| Orlandi, C | 1 |
| Bertocchi, C | 1 |
| de Jong, RS | 1 |
| Damen, RM | 1 |
| Westerveld, BD | 1 |
| Nelis, GF | 1 |
| Shimamoto, Y | 1 |
| Imai, S | 1 |
| Endo, N | 1 |
| Gerardi, DA | 1 |
| Hellman, RM | 1 |
| Conlon, M | 1 |
| Santarelli, MT | 1 |
| Erazo, A | 1 |
| Lluesma Goñalons, M | 1 |
| Garcia Vela, EL | 1 |
| Iida, K | 1 |
| Melekos, MD | 1 |
| Matsouka, P | 1 |
| Fokaefs, E | 1 |
| Pantazakos, A | 1 |
| Repanti, M | 1 |
| Schneider, AM | 1 |
| Schluger, AE | 1 |
| Lowenthal, DA | 1 |
| Koziner, B | 2 |
| Lee, BJ | 2 |
| Wong, G | 1 |
| Oster, W | 1 |
| Forsthuber, T | 1 |
| Hennekeuser, HH | 1 |
| Gamm, H | 1 |
| Lindemann, A | 1 |
| Schmitz, G | 1 |
| Fuhr, HG | 1 |
| Hinterberger, R | 1 |
| Kreiter, H | 1 |
| Thoenes, W | 1 |
| Maor, MH | 1 |
| Silvermintz, KB | 1 |
| Olopade, OI | 1 |
| Larson, RA | 1 |
| Mick, R | 1 |
| Watson, SM | 1 |
| Hoffman, PC | 1 |
| Ultmann, JE | 2 |
| Golomb, HM | 2 |
| Nantel, S | 1 |
| Parboosingh, J | 1 |
| Poon, MC | 1 |
| Alter, R | 1 |
| Joshi, SS | 1 |
| Verdirame, JD | 1 |
| Chilosi, M | 1 |
| Benedetti, F | 1 |
| Conlan, MG | 1 |
| Pagliuca, A | 1 |
| Kaczmarski, R | 1 |
| Montalbán, C | 1 |
| Arechaga, S | 1 |
| Calleja, JL | 1 |
| Bellas, C | 1 |
| Patier, JL | 1 |
| Berenguer, A | 1 |
| García Villanueva, A | 1 |
| Marcos Robles, J | 1 |
| Iyer, RS | 1 |
| Nair, CN | 2 |
| Saikia, T | 1 |
| Kurkure, PA | 1 |
| Pai, SK | 2 |
| Tamura, K | 1 |
| Kosaka, M | 1 |
| Mizuguchi, T | 1 |
| Miyamoto, Y | 1 |
| Jacobs, P | 1 |
| King, HS | 1 |
| Dent, DM | 1 |
| Tucker, R | 1 |
| Rahr, V | 1 |
| Santhosh-Kumar, CR | 1 |
| Ajarim, DS | 1 |
| Shipkey, FD | 1 |
| Ginsberg, SJ | 2 |
| Nissen, N | 1 |
| Henderson, ES | 2 |
| Wassermann, K | 1 |
| Pothoff, G | 1 |
| Heitz, W | 1 |
| Kirn, E | 1 |
| Krueger, GR | 1 |
| Eckert, G | 1 |
| Hilger, HH | 1 |
| Ota, K | 2 |
| Uzuka, Y | 2 |
| Omine, M | 2 |
| Hirashima, K | 1 |
| Sanpi, K | 1 |
| Weick, JK | 4 |
| Files, JC | 1 |
| Eyre, HJ | 2 |
| Pendergrass, KB | 1 |
| Shimokawa, T | 2 |
| Suzue, T | 1 |
| Okabe, K | 3 |
| Toki, H | 3 |
| Takatani, O | 1 |
| Wesley, MN | 2 |
| Ihde, DC | 2 |
| Gilliom, M | 1 |
| Cossman, J | 2 |
| Torras, V | 2 |
| Rodríguez, L | 2 |
| López Vancell, D | 1 |
| Thorling, K | 2 |
| Bentzen, SM | 1 |
| Brincker, H | 2 |
| Christensen, BE | 2 |
| Pedersen, M | 2 |
| Osato, M | 1 |
| Aoyagi, M | 1 |
| Waku, S | 1 |
| Shishido, H | 1 |
| Hildreth, CR | 1 |
| Dana, B | 1 |
| Pierce, HI | 1 |
| Fuller, L | 1 |
| Redman, J | 1 |
| Hagemeister, F | 1 |
| Durr, E | 1 |
| Allen, P | 1 |
| Holmes, L | 1 |
| Velasquez, W | 1 |
| Brack, N | 1 |
| Dornoff, W | 1 |
| Enne, W | 2 |
| Gassmann, W | 1 |
| Heise, J | 1 |
| Cousar, JB | 1 |
| Shapiro, CL | 1 |
| Yeap, BY | 1 |
| Godleski, J | 1 |
| Jochelson, MS | 1 |
| Skarin, AT | 2 |
| Zurborn, KH | 1 |
| Gram, J | 1 |
| Glander, K | 1 |
| Delbrück, K | 1 |
| Pelzer, H | 1 |
| Bruhn, HD | 1 |
| Capnist, G | 1 |
| Sertoli, M | 1 |
| Rancan, L | 1 |
| Moretti, G | 1 |
| Abbadessa, V | 1 |
| Bashir, RM | 1 |
| Whitehouse, JM | 1 |
| Dabich, L | 1 |
| Liepman, MK | 1 |
| Bonnet, JD | 1 |
| Monconduit, M | 1 |
| de Pauw, B | 1 |
| Tanguy, A | 1 |
| Wils, J | 1 |
| Smeets, J | 1 |
| Dienemann, D | 1 |
| Cervos-Navarro, J | 1 |
| Langford, A | 1 |
| Gutiérrez, J | 1 |
| Osorio, G | 2 |
| García, H | 1 |
| Vacarezza, R | 1 |
| Cao, C | 1 |
| Knoflach, P | 1 |
| van Gelder, T | 1 |
| Klooswijk, AI | 1 |
| Schalekamp, MA | 1 |
| Woo, SD | 1 |
| Blake, K | 1 |
| Shu, RS | 1 |
| Freeman, G | 1 |
| Longtine, JA | 1 |
| Pinkus, GS | 2 |
| O'Brien, ME | 1 |
| Easterbrook, P | 1 |
| Powell, J | 1 |
| Blackledge, GR | 1 |
| Jones, L | 1 |
| MacLennan, IC | 1 |
| Delgado, JR | 1 |
| Dominguez, S | 1 |
| Garcia, P | 1 |
| Jaen, J | 1 |
| Santos, JA | 1 |
| Sullivan, MP | 2 |
| Brecher, M | 1 |
| Ramirez, I | 1 |
| Ragab, A | 1 |
| Hvizdala, E | 2 |
| Pullen, J | 2 |
| Shuster, J | 1 |
| Crist, W | 2 |
| Vietti, T | 1 |
| el-Ghamrawy, KA | 1 |
| Zawam, HZ | 1 |
| Abdel-Azim, H | 1 |
| d'Amore, F | 1 |
| Pedersen, NT | 1 |
| Hastrup, J | 1 |
| Jensen, MK | 1 |
| Johansen, P | 1 |
| Andersen, E | 1 |
| Serke, M | 1 |
| Pohl, C | 1 |
| Becker, K | 1 |
| Schrappe-Bächer, M | 1 |
| Knauf, W | 1 |
| Westerhausen, M | 1 |
| Clemens, MR | 1 |
| Helm, EB | 1 |
| Fischer, T | 1 |
| Noorduyn, LA | 1 |
| Torenbeek, R | 1 |
| Drosten, PB | 1 |
| Snow, GB | 2 |
| Balm, AJ | 1 |
| Meyer, CJ | 1 |
| Dragoni, F | 1 |
| Ideström, K | 1 |
| Lindemalm, C | 1 |
| Nielsen, H | 1 |
| Marazuela, M | 2 |
| Yebra, M | 2 |
| Girón, JA | 1 |
| Menéndez, JL | 1 |
| Vargas, JA | 1 |
| España, P | 2 |
| Garcia-Font, M | 1 |
| Durántez, A | 2 |
| Misago, M | 1 |
| Tsukada, J | 1 |
| Nakata, K | 1 |
| Nagata, K | 2 |
| Mori, N | 1 |
| Wake, A | 1 |
| Ogawa, R | 1 |
| Takouda, K | 1 |
| Lahtinen, R | 1 |
| Kuikka, J | 1 |
| Uusitupa, M | 1 |
| Länsimies, E | 1 |
| Kamei, H | 1 |
| Hiura, M | 1 |
| Hirota, Y | 1 |
| Fujise, K | 1 |
| Yazawa, M | 1 |
| Hashimoto, N | 1 |
| Sujino, H | 1 |
| Yanagisawa, T | 1 |
| Kawase, H | 1 |
| Ishihara, F | 1 |
| Kameda, H | 1 |
| Kuraishi, S | 1 |
| Kobayashi, S | 1 |
| Blatt, J | 1 |
| de Andrea, ML | 2 |
| de Camargo, B | 2 |
| Melaragno, R | 1 |
| Debranin, CO | 1 |
| Klemi, P | 1 |
| Steinhauer, EU | 1 |
| Lötzke, E | 1 |
| Jackson, DV | 1 |
| Craig, JB | 1 |
| White, DR | 1 |
| Muss, HB | 1 |
| Richards, F | 1 |
| Powell, BL | 1 |
| Ron, Y | 3 |
| Robinson, E | 1 |
| Tangen, JM | 1 |
| Abrahamsen, AF | 3 |
| Ostenstad, B | 1 |
| Bergheim, J | 1 |
| Chao, NJ | 1 |
| Horning, SJ | 1 |
| Miyoshi, M | 1 |
| Akasi, Y | 1 |
| Komiyama, S | 1 |
| Tosaka, A | 1 |
| Yamazaki, A | 1 |
| Hirokawa, M | 1 |
| Matsushita, K | 1 |
| Asakura, S | 1 |
| Nachman, J | 1 |
| Blatsios, V | 1 |
| Bouros, D | 1 |
| Emmanouel, A | 1 |
| Niotis, M | 1 |
| Sao, H | 1 |
| Mizuta, S | 1 |
| Kamiya, O | 1 |
| Ohara, K | 1 |
| Takeyama, H | 1 |
| Watanabe, E | 1 |
| Yamada, H | 2 |
| Mizuno, H | 1 |
| Ruit, JB | 1 |
| Wielenga, JJ | 1 |
| Michiels, J | 1 |
| Sizoo, W | 1 |
| Shigematsu, N | 2 |
| Ando, Y | 1 |
| Hashimoto, S | 1 |
| Fric, M | 1 |
| Hartmann, A | 1 |
| Klehr, HU | 1 |
| Pfeifer, U | 1 |
| Herberhold, C | 1 |
| Zanchini, R | 1 |
| Cavazzini, G | 1 |
| Amurri, B | 1 |
| Pinto, PC | 1 |
| Hu, E | 1 |
| Bernstein-Singer, M | 1 |
| Pinter-Brown, L | 1 |
| Govindarajan, S | 1 |
| Banavali, SD | 1 |
| Agarwala, S | 1 |
| Kurkure, P | 1 |
| Gonsalves, M | 1 |
| Thomson, GT | 1 |
| Keystone, EC | 1 |
| Sturgeon, JF | 1 |
| Fornasier, V | 1 |
| Rozman, C | 1 |
| Urbano-Ispizua, A | 1 |
| Carreras, E | 1 |
| Marín, P | 1 |
| Sierra, J | 1 |
| Nomdedeu, B | 1 |
| Wheeler, K | 1 |
| Chessells, JM | 1 |
| Mengoli, M | 1 |
| Marchi, M | 1 |
| Rota, E | 1 |
| Bertolotti, M | 1 |
| Gollini, C | 1 |
| Signorelli, S | 1 |
| du Bois, A | 1 |
| Runge, M | 1 |
| Schmid, J | 1 |
| Hillemanns, HG | 1 |
| Kempf, HG | 1 |
| Bagella, MP | 1 |
| Fadda, G | 1 |
| Cherchi, PL | 1 |
| Jarczok, K | 2 |
| Krawczyk-Kuliś, M | 1 |
| Duraj, M | 1 |
| Hołowiecki, J | 1 |
| Rudzka, E | 1 |
| Navigante, AH | 1 |
| Chacón, RD | 1 |
| Bechard, DE | 1 |
| Fairman, RP | 1 |
| DeBlois, GG | 1 |
| Via, CT | 1 |
| Gerstein, G | 1 |
| Topilow, A | 1 |
| Lebowicz, J | 1 |
| Berhardt, B | 1 |
| Chiarieri, D | 1 |
| Pasmantier, MW | 2 |
| Turhan, A | 1 |
| Harrington, DP | 3 |
| Creech, RH | 1 |
| Mann, RB | 1 |
| Hepplestone, A | 1 |
| Gilchrist, NL | 1 |
| Dagg, JH | 1 |
| Evans, IL | 1 |
| Soukop, M | 1 |
| Cáp, J | 1 |
| Misíková, Z | 1 |
| Foltinová, A | 1 |
| Lawrence, TS | 1 |
| Urba, WJ | 1 |
| Sundeen, JT | 1 |
| Dörken, B | 1 |
| Engert, W | 1 |
| Hagen-Aukamp, CH | 1 |
| Stacher, A | 3 |
| Sagher, D | 1 |
| Karrison, T | 1 |
| Schwartz, JL | 1 |
| Larson, R | 1 |
| Meier, P | 1 |
| Strauss, B | 1 |
| Jahn, H | 1 |
| Ruffert, K | 1 |
| Syrbe, G | 1 |
| Kühn, R | 1 |
| Jorke, D | 1 |
| Krüger, HU | 1 |
| Kraft, H | 1 |
| Günther, E | 1 |
| Busch, FW | 1 |
| Satti, MB | 1 |
| Al-Idrissi, HY | 1 |
| Abssod, GH | 1 |
| Abdel Jabar, A | 1 |
| Trédaniel, J | 1 |
| Gerota, I | 1 |
| Bajetta, E | 1 |
| Rilke, F | 1 |
| Banfi, A | 1 |
| Gaynor, M | 1 |
| McDermott, D | 1 |
| Adler, K | 1 |
| Beshevkin, M | 1 |
| Reisman, AM | 1 |
| Todd, D | 1 |
| Glenn, LD | 1 |
| Goldsmith, JC | 1 |
| Sorensen, S | 2 |
| Howe, D | 2 |
| Weisenberger, DD | 1 |
| Hutchins, M | 1 |
| Moravec, DF | 1 |
| Dowling, MD | 1 |
| Mailliard, J | 1 |
| Klassen, LW | 1 |
| Vaughan, WP | 1 |
| von Kalle, AK | 1 |
| Schaadt, M | 1 |
| Kraft, A | 1 |
| Löffler, B | 1 |
| Richter, C | 1 |
| Hofmann, I | 1 |
| Castello, A | 1 |
| Inverardi, D | 1 |
| Coci, A | 1 |
| Pagnucco, G | 1 |
| Merante, S | 1 |
| Magrini, U | 1 |
| Zei, G | 1 |
| Saito, Y | 2 |
| Kikuchi, Y | 1 |
| Hayasaka, K | 1 |
| Amoh, K | 1 |
| Fujita, M | 1 |
| Uekita, Y | 1 |
| Nishino, S | 1 |
| Maiello, E | 1 |
| Calabrese, P | 1 |
| Romito, S | 1 |
| Mazzei, A | 1 |
| Pakulska, J | 1 |
| Gutkowska, J | 1 |
| Eifel, PJ | 1 |
| McClure, S | 1 |
| Meier, CR | 1 |
| Schoetensack, B | 1 |
| Anders, C | 1 |
| Osieka, R | 1 |
| Watanabe, K | 1 |
| Shinbo, T | 1 |
| Kojima, M | 1 |
| Naito, M | 1 |
| Tanahashi, N | 1 |
| Nara, M | 1 |
| Kotlarek-Haus, S | 1 |
| Wołowiec, D | 1 |
| Kuliszkiewicz-Janus, M | 1 |
| Frydecka, I | 1 |
| Urbaniak-Kujda, D | 1 |
| Kuliczkowski, K | 1 |
| Płuzańska, A | 1 |
| Małecka, E | 1 |
| Krykowski, E | 1 |
| Olszańska-Skorek, T | 1 |
| Stempczyńska, J | 1 |
| Polkowska, E | 1 |
| Hyjek, E | 1 |
| Pittrová, H | 1 |
| Koza, V | 1 |
| Vozobulová, V | 1 |
| Cetkovský, P | 1 |
| Skopek, P | 1 |
| Jungerová, J | 1 |
| Cepelák, V | 1 |
| Polianskaia, AM | 1 |
| Ingberman, IaKh | 1 |
| Lindh, J | 1 |
| Lenner, P | 1 |
| Roos, G | 1 |
| Caillaud, JM | 1 |
| Bernard, A | 2 |
| Luboinski, B | 1 |
| Hartmann, O | 2 |
| Kalifa, C | 2 |
| Flamant, F | 2 |
| Lemerle, J | 2 |
| López-Vancell, D | 1 |
| Pringle, KC | 1 |
| Stolar, CJ | 1 |
| Horikoshi, N | 1 |
| Ueno, K | 1 |
| Murashima, M | 1 |
| Lennert, K | 2 |
| Wellens, W | 1 |
| Schmidt, M | 2 |
| Gassel, WD | 2 |
| Kolb, T | 2 |
| Hässler, R | 2 |
| Adedeji, MO | 1 |
| Kunii, A | 1 |
| Baĭsogolov, GD | 1 |
| Shakhtarina, SV | 1 |
| Polonskaia, NIu | 1 |
| Davydov, VA | 1 |
| Kindzel'skiĭ, LP | 1 |
| Gubareva, AA | 1 |
| Rouwen, AJ | 1 |
| Boen-Tan, TN | 1 |
| Stilma, JS | 1 |
| Juncà, J | 1 |
| Lorenzo, JC | 1 |
| Andreu, J | 1 |
| Navas, JJ | 1 |
| Trigg, ME | 1 |
| Frierdich, S | 1 |
| Serraino, D | 1 |
| Hoerni, B | 1 |
| Tangury, A | 1 |
| Ruhl, U | 1 |
| Bey, P | 1 |
| Tubiana, N | 1 |
| Breed, WP | 1 |
| Pirker, R | 1 |
| Schwarzmeier, JD | 1 |
| Lenzhofer, R | 1 |
| Konrad, K | 1 |
| Bettelheim, P | 1 |
| Bauer, K | 1 |
| Prischl, F | 1 |
| Slørdal, L | 1 |
| Kolmannskog, S | 1 |
| Moe, PJ | 1 |
| Prytz, PS | 1 |
| Aarbakke, J | 1 |
| Vecchi, V | 1 |
| Serra, L | 1 |
| Pession, A | 1 |
| Rosito, P | 1 |
| Paolucci, P | 1 |
| Burnelli, R | 1 |
| Vivarelli, F | 1 |
| Mancini, AF | 1 |
| Paolucci, G | 1 |
| Chuang, MW | 1 |
| Tzeng, CH | 1 |
| Chiou, TJ | 1 |
| Chiu, CF | 1 |
| Hsieh, RK | 1 |
| Liu, JH | 1 |
| Vargas, G | 1 |
| Barrantes, J | 1 |
| Jiménez, E | 1 |
| Mikata, A | 1 |
| Shirakawa, S | 2 |
| Shinkai, K | 3 |
| Maruyama, F | 3 |
| Sobue, R | 3 |
| Ito, N | 3 |
| Imura, H | 3 |
| Ino, T | 3 |
| Cubells Riero, J | 1 |
| Pardo García, N | 1 |
| Turmo Martí, J | 1 |
| Vela Ferrer, E | 1 |
| Badía Torroella, RM | 1 |
| González Rivero, MA | 1 |
| Illa Sala, J | 1 |
| Melo Valls, M | 1 |
| Bradstock, KF | 1 |
| Koutts, J | 1 |
| Stanton, A | 1 |
| Lee, CH | 1 |
| Castaldi, P | 1 |
| Kamath, S | 1 |
| Carter, J | 1 |
| Greenberg, M | 1 |
| Brown, T | 1 |
| Dawson, AA | 2 |
| Bennett, B | 1 |
| Moore, NR | 1 |
| Willemze, R | 4 |
| Peters, WG | 4 |
| Colly, LP | 3 |
| Verdeguer, A | 1 |
| Castel, V | 1 |
| Mínguez, JR | 1 |
| Ferris, J | 1 |
| Zubeldia Sánchez, J | 1 |
| Bezanilla Regato, JL | 1 |
| Navajas Gutiérrez, A | 1 |
| Burgos, J | 1 |
| Moya Calderón, E | 1 |
| Lucraft, HH | 2 |
| Allan, NC | 1 |
| McGillivray, JB | 1 |
| Parker, AC | 1 |
| Dłuzewska, A | 1 |
| Cieślińska, A | 1 |
| Hvizdala, EV | 1 |
| Callihan, T | 1 |
| Falletta, J | 1 |
| Sabio, H | 1 |
| Sullivan, M | 1 |
| Wharam, MD | 1 |
| Loetzke, E | 1 |
| Fairey, RN | 1 |
| Voss, N | 1 |
| Kucuk, O | 1 |
| Silverstein, MW | 1 |
| Burgers, JM | 1 |
| Qasim, M | 1 |
| Duez, N | 1 |
| Al-Ismail, SA | 1 |
| Gough, J | 1 |
| Brown, PC | 1 |
| Hart, MJ | 1 |
| White, TT | 1 |
| Rivera-Luna, R | 1 |
| Martinez-Guerra, G | 1 |
| Martinez-Avalos, A | 1 |
| Altamirano-Alvarez, E | 1 |
| Ayon-Cardenas, A | 1 |
| Cardenas-Cardoz, R | 1 |
| Borrego-Roman, R | 1 |
| Lanche-Guevara, T | 1 |
| Lopez-Corella, E | 1 |
| Fritze, D | 1 |
| Mebes, W | 1 |
| Abel, U | 1 |
| Steward, WP | 1 |
| Crowther, D | 2 |
| McWilliam, LJ | 1 |
| Jones, JM | 1 |
| Deakin, DP | 1 |
| Todd, ID | 1 |
| Blackledge, G | 1 |
| Wagstaff, J | 1 |
| Scarffe, JH | 1 |
| Harris, M | 1 |
| Rogers, P | 1 |
| Hill, I | 1 |
| Sinclair-Smith, C | 1 |
| Bowie, M | 1 |
| Palmer, MC | 1 |
| Fitzharris, BM | 1 |
| Robinson, BA | 1 |
| Atkinson, CH | 1 |
| Colls, BM | 1 |
| Correa Alves, A | 1 |
| Machado, JC | 1 |
| Franco, EL | 1 |
| Besa, EC | 1 |
| Diego, J | 1 |
| Alvarez de Mon, M | 1 |
| Vorobiof, DA | 1 |
| Terblanche, AP | 1 |
| Okamura, J | 1 |
| Ikuno, Y | 1 |
| Yamada, S | 1 |
| Tasaka, H | 1 |
| Nibu, K | 1 |
| Ikeda, N | 1 |
| Nakata, T | 1 |
| Satoi, S | 1 |
| Kajiyama, K | 1 |
| Ogasawara, H | 1 |
| Tsuiki, S | 1 |
| Horiguchi, M | 1 |
| Takaki, K | 1 |
| Takagi, S | 1 |
| Tsuboyama, A | 1 |
| Akashi, M | 1 |
| Di Pietro, N | 1 |
| Ganzina, F | 1 |
| Pergola, M | 1 |
| Silvestro, P | 1 |
| Basso, A | 1 |
| Salvatore, M | 1 |
| Jin, BL | 1 |
| Chiou, SS | 1 |
| Chang, TT | 1 |
| Perng, JJ | 1 |
| Chen, TS | 1 |
| Suzuki, Y | 1 |
| Shinozaki, T | 1 |
| Isono, M | 1 |
| Chikada, K | 1 |
| Maeno, H | 1 |
| Sawaki, S | 1 |
| Yamada, K | 1 |
| Koike, S | 1 |
| Uno, K | 1 |
| Moriwaki, S | 1 |
| Tham, RT | 1 |
| de Bruïne, FT | 1 |
| Chastang, C | 1 |
| Herrera, A | 1 |
| Desaint, B | 1 |
| Renoux, M | 1 |
| Bernard, JF | 1 |
| Brousse, N | 1 |
| Boivin, P | 1 |
| Slater, DE | 1 |
| Mertelsmann, R | 1 |
| Higgins, C | 1 |
| McKenzie, S | 1 |
| Schauer, P | 1 |
| Gee, T | 1 |
| Kempin, S | 1 |
| Arlin, Z | 1 |
| Emiliani, E | 1 |
| Gomez, GA | 1 |
| Ruco, LP | 1 |
| Mantovani, L | 1 |
| Kuentz, M | 1 |
| Jouault, H | 1 |
| Farcet, JP | 1 |
| Kardaszewicz, S | 1 |
| Luciak, M | 1 |
| Kubińska, E | 1 |
| Huzarski, J | 1 |
| Mol, JJ | 1 |
| Karim, AB | 1 |
| Veldhuijzen, RW | 1 |
| Nauta, JP | 1 |
| Langenhuijsen, MM | 1 |
| Wen, BC | 1 |
| Anselmo, AP | 1 |
| Baroni, CD | 1 |
| Biagini, C | 1 |
| Tang, WY | 1 |
| He, GF | 1 |
| Din, GX | 1 |
| Sun, ZY | 1 |
| Saeter, G | 1 |
| Dahl, IM | 1 |
| Okamoto, M | 1 |
| Takada, T | 1 |
| Morikawa, K | 1 |
| Bishop, JF | 1 |
| Kaplan, RS | 1 |
| Diggs, CH | 1 |
| Barcos, MP | 1 |
| Losonczy, H | 1 |
| Nagy, I | 1 |
| Willemze, ER | 1 |
| Page, RL | 1 |
| Leifer, CE | 1 |
| Matus, RE | 1 |
| Setdikov, RA | 1 |
| Schrøder, H | 1 |
| Tominaga, S | 1 |
| Prats Viñas, J | 1 |
| Gallego Melcón, S | 1 |
| Pérez Payarols, J | 1 |
| Macía Martí, J | 1 |
| Sánchez de Toledo, J | 1 |
| Ozanne, F | 1 |
| Habrand, JL | 1 |
| Camitta, BM | 1 |
| Lauer, SJ | 1 |
| Casper, JT | 1 |
| Kirchner, PA | 1 |
| Kun, LE | 1 |
| Oechler, HW | 1 |
| Adair, SE | 1 |
| Hanak, H | 1 |
| Boyett, J | 1 |
| Doering, EJ | 1 |
| Trueworthy, R | 1 |
| Ruymann, F | 1 |
| Steuber, CP | 1 |
| Qiu, W | 1 |
| Silverman, EM | 1 |
| Reed, RE | 1 |
| Lynfield, YL | 1 |
| Farhangi, M | 1 |
| Runnels, JL | 1 |
| Maldonado, N | 1 |
| Corcino, J | 1 |
| Kiely, JM | 1 |
| De Souza e Silva, NA | 1 |
| Wilson, DM | 1 |
| Druet, P | 1 |
| Dryll, A | 1 |
| Ryckewaert, A | 1 |
| de Sèze, S | 1 |
| Kahn, MF | 1 |
| Jalota, R | 1 |
| Eichwald, EJ | 1 |
| Krain, LS | 1 |
| Bierman, SM | 1 |
| Aghai, E | 1 |
| Hulu, N | 1 |
| Virag, I | 1 |
| Kende, G | 1 |
| Gregl, A | 1 |
| Prindul, F | 1 |
| Weigel, F | 1 |
| Krack, U | 1 |
| Thorpe, P | 1 |
| Clarysse, A | 1 |
| Davis, P | 1 |
| Palva, T | 1 |
| Palva, A | 1 |
| Dammert, K | 1 |
| Karma, P | 1 |
| Karitzky, D | 1 |
| Jacobi, H | 1 |
| Zucker, RM | 1 |
| Cassen, B | 1 |
| Gutjahr, P | 1 |
| Mims, CH | 1 |
| Costanzi, JJ | 1 |
| Zajackowski, J | 1 |
| Cyklis, R | 1 |
| Halikowska-Lacka, E | 1 |
| Gunz, FW | 2 |
| Levi, JA | 1 |
| Lind, DE | 1 |
| Vincent, PC | 2 |
| Van Thiel, DH | 1 |
| Sherins, RJ | 3 |
| Myers, GH | 1 |
| De Vita, VT | 3 |
| Reilly, CJ | 1 |
| Slack, NH | 1 |
| Webster, J | 1 |
| Walbom-Jorgensen, S | 1 |
| Con, I | 1 |
| Daiber, A | 1 |
| Donoso, A | 1 |
| Mora, F | 1 |
| Le Bourgeois, JP | 1 |
| Delobel, J | 1 |
| Rubin, P | 1 |
| Oliver, I | 1 |
| De Vries, A | 1 |
| Spitzer, SA | 1 |
| Henig, E | 1 |
| Cotton, JR | 1 |
| Searls, AG | 1 |
| Remmers, AR | 1 |
| Lindley, JD | 1 |
| Beathard, GA | 1 |
| Cottom, DL | 1 |
| Fish, JC | 1 |
| Townsend, CM | 1 |
| Ritzmann, SE | 1 |
| Schein, PJ | 1 |
| Bagley, CM | 2 |
| Host, H | 1 |
| Squire, RA | 2 |
| Bush, M | 2 |
| Arseneau, JC | 1 |
| Barnett, LB | 1 |
| Schwartz, E | 1 |
| Myerowitz, RL | 1 |
| Bishop, YM | 1 |
| Moran, EM | 1 |
| Desser, RK | 1 |
| Miller, JB | 1 |
| Rasà, G | 1 |
| Donati, A | 1 |
| Morici, V | 1 |
| Moscato, V | 1 |
| Mukherji, B | 2 |
| Yagoda, A | 2 |
| Krakoff, IH | 2 |
| Frei, E | 2 |
| Bailey, CC | 1 |
| Campbell, RH | 1 |
| Halkin, H | 1 |
| Meytes, D | 1 |
| Militeanu, J | 1 |
| Hugues, J | 1 |
| McElwain, TJ | 1 |
| Boiron, M | 2 |
| Ellison, RR | 1 |
| Sawitsky, A | 1 |
| Rosner, F | 1 |
| Gussoff, B | 1 |
| Karanas, A | 1 |
| Blom, J | 2 |
| Leone, LA | 2 |
| Haurani, F | 1 |
| Kyle, R | 1 |
| Hutchison, JL | 1 |
| Moon, JH | 1 |
| Doak, PB | 1 |
| Montgomerie, JZ | 1 |
| North, JD | 1 |
| Smith, F | 1 |
| Goudemand, M | 1 |
| Sautière-Habay, D | 1 |
| Bauters, F | 1 |
| Lerche-Habart, B | 1 |
| Hoogstraten, B | 1 |
| Glidewell, OJ | 1 |
| Olson, KB | 1 |
| Townsend, SR | 1 |
| Miller, S | 1 |
| Eridani, S | 1 |
| Esposito, R | 1 |
| Ponti, GB | 1 |
| Giangrande, A | 1 |
| Lowenbraun, S | 2 |
| Serpick, AA | 3 |
| Mani, MK | 1 |
| Ravich, RB | 1 |
| Speden, J | 1 |
| Feldman, MJ | 1 |
| Monto, RW | 1 |
| Isaacs, BL | 1 |
| Palmer, RL | 1 |
| Hewlett, JS | 1 |
| Cohen, ML | 1 |
| Weiss, EB | 1 |
| Lewinski, U | 1 |
| Oettgen, HF | 1 |
| Penn, I | 1 |
| Hammond, W | 1 |
| Brettschneider, L | 1 |
| Starzl, TE | 1 |
| Becker, H | 1 |
| Presant, CA | 1 |
| Citarrella, P | 1 |
| Carreca, I | 1 |
| D'Eredità, F | 1 |
| Kurnick, JE | 1 |
| Robinson, WA | 1 |
| Brunning, RD | 1 |
| Religa, H | 1 |
| Sosin, A | 1 |
| Czechowicz, Z | 1 |
| Aur, RJ | 1 |
| Hustu, HO | 1 |
| Simone, JV | 1 |
| Pratt, CB | 1 |
| Pinkel, D | 1 |
| Galton, DA | 1 |
| Jones, B | 1 |
| Kung, F | 1 |
| Nyhan, WL | 1 |
| Hananian, J | 1 |
| Burgert, EO | 1 |
| Mills, SD | 1 |
| Treat, C | 1 |
| Wolman, IJ | 1 |
| Chevalier, L | 1 |
| Denton, R | 1 |
| Sheehe, P | 1 |
| Cline, MJ | 1 |
| Passwell, J | 1 |
| Boichis, H | 1 |
| Cohen, BE | 1 |
| White, LP | 1 |
| Emmer, M | 1 |
| Kutschera, H | 1 |
| Faldini, A | 1 |
| Hall, TC | 1 |
| Choi, OS | 1 |
| Abadi, A | 1 |
| Krant, MJ | 1 |
| Self, SJ | 1 |
| Carter, VH | 1 |
| Noojin, RO | 1 |
| Ghosh, L | 1 |
| Muehrcke, RC | 1 |
| Band, PR | 1 |
| Silverberg, DS | 1 |
| Henderson, JF | 1 |
| Ulan, RA | 1 |
| Wensel, RH | 1 |
| Banerjee, TK | 1 |
| Little, AS | 1 |
| Rosenbaum, EH | 1 |
| Cohen, RA | 1 |
| Glatstein, HR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Phase II Trial of EPOCH Given Either Concurrently or Sequentially With Rituximab in Patients With Intermediate- or High-Grade HIV-Associated B-cell Non-Hodgkin's Lymphoma[NCT00049036] | Phase 2 | 106 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy With Rituximab in HIV-Related B-Cell Non-Hodgkin's Lymphoma[NCT01193842] | Phase 1/Phase 2 | 107 participants (Actual) | Interventional | 2010-10-06 | Completed | ||
| A Phase 1b/2 Investigator Initiated Study of RCHOP in Combination With Selinexor (KPT-330) in B Cell Non-Hodgkin's Lymphoma[NCT03147885] | Phase 1/Phase 2 | 44 participants (Anticipated) | Interventional | 2017-06-20 | Recruiting | ||
| Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas[NCT00554164] | Phase 3 | 1,073 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| An Open-Label, Randomized, Parallel-Group Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHO[NCT00877006] | Phase 3 | 447 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Isatuximab and Bendamustine in Systemic Light Chain Amyloidosis[NCT04943302] | Phase 2 | 0 participants (Actual) | Interventional | 2022-09-30 | Withdrawn (stopped due to PI left institution. Study not moving forward in her absence.) | ||
| A Phase Ib/II, Open-Label Study Evaluating the Safety, Efficacy and Pharmacokinetics of GDC-0199 (ABT-199) in Combination With Rituximab (R) or Obinutuzumab (G) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients With B-Cell[NCT02055820] | Phase 1/Phase 2 | 267 participants (Actual) | Interventional | 2013-11-17 | Completed | ||
| SWOG-9704 A Randomized Phase III Trial Comparing Early High Dose Chemoradiotherapy and an Autologous Stem Cell Transplant to Conventional Dose CHOP Chemotherapy Plus Rituximab for CD20+ B Cell Lymphomas (With Possible Late Autologous Stem Cell Transplant)[NCT00004031] | Phase 3 | 397 participants (Actual) | Interventional | 1997-07-31 | Completed | ||
| Rituximab, Cyclophosphamide, Vincristine, and Prednisone in Combination With Doxorubicin (R-CHOP) Versus in Combination With Pegylated-liposomal Doxorubicin (R-CDOP) as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma: a Random[NCT02428751] | Phase 3 | 216 participants (Anticipated) | Interventional | 2015-09-30 | Recruiting | ||
| A Randomized Phase II Trial Comparing BeEAM With BEAM as Conditioning Regimen for Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)[NCT02278796] | Phase 2 | 108 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| A Phase 1b Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With CD20-Positive B-Cell Non Hodgkin Lymphoma (NHL)[NCT01569750] | Phase 1 | 33 participants (Actual) | Interventional | 2012-06-14 | Completed | ||
| A Phase I/II Trial of VR-CHOP for Patients With Untreated Follicular Lymphoma and Other Low Grade B-Cell Lymphomas[NCT00634179] | Phase 1/Phase 2 | 37 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Phase II Trial of Rituximab and Short Duration Chemotherapy Followed by Zevalin as First-Line Treatment for Patients With Low Grade Follicular Non-Hodgkin's Lymphoma[NCT00193440] | Phase 2 | 40 participants | Interventional | 2002-04-30 | Completed | ||
| Phase II Multicenter Study of Cyclophosphamide, Vincristine, and Prednisone (CVP) Followed by Iodine-131 Anti-B1 Antibody for Patients With Untreated Low-grade Non-Hodgkin's Lymphoma (NHL).[NCT01663714] | Phase 2 | 30 participants (Actual) | Interventional | 2000-02-29 | Completed | ||
| A Prospective Non-randomised Trial of Chemotherapy and Radiotherapy for Osteolymphoma[NCT00141648] | 70 participants (Actual) | Interventional | 2000-09-30 | Completed | |||
| Nivolumab With Standard of Care Chemotherapy for the First Line Treatment of Peripheral T Cell Lymphoma[NCT03586999] | Phase 1/Phase 2 | 18 participants (Actual) | Interventional | 2018-11-07 | Active, not recruiting | ||
| Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.[NCT03964480] | 1,000 participants (Anticipated) | Observational [Patient Registry] | 2018-10-14 | Recruiting | |||
| Randomized Phase III Study of Standard CHOP (S-CHOP) Versus Biweekly CHOP (Bi-CHOP) in Aggressive Non-Hodgkin's Lymphoma (JCOG9809)[NCT00133302] | Phase 3 | 450 participants | Interventional | 1999-02-28 | Terminated | ||
| A Phase II Study of the Novel Proteasome Inhibitor Bortezomib in Combination With Rituximab, Cyclophosphamide and Prednisone in Patients With Relapsed/Refractory Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma (MCL)[NCT00295932] | Phase 1/Phase 2 | 79 participants (Actual) | Interventional | 2005-12-13 | Completed | ||
| Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma[NCT02526823] | Phase 4 | 360 participants (Anticipated) | Interventional | 2015-08-31 | Recruiting | ||
| Phase I Study of Pegylated Liposomal Doxorubicin Combined With Cyclophosphamide and Vincristine in Treatment Progress, Relapse, and Refractory Solid Tumors in Children[NCT04213612] | Phase 1 | 21 participants (Anticipated) | Interventional | 2019-12-30 | Not yet recruiting | ||
| Phase III Randomized Study of R-CHOP V. Dose-Adjusted EPOCH-R With Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas[NCT00118209] | Phase 3 | 524 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| An Open-Label, One Arm, Phase I Safety Study of Anti-CD20 Antibody (Rituximab, Rituxan) Therapy in the Treatment of Primary Sjogren's Syndrome[NCT00101829] | Phase 1 | 12 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| A Phase II Pilot Trial of CHOP Followed by Iodine-131-Labeled Monoclonal Anti-B1 Antibody for Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphomas[NCT00003784] | Phase 2 | 102 participants (Actual) | Interventional | 1999-05-31 | Completed | ||
| Randomized Study of ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Non Previously Treated Patients Aged From 60 to 65 Years With Diffuse Large B-Cell Lymphoma[NCT00135499] | Phase 3 | 138 participants (Actual) | Interventional | 2001-10-16 | Terminated (stopped due to Recruitment too low) | ||
| Randomized Study of ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients Aged From 18 to 59 Years With Diffuse Large B-cell Lymphoma and a Age-adjusted IPI of 1.[NCT00140595] | Phase 3 | 380 participants (Anticipated) | Interventional | 2003-12-31 | Completed | ||
| Study of ACVBP Plus Rituximab in Previously Untreated Patients Aged From 18 to 59 Years With High Risk Diffuse Large B-cell Lymphoma (Age-adjusted IPI = 2-3)[NCT00144807] | Phase 2 | 128 participants (Actual) | Interventional | 2003-12-31 | Completed | ||
| Randomized Study of ACVBP Versus ACVBP Plus Rituximab in Previously Untreated Patients Aged From 18 to 65 Years With Low-risk Localized Diffuse Large B-cell Lymphoma (Age-adjusted IPI = 0)[NCT00140660] | Phase 3 | 223 participants (Actual) | Interventional | 2003-12-31 | Terminated (stopped due to Low acrual) | ||
| Prospective Observational Study Investigating the Cardiotoxicity of Anthracyclines in Patients With Diffuse Large B-Cell[NCT02916316] | 127 participants (Actual) | Observational | 2014-02-12 | Active, not recruiting | |||
| A Multicenter Phase II Study Evaluating BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Prior to Autologous Stem Cell Transplant for First and Second Chemosensitive Relapses in Patients With Follicular Lymphoma[NCT02008006] | Phase 2 | 21 participants (Actual) | Interventional | 2014-07-09 | Terminated (stopped due to Insufficient recruitment and unavailability of the treatment) | ||
| LINFOTARGAM: First-line Treatment With Dose-dense Chemotherapy Plus Rituximab (R-CHOP/14) and Highly Active Antiretroviral Therapy (HAART) in Patients With Diffuse Large B Cell Lymphoma (DLBCL) and Infection With the Human Immunodeficiency Virus (HIV)[NCT00466258] | Phase 4 | 50 participants (Anticipated) | Interventional | 2006-10-31 | Completed | ||
| [NCT01839227] | 87 participants (Actual) | Interventional | 2012-11-30 | Completed | |||
| A Prospective, Open, Randomized Controlled, Multi-center Phase III Clinical Trial Comparing High-dose Epirubicin and Standard-dose Epirubicin in R±CEOP in Newly Diagnosed Young Patients With Medium/High-risk Diffuse Large B-cell Lymphoma[NCT03151044] | Phase 3 | 408 participants (Anticipated) | Interventional | 2016-07-31 | Recruiting | ||
| Safety and Efficacy of Ibritumomab Tiuxetan (Zevalin®) in Association With a Fludarabine Based Reduced Conditioning Regimen and Allogenic Stem Cell Support in Chemo-sensitive Relapsed CD20 Positive Aggressive Non-Hodgkin's Lymphoma Patients.[NCT00607854] | Phase 2 | 31 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Randomized Trial of CHOP Chemotherapy With or Without Rituximab (Chimeric Anti-CD20 Antibody) for HIV-Associated Non-Hodgkin's Lymphoma[NCT00003595] | Phase 3 | 120 participants (Actual) | Interventional | 1999-01-31 | Completed | ||
| A Prospective Multicenters Clinical Cohort Study of the Efficacy and Safety of Stratified Risk Factors for Treatment of Chinese Children With Systemic ALK-positive Anaplastic Large Cell Lymphoma[NCT03971305] | 300 participants (Anticipated) | Observational [Patient Registry] | 2017-05-05 | Recruiting | |||
| A Randomized Study of a New Medical Device for Oral Mucositis (MDOM Trial)[NCT05104268] | Phase 1/Phase 2 | 100 participants (Anticipated) | Interventional | 2021-11-30 | Not yet recruiting | ||
| A Phase 1/Phase 2 Study for the Prevention of Oral Mucositis (SPOM)[NCT05338398] | Phase 1/Phase 2 | 100 participants (Anticipated) | Interventional | 2022-04-15 | Enrolling by invitation | ||
| Phase I Study of Multiple Ascending Dose, to Investigate the Safety and Tolerability of the Use of Copaiba in Patients With Oral Cancer Submitted to Radiotherapy[NCT05308732] | Phase 1 | 36 participants (Anticipated) | Interventional | 2021-05-11 | Recruiting | ||
| Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)[NCT03136497] | Phase 1 | 10 participants (Actual) | Interventional | 2017-09-05 | Active, not recruiting | ||
| Randomized Intergroup Trial of First Line Treatment for Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma With a CHOP-Like Chemotherapy Regimen With or Without the Anti-CD20 Antibody Rituximab[NCT00064116] | Phase 3 | 824 participants (Actual) | Interventional | 2001-05-08 | Completed | ||
| Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma： a Single-arm, Single-centre, Open-label Trial[NCT05786989] | Phase 4 | 32 participants (Anticipated) | Interventional | 2023-02-28 | Recruiting | ||
| Standard Chemotherapy (CHOP Regimen) Versus Sequential High-Dose Chemotherapy With Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas and Poor Prognostic Factors: A Randomized Phase III Study (MISTRAL)[NCT00003215] | Phase 3 | 400 participants (Anticipated) | Interventional | 1997-04-30 | Completed | ||
| Candidate Gene Polymorphisms and Response to Rituximab-CHOP in Patients With Diffuse Large Cell Lymphoma[NCT00590941] | 52 participants (Actual) | Interventional | 2005-02-28 | Completed | |||
| Phase II Trial Investigating Tailoring First-Line Therapy For Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma Based on Mid-Treatment Positron Emission Tomography (PET) Scan Results[NCT00324467] | Phase 2 | 150 participants (Actual) | Interventional | 2006-08-31 | Active, not recruiting | ||
| Adoptive Cell Therapy for B-Cell Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation With Costimulated, Tumor-Derived Lymphocytes[NCT01445132] | Phase 1 | 11 participants (Actual) | Interventional | 2007-01-11 | Completed | ||
| A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas[NCT00001430] | Phase 2 | 49 participants | Interventional | 1995-02-28 | Completed | ||
| Pilot Study of Idiotype Vaccine and EPOCH-Rituximab Chemotherapy in Untreated Mantle Cell Lymphoma[NCT00005780] | Phase 2 | 26 participants (Actual) | Interventional | 2000-06-01 | Completed | ||
| Ovarian Tissue Freezing For Fertility Preservation In Women Facing A Fertility Threatening Medical Diagnosis Or Treatment Regimen: A Study By The National Physicians Cooperative of the Oncofertility Consortium At Northwestern University[NCT00902720] | Phase 4 | 25 participants (Anticipated) | Interventional | 2009-05-31 | Recruiting | ||
| Randomized Phase II Study of Dose-Adjusted EPOCH-Rituximab-Bortezomib (EPOCH-R-B) Induction Followed by Bortezomib Maintenance Versus Observation in Untreated Mantle Cell Lymphoma With Microarray Profiling and Proteomics[NCT00114738] | Phase 2 | 53 participants (Actual) | Interventional | 2005-06-15 | Completed | ||
| Phase II Study of the Association of Velcade to R-CHOP in the Treatment of B Cell Lymphoma[NCT00169468] | Phase 2 | 48 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Open-labeled, Multicenter, Phase I/II Study of Imatinib Combined With ESHAP as Salvage Therapy in Relapsed/Refractory Non-Hodgkin's Lymphoma[NCT02431403] | Phase 1/Phase 2 | 94 participants (Anticipated) | Interventional | 2015-02-28 | Recruiting | ||
| Study on the Incidence of Febrile Episodes During Stem Cells Collection After Chemotherapy in Patients With Multiple Myeloma[NCT00932217] | Phase 3 | 180 participants (Actual) | Interventional | 2004-12-31 | Active, not recruiting | ||
| Burkimab:Study Multicenter of Optimization of the Treatment of LLA-B and the Burkitt's Lymphoma in Adult Patients (From 15 Years Old)[NCT00388193] | Phase 2 | 20 participants (Anticipated) | Interventional | 2006-08-31 | Completed | ||
| HIGH INTENSITY, BRIEF DURATION CHEMOTHERAPY FOR DIFFUSE SMALL NONCLEAVED CELL LYMPHOMA AND THE L-3 SUBTYPE OF ALL: A PILOT STUDY OF A MULTIDRUG REGIMEN[NCT00002494] | Phase 2 | 134 participants (Actual) | Interventional | 1992-05-31 | Completed | ||
| Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.[NCT05049473] | Phase 2 | 100 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | ||
| Maternal Cancer Diagnosis and Treatment During Pregnancy:a Registry for Maternal, Fetal, and Neonatal Outcomes With Longitudinal Follow up of Child Development and Maternal Psychological Well Being[NCT02749474] | 400 participants (Anticipated) | Observational [Patient Registry] | 2003-07-31 | Recruiting | |||
| A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodg[NCT00479167] | Phase 2 | 1 participants (Actual) | Interventional | 2007-05-31 | Terminated (stopped due to Lack of accrual and interest in study) | ||
| A Phase I Clinical Trial of Immunotherapy With Humanized LL2 IgG (Epratuzumab) in Patients With Systemic Lupus Erythematosus[NCT00011908] | Phase 1 | 20 participants | Interventional | 2001-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Complete response defined by the International Response Criteria for Non-Hodgkin's Lymphoma (NCT00049036)
Timeframe: 60 days
| Intervention | proportion (Number) |
|---|---|
| EPOCH + Concurrent Rituximab | 0.69 |
| EPOCH Followed by Rituximab | 0.53 |
The percentage of participants surviving without events (relapse or death) one year after starting treatment. (NCT01193842)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| Phase II: VR-DA-EPOCH | 75.6 |
| Phase II: DA-R-EPOCH | 82.2 |
The percentage of participants surviving one year after starting treatment. (NCT01193842)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| Phase II: VR-DA-EPOCH | 77.6 |
| Phase II: DA-R-EPOCH | 86.7 |
"Percentage of participants with complete response as assessed by Response Evaluation Criteria in Solid Tumors (Phase II) according to treatment arm. Participants are planned to be treated for a total of 6 cycles (21 day cycle length). Participants with CR after Cycle 4 will receive two additional cycles of chemotherapy and complete 6 cycles of chemotherapy. Participants who achieve a partial response (PR) only after Cycle 4 may continue on protocol therapy or they may be removed from the study at the AMC discretion of the physician (local Principal Investigator). Participants with stable disease after 4 cycles (i.e., who did not achieve at least a PR) or progressive disease at any time will be removed from study.~In phase II, there are two arms: Vorinostat RPTD+rituximab-DA-EPOCH arm (VR-DA-EPOCH) and Rituximab-DA-EPOCH arm (DA-R-EPOCH)." (NCT01193842)
Timeframe: Up to 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Phase II: VR-DA-EPOCH | 67.5 |
| Phase II: DA-R-EPOCH | 76.2 |
Recommended phase II dose of vorinostat is defined as the dose level at which 0/6 or 1/6 subjects experience dose limiting toxicity (DLT) with the next higher dose having at least 2/3 or 2/6 subjects encountering DLT (Phase I). Toxicities will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Using a 3+3 design, the recommended phase II dose is defined as the level at which 0/6 or 1/6 patients experiences at dose-limiting toxicity in the first cycle. (NCT01193842)
Timeframe: 21 days
| Intervention | Mg per day of Vorinostat (Number) |
|---|---|
| Phase I: VR-DA-EPOCH | 300 |
Differences from baseline (specified follow-up assessment minus baseline) in absolute CD8 counts. (NCT01193842)
Timeframe: Baseline up to 12 months
| Intervention | cells/mm^3 (Median) | |||
|---|---|---|---|---|
| End of cycle 2 | Treatment discontinuation | 6-month follow-up | 12-month follow-up | |
| Phase I: VR-CHOP, Dose Level 1 | -172 | -81 | -16 | 128 |
| Phase I: VR-DA-EPOCH, Dose Level 1 | 35.5 | -164.5 | -56 | 604 |
| Phase I: VR-DA-EPOCH, Dose Level 2 | -115 | 211 | 275 | 154 |
Differences from baseline (specified follow-up assessment minus baseline) in HIV viral load. Undetectable viral load results were treated as 0 values. (NCT01193842)
Timeframe: Baseline up to 12 months
| Intervention | copies per milliliter (Median) | |||
|---|---|---|---|---|
| End of cycle 2 | Treatment discontinuation | 6-month follow-up | 12-month follow-up | |
| Phase I: VR-CHOP, Dose Level 1 | 28 | 0 | 0 | 0 |
| Phase I: VR-DA-EPOCH, Dose Level 1 | -14518 | -4517 | -55116 | 0 |
| Phase I: VR-DA-EPOCH, Dose Level 2 | -12.5 | 0 | 0 | 0 |
Differences from baseline (specified follow-up assessment minus baseline) in absolute CD4 counts. (NCT01193842)
Timeframe: Baseline up to 12 months
| Intervention | cell/mm^3 (Median) | |||
|---|---|---|---|---|
| End of cycle 2 | Treatment discontinuation | 6-month follow-up | 12-month follow-up | |
| Phase I: VR-CHOP, Dose Level 1 | -218 | -190 | -175 | -84 |
| Phase I: VR-DA-EPOCH, Dose Level 1 | 92 | -39 | 76 | 169 |
| Phase I: VR-DA-EPOCH, Dose Level 2 | -9 | -29 | 31 | 31 |
Differences from baseline (specified follow-up assessment minus baseline) in EBV viral load. (NCT01193842)
Timeframe: Baseline up to 12 months
| Intervention | IU/mL (Median) | |||
|---|---|---|---|---|
| End of Cycle 2 | At treatment discontinuation | 6-month follow-up | 12-month follow-up | |
| Phase I: VR-DA-EPOCH, Dose Level 1 | 0 | 0 | 0 | 0 |
| Phase I: VR-DA-EPOCH, Dose Level 2 | -2436.1 | -1.92 | -1.92 | -1.15 |
| Phase II, DA-R-EPOCH | 0 | -0.28 | 0 | -2.7 |
| Phase II, VR-DA-EPOCH | -0.61 | -2.9 | -1.55 | -0.56 |
Differences from baseline (specified follow-up assessment minus baseline) in (HHV)-8 viral load. (NCT01193842)
Timeframe: Baseline up to 12 months
| Intervention | copies per 100uL (Median) |
|---|---|
| 12-month follow-up | |
| Phase II: VR-DA-EPOCH | 0 |
Differences from baseline (specified follow-up assessment minus baseline) in (HHV)-8 viral load. (NCT01193842)
Timeframe: Baseline up to 12 months
| Intervention | copies per 100uL (Median) | ||
|---|---|---|---|
| At treatment discontinuation | 6-month follow-up | 12-month follow-up | |
| Phase II: DA-R-EPOCH | 0 | 0 | 0 |
Differences from baseline (specified follow-up assessment minus baseline) in HIV viral load. Undetectable viral load results were treated as 0 values. (NCT01193842)
Timeframe: Baseline up to 12 months
| Intervention | median change in copies per mL (Median) | |||
|---|---|---|---|---|
| End of Cycle 2 | At treatment discontinuation | 6-month follow-up | 12-month follow-up | |
| Phase II: DA-R-EPOCH | -25 | -22.5 | -18 | -20 |
| Phase II: VR-DA-EPOCH | -20 | -87 | -20 | 0 |
The percentage of participants with AEs and their worst severity will be tabulated for each treatment arm. If a participant has more than one AE, the most severe AE is analyzed. All adverse events will be assessed by the investigator from the first dose of protocol therapy through the post-treatment discontinuation visit. Participants are planned to be treated for a total of 6 cycles (21 day cycle length), or roughly 4 months. After this evaluation, assessment and reporting of AEs will only be required for all grade 5 AEs and any serious AE (SAE) that the investigator considers related to protocol therapy. (NCT01193842)
Timeframe: Up to 5 years
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Death | Life-threatening | Severe | Moderate | Mild | |
| Phase II: DA-R-EPOCH | 20.0 | 28.9 | 31.1 | 17.8 | 0 |
| Phase II: VR-DA-EPOCH | 28.9 | 37.8 | 20.0 | 8.9 | 2.2 |
Serial plasma samples for pharmacokinetic analysis were collected at 24-48, 48-72, and 72-96 hours after the start of the first chemotherapy infusion. Doxorubicin, etoposide, and vincristine concentrations were determined using a validated liquid chromatography-tandem mass spectrometry method. The clearance was determined by dividing the drug-infusion rate by the steady-state concentrations, which was the average of the three time points. (NCT01193842)
Timeframe: 24-48, 48-72, and 72-96 hours after the start of the first chemotherapy infusion
| Intervention | Liter/hour (Mean) | ||
|---|---|---|---|
| Doxorubicin | Etoposide | Vincristine | |
| Phase I: VR-DA-EPOCH, Dose Level 1 | 78.6 | 3.0 | 22.4 |
| Phase I: VR-DA-EPOCH, Dose Level 2 | 76.0 | 2.4 | 16.8 |
The percentage of participants whose best tumor response is complete response (CR) or partial response (PR). Based on clinical, radiologic (CT), and pathologic criteria, CR requires 1) complete disappearance of all detectable disease and disease-related symptoms if present before therapy, 2) bone marrow aspirate and biopsy to confirm a CR if initially positive or if clinically indicated by new abnormalities in the peripheral blood counts or blood smear, 3) negative PET results, depending on typically, variably, or unknown pre-treatment FDG status, and 4) spleen and/or liver, if considered to be enlarged before therapy on physical examination or CT scan, not being palpable on physical examination and considered normal size by imaging studies, and nodules related to lymphoma disappeared. PR includes 1) ≥50% decrease in sum of product of diameters (SPD), 2) no increase in size of nodes, liver, or spleen, 3) splenic/hepatic nodules regressed by ≥ 50% SPD, 4) no new sites of disease (NCT01193842)
Timeframe: Up to 2 years post treatment
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Complete response | Partial Response | |
| Phase I: Arm C (VR-CHOP) Dose Level 1 | 100 | 0 |
| Phase I: VR-DA-EPOCH, Dose Level 1 | 83.3 | 16.7 |
| Phase I: VR-DA-EPOCH, Dose Level 2 | 83.3 | 16.7 |
EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. EORTC QLQ-C30 includes functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting), and other (dyspnoea, appetite loss, insomnia, constipation/diarrhea, and financial difficulties). This outcome reports the global health status on a scale of 0-100 with a high score for the global health status/QOL represents a high quality of life. (NCT00877006)
Timeframe: Day 1 (prior to treatment), 32 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Bendamustine and Rituximab (BR) | 3.6 |
| R-CHOP/R-CVP | -5.1 |
DOR was defined as the time from first response (CR or PR) to disease progression or relapse, or death due to any cause. (NCT00877006)
Timeframe: Day 1 up to 5.6 years (Treatment Period + Long-Term Follow-up Period)
| Intervention | months (Median) |
|---|---|
| Bendamustine and Rituximab (BR) | 26.5 |
| R-CHOP/R-CVP | 32.1 |
"EFS was defined as the time from randomization to treatment failure, disease progression or relapse, other malignancies, or death from any cause, whichever occurred first.~Treatment failure was defined as failure to achieve a CR or PR after 6 cycles of treatment. If a patient failed to achieve CR or PR by the time of data analysis or early withdrawal, the treatment failure date was set at 126 days (6 cycles of treatment) after randomization or the new anticancer treatment date, whichever is earlier." (NCT00877006)
Timeframe: Day 1 up to 5.6 years (Treatment Period + Long-Term Follow-up Period)
| Intervention | months (Median) |
|---|---|
| Bendamustine and Rituximab (BR) | 31.8 |
| R-CHOP/R-CVP | 32.6 |
PFS was defined as the time from randomization to disease progression or relapse, or death from any cause, whichever occurred first. (NCT00877006)
Timeframe: Day 1 up to 5.6 years (Treatment Period + Long-Term Follow-up Period)
| Intervention | months (Median) |
|---|---|
| Bendamustine and Rituximab (BR) | 31.8 |
| R-CHOP/R-CVP | 33.4 |
OS was defined as the time from randomization to death from any cause. (NCT00877006)
Timeframe: Day 1 up to 5.6 years (Treatment Period + Long-Term Follow-up Period)
| Intervention | months (Median) |
|---|---|
| Bendamustine and Rituximab (BR) | 65.0 |
| R-CHOP/R-CVP | 64.1 |
"Relapsed disease (after CR) and progressive disease (PD) (after PR or SD):~Lymph nodes were considered abnormal if the long axis was greater than 1.5 cm. Lymph nodes with a long axis of 1.1 to 1.5 cm were considered abnormal if its short axis was greater than 1.0 cm.~In patients with no prior history of pulmonary lymphoma, new lung nodules identified by CT require histologic confirmation.~>= 50% increase from nadir in sum of the products of the greatest diameters (SPD) of any previously involved nodes, or in a single involved node, or the size of other lesions (eg, splenic or hepatic nodules). To be considered progressive disease, a lymph node with a diameter of the short axis of less than 1.0 cm must have increased by 2: 50% and to a size of 1.5 cm by 1.5 cm, or more than 1.5 cm in the long axis~other conditions as specified in the protocol" (NCT00877006)
Timeframe: Treatment Period: 18-32 weeks Long-Term Follow-up Period: up to 5 years after the Treatment Period
| Intervention | Participants (Count of Participants) |
|---|---|
| Bendamustine and Rituximab (BR) | 36 |
| R-CHOP/R-CVP | 30 |
CR=complete disappearance of all detectable clinical evidence of disease and disease-related symptoms, if present pretherapy; protocol-specified positron emission tomography (PET) scan assessment criteria; (if the spleen and/or liver were enlarged on the basis of physical examination and/or anatomic imaging before treatment) the liver and/or spleen were considered normal size on physical examination and by anatomic imaging after therapy, with disappearance of all nodules related to lymphoma; (if the bone marrow was involved by lymphoma before treatment) the infiltrate must have cleared on subsequent bone marrow biopsies. (NCT00877006)
Timeframe: 6 to 8 21 or 28-day cycles (18-32 weeks)
| Intervention | percentage of participants (Number) |
|---|---|
| Bendamustine and Rituximab (BR) | 31 |
| R-CHOP/R-CVP | 25 |
Overall Response=participants with Complete Remission (CR) + those with Partial Remission (PR). CR=see Outcome Measure 1 for details. PR= at least a 50% decrease in the sum of the product of the greatest diameters (SPD) of up to 6 of the largest dominant nodes/masses; at least a 50% decrease in the SPD of hepatic and splenic nodules in their greatest transverse diameter; no increase in the size of the liver, spleen, and other nodes; no measurable disease in organs other than the liver or spleen; no new sites of disease; protocol-specified PET scan and bone marrow criteria. (NCT00877006)
Timeframe: 6 to 8 21 or 28-day cycles (18-32 weeks)
| Intervention | percentage of participants (Number) |
|---|---|
| Bendamustine and Rituximab (BR) | 97 |
| R-CHOP/R-CVP | 91 |
(NCT00877006)
Timeframe: 32 weeks (conducted at screening, Day 1 of each cycle, and end-of-treatment visit)
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Heart Rate >=120 and ↑ >=15 bpm | Heart Rate <=50 and ↓ >=15 bpm | Systolic Blood Pressure(BP) >=180 and ↑ >=20 mm Hg | Systolic BP <=90 and ↓ >=20 mm Hg | Diastolic BP >=105 and ↑ from Baseline >=15 mm Hg | Diastolic BP <=50 and ↓ from Baseline >=15 mm Hg | |
| Bendamustine and Rituximab (BR) | 0 | 2 | 2 | 6 | 1 | 2 |
| R-CHOP/R-CVP | 1 | 2 | 2 | 2 | 2 | 2 |
Participants' ECOG Performance Status was evaluated at the end of treatment as improved, stayed the same, or worsened from baseline (see Baseline Characteristics for ECOG Performance Status). (NCT00877006)
Timeframe: Week 32
| Intervention | participants (Number) | ||
|---|---|---|---|
| Improved | Stayed the Same | Worsened | |
| Bendamustine/Rituximab | 32 | 153 | 34 |
| R-CHOP/R-CVP | 28 | 141 | 42 |
AE=any untoward medical occurrence that develops or worsens in severity after dispensation of the study drug and does not necessarily have a causal relationship to the study drug. An AE can, therefore, be any unfavorable and unintended physical sign, symptom, or laboratory parameter that develops or worsens in severity during the course of the study, or significant worsening of the disease under study (or any concurrent disease), whether or not considered related to the study drug. AEs were graded as 1 (mild), 2 (moderate), 3 (severe), 4 (life-threatening), 5 (death). SAE=an adverse event occurring at any dose that results in: death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity (a substantial disruption of one's ability to conduct normal life functions), a congenital anomaly/birth defect, or other important medical event. (NCT00877006)
Timeframe: 32 weeks
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Any AE | Severe AEs (grades 3, 4, 5) | Treatment-related AEs | Deaths | SAEs | Withdrawn due to AEs | |
| Bendamustine and Rituximab (BR) | 221 | 130 | 209 | 12 | 60 | 10 |
| R-CHOP/R-CVP | 213 | 127 | NA | 9 | 49 | 3 |
Death is due to any cause. Data are broken out by patients who died within 30 days of the last dose of study medications, and those who died greater than 30 days of the last dose of study medications. (NCT00877006)
Timeframe: Treatment Period: 18-32 weeks Long-Term Follow-up Period: up to 5 years after the Treatment Period
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| All Deaths | Deaths within 30 days of study treatment | Deaths greater than 30 days of study treatment | |
| Bendamustine and Rituximab (BR) | 40 | 2 | 38 |
| R-CHOP/R-CVP | 32 | 1 | 31 |
Participants were weighed at Baseline and at Endpoint (Week 32); those participants with an increase or decrease of >=10% were considered potentially clinically significant. (NCT00877006)
Timeframe: Baseline, Week 32
| Intervention | participants (Number) | |
|---|---|---|
| Increase >=10% | Decrease >=10% | |
| Bendamustine and Rituximab (BR) | 8 | 18 |
| R-CHOP/R-CVP | 5 | 8 |
(NCT00877006)
Timeframe: 32 weeks
| Intervention | participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Psycholeptics | Sex Hormones and Modulators of the Genital System | Stomatological Preparations | Throat Preparations | Thyroid Therapy | Topical Preparations for Join and Muscular Pain | Unspecified Herbal | Urologicals | Vaccines | Vasoprotectives | Vitamins | |
| Bendamustine and Rituximab (BR) | 69 | 6 | 23 | 3 | 3 | 1 | 3 | 5 | 11 | 1 | 16 |
| R-CHOP/R-CVP | 74 | 4 | 29 | 2 | 1 | 2 | 5 | 4 | 11 | 8 | 21 |
(NCT00877006)
Timeframe: prior to start of treatment
| Intervention | participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Psycholeptics | Sex Hormones and Modulators of the Genital System | Stomatological Preparations | Throat Preparations | Thyroid Therapy | Topical Products for Join and Muscular Pain | Unspecified Herbal | Urologicals | Vaccines | Vasoprotectives | Vitamins | |
| Bendamustine and Rituximab (BR) | 57 | 11 | 0 | 0 | 16 | 1 | 10 | 20 | 2 | 0 | 70 |
| R-CHOP/R-CVP | 59 | 12 | 0 | 0 | 17 | 0 | 10 | 11 | 7 | 0 | 61 |
Clinical laboratory data were graded according to National Cancer Institute's (NCI) CTCAE version 3, and graded as 1 (mild), 2 (moderate), 3 (severe), 4 (life-threatening), 5 (death). The table presents the worst CTCAE grades for serum chemistry test results experienced by participants overall (i.e., the worst post-baseline grade value for each participant and laboratory test across all cycles). (NCT00877006)
Timeframe: 32 weeks (conducted at screening, Day 1 of each cycle, and end-of-treatment visit)
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Albumin: Grade 1 | Albumin: Grade 2 | Albumin: Grade 3 | Albumin: Grade 4 | Albumin: Grades 1-4 | Alkaline Phosphatase: Grade 1 | Alkaline Phosphatase: Grade 2 | Alkaline Phosphatase: Grade 3 | Alkaline Phosphatase: Grade 4 | Alkaline Phosphatase: Grades 1-4 | Creatinine: Grade 1 | Creatinine: Grade 2 | Creatinine: Grade 3 | Creatinine: Grade 4 | Creatinine: Grades 1-4 | Gamma-glutamyl transferase: Grade 1 | Gamma-glutamyl transferase: Grade 2 | Gamma-glutamyl transferase: Grade 3 | Gamma-glutamyl transferase: Grade 4 | Gamma-glutamyl transferase: Grades 1-4 | Hypercalcemia: Grade 1 | Hypercalcemia: Grade 2 | Hypercalcemia: Grade 3 | Hypercalcemia: Grade 4 | Hypercalcemia: Grades 1-4 | Hyperglycemia: Grade 1 | Hyperglycemia: Grade 2 | Hyperglycemia: Grade 3 | Hyperglycemia: Grade 4 | Hyperglycemia: Grades 1-4 | Hyperkalemia: Grade 1 | Hyperkalemia: Grade 2 | Hyperkalemia: Grade 3 | Hyperkalemia: Grade 4 | Hyperkalemia: Grades 1-4 | Hypernatremia: Grade 1 | Hypernatremia: Grade 2 | Hypernatremia: Grade 3 | Hypernatremia: Grade 4 | Hypernatremia: Grades 1-4 | Hypocalcemia: Grade 1 | Hypocalcemia: Grade 2 | Hypocalcemia: Grade 3 | Hypocalcemia: Grade 4 | Hypocalcemia: Grades 1-4 | Hypoglycemia: Grade 1 | Hypoglycemia: Grade 2 | Hypoglycemia: Grade 3 | Hypoglycemia: Grade 4 | Hypoglycemia: Grades 1-4 | Hypokalemia: Grade 1 | Hypokalemia: Grade 2 | Hypokalemia: Grade 3 | Hypokalemia: Grade 4 | Hypokalemia: Grades 1-4 | Hyponatremia: Grade 1 | Hyponatremia: Grade 2 | Hyponatremia: Grade 3 | Hyponatremia: Grade 4 | Hyponatremia: Grades 1-4 | Magnesium: Grade 1 | Magnesium: Grade 2 | Magnesium: Grade 3 | Magnesium: Grade 4 | Magnesium: Grades 1-4 | Phosphorus: Grade 1 | Phosphorus: Grade 2 | Phosphorus: Grade 3 | Phosphorus: Grade 4 | Phosphorus: Grades 1-4 | Aspartate Aminotransferase: Grade 1 | Aspartate Aminotransferase: Grade 2 | Aspartate Aminotransferase: Grade 3 | Aspartate Aminotransferase: Grade 4 | Aspartate Aminotransferase: Grades 1-4 | Alanine Aminotransferase: Grade 1 | Alanine Aminotransferase: Grade 2 | Alanine Aminotransferase: Grade 3 | Alanine Aminotransferase: Grade 4 | Alanine Aminotransferase: Grades 1-4 | Total Bilirubin: Grade 1 | Total Bilirubin: Grade 2 | Total Bilirubin: Grade 3 | Total Bilirubin: Grade 4 | Total Bilirubin: Grades 1-4 | Uric Acid: Grade 1 | Uric Acid: Grade 2 | Uric Acid: Grade 3 | Uric Acid: Grade 4 | Uric Acid: Grades 1-4 | |
| Bendamustine and Rituximab (BR) | 33 | 14 | 3 | 0 | 50 | 41 | 1 | 0 | 0 | 42 | 19 | 3 | 1 | 0 | 23 | 31 | 18 | 3 | 0 | 52 | 6 | 0 | 1 | 0 | 7 | 94 | 20 | 15 | 0 | 129 | 7 | 3 | 1 | 0 | 11 | 8 | 0 | 0 | 0 | 8 | 36 | 8 | 1 | 3 | 48 | 15 | 1 | 0 | 0 | 16 | 18 | 0 | 0 | 0 | 18 | 40 | 0 | 0 | 0 | 40 | 46 | 0 | 0 | 0 | 46 | 7 | 25 | 3 | 0 | 35 | 42 | 2 | 1 | 0 | 45 | 46 | 6 | 2 | 0 | 54 | 14 | 1 | 0 | 0 | 15 | 41 | 0 | 0 | 1 | 42 |
| R-CHOP/R-CVP | 44 | 13 | 0 | 0 | 57 | 25 | 3 | 0 | 0 | 28 | 25 | 1 | 0 | 0 | 26 | 37 | 10 | 6 | 0 | 53 | 6 | 0 | 0 | 0 | 6 | 74 | 34 | 15 | 1 | 124 | 8 | 1 | 0 | 0 | 9 | 10 | 0 | 0 | 0 | 10 | 28 | 6 | 0 | 0 | 34 | 10 | 0 | 0 | 0 | 10 | 16 | 0 | 1 | 0 | 17 | 28 | 0 | 5 | 0 | 33 | 44 | 1 | 1 | 0 | 46 | 5 | 22 | 3 | 1 | 31 | 32 | 2 | 1 | 0 | 35 | 38 | 3 | 1 | 0 | 42 | 7 | 0 | 0 | 0 | 7 | 42 | 0 | 0 | 0 | 42 |
Hematology test data were graded according to National Cancer Institute's (NCI) CTCAE version 3, and graded as 1 (mild), 2 (moderate), 3 (severe), 4 (life-threatening), 5 (death). The table presents the worst CTCAE grades for hematology test results experienced by participants overall (i.e., the worst post-baseline grade value for each participant and hematology test across all cycles). (NCT00877006)
Timeframe: 32 weeks (conducted at screening, Day 1 of each cycle, weekly during treatment, and at the end-of-treatment visit)
| Intervention | participants (Number) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Absolute Neutrophil Count: Grade 1 | Absolute Neutrophil Count: Grade 2 | Absolute Neutrophil Count: Grade 3 | Absolute Neutrophil Count: Grade 4 | Absolute Neutrophil Count: Grades 1-4 | Hemoglobin: Grade 1 | Hemoglobin: Grade 2 | Hemoglobin: Grade 3 | Hemoglobin: Grade 4 | Hemoglobin: Grades 1-4 | Lymphocytes Absolute: Grade 1 | Lymphocytes Absolute: Grade 2 | Lymphocytes Absolute: Grade 3 | Lymphocytes Absolute: Grade 4 | Lymphocytes Absolute: Grades 1-4 | Platelets: Grade 1 | Platelets: Grade 2 | Platelets: Grade 3 | Platelets: Grade 4 | Platelets: Grades 1-4 | White Blood Cells: Grade 1 | White Blood Cells: Grade 2 | White Blood Cells: Grade 3 | White Blood Cells: Grade 4 | White Blood Cells: Grades 1-4 | |
| Bendamustine and Rituximab (BR) | 22 | 51 | 48 | 50 | 171 | 129 | 42 | 5 | 1 | 177 | 1 | 5 | 54 | 83 | 143 | 106 | 14 | 9 | 7 | 136 | 41 | 79 | 65 | 19 | 204 |
| R-CHOP/R-CVP | 14 | 20 | 47 | 104 | 185 | 129 | 51 | 7 | 2 | 189 | 6 | 55 | 55 | 9 | 125 | 72 | 14 | 7 | 8 | 101 | 22 | 49 | 89 | 27 | 187 |
Cmax was determined using the post-dose Cyclophosphamide plasma concentrations on Cycle 1 Day 1. (NCT02055820)
Timeframe: End of Infusion on Cycle 1 Day 1 (cycle length = 21 days)
| Intervention | mcg/mL (Mean) |
|---|---|
| Venetoclax PK Popluation | 32.1 |
Cmax was determined using the post-dose Doxorubicin plasma concentrations. (NCT02055820)
Timeframe: End of Infusion on Cycle 1 Day 1 (cycle length = 21 days)
| Intervention | mcg/mL (Mean) |
|---|---|
| Venetoclax PK Popluation | 1260 |
Cmax was determined using the post-dose obinutuzumab plasma concentrations at the 800 mg Venetoclax Dose using the end of infusion time point on Cycle 1 Day 1. (NCT02055820)
Timeframe: End of Infusion on Cycle 1 Day 1 (cycle length = 21 days)
| Intervention | mcg/mL (Mean) |
|---|---|
| Venetoclax 800 mg | 326 |
Progressive disease (PD) was determined using the modified Lugano classification criteria. For PET-CT-based PD: Score 4 (uptake moderately > liver) or 5 (uptake markedly higher than liver and/or new lesions) with an increase in intensity of uptake from baseline in target nodes and nodal lesions, new FDG-uptake foci of extranodal lesions consistent with lymphoma at interim or end-of-treatment assessment, no non-measured lesions, new FDG-uptake foci consistent with lymphoma, new or recurrent FDG-uptake foci in bone marrow. For CT-based PD: >/= 50% decrease in SPD of up to 6 target measureable nodes and extranodal sites; non-measured lesion should be absent/normal, have regressed, but not increased; no new lesions. (NCT02055820)
Timeframe: Month 12
| Intervention | Percentage of Participants (Number) |
|---|---|
| Venetoclax 200 mg + R-CHOP | 85.71 |
| Venetoclax 400 mg + R-CHOP | 100.00 |
| Venetoclax 600 mg + R-CHOP | 87.50 |
| Venetoclax 800mg + R-CHOP | 66.67 |
| Venetoclax + R-CHOP 800 mg Phase II | 88.99 |
| Venetoclax 200mg + G-CHOP | 100.00 |
| Venetoclax 400mg + G-CHOP | 75.00 |
| Venetoclax 600mg + G-CHOP | 100.00 |
| Venetoclax 800 mg + G-CHOP A | 100.00 |
| Venetoclax 800 mg + G-CHOP B | 100.00 |
CR was defined as follows according to modified Lugano classification for CT-based response: Target nodes/nodal masses must have regressed to NCT02055820)
Timeframe: Baseline up to end of treatment (approx. 6 months)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Venetoclax + R-CHOP 800 mg Phase II | 37.4 |
CR was defined as follows according to modified Lugano classification for PET/CT-based response: Lymph nodes and extra-lymphatic sites with score 1, 2, or 3 with or without a residual mass on 5-point scale with 1) no uptake above background; 2) uptake NCT02055820)
Timeframe: Baseline up to end of treatment (up to approximately 6 months)
| Intervention | Percentage of participants (Number) |
|---|---|
| Venetoclax + R-CHOP 800 mg Phase II | 66.7 |
"Objective Response defined as PR (partial response) or CR (complete response) at end of treatment.~CR: Lymph nodes and extra-lymphatic sites with score 1, 2 or 3 on a 5-point scale (with a higher score being a worse outcome). No evidence of fluorodeoxyglucose (FDG)-uptake disease in marrow. If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy.~PR: Lymph nodes and extralymphatic sites with score of 4 or 5 on the 5-point scale with reduced uptake compared with baseline and residual mass(es) of any size. CT-based response criteria for PR must also be met. No new lesions. In bone marrow residual uptake could be higher than in normal marrow but must be reduced compared with baseline; persistent focal changes in the marrow to be considered for further evaluation with magnetic resonance imaging (MRI) or biopsy or an interval scan. OR=PR+CR" (NCT02055820)
Timeframe: Baseline to end of treatment (up to approximately 6 months)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Venetoclax + R-CHOP 800 mg Phase II | 81.5 |
CR was defined as follows according to modified Lugano classification for PET/CT-based response: Lymph nodes and extra-lymphatic sites with score 1, 2, or 3 with or without a residual mass on 5-point scale with 1) no uptake above background; 2) uptake NCT02055820)
Timeframe: Baseline up to end of treatment (up to approximately 6 months)
| Intervention | Percentage of participants (Number) |
|---|---|
| Venetoclax + R-CHOP 800 mg Phase II | 68.2 |
Cmax was determined using the post-dose rituximab plasma concentrations at the 800 mg Venetoclax Dose using the end of infusion time point on Cycle 1 Day 1. (NCT02055820)
Timeframe: End of Infusion on Cycle 1 Day 1 (cycle length = 21 days)
| Intervention | mcg/mL (Mean) |
|---|---|
| Venetoclax 800 mg | 173 |
Cmin was determined using the pre-dose rituximab plasma concentrations at the 800 mg Venetoclax Dose on Day 1 of Cycle 2. (NCT02055820)
Timeframe: Pre-dose on Cycle 2 Day 1 (cycle length = 21 days)
| Intervention | mcg/mL (Mean) |
|---|---|
| Venetoclax 800 mg | 26.1 |
DLTs were reported according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI CTCAE v4.0). Decrease in B cells, lymphopenia, and leukopenia caused by lymphopenia were not considered DLTs but instead were expected outcomes of study treatment. Any Grade >/= 3 adverse event, that was attributed to having a reasonable possibility of being related to the combined administration of venetoclax plus R-CHOP or G-CHOP, that could not be attributed by the investigator to an alternative, clearly identifiable cause such as tumor progression, concurrent illness or medical condition, or concomitant medication and that occurred during the DLT observation period (start of venetoclax treatment through end of Cycle 2) was considered a DLT for dose-escalation purposes. Grade 3 or 4 neutropenia or thrombocytopenia identified on Day 1 of Cycle 2 or 3, resulting in dose delay were considered DLTs. (NCT02055820)
Timeframe: Start of venetoclax administration (Cycle 1 Day 4 or 3 days after first CHOP dose) up to end of Cycle 2 (cycle length = 21 days)
| Intervention | Participants (Number) |
|---|---|
| Venetoclax 200 mg + R-CHOP | 1 |
| Venetoclax 400 mg + R-CHOP | 0 |
| Venetoclax 600 mg + R-CHOP | 1 |
| Venetoclax 800mg + R-CHOP | 0 |
| Venetoclax 200mg + G-CHOP | 2 |
| Venetoclax 400mg + G-CHOP | 1 |
| Venetoclax 600mg + G-CHOP | 1 |
| Venetoclax 800 mg + G-CHOP A | 0 |
| Venetoclax 800 mg + G-CHOP B | 0 |
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. (NCT02055820)
Timeframe: Baseline up to approximately 36 months
| Intervention | Percentage of Participants (Number) |
|---|---|
| Venetoclax 200 mg + R-CHOP | 100.00 |
| Venetoclax 400 mg + R-CHOP | 100.00 |
| Venetoclax 600 mg + R-CHOP | 100.00 |
| Venetoclax 800mg + R-CHOP | 100.00 |
| Venetoclax + R-CHOP 800 mg Phase II | 99.0 |
| Venetoclax 200mg + G-CHOP | 100.00 |
| Venetoclax 400mg + G-CHOP | 100.00 |
| Venetoclax 600mg + G-CHOP | 100.00 |
| Venetoclax 800 mg + G-CHOP A | 100.00 |
| Venetoclax 800 mg + G-CHOP B | 100.00 |
"AUC was calculated based on measurement of venetoclax concentration in plasma over time. Venetoclax exposure was pooled across Phase I and II for the R-CHOP 800 mg cohorts.~Data are reported as hour*micrograms per milliliter (hr*mcg/mL)" (NCT02055820)
Timeframe: Predose (within 30 minutes) & 2, 4, 6, 8 hours (Hr) postdose on Cycle 1 Day 4 (cycle length = 21 days)
| Intervention | hr*mcg/mL (Mean) |
|---|---|
| Venetoclax 800mg + R-CHOP | .66 |
| Venetoclax 200 mg + R-CHOP | 2.51 |
| Venetoclax 400 mg + R-CHOP | 3.87 |
| Venetoclax 600 mg + R-CHOP | 3.70 |
| Venetoclax + R-CHOP 800 mg | 4.51 |
| Venetoclax 200mg + G-CHOP | 2.55 |
| Venetoclax 400mg + G-CHOP | 4.33 |
| Venetoclax 600mg + G-CHOP | 5.13 |
| Venetoclax + G-CHOP 800mg | 6.20 |
"Cmax was determined based on measurement of venetoclax concentrations in plasma over time. Venetoclax exposure was pooled across Phase I and II for the R-CHOP 800 mg cohorts.~Data are reported as micrograms per milliliter" (NCT02055820)
Timeframe: Predose (within 30 minutes) & 2, 4, 6, 8 Hr postdose on Cycle 1 Day 4 (cycle length = 21 days)
| Intervention | Ug/ML (Mean) |
|---|---|
| Venetoclax + R-CHOP 100 mg | .09 |
| Venetoclax 200 mg + R-CHOP | .58 |
| Venetoclax 400 mg + R-CHOP | .92 |
| Venetoclax 600 mg + R-CHOP | .85 |
| Venetoclax 800mg + R-CHOP | 1.15 |
| Venetoclax 200mg + G-CHOP | .52 |
| Venetoclax 400mg + G-CHOP | 1.26 |
| Venetoclax 600mg + G-CHOP | 1.00 |
| Venetoclax + G-CHOP 800 mg | 1.54 |
Cmin was determined based on measurement of venetoclax concentrations in plasma over time. Venetoclax exposure was pooled across Phase I and II for the R-CHOP 800 mg cohorts. (NCT02055820)
Timeframe: Predose (within 30 minutes) & 2, 4, 6, 8 Hr postdose on Cycle 1 Day 4 (cycle length = 21 days)
| Intervention | mcg/mL (Mean) |
|---|---|
| Venetoclax + R-CHOP 100 mg | 0.0714 |
| Venetoclax 200 mg + R-CHOP | 0.522 |
| Venetoclax 400 mg + R-CHOP | 0.253 |
| Venetoclax 600 mg + R-CHOP | 0.387 |
| Venetoclax 800mg + R-CHOP | 0.640 |
| Venetoclax 200mg + G-CHOP | 0.134 |
| Venetoclax 400mg + G-CHOP | 0.395 |
| Venetoclax 600mg + G-CHOP | 0.612 |
| Venetoclax + G-CHOP 800 mg | 0.628 |
Tmax was determined based on measurement of venetoclax concentrations in plasma over time. Venetoclax exposure was pooled across Phase I and II for the R-CHOP 800 mg cohorts. (NCT02055820)
Timeframe: Predose (within 30 minutes) & 2, 4, 6, 8 Hr postdose on Cycle 1 Day 4 (cycle length = 21 days)
| Intervention | Hour (Mean) |
|---|---|
| Venetoclax + R-CHOP 100 mg | 4.0 |
| Venetoclax 200 mg + R-CHOP | 4.59 |
| Venetoclax 400 mg + R-CHOP | 6.50 |
| Venetoclax 600 mg + R-CHOP | 5.52 |
| Venetoclax 800mg + R-CHOP | 5.53 |
| Venetoclax 200mg + G-CHOP | 5.72 |
| Venetoclax 400mg + G-CHOP | 6.56 |
| Venetoclax 600mg + G-CHOP | 5.30 |
| Venetoclax + G-CHOP 800 mg | 5.79 |
Cmax was determined using the post-dose Vincristine plasma concentrations. (NCT02055820)
Timeframe: End of Infusion on Cycle 1 Day 1 (cycle length = 21 days)
| Intervention | mcg/mL (Mean) |
|---|---|
| Venetoclax PK Popluation | 54.0 |
AUC was determined based on measurement of Predisone concentrations in plasma over time. (NCT02055820)
Timeframe: Predose (within 30 minutes) and 0.5, 1, 2, 4, 6 Hr after prednisone dose on Day 1 of Cycle 1 and 2 (cycle length = 21 days)
| Intervention | hr*mcg/mL (Mean) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 2, Day 1 | |
| Venetoclax PK Popluation | 195 | 184 |
Cmax was determined based on measurement of Predisone concentrations in plasma over time. (NCT02055820)
Timeframe: Predose (within 30 minutes) and 0.5, 1, 2, 4, 6 Hr after prednisone dose on Day 1 of Cycle 1 and 2 (cycle length = 21 days)
| Intervention | Ng/ML (Mean) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 2, Day 1 | |
| Venetoclax PK Popluation | 49.9 | 43.2 |
Tmax was determined based on measurement of Predisone concentrations in plasma over time. (NCT02055820)
Timeframe: Predose (within 30 minutes) and 0.5, 1, 2, 4, 6 Hr after prednisone dose on Day 1 of Cycle 1 and 2 (cycle length = 21 days)
| Intervention | Hour (Mean) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 2, Day 1 | |
| Venetoclax PK Popluation | 2.19 | 3.80 |
Dose intensity was categorized as < 80%, 80% to < 85%, 85% to < 90%, or >/= 90%. (NCT02055820)
Timeframe: Baseline up to Cycle 6 (cycle length = 21 days)
| Intervention | Percentage of Partcipants (Number) | |||
|---|---|---|---|---|
| <80% | 80-<85% | 85-<90% | >=90% | |
| Venetoclax + G-CHOP 800 mg | 83.3 | 0.00 | 16.7 | 0.00 |
| Venetoclax + G-CHOP 800mg B | 100.0 | 0.00 | 0.00 | 0.00 |
| Venetoclax + R-CHOP 800 mg Phase II | 26.0 | 3.4 | 2.9 | 67.6 |
| Venetoclax 200 mg + R-CHOP | 71.4 | 0.00 | 0.00 | 28.6 |
| Venetoclax 200mg + G-CHOP | 100.00 | 0.00 | 0.00 | 0.00 |
| Venetoclax 400 mg + R-CHOP | 0.00 | 0.00 | 0.00 | 100.00 |
| Venetoclax 400mg + G-CHOP | 14.3 | 14.3 | 0.00 | 71.4 |
| Venetoclax 600 mg + R-CHOP | 12.5 | 12.5 | 12.5 | 62.5 |
| Venetoclax 600mg + G-CHOP | 50.0 | 16.7 | 0.00 | 33.3 |
| Venetoclax 800mg + R-CHOP | 0.00 | 0.00 | 0.00 | 100.00 |
Maintenance of relative dose intensity was defined as a dose intensity of >/= 90%. (NCT02055820)
Timeframe: Baseline up to Cycle 6 (cycle length = 21 days)
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| Cyclophosphamide | Doxorubicin | Vincristine | Prednisone | |
| Venetoclax + R-CHOP Arm | 89.5 | 88.6 | 86.6 | 87.4 |
| Venetoclax 600mg + G-CHOP | 77.4 | 77.4 | 78.1 | 81.3 |
Percentage of participants without disease progression up to 2 years post-registration. (NCT00004031)
Timeframe: From registration until death
| Intervention | percentage of participants (Number) |
|---|---|
| CHOP/CHOP-R x 3 | 55.4 |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | 69.1 |
Percentage of participants surviving 2 years post registration (NCT00004031)
Timeframe: up to 2 years post registration
| Intervention | percentage of participants (Number) |
|---|---|
| CHOP/CHOP-R x 3 | 71.1 |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | 73.7 |
"Adverse Events (AEs) are reported by CTCAE Version 2.0. Only adverse events that are possibly, probably or definitely related to study drug are reported.~Higher grades indicate higher severity of adverse events." (NCT00004031)
Timeframe: Duration of treatment and follow up until death or 3 years post registration
| Intervention | Participants (Number) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abdominal pain/cramping | Alkaline phosphatase increase | Allergic reaction | Allergic rhinitis | Alopecia | Anemia | Anorexia | Anxiety/agitation | Apnea | Arthralgia | Arthritis | Ataxia (incoordination) | Bicarbonate decrease | Bilirubin increase | Blurred vision | Bone pain | Bruising | CO diffusion capacity decrease | Cardiac ischemia/infarction | Cardiovascular-other | Catheter related infection | Chest pain,not cardio or pleur | Colitis | Confusion | Conjunctivitis | Constipation/bowel obstruction | Cough | Creatinine increase | Cushingoid appearance | Dehydration | Delusions | Depression | Diarrhea without colostomy | Dizziness/light headedness | Dizziness/vertigo, NOS | Double vision | Dry skin | Dyspepsia/heartburn | Dyspnea | Dysuria | Ear-other | Earache | Edema | Endocrine-other | Epistaxis | Erectile impotence | Eryth/rash/eruption/desq, NOS | Erythema multiforme/blistering | Esophagitis/dysphagia | Eye-other | FEV1 decrease | Fatigue/malaise/lethargy | Febrile neutropenia | Fever without neutropenia | Fever, NOS | Flu-like symptoms-other | Flushing | Focal dermatitis | GGT increase | GI Mucositis, NOS | GI-other | GU-other | GVHD | Gastritis | Gynecomastia | Hallucinations | Hand-foot skin reaction | Headache | Hematuria | Hemorrhage-other | Hiccoughs | Hot flashes | Hyperglycemia | Hyperkalemia | Hypermagnesemia | Hypernatremia | Hypertension | Hyperuricemia | Hypoalbuminemia | Hypocalcemia | Hypoglycemia | Hypokalemia | Hypomagnesemia | Hyponatremia | Hypophosphatemia | Hypotension | Hypoxia | Infection w/o 3-4 neutropenia | Infection with 3-4 neutropenia | Infection, unk ANC | Inner ear-hearing loss | Insomnia | Invol. movement/restlessness | Joint,muscle,bone-other | Keratitis | LVEF decrease/CHF | Leukopenia | Liver-other | Local injection site reaction | Lung-other | Lymphedema | Lymphopenia | Melena/ GI bleeding | Memory loss | Menses changes | Metabolic-other | Mouth dryness | Muscle weakness (not neuro) | Myalgia | Myalgia/arthralgia, NOS | Nail changes | Nausea | Neuro-other | Neuropathic pain | Neutropenia/granulocytopenia | PRBC transfusion | Pain-other | Palpitations | Partial thromboplast time inc | Pericar. effusion/pericarditis | Personality/behavioral change | Petechiae/purpura | Phlebitis | Pigmentation changes/yellowing | Platelet transfusion | Pleural effusions | Pneumonitis/infiltrates | Proctitis | Proteinuria | Prothrombin time increase | Pruritus | Pulmonary edema | Pulmonary fibrosis | RT-GI mucositis, NOS | RT-esophagitis | RT-focal dermatitis, NOS | RT-pain | RT-pharyngeal dysphagia | Rash/desquamation | Rectal bleeding/hematochezia | Rectal/anal fistula | Rectal/perirectal pain | Renal failure | Reportable adverse event, NOS | Respiratory infect w/ neutrop | Respiratory infect w/o neutrop | Respiratory infection, unk ANC | Rigors/chills | SGOT (AST) increase | SGPT (ALT) increase | SIADH | Salivary gland changes | Second primary | Sense of smell | Sensory neuropathy | Sinus bradycardia | Sinus tachycardia | Skin-other | Somnolence/consciousness loss | Stomatitis/pharyngitis | Supraventricular arrhythmia | Surgery-wound infection | Sweating | Syncope | Syndrome-other | Taste disturbance | Thrombocytopenia | Thrombosis/embolism | Transplant-diarrhea | Transplant-granulocytopenia | Transplant-leukopenia | Transplant-pRBC transfusion | Transplant-plt transfusion | Transplant-rash/desquamation | Transplant-stomatitis/pharyng | Transplant-thrombocytopenia | Tremor | Urinary electrolyte wasting | Urinary frequency/urgency | Urinary retention | Urinary tr infect w/ neutrop | Urinary tr infect w/o neutrop | VOD associated weight gain | Vaginal bleeding | Vaginal dryness | Vaginitis | Vision,NOS | Voice change/stridor/larynx | Vomiting | Weakness (motor neuropathy) | Weight gain | Weight loss | |
| CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | 9 | 15 | 8 | 5 | 36 | 89 | 32 | 12 | 1 | 15 | 1 | 6 | 1 | 6 | 4 | 4 | 2 | 2 | 1 | 4 | 11 | 9 | 2 | 5 | 1 | 24 | 32 | 7 | 1 | 7 | 1 | 12 | 49 | 8 | 1 | 1 | 4 | 10 | 26 | 2 | 0 | 1 | 32 | 1 | 4 | 2 | 2 | 1 | 9 | 1 | 3 | 67 | 44 | 17 | 5 | 2 | 18 | 2 | 1 | 10 | 2 | 1 | 3 | 2 | 0 | 2 | 3 | 26 | 4 | 5 | 6 | 3 | 21 | 1 | 1 | 2 | 5 | 2 | 10 | 13 | 1 | 10 | 6 | 9 | 9 | 15 | 6 | 13 | 17 | 2 | 2 | 15 | 2 | 0 | 1 | 3 | 81 | 0 | 0 | 2 | 0 | 80 | 2 | 0 | 3 | 1 | 9 | 10 | 19 | 4 | 2 | 66 | 2 | 1 | 89 | 32 | 17 | 2 | 5 | 1 | 0 | 2 | 0 | 3 | 37 | 3 | 10 | 2 | 1 | 3 | 7 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 35 | 2 | 1 | 3 | 1 | 0 | 3 | 3 | 1 | 15 | 15 | 9 | 1 | 3 | 0 | 2 | 40 | 4 | 12 | 6 | 2 | 57 | 3 | 1 | 11 | 0 | 3 | 16 | 61 | 3 | 3 | 5 | 11 | 1 | 3 | 3 | 1 | 13 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 2 | 1 | 3 | 1 | 1 | 40 | 4 | 8 | 11 |
| CHOP/CHOP-R x 3 | 8 | 9 | 0 | 4 | 43 | 57 | 8 | 2 | 0 | 5 | 0 | 2 | 0 | 3 | 0 | 6 | 0 | 0 | 0 | 0 | 1 | 4 | 0 | 1 | 0 | 14 | 15 | 2 | 0 | 3 | 0 | 3 | 13 | 9 | 1 | 1 | 1 | 6 | 17 | 1 | 1 | 0 | 9 | 0 | 0 | 0 | 1 | 0 | 3 | 0 | 0 | 47 | 10 | 5 | 5 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 6 | 0 | 1 | 0 | 3 | 4 | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 0 | 2 | 0 | 2 | 0 | 1 | 0 | 4 | 6 | 0 | 0 | 9 | 0 | 4 | 0 | 2 | 68 | 1 | 1 | 1 | 1 | 59 | 1 | 2 | 1 | 0 | 1 | 4 | 15 | 2 | 3 | 31 | 1 | 1 | 60 | 3 | 15 | 0 | 1 | 0 | 1 | 0 | 3 | 3 | 2 | 1 | 2 | 0 | 0 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 0 | 0 | 0 | 0 | 1 | 0 | 4 | 0 | 2 | 9 | 2 | 0 | 0 | 1 | 0 | 46 | 2 | 2 | 3 | 0 | 12 | 0 | 0 | 9 | 1 | 0 | 7 | 15 | 3 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 15 | 13 | 7 | 2 |
INDUCTION: Patients receive bortezomib IV on days 1 and 8; rituximab IV, doxorubicin hydrochloride IV over 3-5 minutes, cyclophosphamide IV over 60 minutes, and vincristine sulfate IV over 10 minutes on day 1; and prednisone PO on days 1-5. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression. (NCT00634179)
Timeframe: Cycle 1 for MTD, following completion of therapy for CR, up to 24 weeks
| Intervention | mg/m^2 (Number) |
|---|---|
| MTD of Bortezomib With Vincristine Capped at 1.5 mg | 1.62 |
Response was assessed by computerized tomography (CT) after every 2 cycles of induction therapy, one time at least 4 weeks after completing induction (i.e., prior to maintenance), and then every 3 months while on maintenance therapy. At the conclusion of maintenance therapy, patients underwent one post-treatment scan, with further scans completed at the discretion of the treating physician. Positron emission tomography was permitted but only CT measurements were used to determine response. (NCT00634179)
Timeframe: Following completion of therapy, up to 2 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| Complete Response (CR) | Partial Response (PR) | Overall Response Rate (ORR) | |
| Phase I: Induction | 13 | 6 | 19 |
| Phase II: Maintenance | 19 | 10 | 29 |
Nadir is defined as the lowest laboratory value recorded up to 120 days following the therapeutic dose (or the dosimetric dose for participants who did not receive the therapeutic dose). (NCT01663714)
Timeframe: Up to 120 days following the therapeutic dose (given on Study Day 7, following the dosimetric dose) (or the dosimetric dose for participants who did not receive the therapeutic dose)
| Intervention | 10^3 cells/cubic millimeters (mm^3) (Median) |
|---|---|
| Chemotherapy; TST and Iodine I 131 TST | 0.4 |
Nadir is defined as the lowest laboratory value recorded up to 120 days following the therapeutic dose (or the dosimetric dose for participants who did not receive the therapeutic dose). (NCT01663714)
Timeframe: Up to 120 days following the therapeutic dose (given on Study Day 7, following the dosimetric dose) (or the dosimetric dose for participants who did not receive the therapeutic dose)
| Intervention | Grams/deciliter (g/dL) (Median) |
|---|---|
| Chemotherapy; TST and Iodine I 131 TST | 10.6 |
Nadir is defined as the lowest laboratory value recorded up to 120 days following the therapeutic dose (or the dosimetric dose for participants who did not receive the therapeutic dose). (NCT01663714)
Timeframe: Up to 120 days following the therapeutic dose (given on Study Day 7, following the dosimetric dose) (or the dosimetric dose for participants who did not receive the therapeutic dose)
| Intervention | 10^3 cells/microliter (µL) (Median) |
|---|---|
| Chemotherapy; TST and Iodine I 131 TST | 57.0 |
Nadir is defined as the lowest laboratory value recorded up to 120 days following the therapeutic dose (or the dosimetric dose for participants who did not receive the therapeutic dose). (NCT01663714)
Timeframe: Up to 120 days following the therapeutic dose (given on Study Day 7, following the dosimetric dose) (or the dosimetric dose for participants who did not receive the therapeutic dose)
| Intervention | 10^3 cells/µL (Median) |
|---|---|
| Chemotherapy; TST and Iodine I 131 TST | 1.8 |
CR: complete resolution of all disease-related radiological abnormalities and the disappearance of all signs and symptoms related to the disease. CRu: complete resolution of all disease-related symptoms; residual lymph node mass >1.5 centimeters in the greatest transverse diameter that has regressed by >75%, indeterminate bone marrow, are present. PR: >=50% reduction in the sum of the products of the longest perpendicular diameters of all measurable lesions; no new lesions. Confirmed response required CR, CRu, or PR, which were confirmed by 2 separate response evaluations >=4 weeks apart. (NCT01663714)
Timeframe: Par. were evaluated until death/disease progression or for 2 years in Study BEX104514. Par. who completed 2 years in Study BEX104514 were followed in Study BEX104528 for up to 130 months. Data are included from Study BEX104514 and Study BEX104528.
| Intervention | participants (Number) |
|---|---|
| Chemotherapy; TST and Iodine I 131 TST | 30 |
Par. with response include those with Complete Response (CR: complete resolution of all disease-related radiological abnormalities and the disappearance of all signs and symptoms related to the disease), Complete Response/unconfirmed (CRu: complete resolution of all disease-related symptoms; residual lymph node mass >1.5 centimeters in the greatest transverse diameter that has regressed by >75%, indeterminate bone marrow, are present), or Partial Response (PR: >=50% reduction in the sum of the products of the longest perpendicular diameters of all measurable lesions; no new lesions). (NCT01663714)
Timeframe: Par. were evaluated until death/disease progression or for 2 years in Study BEX104514. Par. who completed 2 years in Study BEX104514 were followed in Study BEX104528 for up to 130 months. Data are included from Study BEX104514 and Study BEX104528.
| Intervention | participants (Number) |
|---|---|
| Chemotherapy; TST and Iodine I 131 TST | 30 |
Supportive care is defined as interventions that help the participants achieve comfort but do not affect the course of a disease. (NCT01663714)
Timeframe: Par. were evaluated until death/disease progression or for 2 years in Study BEX104514. Par. who completed 2 years in Study BEX104514 were followed in Study BEX104528 for up to 130 months. Data are included from Study BEX104514 and Study BEX104528.
| Intervention | participants (Number) |
|---|---|
| Chemotherapy; TST and Iodine I 131 TST | 17 |
CR: complete resolution of all disease-related radiological abnormalities and the disappearance of all signs and symptoms related to the disease, if present before therapy. Confirmed response required CR, which was confirmed by 2 separate response evaluations >=4 weeks apart. (NCT01663714)
Timeframe: Par. were evaluated until death/disease progression or for 2 years in Study BEX104514. Par. who completed 2 years in Study BEX104514 were followed in Study BEX104528 for up to 130 months. Data are included from Study BEX104514 and Study BEX104528.
| Intervention | participants (Number) |
|---|---|
| Chemotherapy; TST and Iodine I 131 TST | 21 |
CR: complete resolution of all disease-related radiological abnormalities and the disappearance of all signs and symptoms related to the disease, if present before therapy. (NCT01663714)
Timeframe: Par. were evaluated until death/disease progression or for 2 years in Study BEX104514. Par. who completed 2 years in Study BEX104514 were followed in Study BEX104528 for up to 130 months. Data are included from Study BEX104514 and Study BEX104528.
| Intervention | participants (Number) |
|---|---|
| Chemotherapy; TST and Iodine I 131 TST | 21 |
Overall survival is defined as the time from the treatment start date to the date of death from any cause. (NCT01663714)
Timeframe: Par. were evaluated until death/disease progression or for 2 years in Study BEX104514. Par. who completed 2 years in Study BEX104514 were followed in Study BEX104528 for up to 130 months. Data are included from Study BEX104514 and Study BEX104528.
| Intervention | months (Median) |
|---|---|
| Chemotherapy; TST and Iodine I 131 TST | NA |
Time to progression or progression-free survival is defined as the time from the dosimetric dose to the first documented occurrence of disease progression or death. Disease progression is defined as a >=50% increase from the nadir value (lowest laboratory value recorded following administration of the study medication) of the sum of the products of the longest perpendicular diameters of all measurable lesions or the appearance of any new lesion. Individual lesions must be >1.5 cm in diameter by radiographic evaluation or >1 cm in diameter by physical examination. (NCT01663714)
Timeframe: Par. were evaluated until death/disease progression or for 2 years in Study BEX104514. Par. who completed 2 years in Study BEX104514 were followed in Study BEX104528 for up to 130 months. Data are included from Study BEX104514 and Study BEX104528.
| Intervention | months (Median) |
|---|---|
| Chemotherapy; TST and Iodine I 131 TST | 110.2 |
Time to treatment failure is defined as the time from the start of treatment to the first occurrence of study withdrawal, progression, or death. (NCT01663714)
Timeframe: Par. were evaluated until death/disease progression or for 2 years in Study BEX104514. Par. who completed 2 years in Study BEX104514 were followed in Study BEX104528 for up to 130 months. Data are included from Study BEX104514 and Study BEX104528.
| Intervention | months (Median) |
|---|---|
| Chemotherapy; TST and Iodine I 131 TST | 78.9 |
To determine TBRT, the percent-injected activity (PIA) is calculated from the background-corrected (BC) total body count (TBC) at D 0; D 2/3/4; and D 7. The time from the DD to the acquisition of whole body count (WBC) is then determined. The PIA remaining at each time point (TP) is then calculated by dividing the BC WBC for that TP by the BC WBC from the first TP (D 0) * 100. To determine RT, a best-fit line from 100% (pre-plotted D 0 value) through 2 plotted points (other TPs) is made. TBRT=the x-axis value at the point where the line intersects the horizontal 37% injected activity line. (NCT01663714)
Timeframe: Day (D) 0; D 2, 3, or 4; and D 6 or 7
| Intervention | hours (Mean) |
|---|---|
| Chemotherapy; TST and Iodine I 131 TST | 103.7 |
DOR=the time from the first documented response (for par. with CR) until disease progression (DP). DP=a >=50% increase from the nadir value (lowest laboratory value recorded following administration of study medication) of the sum of the products of the longest perpendicular diameters of all measurable lesions or the appearance of any new lesion. Individual lesions must be >1.5 centimeters (cm) in diameter by radiographic evaluation or >1 cm in diameter by physical examination. Responses had to be confirmed by 2 separate evaluations occurring >=4 weeks apart. (NCT01663714)
Timeframe: Par. were evaluated until death/disease progression or for 2 years in Study BEX104514. Par. who completed 2 years in Study BEX104514 were followed in Study BEX104528 for up to 130 months. Data are included from Study BEX104514 and Study BEX104528.
| Intervention | months (Median) | |
|---|---|---|
| Unconfirmed Responders with CR | Confirmed Responders with CR | |
| Chemotherapy; TST and Iodine I 131 TST | 129.6 | 129.6 |
DOR=the time from the first documented response (for par. with CR, CRu, or PR) until disease progression (DP). DP=a >=50% increase from the nadir value (lowest laboratory value recorded following administration of study medication) of the sum of the products of the longest perpendicular diameters of all measurable lesions or the appearance of any new lesion. Individual lesions must be >1.5 centimeters (cm) in diameter by radiographic evaluation or >1 cm in diameter by physical examination. Responses had to be confirmed by 2 separate evaluations occurring >=4 weeks apart. (NCT01663714)
Timeframe: Par. were evaluated until death/disease progression or for 2 years in Study BEX104514. Par. who completed 2 years in Study BEX104514 were followed in Study BEX104528 for up to 130 months. Data are included from Study BEX104514 and Study BEX104528.
| Intervention | months (Median) | |
|---|---|---|
| Unconfirmed Responders | Confirmed Responders | |
| Chemotherapy; TST and Iodine I 131 TST | 129.6 | 129.6 |
"The administration of murine antibodies may form HAMA. A HAMA assay was performed using the ImmunoSTRIP HAMA IgG enzyme-linked immune absorbent assay by a central laboratory (Covance Classic Laboratory Services, Indianapolis, IN). To be positive, a participant had to have a positive HAMA assessment during the first 24 months." (NCT01663714)
Timeframe: Day 1 to Day 730 (24 months) after receiving the dosimetric dose
| Intervention | participants (Number) | |
|---|---|---|
| Positive | Negative | |
| Chemotherapy; TST and Iodine I 131 TST | 0 | 30 |
An SAE is defined as any event occurring at any dose that results in any of the following outcomes: death, a life-threatening adverse drug experience (at immediate risk of death from the experience as it occurred), inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity, or a congenital anomaly/birth defect. Important medical events that may not result in death, be life threatening, or require hospitalization may be considered to be a serious adverse drug experience when based upon appropriate medical judgment. (NCT01663714)
Timeframe: Par. were evaluated until death/disease progression or for 2 years in Study BEX104514. Par. who completed 2 years in Study BEX104514 were followed in Study BEX104528 for up to 130 months. Data are included from Study BEX104514 and Study BEX104528.
| Intervention | participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Febrile neutropenia | Anaemia | Neutropenia | Thrombocytopenia | Granulocytopenia | Leukopenia | Acute myeloid leukaemia | Basal cell carcinoma | Myelodysplastic syndrome | Squamous cell carcinoma | Perirectal abscess | Neutropenic infection | Pyrexia | Cystitis hemorrhagic | |
| Chemotherapy; TST and Iodine I 131 TST | 5 | 2 | 2 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 |
AEs were graded using the Common Toxicity Criteria from the Cancer Therapy Evaluation Program, Division of Cancer Therapy, National Cancer Institute. Grades: 0 = No AE or within normal limits; 1 = Mild AE; 2 = Moderate AE; 3 = Severe and undesirable AE; 4 = Life-threatening or disabling AE; 5 = Death related to AE. (NCT01663714)
Timeframe: Par. were evaluated until death/disease progression or for 2 years in Study BEX104514. Par. who completed 2 years in Study BEX104514 were followed in Study BEX104528 for up to 130 months. Data are included from Study BEX104514 and Study BEX104528.
| Intervention | participants (Number) | ||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ANC <1000 cells/mm^3 | WBC <2000 cells/mm^3 | Platelets <50000 cells/mm^3 | Hemoglobin <8.0 g/dL | Neutropenia | Leukopenia | Febrile neutropenia | Thrombocytopenia | Anemia | Granulocytopenia | Lymphopenia | Alopecia | Night sweats | Acute myeloid leukaemia | Basal cell carcinoma | Myelodysplastic syndrome | Prostate cancer | Squamous cell carcinoma | Perirectal abscess | Urinary tract infection | Cystitis | Neutropenic infection | Otitis media | Periorbital cellulitis | Aphasia | Cerebrovascular accident | Headache | Hypoaesthesia | VIIth nerve paralysis | Asthenia | Pyrexia | Myalgia | Pain in extremity | Depression | Insomnia | Amenorrhoea | Breast mass | Conjunctivitis | Constipation | Drug hypersensitivity | Aspartate aminotransferase increased | Cystitis hemorrhagic | Epistaxis | |
| Chemotherapy; TST and Iodine I 131 TST | 29 | 23 | 12 | 2 | 15 | 6 | 5 | 4 | 3 | 1 | 1 | 9 | 1 | 2 | 2 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
AEs were graded using the Common Toxicity Criteria from the Cancer Therapy Evaluation Program, Division of Cancer Therapy, National Cancer Institute. Grades: 0 = No AE or within normal limits; 1 = Mild AE; 2 = Moderate AE; 3 = Severe and undesirable AE; 4 = Life-threatening or disabling AE; 5 = Death related to AE. The Investigator assessed whether the AE was possibly or probably related to study drug. In addition, all laboratory-derived hematologic toxicities (values outside the normal range) were assumed to be possibly or probably related to study drug. (NCT01663714)
Timeframe: Par. were evaluated until death/disease progression or for 2 years in Study BEX104514. Par. who completed 2 years in Study BEX104514 were followed in Study BEX104528 for up to 130 months. Data are included from Study BEX104514 and Study BEX104528.
| Intervention | participants (Number) | ||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ANC <1000 cells/mm^3 | WBC <2000 cells/mm^3 | Platelets <50000 cells/mm^3 | Hemoglobin <8.0 g/dL | Neutropenia | Leukopenia | Febrile neutropenia | Thrombocytopenia | Anemia | Granulocytopenia | Lymphopenia | Alopecia | Night sweats | Perirectal abscess | Urinary tract infection | Cystitis | Neutropenic infection | Otitis media | Periorbital cellulitis | Acute myeloid leukaemia | Basal cell carcinoma | Myelodysplastic syndrome | Squamous cell carcinoma | Headache | VIIth nerve paralysis | Depression | Insomnia | Conjunctivitis | Constipation | Pyrexia | Aspartate aminotransferase increased | Myalgia | Cystitis hemorrhagic | Amenorrhoea | Epistaxis | |
| Chemotherapy; TST and Iodine I 131 TST | 29 | 23 | 12 | 2 | 15 | 6 | 5 | 4 | 3 | 1 | 1 | 9 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
The primary cause of death of the participants was assessed by the Investigator. (NCT01663714)
Timeframe: Par. were evaluated until death/disease progression or for 2 years in Study BEX104514. Par. who completed 2 years in Study BEX104514 were followed in Study BEX104528 for up to 130 months. Data are included from Study BEX104514 and Study BEX104528.
| Intervention | participants (Number) | ||
|---|---|---|---|
| Progression of lymphoma | Complications related to study drug | Other | |
| Chemotherapy; TST and Iodine I 131 TST | 5 | 1 | 3 |
Nadir is defined as the lowest laboratory value recorded up to 120 days following the therapeutic dose (or the dosimetric dose for participants who did not receive the therapeutic dose). (NCT01663714)
Timeframe: Up to 120 days following the therapeutic dose (given on Study Day 7, following the dosimetric dose) (or the dosimetric dose for participants who did not receive the therapeutic dose)
| Intervention | days (Median) | |||
|---|---|---|---|---|
| ANC | Hemoglobin | Platelets | WBC count | |
| Chemotherapy; TST and Iodine I 131 TST | 49.0 | 49.0 | 35.5 | 44.0 |
TTR to BL grade (gr.) for par. with a Gr. 0 toxicity (tox.=lab. value outside the normal range) at BL=time from the last administration of study drug (SD) to the first post-nadir (PN) date with Gr. 0 toxicity with no other Gr. 1-4 toxicities recorded within the next week. For par. with a higher gr. tox. at BL, TTR=time from the last administration of SD to the first PN date with the BL gr. or better with no other higher gr. toxicities recorded during the next week. Each lab. established its own reference range using data from its own equipment/methods; there is no standard reference range. (NCT01663714)
Timeframe: Up to 120 days following the therapeutic dose (given on Study Day 7, following the dosimetric dose) (or the dosimetric dose for participants who did not receive the therapeutic dose)
| Intervention | days (Median) | |||
|---|---|---|---|---|
| Time to recovery to baseline ANC, n=30 | Time to recovery to baseline hemoglobin, n=28 | Time to recovery to baseline platelets, n=30 | Time to recovery to baseline WBC count, n=29 | |
| Chemotherapy; TST and Iodine I 131 TST | 77.0 | 76.5 | 60.5 | 126.5 |
Toxicity assessed using NCI-CTC v. 3.0 (NCT00295932)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| 1.3 mg/m2 Bortezomib; 750 mg/m2 Cyclophosphamide | 4 |
| 1.6 mg/m2 Bortezomib; 750 mg/m2 Cyclophosphamide | 6 |
| 1.6 mg/m2 Bortezomib; 1000 mg/m2 Cyclophosphamide | 3 |
| 1.8 mg/m2 Bortezomib; 1000 mg/m2 Cyclophosphamide | 4 |
| Dose Level 1- 1.0 mg/m2 Bortezomib; 750 mg/m2 Cyclophosphamid | 2 |
| Dose Level 2 - 1.3 mg/m2 Bortezomib; 750 mg/m2 Cyclophosphamid | 18 |
| Dose Level 3 - 1.3 mg/m2 Bortezomib; 1000 mg/m2 Cyclophospham | 3 |
| Dose Level 4 - 1.5 mg/m2 Bortezomib; 1000 mg/m2 Cyclophosphami | 4 |
| Dose Level 5 - 1.3 mg/m2 Bortezomib; 1000 mg/m2 Cyclophospham | 10 |
| Weekly Bortezomib Dosing Schedule | 12 |
| Twice-weekly Bortezomib Dosing Schedule | 13 |
Maximum tolerated dose of Bortezomib in combination with Rituximab, Cyclophosphamide and Prednisone in Phase I participants (NCT00295932)
Timeframe: 2 years
| Intervention | mg/m^2 of Bortezomib (Number) | |
|---|---|---|
| Weekly Bortezomib | Twice-Weekly Bortezomib | |
| Arm I | 1.8 | 1.5 |
The overall response rate is defined as the percentage of participants with a response (Complete Response or Partial Response) (NCT00118209)
Timeframe: Up to 5 years post-registration
| Intervention | percentage of participants (Number) |
|---|---|
| Arm B - DA-EPOCH-R | 86.7 |
| Arm A - R-CHOP | 88.0 |
Overall survival is defined as the time from randomization to death due to any cause. The overall survival (OS) rate (percentage of participants who are still alive) at 2 and 5 years Kaplan Meier estimates and 95% confidence intervals are reported below. (NCT00118209)
Timeframe: Up to 5 years post-registration
| Intervention | percentage of participants (Number) | |
|---|---|---|
| 2-year OS rate | 5-year OS rate | |
| Arm A - R-CHOP | 85.7 | 78.5 |
| Arm B - DA-EPOCH-R | 86.5 | 77.5 |
"Progression-free survival (PFS) is defined as the time from randomization to progression, relapse, or death from any cause, whichever occurred first. Progression (PD) or Relapse>~≥ 50% increase from nadir in the SPD of any previously identified abnormal node for PRs or nonresponders.>~Appearance of any new lesion during or after completion of therapy.>~PET+ is not a criterion for progressive disease. Patients only with PET+ findings must have evidence of progression on CT or biopsy proven.>~The PFS rate (percentage of participants who are alive and progression-free) at 2 and 5 years Kaplan Meier estimates and 95% Confidence Intervals are reported below." (NCT00118209)
Timeframe: Up to 5 years post-registration
| Intervention | percentage of participants (Number) | |
|---|---|---|
| 2-year PFS | 5-year PFS | |
| Arm A - R-CHOP | 75.5 | 66.0 |
| Arm B - DA-EPOCH-R | 78.9 | 68.0 |
Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Toxicity Criteria (CTC v2.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT00005780)
Timeframe: Up to 30 days after last intervention, up to 12.5 months or 1.04 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab | 26 |
PFS is time from on study date until disease relapse or progression, death, or date of last follow-up. Progression was measured by the International Workshop to Standardize Response Criteria for non-Hodgkin's Lymphoma and is defined as ≥50% increase from nadir in the sum of the products of the greatest diameters (SPD) of any previously involved node or the appearance of any new lesion. (NCT00005780)
Timeframe: From participants on study date until date of disease relapse or progression, death, or date of last follow-up, assessed up to 245.8 months
| Intervention | Months (Median) |
|---|---|
| Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab | 23.5 |
OS was determined by the Kaplan-Meier method and is defined as the time from treatment start date until date of death or last follow-up. (NCT00005780)
Timeframe: Time from treatment start date until date of death or date last follow-up, up to 250 months
| Intervention | Months (Median) |
|---|---|
| Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab | 89.7 |
Participants with an immune response to idiotype vaccine measured by enzyme-linked immunosorbent assay (ELISA) to detect antibody binding to tumor cells. Positive response was defined as at least a fourfold increase in antibody titer. (NCT00005780)
Timeframe: Weeks 12 to 32
| Intervention | percentage of participants (Number) |
|---|---|
| Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab | 30 |
Participants with an immune response against carrier molecule KLH measured by enzyme-linked immunosorbent assay (ELISA) to detect antibody binding to tumor cells. Positive response was defined as at least a fourfold increase in antibody titer. (NCT00005780)
Timeframe: After vaccinations administered at 0, 1, 2, 3 and 5 months
| Intervention | percentage of participants (Number) |
|---|---|
| Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab | 74 |
PFS is defined as the time from start of treatment until disease relapse or progression, death, or last follow-up. Progression was measured by the International Workshop to Standardize Response Criteria for non-Hodgkin's Lymphoma and is defined as ≥50% increase from nadir in the sum of the products of the greatest diameters (SPD) of any previously involved node or the appearance of any new lesion (NCT00005780)
Timeframe: Time from treatment start date until date of disease relapse or progression, death, or date last follow-up, an average of 25 months
| Intervention | Months (Median) |
|---|---|
| Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab | 25.0 |
Recovery of CD4+ was measured by flow cytometry. Blood samples were collected via apheresis and analyzed by multicolor flow cytometry in peripheral blood mononuclear cells (PBMCs) for cluster of differentiation 4 (CD4). Time to recovery of CD4 T lymphocytes was defined as the time required for CD4 T lymphocytes to increase above the lower limit of normal of the normal laboratory value range of 359 cells/mcL (NCT00005780)
Timeframe: After chemotherapy before vaccination, up to 6 months
| Intervention | Months (Median) |
|---|---|
| Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab | 3 |
Response was measured by the International Workshop to Standardize Response Criteria for non-Hodgkin's Lymphoma. Complete Response (CR) is a complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy, and normalization of those biochemical abnormalities (e.g., Lactate dehydrogenase (LDH) definitely assignable to the lymphoma. Complete Response Unconfirmed (CRu) is as per CR criteria except that if a residual node is > 1.5cm, it must have regressed by > 75% in the sum of the products of the greatest diameters (SPD). Partial Response (PR) is ≥50% decreased in the SPD of 6 largest dominant nodes or nodal masses. Stable Disease (SD) is defined as less than a PR but not progressive disease. Progression is ≥50% increase from nadir in the SPD of any previously involved node or the appearance of any new lesion. (NCT00005780)
Timeframe: After 6 cycles of EPOCH-R therapy, an average of 18 weeks
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Complete Response | Complete Response Unconfirmed | Partial Response | Stable Disease | Progression | |
| Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab | 80.8 | 7.7 | 7.7 | 0 | 3.8 |
Serious and/or non-serious adverse events were assessed by the Common Toxicity Criteria (CTC v2.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 3 is severe, Grade 4 is life-threatening, and Grade 5 is death related to adverse event. (NCT00005780)
Timeframe: Up to 30 days after last intervention, up to 12.5 months or 1.04 years
| Intervention | percentage of participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergic reaction | Anemia | Febrile neutropenia | Leukopenia | Lymphopenia | Neutropenia | Thrombocytopenia | Thrombosis | Infusion related reaction | Serum glutamic oxaloacetic transaminase (SGOT) elevation | Serum glutamic pyruvic transaminase (SGPT) elevation | Infection | Hyperglycemia | Hypomagnesemia | Cerebrovascular ischemia | Motor neuropathy | Sensory neuropathy | Back pain | Dyspnea | Erectile dysfunction | |
| Grade 3 | 3.8 | 69.2 | 42.3 | 0 | 38.5 | 0 | 50 | 15.4 | 3.8 | 3.8 | 3.8 | 15.4 | 3.8 | 3.8 | 0 | 11.5 | 3.8 | 3.8 | 3.8 | 3.8 |
| Grade 4 | 0 | 3.8 | 3.8 | 84.6 | 0 | 88.5 | 7.7 | 0 | 0 | 0 | 0 | 3.8 | 0 | 0 | 3.8 | 0 | 0 | 0 | 0 | 0 |
| Grade 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Participants with tumor specific T-cell responses during B-cell recovery was assessed in a Clinical Laboratory Improvement Amendments (CLIA) certified lab and were measured by flow cytometry and/or enzyme-linked immunosorbent spot (ELISPOT). A positive response required the response to be at least twice the negative controls. (NCT00005780)
Timeframe: After vaccinations administered at 0, 1, 2, 3 and 5 months
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Peripheral blood mononuclear cells (PBMC) | Granulocyte macrophage colony-stimulating factor (GM-CSF) | Tumor necrosis factor α (TNFα) | Interferon-gamma (IFN-γ) | |
| Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab | 87 | 65 | 52 | 74 |
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT00114738)
Timeframe: Date treatment consent signed to date off study, approximately 143 months and 7 days
| Intervention | Participants (Count of Participants) |
|---|---|
| EPOCH-R+Bortezomib | 53 |
Overall Survival is the time between the first day of treatment to the day of death. The primary evaluation will be a Kaplan-Meier analysis with a two tailed log rank test. (NCT00114738)
Timeframe: up to 9.9 years
| Intervention | Months (Median) |
|---|---|
| EPOCH-R+Bortezomib | 80.4 |
Time interval from start of treatment to documented evidence of disease progression. Progression is defined by at least one of the following: ≥50% increase in the sum of the products of at least two lymph nodes, appearance of new lymph nodes, ≥50% increase in the size of the liver and/or spleen as determined by measurement below the respective costal margin, appearance of new palpable hepatomegaly or splenomegaly that was not previously present, and ≥50% increase in the absolute number of circulating lymphocytes. (NCT00114738)
Timeframe: up to 9.9 years
| Intervention | Months (Median) |
|---|---|
| EPOCH-R+Bortezomib | 29.3 |
Overall Survival is the time between the first day of treatment to the day of death. The primary evaluation will be a Kaplan-Meier analysis with a two tailed log rank test. (NCT00114738)
Timeframe: up to 9.9 years
| Intervention | Months (Median) |
|---|---|
| Bortezomib Maintenance | 78.6 |
| Observation | 87.5 |
| Not Randomized | 31.6 |
Time interval from start of treatment to documented evidence of disease progression. Progression is defined by at least one of the following: ≥50% increase in the sum of the products of at least two lymph nodes, appearance of new lymph nodes, ≥50% increase in the size of the liver and/or spleen as determined by measurement below the respective costal margin, appearance of new palpable hepatomegaly or splenomegaly that was not previously present, and ≥50% increase in the absolute number of circulating lymphocytes.The primary evaluation will be a Kaplan-Meier analysis with a two tailed log rank test. (NCT00114738)
Timeframe: up to 5 years
| Intervention | Months (Median) |
|---|---|
| Bortezomib Maintenance | 27.2 |
| Observation | 33.5 |
| Not Randomized | 7.8 |
Clinical response is assessed by the response criteria for lymphomas and is defined as a fraction of patients who have a complete response (CR) or a complete response (CR) + partial response (PR). A complete response is disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy, and normalization of those biochemical abnormalities (e.g. lactate dehydrogenase) definitely assignable to the lymphoma. Partial response is ≥50% decreased in the sum of the products of the greatest diameters of 6 largest dominant nodes or nodal masses. No increase in size of nodes, liver or spleen and no new sites of disease. Progressive disease is defined by at least one of the following: ≥50% increase in the sum of the products of at least two lymph nodes appearance of new lymph nodes, ≥50% increase in the size of the liver and/or spleen, ≥50% increase in the absolute number of circulating lymphocytes. (NCT00114738)
Timeframe: up to 22 weeks after initiation of therapy
| Intervention | Percentage of patients (Number) | ||||
|---|---|---|---|---|---|
| Overall Response (CR+PR) | Complete Response | Stable Disease | Progressive Disease | Not Evaluable | |
| EPOCH-R+Bortezomib | 92.5 | 86.7 | 3.8 | 1.9 | 1.9 |
171 reviews available for prednisone and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine H | 2021 |
Effectiveness of Bendamustine-Rituximab Compared to R-CHOP/R-CVP as a First-Line Treatment of Indolent Non-Hodgkin's Lymphoma or Mantle-Cell Lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; | 2022 |
Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Diseases; Cyclophosphamide; Doxorubic | 2020 |
Chemotherapy for non-Hodgkin lymphoma in the hemodialysis patient: A comprehensive review.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemother | 2021 |
Primary adrenal non-Hodgkin lymphoma: a case report and review of the literature.
Topics: Abdominal Pain; Adrenal Gland Neoplasms; Adrenalectomy; Antineoplastic Combined Chemotherapy Protoco | 2017 |
Double-Hit Large B Cell Lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Female; Ge | 2017 |
The Deauville criteria cannot differentiate between responding and non-responding non-Hodgkin lymphoma patients.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; C | 2018 |
Non-Hodgkin lymphoma, diagnostic, and prognostic particularities in children - a series of case reports and a review of the literature (CARE compliant).
Topics: Abdominal Pain; Anemia, Iron-Deficiency; Antineoplastic Combined Chemotherapy Protocols; Asparaginas | 2018 |
Growth hormone-secreting pituitary macroadenoma presenting concurrently with non-Hodgkin's lymphoma and responding to doxorubicin treatment: case report and review of the literature.
Topics: Adenoma; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protoco | 2018 |
Front-Line Treatment of High Grade B Cell Non-Hodgkin Lymphoma.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 2019 |
[Non-Hodgkin lymphoma of maxillofacial soft tissue: a report of two cases and review of the literature].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphom | 2013 |
Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients.
Topics: Anti-HIV Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combi | 2013 |
Primary non-Hodgkin's lymphoma of the bladder: case report and literature review.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2013 |
Pharmacokinetic evaluation of vincristine for the treatment of lymphoid malignancies.
Topics: Antineoplastic Agents; Cyclophosphamide; Doxorubicin; Drug Evaluation, Preclinical; Humans; Leukemia | 2014 |
[Malignant lymphoma and adult T-cell leukemia-lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Deoxycytidi | 2014 |
Excellent outcome of young adults with aggressive non-Hodgkin lymphomas treated with CHOP-like regimens.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2014 |
Progressive Multifocal Leukoencephalopathy Following Treatment with Rituximab in an HIV-Negative Patient with Non-Hodgkin Lymphoma. A Case Report and Literature Review.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain; Cyclophosphamide; Doxo | 2014 |
A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine | 2015 |
CHOP-like-14 compared to CHOP-like-21 for patients with aggressive lymphoma--a meta-analysis of randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Administration S | 2016 |
[NON-HODGKIN'S LYMPHOMA OF THE FEMALE GENITAL SYSTEM--A LITERATURE REVIEW].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Genital Neopl | 2015 |
Limited Stage Aggressive Non-Hodgkin Lymphoma: What Is Optimal Therapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Combined Modality Therapy; Cyclop | 2016 |
Indolent Lymphomas That Present With Clinically Aggressive Features: A Subset of Low-Grade Lymphomas With a Behavior Inconsistent With the Histologic Diagnosis.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomar | 2016 |
Enteroviral infection in patients treated with rituximab for non-Hodgkin lymphoma: a case series and review of the literature.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Immunological; Antineopl | 2017 |
Extranodal lymphoma: a reappraisal.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2008 |
Recent developments in the treatment of aggressive non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2009 |
[Recent advances and the treatment strategies of AIDS-related malignant lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2008 |
[Radiotherapy indications in non-Hodgkin lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 2009 |
Non-Hodgkin's lymphoma in systemic sclerosis: case and literature review.
Topics: Adult; Age Factors; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineopla | 2010 |
High dose intensity doxorubicin in aggressive non-Hodgkin's lymphoma: a literature-based meta-analysis.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxor | 2010 |
Rituximab-associated neutropenia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2010 |
Intrathecal chemotherapy in lymphomatous meningitis.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nerv | 2011 |
[Listeriosis in non-Hodgkin's lymphoma following outpatient R-CHOP therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Listeri | 2010 |
[Plasmacytoid dendritic cell tumor].
Topics: Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Bone | 2011 |
A meta-analysis on Rituximab combined CHOP chemotherapy for non-Hodgkin lymphoma in China.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2011 |
Lymphoma study group of JCOG.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2012 |
Rituximab in combination with chemotherapy versus chemotherapy alone in HIV-associated non-Hodgkin lymphoma: a pooled analysis of 15 prospective studies.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Antir | 2012 |
[Intravascular NK-cell lymphoma: a clinicopathologic study and literature review].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CD3 Complex; CD56 Antigen; Cyclophosphamide; D | 2011 |
Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia.
Topics: Adolescent; Adult; Aged; Alemtuzumab; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodie | 2002 |
Leptomeningeal involvement in a patient with splenic lymphoma with villous lymphocytes.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cerebrospinal Fluid; Cranial Irradiation; Cycl | 2002 |
[Treatment of high-grade, disseminated non-Hodgkin's lymphoma in elderly patients].
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Antineoplastic Combined Chemotherapy Protocols; Clinica | 2002 |
Non-Hodgkin's lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, AID | 2002 |
An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2003 |
Immunochemotherapy: the new standard in aggressive non-Hodgkin's lymphoma in the elderly.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2003 |
A new approach to the diagnosis and treatment of intravascular lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Ther | 2003 |
Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; C | 2003 |
[Erythema nodosum association with malignant lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Diagnosis, Dif | 2003 |
Non-hodgkins lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Combined Mo | 2003 |
[THERAPY OF HEMOLYMPHOPATHIES WITH PREDNISONE AT HIGH DOSES].
Topics: Hodgkin Disease; Humans; Leukemia; Leukemia, Myeloid; Liver; Lymphoma; Lymphoma, Large B-Cell, Diffu | 1964 |
New therapeutic approaches to non-Hodgkin's lymphomas.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; C | 2003 |
[Hematologic tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Dacarbazine | 2003 |
A review of recruitment criteria, patient characteristics and results of CHOP chemotherapy in prospective randomized phase III clinical trials for aggressive non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Cyclophosphamid | 2003 |
What is the treatment of choice for advanced-stage Hodgkin's lymphoma: ABVD, Stanford V, or BEACOPP?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphami | 2004 |
Long-term efficacy of the CHVmP/BV regimen used for aggressive non-Hodgkin's lymphoma in three randomised EORTC trials.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials, | 2004 |
Effective immunochemotherapy for aggressive non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2004 |
Clinical trials for malignant lymphoma in Japan.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cy | 2004 |
Outcome of elderly patients with aggressive Non-Hodgkin's lymphoma refractory to or relapsing after first-line CHOP or CHOP-like chemotherapy: a low probability of cure.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Disease Progress | 2004 |
Targeting the proapoptotic factor Bcl-2 in non-Hodgkin's lymphoma.
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclo | 2004 |
[Malignant lymphoma, multiple myeloma and myeloproliferative diseases in the elderly].
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2004 |
New treatment strategies for aggressive lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Doxorubi | 2004 |
Perspectives of the management of childhood lymphoma: experience at Tygerberg Hospital, Western Cape, South Africa.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Transfusion; Child; Combined | 2005 |
[Progress in therapeutic strategy for malignant lymphoma].
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2005 |
Chemotherapy dose intensity in non-Hodgkin's lymphoma: is dose intensity an emerging paradigm for better outcomes?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality | 2005 |
Best treatment of aggressive non-Hodgkin's lymphoma: a French perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease Progression; Do | 2005 |
Overview of Southwest Oncology Group clinical trials in non-Hodgkin lymphoma.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 2005 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Fourth biannual report of the Cochrane Haematological Malignancies Group.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2006 |
Primary uterine lymphoma: report of 2 cases and review of literature.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclop | 2006 |
Diffuse aggressive histologies of non-hodgkin lymphoma: treatment and biology of limited disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Non | 2006 |
Treatment of diffuse large B-cell lymphoma: a risk-based approach.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2006 |
Treatment of non-Hodgkin's lymphoma: a look over the past decade.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2006 |
Childhood CD4+/CD56+ hematodermic neoplasm: case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; CD4 Antigens; CD56 Antigen; Child; Cyc | 2006 |
The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2007 |
[An update on recent developments in non-Hodgkin's lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2007 |
Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody Specificity; Antig | 2007 |
Primary effusion lymphoma.
Topics: Anti-Retroviral Agents; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Cyclophospham | 2007 |
[Recent progress in rituximab therapy and its resistance--how do we overcome?].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic | 2007 |
Non-Hodgkin's lymphoma in the elderly. Part 2: treatment of diffuse aggressive lymphomas.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic | 2007 |
[High-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Forecasting; Hu | 2008 |
CNOP (mitoxantrone) chemotherapy is inferior to CHOP (doxorubicin) in the treatment of patients with aggressive non-Hodgkin lymphoma (meta-analysis).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Non | 2008 |
The development of pericarditis following peripheral blood stem cell transplantation: a case report.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protoco | 2008 |
Advances in adult non-Hodgkin's lymphoma. Current concepts of classification, diagnosis, and management.
Topics: Adult; Bleomycin; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Therapy, Combination; Humans; L | 1980 |
Non-Hodgkin's lymphomas.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin | 1984 |
Non-Hodgkin's lymphoma occurring after Hodgkin's disease. Four new cases and a review of the literature.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1984 |
Transverse nail ridgings (Beau's lines) induced by chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; Dexame | 1994 |
Treatment of aggressive non-Hodgkin' lymphomas. Lessons from the past 10 years.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Dexamethaso | 1994 |
[New therapy of patients with malignant lymphoma using G-CSF].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; | 1994 |
[CHOP-Bleo therapy in high-malignancy non-Hodgkin lymphoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1994 |
Intensive treatment of AIDS-related non-Hodgkin's lymphomas with the MACOP-B protocol.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin | 1995 |
[High dose chemotherapy followed by hematopoietic stem cell transplantation for malignant lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality Therapy; Cyt | 1995 |
Reactivation toxoplasmic retinochoroiditis in patients undergoing bone marrow transplantation: is there a role for chemoprophylaxis?
Topics: Animals; Antibodies, Protozoan; Antineoplastic Combined Chemotherapy Protocols; Antiprotozoal Agents | 1995 |
[Elderly non-Hodgkin's lymphoma arising in left brachial soft tissue].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arm; Bleomycin; Combined Modality Therapy; Cyc | 1993 |
Polymyositis-dermatomyositis and non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cycloph | 1993 |
What treatment for elderly patients with aggressive lymphoma?
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Hu | 1994 |
[Primary, highly malignant B-cell lymphoma of the prostate. Apropos of a case and review of the literature].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, B-C | 1994 |
[Recent progress in the chemotherapy of malignant lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Cyclophosphamid | 1995 |
[Recent progress in the treatment of malignant lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 1994 |
[Therapy of high-grade non-Hodgkin's lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 1994 |
Prednisone, oral etoposide, and novantrone for treatment of non-Hodgkin's lymphoma: a preliminary report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Lymphoma, Non-Hodgk | 1994 |
[Reversible myelofibrosis in angioimmunoblastic lymphadenopathy].
Topics: Biopsy, Needle; Bone Marrow; Drug Therapy, Combination; Female; Humans; Immunoblastic Lymphadenopath | 1994 |
[Chemotherapy for malignant lymphoma in Western countries and Japan].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, | 1993 |
Retroperitoneal reticulum cell sarcoma: a cause of paraneoplastic pemphigus.
Topics: Aged; Autoantibodies; Biopsy; Combined Modality Therapy; Cyclophosphamide; Cytoskeletal Proteins; De | 1993 |
Cerebral non-Hodgkin's lymphoma discovered when treating Hodgkin's disease.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Carmustine; Cyc | 1993 |
What is the role of third generation regimens for initial therapy of non-Hodgkin's lymphomas?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Non | 1993 |
[High-grade non-Hodgkin lymphoma: diagnosis and therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Thera | 1996 |
Clinical analysis of 670 cases in two trials of the European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group subtyped according to the Revised European-American Classification of Lymphoid Neoplasms: a comparison with the W
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Combined Modality Therapy; C | 1996 |
Ifosfamide in the treatment of lymphoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; | 1996 |
[Non-Hodgkin lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Cyclophospha | 1996 |
Chemotherapy of intermediate-grade non-Hodgkin's lymphoma: is "more" or "less" better?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials, Phase II as Topic; Cyclo | 1995 |
[High-clore chemotherapy followed by autologous peripheral blood stem cell transplantation (PBSCT) for patients with malignant lymphoma--its role in the treatment strategy for non-Hodgkin's lymphoma, and ESHAP + PBSCT therapy].
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cell Separation; Cisplatin; Cytarabine; | 1996 |
Clinical reversal of multidrug resistance.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Membe | 1996 |
Primary cerebral lymphoma--a case report and review of the management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cerebellar Neoplasms; Cyclophosphamide; Doxorubicin; | 1995 |
Primary extramedullary leukemia of the prostate: case report and review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; C | 1996 |
[Metastatic malignant melanoma in treated non-Hodgkin's lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Humans; Lymph Nodes; Lymphatic | 1996 |
[Recent progress in the management of malignant lymphoma].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin | 1997 |
Acute liver failure due to hepatic involvement by hematologic malignancy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Leukemia, Lym | 1997 |
Primary non-Hodgkin's lymphoma of the common bile duct.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormon | 1997 |
Overview of treatment of localized low-grade lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; California; Chemotherap | 1997 |
[Diagnosis and therapy of malignant thyroid lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Cytodia | 1997 |
Diagnostic dilemma in pancreatic lymphoma. Case report and review.
Topics: Azathioprine; Cyclosporine; Diagnosis, Differential; Fatal Outcome; Female; Humans; Kidney Transplan | 1997 |
[Treatment of lymphoma in the aged].
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubi | 1998 |
[Treatment strategy of high malignancy non-Hodgkin lymphomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 1998 |
[A case of retroperitoneal malignant lymphoma successfully treated by chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Administra | 1998 |
[Primary MALT-type lymphoma of the breast].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cycloph | 1998 |
[Chylothorax resulting from malignant non Hodgkin's lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chylothorax; Cyclophosphamide; Cytarabine | 1998 |
[Dose-effects and chemotherapy dose intensity of aggressive non-Hodgkin's lymphomas in the adult].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Dose-R | 1998 |
A cutaneous agranular CD2- CD4+ CD56+ "lymphoma": report of two cases and review of the literature.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CD2 Antigens; CD4 An | 1998 |
Management of intermediate-grade lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Non | 1998 |
[Chemotherapy for non-Hodgkin's lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphami | 1998 |
[New antitumor drugs for non-Hodgkin's lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Phytogenic; A | 1998 |
Hodgkin's disease following extranodal marginal zone B-cell lymphoma in remission.
Topics: Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Combined Modality | 1999 |
Intermediate and high grade non Hodgkin's lymphoma in the elderly.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclop | 1999 |
[Treatment of malignant lymphoma with extranodal lesions--current trends and new strategies in chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Cyclophosphamid | 1999 |
Intensified CHOP in non-Hodgkin's lymphoma: what we know and what we need to know.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Dose-Res | 1999 |
The prednisone dosage in the CHOP chemotherapy regimen for non-Hodgkin's lymphomas (NHL): is there a standard?
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; D | 2000 |
Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Doxorubicin | 2001 |
Primary non-Hodgkin's lymphoma of the gall bladder.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxo | 2000 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Therapy of PCNSL at the Massachusetts General Hospital with high dose methotrexate and deferred radiotherapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Boston; Brain Neopl | 2001 |
Therapeutic management of refractory or relapsed primary central nervous system lymphomas.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervous Sys | 2001 |
High-dose sequential (HDS) chemotherapy for high-risk non-Hodgkin's lymphoma: long-term analysis and future developments.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2001 |
Potential of chromosomal and matrix-based comparative genomic hybridization for molecular diagnostics in lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human; Cyclopho | 2001 |
Management of localized (stage I and II) clinically aggressive lymphomas.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Top | 2001 |
Therapeutic strategies for aggressive lymphomas: the trials of the DSHNHL.
Topics: Adolescent; Adult; Age Factors; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2001 |
Treatment strategies in elderly patients with aggressive histology lymphoma.
Topics: Age Factors; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Co | 2001 |
Rituximab in the treatment of diffuse large B-cell lymphomas.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2002 |
Rituximab in combination with CHOP or fludarabine in low-grade lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2002 |
Immunochemotherapy in indolent non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combi | 2002 |
Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
Primary lymphoma of the kidney. Report of a case and update of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bleomycin; Combined Modality Therapy | 2002 |
Chemotherapy of non-Hodgkin's lymphomas: Eastern Cooperative Oncology Group experience.
Topics: Altretamine; Bleomycin; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Ad | 1977 |
Overview of four clinical studies of chemotherapy for stage III and IV non-Hodgkin's lymphomas by the Cancer and Leukemia Group B.
Topics: Adult; Bleomycin; Clinical Trials as Topic; Cyclophosphamide; Drug Administration Schedule; Drug The | 1977 |
Chemotherapy for Hodgkin's disease and aggressive non-Hodgkin's lymphoma. More is better, or is it?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chemotherapy, Adjuvant; | 1992 |
Non-Hodgkin's lymphomas in children. II. Treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Clinical Protoco | 1992 |
Non-Hodgkin's lymphoma presenting with cardiac tamponade.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cardiac Tamponade; Cyclophosphamide; Doxorubic | 1992 |
[Massive bilateral non-Hodgkin's lymphoma of the adrenal glands].
Topics: Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1990 |
The place of third-generation regimens in the treatment of adult aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dexamethas | 1991 |
Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Doxor | 1991 |
[Problems of cancer treatment in the elderly from the viewpoint of the chemotherapist--focusing on malignant lymphomas as a model of chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphom | 1990 |
[A bulky mass non-Hodgkin's lymphoma with dysuria in the rectovesical space].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphom | 1990 |
Therapy for childhood non-Hodgkin's lymphomas, nonlymphoblastic type. Review of recent studies and current recommendations.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Brain Neoplasms; Cell Differentiation | 1990 |
[The place of bone marrow autografts in the treatment of Hodgkin's and non-Hodgkin's lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Dacarbazine; | 1988 |
European experience with ifosfamide in lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Etoposide; Europe; Hodgkin Disease; Human | 1989 |
The role of radiation therapy in the management of the non-Hodgkin's lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Combined Modali | 1985 |
[Cancer curable by chemotherapy: malignant lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cyclophosphamide; Hodgk | 1989 |
[Current status of chemotherapy in the treatment of malignant lymphomas].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1989 |
[Glucocorticosteroids in the treatment of acute leukemia and lymphosarcoma in children].
Topics: Acute Disease; Administration, Oral; Age Factors; Antimetabolites; Antineoplastic Agents; Drug Syner | 1972 |
Non-Hodgkin's lymphoma: recent observations on natural history and intensive treatment.
Topics: Antineoplastic Agents; Burkitt Lymphoma; Cyclophosphamide; Follow-Up Studies; Humans; Lymphoma; Lymp | 1972 |
Proceedings: Malignant lymphoma: treatment with combination chemotherapy.
Topics: Adolescent; Adult; Aged; Alkylating Agents; Antineoplastic Agents; Carmustine; Cyclophosphamide; Dru | 1972 |
Recently recognized complications of cancer chemotherapy.
Topics: Antineoplastic Agents; Burkitt Lymphoma; Cyclophosphamide; Death, Sudden; Drug Therapy, Combination; | 1974 |
[Danger of hyperuricemia in the treatment of acute leukemia, lymphosarcoma and reticulosarcoma].
Topics: Acute Disease; Allopurinol; Antineoplastic Agents; Child; Humans; Leukemia, Lymphoid; Lymphoma, Non- | 1974 |
[Cancerostatic ingredients of higher plants].
Topics: Adenocarcinoma; Alkaloids; Animals; Antineoplastic Agents; Chemical Phenomena; Chemistry; Colchicine | 1971 |
436 trials available for prednisone and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification: a post-hoc analysis of the PETAL trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Fluorodeoxyglucose F1 | 2022 |
Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma.
Topics: Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Mutation; Neopla | 2023 |
Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cyclophosphamide; Doxorubicin; Etopos | 2021 |
Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial).
Topics: Adult; Aged; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; CD4 Lymphocyte Count; | 2020 |
Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I Study.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Hydr | 2021 |
Infectious diseases and immunological markers associated with patients with non-Hodgkin lymphoma treated with rituximab.
Topics: Adult; Aged; Antibodies, Bacterial; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cycl | 2018 |
Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin | 2018 |
First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxoru | 2019 |
First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxoru | 2019 |
First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxoru | 2019 |
First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxoru | 2019 |
Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bridged Bic | 2019 |
Dose-adjusted EPOCH regimen as first-line treatment for non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis: a single-arm, open-label, phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Ly | 2020 |
Primary non-Hodgkin lymphoma in the pterygopalatine fossa. A peculiar diagnosis with a minimally invasive endoscopic approach.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclo | 2014 |
Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-NHL: a Children's Oncology Group Report.
Topics: Acute Kidney Injury; Adolescent; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Che | 2013 |
Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
A phase III randomized trial of high-dose CEOP + filgrastim versus standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year follow-up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Epirubici | 2014 |
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Com | 2014 |
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Com | 2014 |
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Com | 2014 |
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Com | 2014 |
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Com | 2014 |
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Com | 2014 |
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Com | 2014 |
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Com | 2014 |
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Com | 2014 |
Feasibility and safety of a reduced duration of therapy of colony-stimulating factor in a dose-dense regimen.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derive | 2014 |
A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Disease-F | 2015 |
Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial).
Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Agents; Antineoplastic Combined Chemothera | 2016 |
Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2016 |
Phase III of Study of R-CHOP-21 vs R-CHOP-14 for Untreated Stage III and IV B-cell Non-Hodgkin's Lymphoma: a Report from Iran.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopho | 2016 |
Efficacy and safety of triple therapy with aprepitant, ondansetron, and prednisone for preventing nausea and vomiting induced by R-CEOP or CEOP chemotherapy regimen for non-Hodgkin lymphoma: a phase 2 open-label, randomized comparative trial.
Topics: Activities of Daily Living; Adult; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Drug | 2017 |
Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP r
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cycl | 2008 |
CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2009 |
[Role of modified radiotherapy in the combined treatment of orbital non-Hodgkin lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cataract; Conjunctivitis; Cyclophospham | 2009 |
Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients--analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cohort Studies; Cyclophosphamide; D | 2009 |
Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2009 |
Long term outcome of localized aggressive non-Hodgkin lymphoma treated with a short weekly chemotherapy regimen (doxorubicin, cyclophosphamide, bleomycin, vincristine, and prednisone) and involved field radiotherapy: result of a Gruppo Italiano Multiregio
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 2009 |
Positron emission tomography guided therapy of aggressive non-Hodgkin lymphomas--the PETAL trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-D | 2009 |
In vitro and in vivo study on the antioxidant activity of dexrazoxane.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Bleomycin; Chromans; Cyclophosphamide; | 2010 |
Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2010 |
Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Combined Modali | 2010 |
Limited chemotherapy and shrinking field radiotherapy for Osteolymphoma (primary bone lymphoma): results from the trans-Tasman Radiation Oncology Group 99.04 and Australasian Leukaemia and Lymphoma Group LY02 prospective trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antin | 2011 |
Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cyclophosph | 2010 |
Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cyclophosph | 2010 |
Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cyclophosph | 2010 |
Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cyclophosph | 2010 |
Phase III trial of CHOP-21 versus CHOP-14 for aggressive non-Hodgkin's lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG 9809.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cyc | 2011 |
[Treatment outcome analysis of CTOP or CHOP regimen in newly diagnosed aggressive non-Hodgkin's lymphoma patients-results of a prospective, open, randomized, multicenter clinical trial].
Topics: Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Prednisone; Prospective Studies; Treatment Outcome | 2010 |
Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma.
Topics: Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boro | 2011 |
Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2011 |
A long-term follow-up study of prospective 80%-dose CHOP followed by involved-field radiotherapy in elderly lymphoma patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-F | 2011 |
Phase I trial examining addition of gemcitabine to CHOP in intermediate grade NHL.
Topics: Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protoco | 2011 |
Front-line immunochemotherapy for aggressive non-Hodgkin lymphoma using dose-dense rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone plus granulocyte-macrophage colony stimulating factor and pegfilgrastim as support.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2012 |
Prognostic significance of serum proangiogenic molecules in patients with de novo non-Hodgkin lymphomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenic Proteins; Antineoplastic Combined Chemotherap | 2012 |
Phase II study of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) therapy for newly diagnosed patients with low- and low-intermediate risk, aggressive non-Hodgkin's lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG95
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 2012 |
Addition of amifostine to the CHOP regimen in elderly patients with aggressive non-Hodgkin lymphoma: a phase II trial showing reduction in toxicity without altering long-term survival.
Topics: Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamid | 2012 |
Case report: Sodium dichloroacetate (DCA) inhibition of the "Warburg Effect" in a human cancer patient: complete response in non-Hodgkin's lymphoma after disease progression with rituximab-CHOP.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2013 |
Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 2002 |
A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cycloph | 2002 |
Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Bleomycin; Cispla | 2002 |
Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dr | 2002 |
Stage I-IIE primary non-Hodgkin's lymphoma of the testis: results of a prospective trial by the GOELAMS Study Group.
Topics: Adult; Age Factors; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2002 |
[Effectiveness of high-dose polychemotherapy and autologous hemopoietic cell transplantation in patients with low-grade non-Hodgkin lymphoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Dexa | 2002 |
Dose-intensified CHOP (double-CHOP) followed by consolidation with high-dose chemotherapy for high and high-intermediate risk aggressive non-Hodgkin's lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 2002 |
Comparative study of low-dose oral granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone in prevention of nausea and vomiting induced by CHOP-therapy in young patients with non-Hodgkin's lymphoma.
Topics: Administration, Oral; Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols | 2002 |
A randomised multicentre trial of modified CHOP versus MCOP in patients aged 65 years and over with aggressive non-Hodgkin's lymphoma.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2003 |
A dose-finding study of glycosylated G-CSF (Lenograstim) combined with CHOP therapy for stem cell mobilization in patients with non-Hodgkin's lymphoma.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Analysis of Variance; Antigens, CD34; Antineoplastic Comb | 2003 |
Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dise | 2003 |
[Clinical comparison of CHO regimen versus CHOP regimen for treatment of patients with intermediate-grade non-Hodgkin's lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; | 2003 |
[Preliminary outcome for patients with relapsed or resistant advanced non-Hodgkin's lymphoma treated by EPOCH regimen].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 2003 |
[Effectiveness of dose-intensive polychemotherapy with autologous hemopoietic cell transplantation for high-grade non-Hodgkin lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Dex | 2003 |
A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamid | 2003 |
A randomized trial comparing intensified CNOP vs. CHOP in patients with aggressive non-Hodgkin's lymphoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disea | 2003 |
Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; C | 2003 |
Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2003 |
Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival | 2003 |
First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: phase II trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2003 |
CHOP with high dose cyclophosphamide consolidation versus CHOP alone as initial therapy for advanced stage, indolent non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; | 2003 |
CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Granulo | 2003 |
Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Free Surv | 2003 |
Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Free Surv | 2003 |
Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Free Surv | 2003 |
Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Free Surv | 2003 |
Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Free Surv | 2003 |
Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Free Surv | 2003 |
Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Free Surv | 2003 |
Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Free Surv | 2003 |
Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Free Surv | 2003 |
Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Free Surv | 2003 |
Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Free Surv | 2003 |
Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Free Surv | 2003 |
Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Free Surv | 2003 |
Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Free Surv | 2003 |
Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Free Surv | 2003 |
Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Free Surv | 2003 |
Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Free Surv | 2003 |
Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Free Surv | 2003 |
Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Free Surv | 2003 |
Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Free Surv | 2003 |
Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Free Surv | 2003 |
Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Free Surv | 2003 |
Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Free Surv | 2003 |
Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Free Surv | 2003 |
Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Free Surv | 2003 |
High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Australia; B-Lymphocytes; Bone Marrow Purging | 2003 |
Fourteen-day CHOP supported with granulocyte colony-stimulating factor in patients with aggressive non-Hodgkin's lymphoma: results of a phase II study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopho | 2003 |
Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Australia; Combined Modalit | 2003 |
[Clinical trial of the monoclonal antibody drug mabthera (Rituximab) in the treatment of non-Hodgkin lymphoma].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2003 |
Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Administra | 2004 |
P-CHOP: cisplatin (P) added to the standard CHOP regimen as first-line treatment for aggressive non-Hodgkin lymphoma: a single-institution phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide | 2003 |
Treatment of AIDS related non-Hodgkin's lymphoma with combination mitoguazone dihydrochloride and low dose CHOP chemotherapy: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; | 2004 |
Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 2004 |
Intensive sequential chemotherapy with hematopoietic growth factor support for non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus.
Topics: Adult; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; CD4 Lymphocyte Count; Cyclop | 2004 |
A third generation regimen VACOP-B with or without adjuvant radiotherapy for aggressive localized non-Hodgkin's lymphoma: report from the Italian Non-Hodgkin's Lymphoma Co-operative Study Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxo | 2004 |
Parental longevity and prognosis in elderly patients with aggressive non-Hodgkin's lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; | 2004 |
Long-term follow-up after high-dose chemotherapy and autologous stem-cell transplantation for high-grade B-cell lymphoma suggests an improved outcome for high-risk patients with respect to the age-adjusted International Prognostic Index.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dis | 2004 |
Quality of life assessment in elderly patients with aggressive non-Hodgkin's Lymphoma treated with anthracycline-containing regimens. Report of a prospective study by the Intergruppo Italiano Linfomi.
Topics: Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Appetite; Bleomycin; Cyclophos | 2004 |
A phase II trial of adjuvant low-dose total body irradiation in non-Hodgkin's lymphoma patients following standard CHOP.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 2004 |
Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Cycl | 2004 |
Outcome of children with B cell lymphoma in Venezuela with the LMB-89 protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Cytarabine; Disease Progres | 2004 |
Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral T | 2004 |
Phase II study of cyclophosphamide,epirubicin, vincristine, prednisone, and etoposide (CEOP-E) for aggressive non-Hodgkin 's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cycl | 2004 |
Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Gro
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyc | 2004 |
[VNCOP-B (etoposide, mitoxantrone, cyclophosphamide, vincristine, predonisolone, bleomycin) therapy in elderly patients with aggressive non-Hodgkin lymphoma--a study of efficacy and safety, final report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Drug Administrati | 2005 |
Long-term follow-up of a randomized trial of fludarabine-mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Su | 2005 |
Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 2005 |
ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Ther | 2005 |
ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Ther | 2005 |
ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Ther | 2005 |
ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Ther | 2005 |
Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncolo
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2005 |
Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin's lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-F | 2005 |
Fertility and ovarian function are preserved in women treated with an intensified regimen of cyclophosphamide, adriamycin, vincristine and prednisone (Mega-CHOP) for non-Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Fertil | 2005 |
Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Do | 2005 |
Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non-Hodgkin's lymphomas.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Frail Elderly; Huma | 2005 |
Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2005 |
Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2005 |
Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2005 |
Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2005 |
Long-term outcome of localized high-grade non-Hodgkin's lymphoma treated with high dose CHOP regimen and involved field radiotherapy: results of a GOELAMS study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclop | 2005 |
Self-reported quality of life in elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 2005 |
Gemcitabine, vinorelbine and prednisone for refractory or relapsed aggressive lymphoma, results of a phase II single center study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; D | 2005 |
Prospective randomized study comparing MEMID with a chop-like regimen in elderly patients with aggressive non-Hodgkin's lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease-Free | 2005 |
Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosph | 2006 |
Comparison of CHOP versus CIOP in good prognosis younger patients with histologically aggressive non-Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cyclophosphami | 2005 |
Autologous stem cell transplantation following induction therapy with an anthracycline-based regimen including interferon-alpha for low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease Pr | 2004 |
Overview of Southwest Oncology Group clinical trials in non-Hodgkin lymphoma.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 2005 |
A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; CD4 Ly | 2005 |
Late non-neoplastic events in patients with aggressive non-Hodgkin's lymphoma in four randomized European Organisation for Research and Treatment of Cancer trials.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Europe; Female; Follow-Up S | 2005 |
Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2005 |
Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Antineoplastic Combined Chemothera | 2005 |
To irradiate or not to irradiate--that is the question.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2005 |
Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2006 |
Frontline therapy with early intensification and autologous stem cell transplantation versus conventional chemotherapy in unselected high-risk, aggressive non-Hodgkin's lymphoma patients: a prospective randomized GEMOH report.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dise | 2006 |
Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cyclophosphamide; Cyta | 2006 |
Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival--results of the German
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adult; Age Factors; Anti-Retroviral Agents | 2006 |
A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyc | 2006 |
Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2006 |
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Ag | 2006 |
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Ag | 2006 |
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Ag | 2006 |
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Ag | 2006 |
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Ag | 2006 |
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Ag | 2006 |
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Ag | 2006 |
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Ag | 2006 |
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Ag | 2006 |
Surgery and chemotherapy versus chemotherapy as treatment of high-grade MALT gastric lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Fr | 2006 |
Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Do | 2006 |
Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL).
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Su | 2006 |
Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2006 |
ESHAP salvage therapy for refractory and relapsed non-Hodgkin's lymphoma: a single center experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2006 |
Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cyclophosphamide | 2007 |
The multicenter trial SAKK 37/95 of cladribine, cyclophosphamide and prednisone in the treatment of chronic lymphocytic leukemias and low-grade non-Hodgkin's lymphomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Combined Modality Therapy; Cycloph | 2007 |
Pegfilgrastim to support CHOP-14 in elderly patients with non-Hodgkin's lymphoma.
Topics: Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Respons | 2006 |
Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON).
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Belgium; Child; Cyclophosphamide; | 2007 |
Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2007 |
Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cohort Studi | 2007 |
High dose CHOP: a phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Adm | 2007 |
Community-based trial of R-CHOP and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2007 |
Rituximab and dose dense chemotherapy in primary breast lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2007 |
The impact of high-dose sodium selenite therapy on Bcl-2 expression in adult non-Hodgkin's lymphoma patients: correlation with response and survival.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Down-Regulation; Doxorubici | 2007 |
Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2008 |
Herpes zoster--the best approach.
Topics: Adult; Aged; Child; Clinical Trials as Topic; Cytarabine; Herpes Zoster; Hodgkin Disease; Humans; Im | 1980 |
Childhood non-Hodgkin's lymphoma. The results of a randomized therapeutic trial comparing a 4-drug regimen (COMP) with a 10-drug regimen (LSA2-L2).
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; | 1983 |
[Polychemotherapy of lymphosarcoma by the COP program].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; C | 1984 |
P-VABEC: a prospective study of a new weekly chemotherapy regimen for elderly aggressive non-Hodgkin's lymphoma.
Topics: Actuarial Analysis; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamid | 1993 |
Successful application of a previously derived prognostic index in the analysis of a randomised trial of 281 patients with high grade non-Hodgkin's lymphoma (HIGNHL).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Huma | 1993 |
Cytokine efficiency in the treatment of high-grade malignant non-Hodgkin's lymphomas: results of a randomized double-blind placebo-controlled study with intensified COP-BLAM +/- rhGM-CSF.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modalit | 1994 |
Chlorambucil/prednisone vs. CHOP in symptomatic low-grade non-Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden.
Topics: Actuarial Analysis; Aged; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Chlorambuc | 1994 |
Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma: high remission rates and reversion to negative of peripheral blood bcl-2 rearrangement.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Biomark | 1994 |
A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Dexam | 1994 |
EORTC study of non-Hodgkin's lymphoma: phase III study comparing CHVmP-VB and ProMACE-MOPP in patients with stage II, III, and IV intermediate- and high-grade lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; C | 1994 |
MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxo | 1994 |
Comparison of front-line chemotherapy for aggressive non-Hodgkin's lymphoma using the CAP-BOP regimens. The Nebraska Lymphoma Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 1994 |
Combination chemotherapy with COP-BLAM III for intermediate and high-grade non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1994 |
Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined | 1994 |
The cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, and procarbazine (COPBLAM-I) regimen for intermediate-grade non-Hodgkin's lymphoma. Long term follow-up in 51 patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cause of Death; | 1994 |
Peripheral T-cell non-Hodgkin's lymphomas of low malignancy: prospective study of 25 patients with pleomorphic small cell lymphoma, lymphoepitheloid cell (Lennert's) lymphoma and T-zone lymphoma. The Kiel Lymphoma Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubici | 1994 |
Recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to chemotherapy in aggressive non-Hodgkin's lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chemotherapy, Ad | 1994 |
Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dexamethasone; Disease- | 1995 |
Selection of patients for randomised trials: a study based on the MACOP-B vs CHOP in NHL study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Hum | 1994 |
Effect of granulocyte colony-stimulating factor in patients with diffuse large cell lymphoma treated with intensive chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Dise | 1994 |
Modified MACOP-B chemotherapy for intermediate and high grade non Hodgkins lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1994 |
P-VEBEC: a new 8-weekly schedule with or without rG-CSF for elderly patients with aggressive non-Hodgkin's lymphoma (NHL).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1994 |
CEOP-B alternated with VIMB in intermediate-grade and high-grade non-Hodgkin's lymphoma: a pilot study.
Topics: Actuarial Analysis; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocol | 1995 |
[The effects of COP-BLAM regimen with G-CSF for intermediate and high grade non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 1995 |
Granulocyte colony-stimulating factor (G-CSF) allows the delivery of effective doses of CHOP and CVP regimens in non-Hodgkin lymphomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Response Relationship, | 1995 |
MACOP-B vs F-MACHOP regimen in the treatment of high-grade non-Hodgkin's lymphomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Diseases; Cyclophospha | 1995 |
COP-BLAM regimen combined with granulocyte colony-stimulating factor and high-grade non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 1995 |
[Usefulness of COP-BLAM therapy with concomitant G-CSF in elderly patients with non-Hodgkin's lymphoma in comparison with patients not given G-CSF].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Fema | 1995 |
FMP regimen (fludarabine, mitoxantrone, prednisone) as therapy in recurrent low-grade non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sc | 1995 |
Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined | 1995 |
Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 1995 |
Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfa | 1995 |
Long-term results of a multicentre randomised, comparative phase III trial of CHOP versus CNOP regimens in patients with intermediate- and high-grade non-Hodgkin's lymphomas. Novantrone International Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Di | 1995 |
Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cy | 1995 |
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 1993 |
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 1993 |
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 1993 |
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 1993 |
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 1993 |
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 1993 |
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 1993 |
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 1993 |
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 1993 |
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 1993 |
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 1993 |
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 1993 |
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 1993 |
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 1993 |
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 1993 |
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 1993 |
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 1993 |
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 1993 |
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 1993 |
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 1993 |
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 1993 |
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 1993 |
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 1993 |
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 1993 |
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 1993 |
Effective therapy for poor-prognosis non-Hodgkin's lymphoma with 8 weeks of high-dose-intensity combination chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1993 |
EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Adm | 1993 |
Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas.
Topics: Adolescent; Adult; Aged; Antibodies; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infec | 1993 |
Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1993 |
Effects of interleukin-3 following chemotherapy of non-Hodgkin's lymphoma. A prospective, controlled phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cyclophosphamide; Dox | 1995 |
Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: a Childrens Cancer Group study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cause of Death; Child; Chi | 1995 |
Infusional chemotherapy (EPOCH) in patients with refractory or relapsed lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Res | 1995 |
A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopho | 1995 |
Full dose CHOP chemotherapy in elderly patients with non-Hodgkin's lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 1995 |
Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Comb | 1995 |
Effect of treatment on the prognostic value of S-phase fraction in non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemothera | 1994 |
Disseminated nonlymphoblastic lymphoma of childhood: a Childrens Cancer Group study, CCG-552.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschoo | 1994 |
Treatment of localized non-Hodgkin's lymphomas of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 1994 |
Prednisone, oral etoposide, and novantrone for treatment of non-Hodgkin's lymphoma: a preliminary report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Lymphoma, Non-Hodgk | 1994 |
New aspects in the treatment of advanced low-grade non-Hodgkin's lymphomas: prednimustine/mitoxantrone versus cyclophosphamide/vincristine/prednisone followed by interferon alfa versus observation only--a preliminary update of the German Low-Grade Lymphom
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Germany; | 1994 |
Full-dose chemotherapy for non-Hodgkin's lymphoma in the elderly. Dutch Hematology-Oncology in Adults Study Group.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 1994 |
A phase II study of continuous infusion recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma in first remission.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cyclophosphamide | 1994 |
Randomised comparison of CHOEP versus alternating hCHOP/IVEP for high-grade non-Hodgkin's lymphomas: treatment results and prognostic factor analysis in a multi-centre trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1994 |
Combined use of interferon alpha-2, chlorambucil and prednisone in previously treated patients with low-grade non-Hodgkin's lymphomas. Results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Female; Humans; Interfero | 1993 |
[Comparison of effectiveness of adriamycin and epirubicin administered in the CHOP protocol to patients with malignant non-hodgkin's lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Epirubic | 1993 |
[Alternating CHOP-MEVP chemotherapy for advanced-stage, intermediate- and high-grade non-Hodgkin's lymphomas].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Adm | 1993 |
Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) after chemotherapy in patients with non-Hodgkin's lymphoma; a placebo-controlled double blind phase III trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Double-Bl | 1993 |
Stage III abdominal non-Hodgkin's lymphoma in Costa Rican children: comparison of two consecutive trials of treatment.
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasm | 1994 |
Mitoxantrone, teniposide, chlorambucil and prednisone (MVLP) for relapsed non-Hodgkin's lymphoma. The impact of advanced age and performance status.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophospha | 1993 |
A phase II trial of a chemotherapy combination in elderly patients with aggressive lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide | 1993 |
Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a prospective randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modali | 1993 |
[Comparative study of 1st generation versus 2d generation (CAVPE) combinations in intermediate and high-grade lymphomas].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopho | 1993 |
A comparative study of CHOP versus MEVP (mitoxantrone, etoposide, vindesine, prednisolone) therapy for intermediate-grade and high-grade non-Hodgkin's lymphoma: a prospective randomized study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopho | 1993 |
The rationale of therapy with mitoxantrone in non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Co-operative Study Group, (NHLCSG) Italy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cyclophosphamide; | 1993 |
Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Cyclophosphamide; Doxorubicin; F | 1993 |
Anthracycline containing regimens in intermediate grade lymphoma. Italian Cooperative Study Group on Intermediate Grade Malignant Lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Idarub | 1993 |
Autologous bone marrow transplantation in poor-prognosis intermediate-grade and high-grade B-cell non-Hodgkin's lymphoma in first remission: a pilot study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modalit | 1993 |
Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: a report of CCG-551 from the Childrens Cancer Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 1993 |
Aggressive chemotherapy in the treatment of Burkitt's and non-Burkitt's undifferentiated lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophos | 1995 |
Phase III comparative trial using CHOP vs CIOP in the treatment of advanced intermediate-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; | 1995 |
Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate- and high-grade malignant non-Hodgkin's lymphoma (NHL).
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cost | 1995 |
Pharmacokinetic and pharmacodynamic studies of subcutaneously administered recombinant human interleukin-3 following chemotherapy for non-Hodgkin's lymphoma.
Topics: Administration, Cutaneous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 1995 |
Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bleomycin; Cyclophosphamid | 1996 |
ProMECE-CytaBOM vs MACOP-B in advanced aggressive non-Hodgkin's lymphoma: long term results of a multicenter study of the Italian Lymphoma Study Group (GISL).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Cyclophos | 1995 |
Intermediate and high-grade gastric non-Hodgkin's lymphoma: a prospective study of non-surgical treatment with primary chemotherapy, with or without radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; | 1995 |
A phase II trial of prednisone, oral etoposide, and novantrone (PEN) as initial treatment of non-Hodgkin's lymphoma in elderly patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Etopo | 1995 |
Short-term rhG-CSF priming before chemotherapy does mobilize blood progenitors but does not prevent chemotherapy induced myelotoxicity: a randomized study of patients with non-Hodgkin's lymphomas.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Di | 1995 |
Administration of rhG-CSF increases complete remission rates after CHOP and ProMACE/CytaBOM for non-Hodgkin's lymphoma: a pilot study. Hokkaido Study Group of Malignant Lymphoma and rhG-CSF.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; C | 1995 |
Biweekly COP-BLAM (cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin and procarbazine) regimen combined with granulocyte colony stimulating factor (G-CSF) for intermediate-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow | 1996 |
Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Presch | 1996 |
Severe myelotoxicity of oral etoposide in heavily pretreated patients with non-Hodgkin's lymphoma or chronic lymphatic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 1996 |
High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter s
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplant | 1996 |
Clinical analysis of 670 cases in two trials of the European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group subtyped according to the Revised European-American Classification of Lymphoid Neoplasms: a comparison with the W
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Combined Modality Therapy; C | 1996 |
[Biweekly cyclophosphamide, epirubicin, vincristine and prednisolone (CEOP) chemotherapy for the elderly patients with aggressive non-Hodgkin's lymphoma. Tochigi Malignant Lymphoma Study Group for the Elderly Patients].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule | 1996 |
Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: determination of the maximum-tolerated dose of ProMACE-CytaBOM.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Doxo | 1996 |
Recombinant human granulocyte-macrophage colony-stimulating factor after combined chemotherapy in high-grade non-Hodgkin's lymphoma--a randomised pilot study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Double-Bl | 1995 |
A randomised comparison of a third-generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma: a British National Lymphoma Investigation report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etop | 1996 |
[Radiotherapy of primary extranodal non-Hodgkin's lymphoma of the head and neck region. Results of a prospective multicenter study. Study Group NHL: early studies].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemothe | 1996 |
Monitoring bulky mediastinal disease with gallium-67, CT-scan and magnetic resonance imaging in Hodgkin's disease and high-grade non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Ther | 1996 |
Primary non-Hodgkin's lymphoma of the stomach: three radical modalities of treatment in 75 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Com | 1996 |
Treatment of non-Hodgkin's lymphoma of Waldeyer's ring: radiotherapy versus chemotherapy versus combined therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 1996 |
Vincristine, doxorubicin, cyclophosphamide, prednisone and etoposide (VACPE) in high-grade non-Hodgkin's lymphoma--a multicenter phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 1995 |
Efficacy of delayed granulocyte colony-stimulating factor after full dose CHOP therapy in non-Hodgkin's lymphoma: a pilot study for a leukocyte count oriented regimen.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopho | 1995 |
A new protocol (MiCEP) for the treatment of intermediate or high-grade non-Hodgkin's lymphoma in the elderly.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Etopo | 1996 |
Interferon alpha 2b as maintenance therapy in low grade malignant lymphoma improves duration of remission and survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; C | 1996 |
The treatment of elderly patients with aggressive non-Hodgkin's lymphomas: feasibility and efficacy of an intensive multidrug regimen.
Topics: Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Antifungal Agents; Antineoplastic Combined Chem | 1996 |
Prognostic implications of ploidy and proliferative activity in the diffuse, aggressive non-Hodgkin's lymphomas.
Topics: Adult; Aged; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bleomycin; Cell Div | 1996 |
Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 1996 |
CHOP vs. ProMACE-CytaBOM in the treatment of aggressive non-Hodgkin's lymphomas: long-term results of a multicenter randomized trial.(PETHEMA: Spanish Cooperative Group for the Study of Hematological Malignancies Treatment, Spanish Society of Hematology).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophos | 1996 |
Alternating chemotherapy and radiotherapy for limited-stage intermediate and high-grade non-Hodgkin's lymphomas: long-term results for 96 patients with tumors > 5 cm.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined | 1996 |
Peripheral T-cell lymphomas respond well to vincristine, adriamycin, cyclophosphamide, prednisone and etoposide (VACPE) and have a similar outcome as high-grade B-cell lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 1996 |
A prospective study of VEC-POB and POCE chemotherapy in aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Epirubicin | 1997 |
Consolidation therapy with idarubicin, cisplatin and prednisone (CIP) after P-VABEC regimen in the treatment of intermediate and high grade non-Hodgkin's lymphoma of the elderly.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bleomycin; Bone Marrow; Cis | 1997 |
Multiple statistics for multiple events, with application to repeated infections in the growth factor studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Drug Thera | 1997 |
Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Etop | 1997 |
[Biweekly CHOP-E chemotherapy for aggressive non-Hodgkin's lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Adm | 1997 |
Impact of high-dose salvage therapy (BEAM) on overall survival in younger patients with advanced large-cell lymphomas entered into BNLI trials.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1997 |
Persistent improved results after adding vincristine and bleomycin to a cyclophosphamide/hydroxorubicin/Vm-26/prednisone combination (CHVmP) in stage III-IV intermediate- and high-grade non-Hodgkin's lymphoma. The EORTC Lymphoma Cooperative Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1997 |
Long-term survival advantage of MACOP-B over CHOP in intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Follow-Up | 1997 |
Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; | 1997 |
Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival--a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Cyclophosphami | 1997 |
A phase I trial to assess the value of recombinant human granulocyte colony stimulating factor (R-MeTHuG-CSF, filgrastim) in accelerating the dose rate of chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma (NHL). The Central Lymphoma Grou
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Adm | 1996 |
Cyclophosphamide, doxorubicin, vincristine, and prednisone versus intensive chemotherapy in non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Erythroid Precursor C | 1997 |
Treatment of children and young adults with early-stage non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined | 1997 |
Prognostic factors in elderly patients with non-Hodgkin's lymphoma treated with cyclophosphamide, vincristine, prednisone, bleomycin, Adriamycin, procarbazine (COP-BLAM) therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1997 |
A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma.
Topics: Adult; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; D | 1997 |
Clinical features, treatment and outcome in a series of 93 patients with low-grade gastric MALT lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antineoplastic Agents, Alkylating; Antineopla | 1997 |
Stage I non-Hodgkin's lymphoma treated with doxorubicin-containing chemotherapy with or without radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined | 1997 |
Epirubicin (CEOP-Bleo) versus idaurubicin (CIOP-Bleo) in the treatment of elderly patients with aggressive non-Hodgkin's lymphoma: dose escalation studies.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1997 |
CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-F | 1998 |
Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide | 1998 |
Inhibin A concentrations in the sera of young women during and after chemotherapy for lymphoma: correlation with ovarian toxicity.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Ther | 1998 |
CHOP therapy: has shorter-course therapy had an impact on lymphomas?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Dexamethaso | 1998 |
Autologous stem cell transplantation for aggressive non-Hodgkin's lymphomas in first complete or partial remission: a retrospective analysis of the outcome of 52 patients according to the age-adjusted International Prognostic Index.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclop | 1998 |
Results of treatment with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) for non-Hodgkin's aggressive lymphoma analyzed according to the International Prognostic Index.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease- | 1997 |
A phase I trial of high dose ProMACE-CytaBOM with granulocyte colony stimulating factor for patients with non-Hodgkin's lymphoma.
Topics: Adult; Age Factors; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Bleomycin | 1998 |
Primary cutaneous large-cell lymphoma: analysis of 49 patients included in the LNH87 prospective trial of polychemotherapy for high-grade lymphomas. Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 1998 |
[High-dose biweekly CHOP chemotherapy with granulocyte colony-stimulating factor support for patients with aggressive non-Hodgkin lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Administr | 1998 |
Clinical implications of serum levels of soluble CD30 in 70 adult anaplastic large-cell lymphoma patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cyta | 1998 |
[Clinical study on the inhibitory effect of a 5-HT3 antagonist, granisetron, for nausea and vomiting induced by chemotherapy (CHOP, VEPA, high-dose ETP) for non-Hodgkin's lymphoma].
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bleomyc | 1998 |
Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doub | 1998 |
[Value of radiotherapy in disseminated highly malignant non-Hodgkin's lymphoma. Comment on the article by U. Kaiser, R. Pfab, K. Havemann, Strahlenther Onkol 1997, 173, 136-40 (No. 3)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 1998 |
Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival | 1998 |
Effects of recombinant granulocyte colony-stimulating factor (G-CSF) in patients treated with ProMACE-CytaBOM for HIV-related non-Hodgkin's lymphoma (NHL).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cohort Studies; Cyclophosphamide; | 1998 |
[EPOCH therapy for relapsed/refractory lymphoid malignancies].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Dr | 1998 |
[Results of treating patients with highly malignant non-Hodgkin's lymphomas; comparison of treatment efficacy with CHOP and CBVPM-AVBP].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Fr | 1998 |
Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease | 1998 |
Pulmonary toxicity after granulocyte colony-stimulating factor-combined chemotherapy for non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; | 1998 |
Alternating triple therapy for the treatment of intermediate grade and immunoblastic lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; Cytarabine; | 1998 |
[Comparison of chemotherapy CHOP vs. CHOP/VIA in the treatment of aggressive non-Hodgkin's lymphoma: a randomized multicenter study of 132 patients. The PETHEMA group. Program for Study and Therapeutics of malignant hemopathies. Spanish Association of Hem
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Data Interpretation, S | 1998 |
Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Antineoplastic Combined Chemotherapy Protocols; Cycloph | 1998 |
VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplant | 1998 |
A phase I trial of standard and cyclophosphamide dose-escalated CHOP with granulocyte colony stimulating factor in elderly patients with non-Hodgkin's lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-F | 1998 |
Phase II study of mitoguazone, cyclophosphamide, doxorubicin, vincristine and prednisone for patients with diffuse histologic subtypes of non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Study (PE481).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; | 1998 |
High-dose intensity cyclophosphamide, epidoxorubicin, vincristine and prednisone by shortened intervals and granulocyte colony-stimulating factor in non-Hodgkin's lymphoma: a phase II study.
Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Epirubicin | 1998 |
The MACOP-B and VACOP-B combination chemotherapy for young patients with intermediate-grade non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dise | 1998 |
Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Cyclophos | 1998 |
Addition of etoposide to CHOP chemotherapy in untreated patients with high-grade non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopho | 1998 |
[Clinical observation on 112 cases with non-Hodgkin's lymphoma treated by Chinese herbs combined with chemotherapy].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CD4-CD8 Ratio; Child; Cyclo | 1997 |
[The treatment results in children diagnosed with non-Hodgkin's lymphomas and acute B-cell lymphoblastic leukemias treated by the BFM protocols. The report of the POGM (Pediatric Oncology Group of Madrid)].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantatio | 1998 |
Bcl-2 gene rearrangements and apoptosis rates in patients with non-Hodgkin's lymphoma during chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cyclophosphamide; Epirubicin; Fema | 1999 |
Primary central nervous system non-Hodgkin's lymphoma (PCNSL): survival advantages with combined initial therapy? A final report of the North Central Cancer Treatment Group (NCCTG) Study 86-72-52.
Topics: Adult; Age Distribution; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 1999 |
[Study of optimal CHOP dose ranges for elderly patients with non-Hodgkin's lymphoma].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 1999 |
CEOP treatment results and validity of the International Prognostic Index in Chinese patients with aggressive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Epirubici | 1998 |
[Epirubicin containing regimens in advanced malignant tumors report of 516 cases. Epirubicin Collaborative Study Group].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell L | 1997 |
Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cohort Studies; | 1999 |
Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 1999 |
A phase II trial of 200% ProMACE-CytaBOM in patients with previously untreated aggressive lymphomas: analysis of response, toxicity, and dose intensity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cohort Studies; Cyclophospha | 1999 |
How do patients with aggressive non-Hodgkin's lymphoma treated with third-generation regimens (MACOP-B and F-MACHOP) fare in the long-term?
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cyta | 1999 |
CEOP-B/VIMB vs. promace-CytaBOM in the treatment of intermediate or high grade non-Hodgkin's lymphoma: A randomised multicenter study of Southern Italy Cooperative Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 2000 |
A randomized EPOCH vs. CHOP front-line therapy for aggressive non-Hodgkin's lymphoma patients: long-term results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposid | 1999 |
Feasibility of high-dose chemotherapy without stem cell support as a first-line treatment for non-Hodgkin's aggressive lymphoma: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Cyclophosphami | 2000 |
VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: a study by the non-Hodgkin's Lymphoma Co-operative Study Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Combined | 2000 |
Operative and conservative management of primary gastric lymphoma: interim results of a German multicenter study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 2000 |
Adding high-dose tamoxifen to CHOP does not influence response or survival in aggressive non-Hodgkin's lymphoma: an interim analysis of a randomized phase III trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Proto | 2000 |
A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 2000 |
Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; | 2000 |
Outcome of CNS disease at diagnosis in disseminated small noncleaved-cell lymphoma and B-cell leukemia: a Children's Cancer Group study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Child; | 2000 |
A comparison of elderly patients with aggressive histology lymphoma who were entered or not entered on to a randomized phase II trial.
Topics: Actuarial Analysis; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophospham | 2000 |
Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission. Groupe d'Etude les Lymphomes de l'Adulte (GELA).
Topics: Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow | 2000 |
[Different chemotherapy protocols for intermediate and high grade malignant non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Cyclophos | 1997 |
A dose-finding study of liposomal daunorubicin with CVP (COP-X) in advanced NHL.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Daunorubicin; Dose-Response Relati | 2000 |
Etoposide, mitoxantrone and prednisone: a salvage regimen with low toxicity for refractory or relapsed non-Hodgkin's lymphoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Ma | 2000 |
Randomized comparison of mobilization kinetics of circulating CD34+ cells between biweekly CHOP and dose-escalated CHOP with the prophylactic use of lenograstim (glycosylated rHuG-CSF) in aggressive non-Hodgkin's lymphoma. The lenograstim/Lymphoma Study G
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modali | 2000 |
[The therapeutic efficacy and toxicity of the liposomal form of daunorubicin (Daunoxome) in lymphosarcoma patients].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Che | 2000 |
A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant | 2000 |
[High-dose chemotherapy with autologous peripheral blood stem cell transplantation for treatment of non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dox | 2000 |
Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathies; Cy | 2000 |
Phase II study of infusional chemotherapy with doxorubicin, vincristine and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive non-Hodgkin's lymphoma: CALGB 9255. Cancer and Leukemia Group B.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Do | 2000 |
Transplantation potential of peripheral whole blood primed by VACOP-B chemotherapy plus filgrastim (r-metHuG-CSF) in patients with aggressive non-Hodgkin's lumphoma.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cell Culture Techn | 2000 |
Effect of cell determinant (CD)34+ cell dose on the cost and consequences of peripheral blood stem cell transplantation for non-Hodgkin's lymphoma patients in front-line therapy.
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Component R | 2000 |
Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Purging; Cispl | 2000 |
Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cause of Death; Cyclop | 2001 |
Primary lymphoma of bone: a prospective study of 28 cases.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Neoplasms; | 2000 |
Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.
Topics: Adult; AIDS-Related Opportunistic Infections; Antineoplastic Combined Chemotherapy Protocols; Antire | 2001 |
Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: a Southwest Oncology Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease-Free Surviv | 2001 |
Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2001 |
Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2001 |
Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2001 |
Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2001 |
Efficacy of vinorelbine, epirubicin and prednisone combination regimen in pretreated elderly patients with aggressive non-Hodgkin's lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Humans; | 2001 |
Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, High | 2001 |
Cemp, a mitoxantrone containing combination, in the treatment of intermediate and high grade non-hodgkin's lymphoma: an effective and non toxic therapeutic alternative for adult and elderly patients.
Topics: Actuarial Analysis; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophospham | 2001 |
Radiation therapy after a partial response to CHOP chemotherapy for aggressive lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 2001 |
Continuous infusion of vincristine-doxorubicin with bolus of dexamethasone(VAD) alternated with CHEP in the treatment of patients over 60 years old with aggressive non-Hodgkin's lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Doxorubicin; | 2001 |
A prospective randomized study of Chop versus Chop plus alpha-2B interferon in patients with intermediate and high grade non-Hodgkin's lymphoma: the International Oncology Study Group NHL1 Study .
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Inter | 2000 |
Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival | 2001 |
Treatment of aggressive non-Hodgkin's lymphoma in elderly patients with thiotepa, Novantrone (mitoxantrone), vincristine, prednisone (TNOP).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lymphoma, N | 2001 |
The consequences of treatment and disease in patients with primary CNS non-Hodgkin's lymphoma: cognitive function and performance status. North Central Cancer Treatment Group.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neo | 1999 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
CHOP chemotherapy with preemptive granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma: a dose-intensity analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-F | 2000 |
CHOP versus CHOP plus ESHAP and high-dose therapy with autologous peripheral blood progenitor cell transplantation for high-intermediate-risk and high-risk aggressive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Ther | 2000 |
A multicenter trial of infusional etoposide, doxorubicin, and vincristine with cyclophosphamide and prednisone (EPOCH) in patients with relapsed non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Do | 2001 |
Neuroendocrine changes during the evolution of doxorubicin-induced left ventricular dysfunction in adult lymphoma patients.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Atrial Nat | 2001 |
Full-dose CHOP chemotherapy combined with granulocyte colony-stimulating factor for aggressive non-Hodgkin's lymphoma in elderly patients: a prospective study.
Topics: Aged; Aging; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphami | 2001 |
Comparison of long-term outcome of children and adolescents with disseminated non-lymphoblastic non-Hodgkin lymphoma treated with COMP or daunomycin-COMP: A report from the Children's Cancer Group.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chil | 2001 |
Potential of chromosomal and matrix-based comparative genomic hybridization for molecular diagnostics in lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human; Cyclopho | 2001 |
Consolidation radiotherapy to bulky disease in aggressive NHL. First results of the NHL B-94 trial of the DSHNHL.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease | 2001 |
Radiotherapy in early stage gastrointestinal lymphoma: results of the German GIT-NHL group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease | 2001 |
Health-related quality of life and its potential prognostic implications in patients with aggressive lymphoma: a Nordic Lymphoma Group Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appetite; Bleomycin; Cyclop | 2001 |
Granulocyte colony-stimulating factor in induction treatment of children with non-Hodgkin's lymphoma: a randomized study of the French Society of Pediatric Oncology.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Child; Child, Preschool; Cyclopho | 2002 |
Outcome is not improved by the use of alternating chemotherapy in elderly patients with aggressive lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Drug | 2001 |
Influence of amifostine on toxicity of CHOP in elderly patients with aggressive non-Hodgkin's lymphoma--a phase II study.
Topics: Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamid | 2002 |
Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols | 2002 |
Combination chemotherapy and radiotherapy in non-Hodgkin's lymphomata.
Topics: Antineoplastic Agents; Bleomycin; Bone Marrow; Clinical Trials as Topic; Cyclophosphamide; Doxorubic | 1975 |
Combination chemotherapy in non-Hodgkin's lymphoma: results of long-term followup.
Topics: Adolescent; Adult; Aged; Bleomycin; Child; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; | 1977 |
Chemotherapy of non-Hodgkin's lymphoma: 10 years' experience in the Southwest Oncology Group.
Topics: Bleomycin; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration | 1977 |
Chemotherapy of non-Hodgkin's lymphomas: Eastern Cooperative Oncology Group experience.
Topics: Altretamine; Bleomycin; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Ad | 1977 |
Overview of four clinical studies of chemotherapy for stage III and IV non-Hodgkin's lymphomas by the Cancer and Leukemia Group B.
Topics: Adult; Bleomycin; Clinical Trials as Topic; Cyclophosphamide; Drug Administration Schedule; Drug The | 1977 |
Non-cross-resistant combinations in stage IV non-Hodgkin's lymphomas.
Topics: Adolescent; Adult; Aged; Bleomycin; Child; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; | 1977 |
Team approach to management of non-Hodgkin's lymphomas: past and present.
Topics: BCG Vaccine; Bleomycin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Therapy, Combi | 1977 |
Protected environment-prophylactic antibiotic program for malignant lymphoma. Randomized trial during chemotherapy to induce remission.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Bleomycin; Cyclophosphamide; D | 1979 |
BCNU with and without cyclophosphamide, vincristine, and prednisone (COP) and cycle-active therapy in non-Hodgkin's lymphoma.
Topics: Carmustine; Cell Cycle; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Drug Therapy, Combin | 1977 |
Total-body irradiation in the treatment of lymphocytic lymphoma.
Topics: Blood Platelets; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Humans; Lymp | 1977 |
Advanced lymphocytic lymphoma: randomized comparisons of chemotherapy and radiotherapy, alone or in combination.
Topics: Adult; Aged; Blood Platelets; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; | 1977 |
Combination chemotherapy of non-Hodgkin lymphoma.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Female | 1978 |
Combination chemotherapy for non-Hodgkin lymphomas: a ten year follow-up study.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Drug Administration Schedule; Dru | 1979 |
Combination versus successive single agent chemotherapy in lymphocytic lymphoma.
Topics: Adult; Aged; Bone Marrow; Cyclophosphamide; Cystitis; Drug Therapy, Combination; Female; Hemorrhage; | 1978 |
Chemotherapy (cyclophosphamide, vincristine, and prednisone) versus radiotherapy (total body irradiation) for stage III-IV poorly differentiated lymphocytic lymphoma.
Topics: Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Age | 1978 |
Treatment of advanced non-Hodgkin's lymphomas with favorable histologies: preliminary results of a prospective trial.
Topics: Cyclophosphamide; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Prednisone; Prospe | 1976 |
Combination chemotherapy of the malignant lymphomas: a controlled clinical trial.
Topics: Adolescent; Adult; Aged; Cyclophosphamide; Drug Therapy, Combination; Evaluation Studies as Topic; F | 1976 |
Lymphosarcoma. A comparison of extended to conservative chemotherapy.
Topics: Adult; Aged; Carmustine; Chlorambucil; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; | 1976 |
New experimental and clinical data on leukaemia immunotherapy.
Topics: Adolescent; Adult; Amantadine; Animals; Bacterial Vaccines; BCG Vaccine; Cell Line; Central Nervous | 1975 |
Therapy of advanced lymphocytic lymphoma a preliminary report of a randomized trial between combination chemotherapy (CVP) and intensive radiotherapy.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents; Bone Marrow; Clinical Trials as Topic; Cyclopho | 1975 |
Cyclic alternating chemotherapy of high-grade malignant non-Hodgkin lymphomas with VIM-Bleo and CHOP.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubici | 1992 |
Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dexamethas | 1992 |
Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Do | 1992 |
Non-Hodgkin's lymphomas in children. II. Treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Clinical Protoco | 1992 |
F-MACHOP in advanced aggressive lymphoma.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Do | 1992 |
A phase I/II study of dose and administration of non-glycosylated bacterially synthesized G-M CSF in chemotherapy-induced neutropenia in patients with non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; | 1992 |
Results of a randomized study of previously-untreated intermediate and high grade lymphoma using CHOP versus CNOP.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Do | 1992 |
Treatment results with an aggressive chemotherapeutic regimen (MACOP-B) for intermediate- and some high-grade non-Hodgkin's lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Tran | 1990 |
Combination chemotherapy for advanced diffuse large cell lymphoma. The adverse effects of bone marrow invasion, gastrointestinal tract involvement or high bulk disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Car | 1990 |
A randomized comparison of methotrexate dose and the addition of bleomycin to CHOP therapy for diffuse large cell lymphoma and other non-Hodgkin's lymphomas. Cancer and Leukemia Group B study 7851.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dose-Response Rel | 1990 |
[Clinical effect of recombinant human G-CSF on neutropenia induced by chemotherapy for non-Hodgkin's lymphoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Do | 1990 |
Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Cause of Death; Cyclophospha | 1990 |
[A double-blind, cross-over clinical trial of recombinant human G-CSF on neutropenia induced by chemotherapy for non-Hodgkin's lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Double-Blind Method; | 1990 |
Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Doxor | 1991 |
[Non-Hodgkin's lymphomas. Results of alternating chemotherapy versus sequential chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dexamethasone; Doxorubi | 1990 |
Phase III trial of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) versus cisplatin, etoposide, bleomycin and prednisone (CisEBP) for the treatment of advanced non-Hodgkin's lymphoma of high grade malignancy. The Danish Lymphoma Study Gro
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; | 1990 |
Combination chemotherapy of intermediate-grade and high-grade non-Hodgkin's lymphoma with MACOP-B: a Southwest Oncology Group study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Huma | 1991 |
Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Doxor | 1991 |
Stage I-II low-grade lymphomas: a prospective trial of combination chemotherapy and radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; C | 1991 |
Prospective multicenter trial for the response-adapted treatment of high-grade malignant non-Hodgkin's lymphomas: updated results of the COP-BLAM/IMVP-16 protocol with randomized adjuvant radiotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1991 |
ProMACE-MOPP vs MACOP-B in high grade non-Hodgkin's lymphomas: a randomised study in a multicenter cooperative study group (NHLCSG).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Eto | 1991 |
MACOP-B vs F-MACHOP in the treatment of high-grade non-Hodgkin's lymphomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Cyclophosphamide; Cyt | 1991 |
ProMACE-cytaBOM versus MACOP-B in intermediate and high grade NHL. Preliminary results of a prospective randomized trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1991 |
Alternated versus syncopated CHOP-PVB: two studies for the treatment of non-Hodgkin's lymphoma by the Southwest Oncology Group.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cycloph | 1991 |
Superiority of second over first generation chemotherapy in a randomized trial for stage III-IV intermediate and high-grade non-Hodgkin's lymphoma (NHL): the 1980-1985 EORTC trial. The EORTC Lymphoma Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1991 |
Phase II study of cyclophosphamide (C), epirubicin (E), oncovin (O), prednisone (P), methotrexate (M) + leucovorin and bleomycin (B) (CEOP-MB) in intermediate and high grade non-Hodgkin lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophos | 1991 |
ProMACE-C-MOPP in aggressive non-Hodgkin's lymphoma. Long-term results in 45 patients treated in a single institution.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 1991 |
High-dose cyclophosphamide-high-dose methotrexate with coordinated intrathecal therapy for advanced nonlymphoblastic lymphoma of childhood: results of a Pediatric Oncology Group study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 1991 |
[Malignant lymphoma associated with HIV infection].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modalit | 1991 |
The F-MACHOP sequential combination chemotherapy regimen in advanced diffuse aggressive lymphomas: long-term results.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Protocols; Cyclophospham | 1991 |
Cardiotoxicity of epirubicin and doxorubicin: a double-blind randomized study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Double-Blind Method; Doxorubicin; | 1991 |
A new treatment protocol for childhood non-Hodgkin's lymphoma: preliminary evaluation.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 1990 |
Sequential versus alternating chemotherapy for high-grade non-Hodgkin's lymphomas: preliminary results of a phase III multicentre trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Dose-Re | 1990 |
Vincristine infusion with CHOP-CCNU in diffuse large-cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophospham | 1990 |
[Weekly CHOP chemotherapy in the treatment of intermediate-grade non-Hodgkin's lymphomas--cooperative group study by seven institutes].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopho | 1990 |
CEOP regimen in the treatment of advanced low-grade non-Hodgkin's lymphomas: preliminary report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Evaluation; Epir | 1990 |
[Adult acute lymphoblastic leukemia: preliminary results of the LAL-86 protocol].
Topics: Actuarial Analysis; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; | 1990 |
[Low-grade non-Hodgkin's lymphoma in the adult: new therapeutic approaches].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Doxorubicin; | 1987 |
Southwest oncology group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Cy | 1987 |
Ketoconazole versus nystatin as prophylaxis against fungal infection for lymphoma patients receiving chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Cyclophos | 1987 |
Prospectively randomized clinical trial of three intensive chemotherapy regimens for the treatment of advanced unfavorable histology non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical | 1987 |
A randomized trial of high-dose methotrexate versus standard-dose methotrexate following cyclophosphamide, doxorubicin (adriamycin), vincristine, and prednisone with or without bleomycin in the therapy of diffuse large cell lymphoma: preliminary report of
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Humans; Ly | 1987 |
German-Austrian multicenter trial for aggressive non-Hodgkin lymphomas: COP-BLAM/IMVP-16 chemotherapy with randomized adjuvant radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Combined Modali | 1988 |
[Multicenter prospective risk-adapted study on the therapy of non-Hodgkin's lymphomas of high malignancy. Use of COP-BLAM/IMVP-16 and randomized adjuvant radiotherapy--study concept and preliminary results].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Combined Modali | 1988 |
Combined modality treatment for stage I-II non-Hodgkin's lymphomas: CVP versus BACOP chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Cobalt Radioiso | 1988 |
The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 1988 |
[Sequential alternating chemotherapy of highly malignant non-Hodgkin's lymphomas with VIM-Bleo and CHOP. Initial results].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Cy | 1989 |
[Risk-adapted therapy of highly malignant non-Hodgkin's lymphomas with COP-BLAM/IMVP-16: a prospective multicenter study].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials | 1989 |
Comparison of CHOP-B vs CEOP-B in 'poor prognosis' non-Hodgkin's lymphomas. A randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Cy | 1989 |
CBVPM/AVBP versus HCOMLA chemotherapy in non-Hodgkin lymphoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Cy | 1987 |
[Modified CHOP-Bleo protocol in the treatment of malignant non-Hodgkin's lymphoma of low cell differentiation].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cell Differentia | 1988 |
The role of radiation therapy in the management of the non-Hodgkin's lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Combined Modali | 1985 |
Similar efficacy of 6 and 18 months of therapy with four drugs (COMP) for localized non-Hodgkin's lymphoma of children: a report from the Childrens Cancer Study Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Clinical Trials | 1989 |
CHOP-VP16 chemotherapy and involved field irradiation for high grade non-Hodgkin's lymphomas: a phase II multicentre study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1989 |
Non-Hodgkin's lymphomas in 137 patients aged 70 years or older: a retrospective European Organization for Research and Treatment of Cancer Lymphoma Group Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Do | 1988 |
Lymphoblastic lymphoma in children--a randomized trial comparing LSA2-L2 with the A-COP+ therapeutic regimen: a Pediatric Oncology Group Study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Clinical Trials as Topic; Combine | 1988 |
[Multicenter study of the treatment of highly malignant non-Hodgkin's lymphomas with polychemotherapy (CHOPV) and irradiation].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; C | 1987 |
Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as T | 1987 |
The effect of intensive intermittent maintenance therapy in advanced low-grade non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Cyclophosphami | 1987 |
EORTC trial non-Hodgkin lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; C | 1987 |
Combination chemotherapy including epirubicin for the management of non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical | 1987 |
Treatment of non-Hodgkin's lymphoma in Mexican children. The effectiveness of chemotherapy during malnutrition.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 1987 |
[Phase III study of chemotherapy in low-malignancy non-Hodgkin's lymphomas: comparison of vincristine-vindesine combination chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Humans; | 1987 |
Maintenance chlorambucil after CVP in the management of advanced stage, low-grade histologic type non-Hodgkin's lymphoma. A randomized prospective study with an assessment of prognostic factors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Drug Evaluation; Fem | 1988 |
Lymphoblastic lymphoma in adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Clinical Trials as | 1986 |
Cyclophosphamide, vincristine, adriamycin, and prednisone (CHOP) with and without intermediate dose methotrexate for the treatment of non-Hodgkin's lymphomas of diffuse histology.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubi | 1987 |
A randomized trial of high dose cyclophosphamide, vincristine, and prednisone plus or minus doxorubicin (CVP versus CAVP) with long-term follow-up in advanced non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Follow-Up Studies; He | 1987 |
Pediatric Oncology Group experience with modified LSA2-L2 therapy in 107 children with non-Hodgkin's lymphoma (Burkitt's lymphoma excluded).
Topics: Adolescent; Antineoplastic Agents; Asparaginase; Bone Marrow; Carmustine; Child; Child, Preschool; C | 1985 |
[Possibilities of using polychemotherapy according to the COP protocol in lymphosarcoma of the gastrointestinal tract].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; E | 1985 |
Combination chemotherapy of advanced lymphocytic lymphoma. Importance of histologic classification in evaluating response.
Topics: Biopsy; Clinical Trials as Topic; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Fema | 1974 |
Combination chemotherapy of lymphomas other than Hodgkin's disease.
Topics: Adolescent; Adult; Aged; Bone Marrow; Bone Marrow Cells; Cyclophosphamide; Drug Therapy, Combination | 1974 |
Combined cyclophosphamide vincristine, and prednisone therapy of malignant lymphoma.
Topics: Adolescent; Adult; Age Factors; Aged; Bone Marrow Examination; Child; Child, Preschool; Cyclophospha | 1971 |
1101 other studies available for prednisone and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Treatment with doxorubicin-based protocol in cardiac involvement diffuse large B-cell lymphoma: A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Lymph | 2022 |
Rituximab, Methotrexate, Carmustine, Etoposide, and Prednisone (RMBVP) for the treatment of relapsed/refractory primary central nervous system lymphoma: a retrospective single-center study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System; Central Ne | 2022 |
Feasibility of high-dose methotrexate administered on day 1 of (R)CHOP in aggressive non-Hodgkin lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Feasibility Studies; | 2022 |
Chidamide with PEL regimen (prednisone, etoposide, lenalidomide) for elderly or frail patients with relapsed/refractory diffuse large B-Cell lymphoma -results of a single center, retrospective cohort in China.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Etoposide; Frail E | 2022 |
Clinical Outcomes of Patients With B-Cell Non-Hodgkin Lymphoma in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Etoposid | 2022 |
Risk of diabetes and the impact on preexisting diabetes in patients with lymphoma treated with steroid-containing immunochemotherapy.
Topics: Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus; Humans; Insulins; Lymphoma, Non-Hodgkin; | 2022 |
Mantle cell lymphoma negative for t(11,14) involving the kidneys: a case report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; | 2022 |
Cardiovascular outcomes of patients treated for non-Hodgkin lymphoma with first-line doxorubicin-based chemotherapy.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Human | 2022 |
Myocardial work-A new tool for early detection of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone chemotherapy induced-cardiotoxicity in hematological patients.
Topics: Antineoplastic Agents; Cardiotoxicity; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, Non- | 2023 |
Treatment Resulting Changes in Volumes of High-
Topics: Adipose Tissue; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Fluor | 2023 |
Primary breast B-cell non-Hodgkin’s lymphoma of the breast. Case Report and review of the literature
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Fe | 2023 |
Evaluation of mechlorethamine, vinblastine, procarbazine, and prednisone for the treatment of resistant multicentric canine lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Doxorubicin; Lymphoma; | 2023 |
ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma.
Topics: Cyclophosphamide; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Ce | 2023 |
Rare case of primary bone lymphoma of the femur.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Femur; Humans; Lympho | 2023 |
Outcomes of patients with indolent lymphoma treated with bendamustine plus rituximab compared to rituximab plus CVP or CHOP chemoimmunotherapy in Ontario.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxoru | 2023 |
EBF1, MYO6 and CALR expression levels predict therapeutic response in diffuse large B-cell lymphomas.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Biomarkers; Cyclophosphamide; Doxorubicin; Humans; Lym | 2023 |
In vitro compatibility and stability of admixtures containing etoposide, epirubicin hydrochloride and vindesine sulphate in a single infusion bag.
Topics: Cyclophosphamide; Doxorubicin; Drug Stability; Epirubicin; Etoposide; Humans; Infusion Pumps; Lympho | 2019 |
Modified EPOCH for high-risk non-Hodgkin lymphoma in sub-Saharan Africa.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; CD4 Lymphocyte Count; Cyclophosph | 2020 |
RNA disruption indicates CHOP therapy efficacy in canine lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dog Diseases; Dogs; Doxor | 2019 |
[The 475th case: renal tubular acidosis, renal failure, anemia, and lactic acidosis].
Topics: Acidosis, Lactic; Acidosis, Renal Tubular; Anemia; Antineoplastic Agents; Biopsy; Creatinine; Erythr | 2020 |
Cardio-oncology for better lymphoma therapy outcomes.
Topics: Cyclophosphamide; Doxorubicin; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Neoplasms; Prednisone; Ritux | 2020 |
The justification of vincristine dose capping: tradition, tradition…tradition!
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; In | 2020 |
An Autopsy Case of Varicella Zoster Virus Encephalitis with Multiple Brain Lesions.
Topics: Acyclovir; Aged; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Autopsy; Brain; C | 2020 |
Impact of prednisolone dosage in the CHOP regimen for follicular lymphoma: a retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Surface Area; Cyclophosphamide; Di | 2020 |
Unilateral multiple serous retinal detachments secondary to non-Hodgkin's lymphoma responsive to systemic steroids.
Topics: Adult; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Neoplasm Recurrence, Lo | 2021 |
Excellent outcomes of transformed lymphomas in the rituximab era without autologous stem cell transplantation: an Australian single-centre experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Cyclophosphamide; Disease-Free Surv | 2021 |
Early interval and serial positron emission tomography-computed tomography (PET-CT) after an indeterminate response defined by a PET scored 4 on the Deauville scale in lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 2020 |
Cardiovascular adverse events following treatment for non-Hodgkin lymphoma.
Topics: Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Non-Hodgkin; Prednisone; Rituximab; Vincristine | 2020 |
Cardiovascular adverse events following treatment for non-Hodgkin lymphoma - Authors' reply.
Topics: Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Non-Hodgkin; Prednisone; Rituximab; Vincristine | 2020 |
Non-Hodgkin's lymphoma in an elderly patient with renal dysfunction: a case report.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2020 |
3D echocardiography, arterial stiffness, and biomarkers in early diagnosis and prediction of CHOP-induced cardiotoxicity in non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cardiotoxicity; Cycl | 2020 |
Effects of filgrastim versus pegfilgrastim on outcomes of DA-R-EPOCH for non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Filgrastim | 2021 |
High incidence of fractures after R-CHOP-like chemotherapy for aggressive B-cell non-Hodgkin lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Child, Preschool; Cyclophosphamide; D | 2021 |
Outcomes of methotrexate-associated lymphoproliferative disorders in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Antirheumatic Agents | 2021 |
Factors for the optimal selection of granulocyte colony-stimulating factor preparations and predictors for R-CHOP dose reductions/delays among patients with non-Hodgkin B-cell lymphoma (STOP FN in NHL 2 subanalysis).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Febrile Neutropenia; | 2021 |
Individualized Treatment and Palliative Care for A 90-Year-Old Patient with Primary Gastric Diffuse Large-B Cell Lymphoma: 4 Year Follow-up and Inspiration.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2021 |
Conversion to supportive care with biosimilar pegfilgrastim-cbqv enables budget-neutral expanded access to R-CHOP treatment in non-Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biosimilar Pharmaceuticals; Cost-Benefit Analysis; C | 2021 |
[Optimization of rituximab dosing schedule in R-CHOP therapy for diffuse large B-cell lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Japan; Lympho | 2021 |
Risk factors for neutropenic fever in non-Hodgkin's lymphoma patients with primary granulocyte colony-stimulating factor prophylaxis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Granulo | 2021 |
Do You Know Pixantrone?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity; Clinical Trials as Topic; Cyclophosp | 2017 |
Geographical differences in survival of dogs with non-Hodgkin lymphoma treated with a CHOP based chemotherapy protocol.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dog Diseases; Dogs; Doxor | 2017 |
Control of Constipation in Patients Receiving CHOP or CHOP-Like Chemotherapy Regimens for Non-Hodgkin's Lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antacids; Antineoplastic Combined Chemotherapy Protocols | 2017 |
Incidence and risk factors of febrile neutropenia in patients with non-Hodgkin B-cell lymphoma receiving R-CHOP in a single center in Japan.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2017 |
18F-FDG-PET/CT Pulmonary Infiltrates in Non-Hodgkin Lymphoma Patients Treated with Combined Immunochemotherapy: Incidence and Clinical Characteristics.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Immunological; Antineoplastic Combine | 2017 |
Frequency, risk factors, and outcomes of central nervous system relapse in lymphoma patients treated with dose-adjusted EPOCH plus rituximab.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 2017 |
Efficacy of palonosetron to prevent delayed nausea and vomiting in non-Hodgkin's lymphoma patients undergoing repeated cycles of the CHOP regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Do | 2018 |
Comparison between Antiemetic Effects of Palonosetron and Granisetron on Chemotherapy-Induced Nausea and Vomiting in Japanese Patients Treated with R-CHOP.
Topics: Adult; Aged; Aging; Antibodies, Monoclonal, Murine-Derived; Antiemetics; Antineoplastic Combined Che | 2017 |
Primary central nervous system lymphoma: Retrospective analysis of 34 cases in a single centre.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Child | 2018 |
Incidence of interstitial pneumonitis in non-Hodgkin's lymphoma patients receiving immunochemotherapy with pegylated liposomal doxorubicin and rituximab.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; C | 2018 |
Hyperglycemia during first-line R-CHOP or dose adjusted R-EPOCH chemotherapy for non-Hodgkin lymphoma is prevalent and associated with chemotherapy alteration - a retrospective study.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Blood | 2018 |
The effect of the dexamethasone, cytarabine, and cisplatin (DHAP) regimen on stem cell mobilization and transplant outcomes of patients with non-Hodgkin's lymphoma who are candidates for up-front autologous stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy | 2018 |
An Uncommon Mimic of Acute Coronary Syndrome: Infiltrating Non-Hodgkins Lymphoma.
Topics: Acute Coronary Syndrome; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2018 |
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chemokines; Cyclophospham | 2018 |
Synchronous papillary thyroid cancer and non-Hodgkin lymphoma: Case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary; Clinical Decision-Making; Cycl | 2018 |
Uncommon cause of dysphagia: paraneoplastic achalasia.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2018 |
Outcome after high-dose chemotherapy and autologous stem cell transplantation in patients with aggressive B-cell non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Daunorubi | 2018 |
[Primary renal lymphoma: a clinical analysis of 5 cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; | 2018 |
[Enlargement of mandibular canal and lower lip hypoesthesia revealing non-Hodgkin’s lymphoma of the mandible].
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biops | 2016 |
Impact of HIV Infection on the Clinical Presentation and Survival of Non-Hodgkin Lymphoma: A Prospective Observational Study From Botswana.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Ac | 2018 |
Complications Associated With Dose-adjusted EPOCH-rituximab Therapy for Non-Hodgkin Lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2018 |
Primary gastric diffuse large B-cell lymphoma: The role of dose-dense chemotherapy.
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Fema | 2019 |
Primary Cardioprotection Reduces Mortality in Lymphoma Patients with Increased Risk of Anthracycline Cardiotoxicity, Treated by R-CHOP Regimen.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzym | 2018 |
How dogs are teaching researchers new tricks for treating cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Clinical Trials, Veterinar | 2018 |
Substitution of mitoxantrone for doxorubicin in a multidrug chemotherapeutic protocol for first-line treatment of dogs with multicentric intermediate- to large-cell lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dog Diseases; Dogs; Doxor | 2019 |
Incidental finding of non-Hodgkin's lymphoma in a patient affected by castration-sensitive prostate cancer: A case report.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carci | 2019 |
Long-term fatigue in survivors of non-Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross-sectional study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cancer S | 2019 |
[Comparison of Pegfilgrastim and Filgrastim for the Primary Prophylactic Effect for Preventing Febrile Neutropenia in Patients Undergoing Rituximab with Dose-adjusted EPOCH Chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposid | 2019 |
Long-term results with the adapted LMB 96 protocol in children with B-cell non Hodgkin lymphoma treated in Iraq: comparison in two subsequent cohorts of patients.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biopsy; Child; Child, Pres | 2019 |
Primary non-Hodgkin's lymphoma of the vagina (PNHLV): a gynaecologist's enigma!
Topics: Abdominal Pain; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protoco | 2019 |
[Triple expressor lymphoma in a kidney transplant patient].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Doxorubic | 2019 |
A Novel Predictor of Chemotherapeutic Cardiotoxicity in Patients with Non-Hodgkin Lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity; Cyclophosph | 2019 |
Remission of Late-Onset Post-Liver Transplantation Non-Hodgkin Lymphoma.
Topics: Adult; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cycloph | 2019 |
Treatments for non-Hodgkin lymphoma in HIV-positive patients: quantifying incremental benefit from 1993 to 2004 by metaregression.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Antiretrovir | 2013 |
The relationship between learned resourcefulness and cancer-related fatigue in patients with non-Hodgkin lymphoma.
Topics: Adaptation, Psychological; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2013 |
Update: NCCN non-Hodgkin's lymphoma clinical practice guidelines.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2004 |
Concomitant typhlitis and Clostridium difficile colitis developed after first R-CHOP chemotherapy in a non-Hodgkin lymphoma patient.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic | 2013 |
Characteristics of children with non-hodgkin lymphoma associated with primary immune deficiency diseases: descriptions of five patients.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2013 |
Multifocal primary bone lymphoma: durable complete remission after R-CHOP chemotherapy.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone and Bon | 2013 |
Ribonuclease binase inhibits primary tumor growth and metastases via apoptosis induction in tumor cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma | 2013 |
Lymphotoxin alpha (LTA) polymorphism is associated with prognosis of non-Hodgkin's lymphoma in a Chinese population.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Protei | 2013 |
Mapping the redox state of CHOP-treated non-Hodgkin's lymphoma xenografts in mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cyclophosphamide; Doxorub | 2013 |
Fifteenth biannual report of the Cochrane Haematological Malignancies Group--focus on non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
Non-Hodgkin lymphoma mimics retroperitoneal fibrosis.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biops | 2013 |
[Diagnosis and treatment of primary colorectal non-Hodgkin's lymphoma: analysis of 52 cases].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Col | 2013 |
Prognostic role of serum lactate dehydrogenase beyond initial diagnosis: a retrospective analysis of patients with diffuse large B cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2013 |
[Current technologies in radiotherapy for non-Hodgkin lymphomas].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; | 2013 |
[Treatment outcome in primary testicular non-Hodgkin lymphoma].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2013 |
High-dose etoposide plus granulocyte colony-stimulating factor as an effective chemomobilization regimen for autologous stem cell transplantation in patients with non-Hodgkin Lymphoma previously treated with CHOP-based chemotherapy: a study from the Conso
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cisplatin; | 2014 |
Myeloablation for lymphoma--question answered?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Lymph | 2013 |
AIDS-lymphoma (ARL): one more step along the way.
Topics: Anti-HIV Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combi | 2013 |
Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin's lymphoma in England and Wales.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2014 |
[Localized primary bone lymphoma: about four cases].
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Incidence and risk-factors of CHOP/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2014 |
[Diagnosis and treatment of primary testicular non-Hodgkin lymphoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cerebrospinal Fluid; Chemotherapy, Adjuvant; C | 2014 |
Survival of patients with transformed lymphoma in the rituximab era.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2014 |
Unilateral lower extremity swelling as a rare presentation of non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cycl | 2014 |
Two-dimensional speckle tracking echocardiography combined with high-sensitive cardiac troponin T in early detection and prediction of cardiotoxicity during epirubicine-based chemotherapy.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemoth | 2014 |
Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Severe neutropenia and relative dose intensity among patients<65 and ≥65 years with non-Hodgkin's lymphoma receiving CHOP-based chemotherapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic | 2014 |
Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2014 |
Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2014 |
Romiplostim before splenectomy in a patient with aggressive non-Hodgkin lymphoma and poor response to platelet transfusions.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2014 |
SIE-SIES-GITMO guidelines for the management of adult peripheral T- and NK-cell lymphomas, excluding mature T-cell leukaemias.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; | 2014 |
Post-chemotherapy cognitive impairment in patients with B-cell non-Hodgkin lymphoma: a first comprehensive approach to determine cognitive impairments after treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or rituximab a
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Bra | 2015 |
Herpes simplex virus-related oral mucositis in patients with lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Antiviral Ag | 2014 |
Successful treatment of non-Hodgkin's lymphoma using R-CHOP in a patient with Wiskott-Aldrich syndrome followed by a reduced-intensity stem cell transplant.
Topics: Adolescent; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Prognostic significance of geriatric assessment in combination with laboratory parameters in elderly patients with aggressive non-Hodgkin lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 2015 |
Institutional review of primary non-hodgkin lymphoma of the female genital tract: a 33-year experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined | 2014 |
Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine | 2014 |
A treatment for activated B-cell-like DLBCL?
Topics: Adenine; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherap | 2014 |
Impact of lymphoma treatments on spermatogenesis and sperm deoxyribonucleic acid: a multicenter prospective study from the CECOS network.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Case-Control Studies; Combined Mod | 2014 |
[Prognostic impact of anthracyclines in the treatment of aggressive lymphoma in patients over 70 years].
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cy | 2015 |
Clinical analysis of chronic lung injury in patients with non-Hodgkin lymphoma after CHOP chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Do | 2014 |
Primary extranodal non-Hodgkin's lymphoma: clinicopathological features, survival and treatment outcome in two cancer centers of southern Turkey.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2014 |
Reduced-dose (two-thirds) R-CHOP chemotherapy for elderly patients with non-Hodgkin lymphoma.
Topics: Academic Medical Centers; Aged; Aged, 80 and over; Aging; Antibodies, Monoclonal, Murine-Derived; An | 2015 |
Management and prognosis of 66 patients with B-cell non-Hodgkin lymphoma presenting with initial spinal cord compression: a French retrospective multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Centr | 2015 |
Retrospective analysis of relative dose intensity in patients with non-Hodgkin lymphoma receiving CHOP-based chemotherapy and pegfilgrastim.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic A | 2014 |
Incidence of pneumonitis in patients with non-Hodgkin lymphoma receiving chemoimmunotherapy with rituximab.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemother | 2015 |
Pre-existing arterial hypertension as a risk factor for early left ventricular systolic dysfunction following (R)-CHOP chemotherapy in patients with lymphoma.
Topics: Adult; Age Distribution; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2014 |
Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biphenyl | 2014 |
[Efficacy and safety of rituximab combined with CHOP or combined with dose fractionated CHOP in the treatment of primary gastric diffuse large B cell lymphoma].
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Single nucleotide polymorphisms in ABCB1 and CBR1 can predict toxicity to R-CHOP type regimens in patients with diffuse non-Hodgkin lymphoma.
Topics: Alcohol Oxidoreductases; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2015 |
BRAF V600E and MAP2K1 mutations in hairy cell leukemia and splenic marginal zone lymphoma cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; | 2015 |
A treacherous case of primary non-Hodgkin lymphoma of the bone: appearances can be deceptive.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine | 2015 |
Testicular non-Hodgkin's lymphoma presenting in a young adult.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Cryopreservation; Cyclop | 2015 |
[Supportive care for patients with non-Hodgkin lymphoma receiving R-CHOP chemotherapy].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2015 |
Rates and durability of response to salvage radiation therapy among patients with refractory or relapsed aggressive non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2015 |
Adult non Hodgkin's lymphoma patients: experience from a tertiary care cancer centre in north east India.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2015 |
[Le lymphome primitif du sein].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2014 |
Organizing pneumonia appearing in B-cell chronic leukemia malignancy progression - a case report.
Topics: Aged; Cryptogenic Organizing Pneumonia; Disease Progression; Humans; Leukemia, Lymphocytic, Chronic, | 2015 |
Treatment of feline intermediate- to high-grade lymphoma with a modified university of Wisconsin-Madison protocol: 119 cases (2004-2012).
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Anti | 2016 |
Retrospective analysis for treatment of naïve canine multicentric lymphoma with a 15-week, maintenance-free CHOP protocol.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Anti | 2016 |
Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2015 |
Head and neck extra nodal NHL (HNENL)--Treatment Outcome and Pattern of failure--A Single Institution Experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Child; C | 2015 |
Comprehensive geriatric assessment in elderly patients with newly diagnosed aggressive non-Hodgkin lymphoma treated with multi-agent chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 2015 |
A rare case of primary cardiac lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Dyspnea; Heart | 2015 |
Risk of secondary hypogammaglobulinaemia after Rituximab and Fludarabine in indolent non-Hodgkin lymphomas: A retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cycloph | 2015 |
Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Burkitt Lymphoma; Central Ner | 2016 |
GALECTIN-3 AS A PROGNOSTIC BIOMARKER IN PATIENTS WITH NON-HODGKIN LYMPHOMA.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Arrhyt | 2015 |
[Clinical Study of Non Hodgkin's Lymphoma Treated with Enhanced Chemotherapy Regimen and Increased Treatment Courses].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin | 2015 |
Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (EPOCH) With or Without Rituximab as First-Line Therapy for Aggressive Non-Hodgkin Lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cyclophosphamide; Disease-Free Surviv | 2016 |
Activation of the Constitutive Androstane Receptor Increases the Therapeutic Index of CHOP in Lymphoma Treatment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Coculture | 2016 |
Ureteric lymphoma as a rare cause of right lower ureteric obstruction.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Constriction | 2016 |
Routine Primary Prophylaxis for Febrile Neutropenia with Biosimilar Granulocyte Colony-Stimulating Factor (Nivestim) or Pegfilgrastim Is Cost Effective in Non-Hodgkin Lymphoma Patients undergoing Curative-Intent R-CHOP Chemotherapy.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biosimilar P | 2016 |
CHOP Chemotherapy for Aggressive Non-Hodgkin Lymphoma with and without HIV in the Antiretroviral Therapy Era in Malawi.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antirheumatic Agents; Cyclophosphamide; Doxor | 2016 |
Obese non-Hodgkin lymphoma patients tolerate full uncapped doses of chemotherapy with no increase in toxicity, and a similar survival to that seen in nonobese patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2016 |
Lack of efficacy of imiquimod in patients with basal cell carcinoma previously treated with rituximab for B cell lymphoma: two case reports.
Topics: Aminoquinolines; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cyclophosph | 2016 |
'Real Life' experience in a 'difficult to treat' patient population of non-Hodgkin lymphomas using the R-COMP regimen.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; H | 2016 |
A retrospective analysis of combination chemotherapy consisting cyclophosphamide, vincristine, prednisolone and procarbazine (C-MOPP) for pretreated aggressive non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Di | 2016 |
Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antin | 2016 |
A retrospective study of R-CHOP/CHOP therapy-induced nausea and vomiting in non-Hodgkin's lymphoma patients: a comparison of intravenous and oral 5-HT3 receptor antagonists.
Topics: Antibodies, Monoclonal, Murine-Derived; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; | 2016 |
Clinical and Cost Comparison Evaluation of Inpatient Versus Outpatient Administration of EPOCH-Containing Regimens in Non-Hodgkin Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Cos | 2017 |
[Efficacy of surgery and rituximab in primary gastric diffuse large B-cell lymphoma].
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2016 |
The metronomic therapy with prednisone, etoposide, and cyclophosphamide reduces the serum levels of VEGF and circulating endothelial cells and improves response rates and progression-free survival in patients with relapsed or refractory non-Hodgkin's lymp
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, H | 2016 |
Prognostic Significance of New-Onset Atrial Fibrillation in Patients With Non-Hodgkin's Lymphoma Treated With Anthracyclines.
Topics: Aged; Anthracyclines; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy P | 2016 |
Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.
Topics: Acrylamides; Active Transport, Cell Nucleus; Animals; Antineoplastic Combined Chemotherapy Protocols | 2016 |
Gastric Mucosa-associated Lymphoid Tissue Lymphoma: Posttransplant Lymphopoliferative Disorder.
Topics: Adult; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; H | 2016 |
Bilateral primary adrenal lymphoma with adrenal insufficiency.
Topics: Adrenal Gland Neoplasms; Adrenal Insufficiency; Antibodies, Monoclonal, Murine-Derived; Antineoplast | 2016 |
Primary non-Hodgkin's lymphoma of the tongue: a diagnostic dilemma of unusual case presentation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Differential; Do | 2017 |
Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma.
Topics: Adult; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Asparag | 2017 |
Reformulating the hazard ratio to enhance communication with clinical investigators.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Doxorubi | 2008 |
[Primary cervical epidural low-grade non-hodgkin's lymphoma: a case report and review of the literature].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; | 2008 |
Progressive respiratory distress in a patient with splenic marginal zone lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Cyclophosphamide; Doxorubicin; | 2008 |
Insulin-like growth factor-1 is essential to the increased mortality caused by excess growth hormone: a case of thyroid cancer and non-Hodgkin's lymphoma in a patient with pituitary acromegaly.
Topics: Acromegaly; Adenoma; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Pro | 2009 |
Long-term results of dose-intensive chemotherapy with G-CSF support (TCC-NHL-91) for advanced intermediate-grade non-Hodgkin's lymphoma: a review of 59 consecutive cases treated at a single institute.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 2008 |
Acute upper arm ischaemia: a rare presentation of non-Hodgkin's lymphoma.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Arm; | 2010 |
Paraneoplastic pemphigus associated with non-Hodgkin lymphoma.
Topics: Acantholysis; Animals; Antineoplastic Combined Chemotherapy Protocols; Back; Cyclophosphamide; Doxor | 2008 |
[Prognosis of primary non-Hodgkin's lymphoma of the breast].
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bre | 2008 |
A 36-year-old man with paresthesias and a headache.
Topics: Adult; Amlodipine; Biopsy; Diagnosis, Differential; Drug Therapy, Combination; Guanine; Headache; He | 2008 |
High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2009 |
Drug-induced pneumonitis detected earlier by 18F-FDG-PET than by high-resolution CT: a case report with non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Fluorodeoxyglucose F1 | 2008 |
A case of malignant primary non-Hodgkin's lymphoma in skeletal muscle treated by exclusive chemotherapy.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyc | 2009 |
Classification updates and clinical investigations in indolent non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; A | 2008 |
Clinical investigations in aggressive non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2008 |
FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin's lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2009 |
Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclo | 2009 |
A rare diagnosis of pancreatic tumour.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2009 |
Rituximab as monotherapy and in addition to reduced CHOP in children with primary immunodeficiency and non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2009 |
[Non-Hodgkin's primitive lymphoma of the testis: long-term prognosis associated with treatment combining systemic and intrathecal chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Huma | 2009 |
Neurolymphomatosis mimicking chemotherapy-induced ototoxicity.
Topics: Acyclovir; Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Antiviral Agents; Audiometry; Cran | 2009 |
Peripheral neuropathy in a cat with renal lymphoma.
Topics: Animals; Antineoplastic Agents, Hormonal; Cat Diseases; Cats; Euthanasia, Animal; Kidney Neoplasms; | 2009 |
Lymphoma in the Waldeyer ring: a great masquerader.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2009 |
Accelerated R-COP: a pilot study for the treatment of advanced low grade lymphomas that has a high complete response rate.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2009 |
A prospective study of left ventricle function after treatment with rapid-infusion rituximab in patients with non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2009 |
Epstein-Barr virus negative large B-cell lymphoma during long term immunomodulatory therapy for T-cell large granular lymphocytic leukaemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Disease Progression; | 2010 |
[Therapeutic management of central nervous system lymphomas in a single hematological institute].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2009 |
Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-D | 2009 |
18F-FDG PET/CT in primary non-Hodgkin's lymphoma of the sinonasal tract.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; D | 2010 |
A case of bullous disease limited to the skin illustrates the spectrum of neoplasia-induced autoimmunity.
Topics: Aged, 80 and over; Antibodies, Antinuclear; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-D | 2009 |
[Non-pegylated liposomal doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab for the treatment of non-Hodgkin's lymphoma: study of 26 patients].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2010 |
Primary non-Hodgkin lymphoma of cervix successfully treated with rituximab: positron emission tomography images before and after therapy: a case report.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineo | 2010 |
Clinical features and treatment outcomes of non-Hodgkin's lymphomas involving rare extranodal sites: a single-center experience.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclo | 2010 |
Non-Hodgkin's lymphoma following treatment with etanercept in ankylosing spondylitis.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2011 |
Squamous cell carcinoma of the conjunctiva invading the orbit in a non-Hodgkin lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Conjunctival Neoplas | 2009 |
Long-term results of pirarubicin versus doxorubicin in combination chemotherapy for aggressive non-Hodgkin's lymphoma: single center, 15-year experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemother | 2010 |
Long term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with PROMECE-CYTABOM plus involved-field radiation therapy: a study by the Gruppo Italiano Studio Linfomi.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Disea | 2010 |
Correlation of pretransplant and early post-transplant response assessment with outcomes after reduced-intensity allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophospham | 2010 |
[Management of lymphoma with respect to pathologic classification: updates and controversies].
Topics: Anaplastic Lymphoma Kinase; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineopl | 2009 |
Reversibility of the effects of the chemotherapeutic regimen for non-Hodgkin lymphoma, cyclophosphamide, doxorubicin, vincristine, and prednisone, on the male rat reproductive system and progeny outcome.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Protocols; | 2010 |
Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin's lymphoma patients.
Topics: Actins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blotting, Western; Cyclop | 2010 |
Indolent lymphoma: can rituximab resolve the watch-and-wait debate?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2010 |
Severe pulmonary adverse effects in lymphoma patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus rituximab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2010 |
[Treatment options in non-Hodgkin lymphomas].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2010 |
[Tunisian experience in the treatment of aggressive non Hodgkin's lymphoma in adults: about 337 patients].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2010 |
Periorbital non-Hodgkin's lymphoma after blunt trauma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2010 |
Circulating cell-free and Epstein-Barr virus DNA in pediatric B-non-Hodgkin lymphomas.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 2010 |
Clinical features and treatment outcomes of 14 cases of primary ovarian non-Hodgkin's lymphoma: a single-center experience.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
Can a blood test monitor lymphoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Daunorubicin; DNA, Viral; Epste | 2010 |
Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies.
Topics: Adult; Aged; Antibodies; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, C | 2010 |
Successful long-term immunologic reconstitution by allogeneic hematopoietic stem cell transplantation cures patients with autosomal dominant hyper-IgE syndrome.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Hematopoi | 2010 |
Hyperglycemia during chemotherapy for hematologic and solid tumors is correlated with increased toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2011 |
Langerhans cell histiocytosis in a child with non-Hodgkin lymphoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cyclosporine; Cytarabi | 2010 |
Intermediate dose of nonpegylated liposomal doxorubicin combination (R-CMyOP) as first line chemotherapy for frail elderly patients with aggressive lymphoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2011 |
Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dacarbazine | 2011 |
Impact of CD40 expression by flowcytometry on outcome of patients with non-Hodgkin's lymphoma.
Topics: Adolescent; Aged; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; CD40 Antigens; Cycl | 2009 |
Radiographic enlargement of mandibular canal as first feature of non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Differential; Doxorubic | 2010 |
Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Antibodies, Monoclonal, Murine-Derived; Anti | 2011 |
Rituximab tolerability when given before or after CHOP.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2011 |
Two cases of Pneumocystis jiroveci pneumonia with non-Hodgkin's lymphoma after CHOP-based chemotherapy containing rituximab.
Topics: Aged; Anti-Infective Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemoth | 2010 |
Increased monocyte chemotactic protein-1 concentration and monocyte count independently associate with a poor prognosis in dogs with lymphoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemokine CCL2; Cycl | 2011 |
Incidence of neutropenia, chemotherapy delivery, and use of colony-stimulating factor in patients with non-Hodgkin lymphoma of different age groups.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colony-Stimulating F | 2011 |
Treatment of a patient with adnexal lymphoma with Rituximab.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2011 |
Unusual presentation of gastric plasmablastic lymphoma in HIV-negative patient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; HIV; HIV Infections; | 2012 |
Outcome and haemato-toxicity of two chemotherapy regimens for childhood non-Hodgkin's lymphoma in a Kenyan hospital.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Cytarabine; Dis | 2009 |
Cutaneous fusariosis developing in a post-irradiation site.
Topics: Adult; Combined Modality Therapy; Cyclosporine; Debridement; Dermatomycoses; Female; Fusarium; Human | 2011 |
Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era: a multicenter study of 95 patients in Japan.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antin | 2012 |
Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of non-Hodgkin's lymphoma patients with cardiac risk factors.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular D | 2012 |
Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of non-Hodgkin's lymphoma patients with cardiac risk factors.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular D | 2012 |
Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of non-Hodgkin's lymphoma patients with cardiac risk factors.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular D | 2012 |
Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of non-Hodgkin's lymphoma patients with cardiac risk factors.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular D | 2012 |
Lymphosarcoma associated with Heterobilharzia americana infection in a dog.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dog Diseases; Dogs; Doxor | 2011 |
CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group.
Topics: Adolescent; Adult; Age of Onset; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Che | 2012 |
Neurological syndrome after R-CHOP chemotherapy for a non-Hodgkin lymphoma: what is the diagnosis?
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2011 |
Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clini | 2012 |
Severe high-density lipoprotein deficiency associated with autoantibodies against lecithin:cholesterol acyltransferase in non-Hodgkin lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2012 |
Primary extranodal T-cell non-Hodgkin lymphoma of the tongue.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cyclophosphamide; Dose Fra | 2012 |
Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factor.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antigens, CD34; Antineoplastic Combined Chemoth | 2012 |
Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy.
Topics: Adoptive Transfer; Animals; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therap | 2012 |
[A very elderly case of complete remission by chemotherapy in a patient of primary esophageal non-Hodgkin lymphoma].
Topics: Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Com | 2012 |
[Primary pulmonary Non-Hodgkin's lymphoma: report of a case].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lung Neoplasm | 2012 |
Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2012 |
Non-Hodgkin lymphoma during the 1st trimester of pregnancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Epirubicin; Female; Humans; | 2012 |
Painless, rapidly increasing maxillary swelling and erythematous mucosa: differential diagnosis and therapy.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cycl | 2012 |
Vincristine-induced unilateral ptosis with serendipitous response to modafinil.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzhydryl | 2011 |
Acute liver failure related to chemotherapy.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclo | 2012 |
Renal angiomyolipomatosis and Kaposi's sarcoma: a possible link disrupted by sirolimus.
Topics: Aged; Angiomyolipoma; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Combined Modality Ther | 2012 |
Cryptococcal osteomyelitis and meningitis in a patient with non-hodgkin's lymphoma treated with PEP-C.
Topics: Aged; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cryptococcus neoformans; Cy | 2012 |
Primary prophylaxis with granulocyte colony-stimulating factor (GCSF) reduces the incidence of febrile neutropenia in patients with non-Hodgkin lymphoma (NHL) receiving CHOP chemotherapy treatment without adversely affecting their quality of life: cost-be
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cost | 2013 |
[Giant splenomegaly and non-Hodking´s lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; | 2012 |
Point prevalence of Pneumocystis pneumonia in patients with non-Hodgkin lymphoma according to the number of cycles of R-CHOP chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
Successful treatment of primary central nervous system lymphoma without irradiation in children: single center experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Child; | 2012 |
Generalized granuloma annulare and non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cycl | 2013 |
Analysis of chemotherapy-induced neutropenia and optimal timing for prophylactic use of G-CSF in B-cell non-Hodgkin lymphoma patients treated with R-CHOP.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Null phenotype non-Hodgkin lymphoma presenting as a large chest wall mass: case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 2012 |
Primary endometrial non-Hodgkin's lymphoma treated by chemotherapy and radiotherapy.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Comb | 2013 |
International prognostic index-based outcomes for diffuse large B-cell lymphomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopho | 2002 |
[Coexistence of pure red cell aplasia and autoimmune hemolytic anemia occurring during remission of malignant lymphoma].
Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dox | 2002 |
Th1/Th2 cytokine expression and its relationship with tumor growth in B cell non-Hodgkin's lymphoma (NHL).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2002 |
CNOP for diffuse aggressive non-Hodgkin's lymphoma: the Nebraska lymphoma study group experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 2002 |
Anemia of cancer in intermediate-grade non-Hodgkin's lymphoma.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Community Health Services; Cyclophosph | 2002 |
Role of endothelin-1 in the development of a special type of cardiomyopathy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; | 2002 |
A relapsed non-Hodgkin lymphoma presenting as panhypopituitarism successfully treated by chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Etoposide; Female | 2002 |
Retrospective comparison between CHOP-PVP and CHOP protocols for non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Doxorubi | 2002 |
Low-dose epirubicin in combination with cyclophosphamide, vinblastine and prednisone (mini-CEOP) for the treatment of aggressive non-Hodgkin's lymphoma in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-F | 2002 |
[Primary malignant non-Hodgkin's lymphoma of the heart].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cyclophosphamide; Doxorubicin; | 2002 |
Optimal therapy of primary ocular lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Eye Neopl | 2002 |
Use of random skin biopsy to diagnose intravascular lymphoma presenting as fever of unknown origin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Differential; Doxorubic | 2003 |
High survival rate in childhood non-Hodgkin lymphoma without CNS involvement: results of BFM 95 study in Kuwait.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; Child; Child, Presch | 2003 |
Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Res | 2003 |
Successful chemotherapy in a male patient with malignant lymphoma and Leber's hereditary optic neuropathy (LHON).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cells, Cultured; Combined Modality Therapy; C | 2003 |
[Gemcitabine in the treatment of relapsed or refractory non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2002 |
[Uveal lymphoid infiltration with systemic extension].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Choroid Diseases; Choroid Neoplas | 2003 |
Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: results of a prospective, multicenter study of the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Fr | 2002 |
Primary non-Hodgkin's lymphoma of the uterine cervix successfully treated by neoadjuvant chemotherapy: case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Hyste | 2003 |
[Clinical analysis of 75 patients with nasopharyngeal non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; C | 2003 |
[Primary non-Hodgkin's lymphoma of the thyroid. A case report and review of the literature].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Ant | 2003 |
Aggressive lymphoma: improving treatment outcome with rituximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2002 |
Primary non-Hodgkin's lymphoma of the bladder with bone marrow involvement.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Marrow; Bone Neoplasms; | 2003 |
Remission of follicular non-Hodgkin's lymphoma with denileukin diftitox (ONTAK) after progression during rituximab, CHOP and fludarabine therapy.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antine | 2003 |
ACOD, a modified CHOP regimen for elderly patients with aggressive non-Hodgkin's lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 2003 |
Presentation serum selenium predicts for overall survival, dose delivery, and first treatment response in aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bi | 2003 |
Combined lamivudine and interferon-alpha therapy for chemotherapy-induced reactivation of hepatitis B virus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Hepatitis B; He | 2003 |
Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with Lamivudine.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxo | 2003 |
Fludarabine versus cyclophosphamide, vincristine, and prednisone in recurrent low-grade lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Lymphoma, Non-Hodgkin; Pre | 2003 |
[Synchronous chromophobe renal carcinoma and centrocytic lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Combined Modality Ther | 2003 |
Abdominal irradiation after chemotherapy in non-Hodgkin's lymphoma: review of 32 patients.
Topics: Abdomen; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; | 2003 |
Richter's syndrome: a novel presentation.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; | 2003 |
[Treatment of malignant non-Hodgkin's lymphoma. Economic impact of rituximab (Mabthera) versus conventional chemotherapy].
Topics: Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2003 |
Impact of concomitant antiblastic chemotherapy and highly active antiretroviral therapy on human immunodeficiency virus (HIV) viremia and genotyping in HIV-infected patients with non-Hodgkin lymphoma.
Topics: Adolescent; Adult; Anti-HIV Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; | 2003 |
Lymphoblastic lymphoma of childhood and the LSA2-L2 protocol: the 30-year experience at Memorial-Sloan-Kettering Cancer Center.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 2003 |
[A further possible indication for use of prednisone: several mesenchymal neoplasms].
Topics: Child; Humans; Infant; Leukemia; Leukemia, Myeloid; Liver; Liver Neoplasms; Lymphoma, Large B-Cell, | 1955 |
[Reticulosarcoma of the scapula; treatment with delta cortisone].
Topics: Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasms; Prednisone; Sarcoma; Scap | 1957 |
[Massive dosage of prednisone in lymphogranuloma, lymphosarcoma and reticulum cell sarcoma].
Topics: Hodgkin Disease; Humans; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasms | 1957 |
Cutaneous lymphoblastoma: a case of reticulum cell sarcoma with prominent skin manifestations and a brief but dramatic remission with prednisone therapy.
Topics: Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Medical Records; Neoplasms; Predniso | 1958 |
[A case of reticulosarcoma treated with large doses of prednisone].
Topics: Cell- and Tissue-Based Therapy; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neop | 1959 |
Innovative strategies in lymphoma therapy.
Topics: Alemtuzumab; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2003 |
[Contribution to the treatment of lymphosarcoma].
Topics: Antineoplastic Agents; Humans; Liver Neoplasms; Lung Neoplasms; Lymphoma, Non-Hodgkin; Prednisone | 1961 |
Large doses of prednisone and prednisolone in the treatment of malignant lymphoproliferative disorders.
Topics: Humans; Leukemia; Leukemia, Lymphoid; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders | 1962 |
Polyneuritis preceding lymphoblastic lymphoma.
Topics: Humans; Lymphoma; Lymphoma, Non-Hodgkin; Neuritis; Polyradiculopathy; Precursor Cell Lymphoblastic L | 1963 |
[The use of Degranol pills in hemoblastosis and other neoplastic diseases].
Topics: Humans; Leukemia; Leukemia, Lymphoid; Lymphogranuloma Venereum; Lymphoma; Lymphoma, Large B-Cell, Di | 1963 |
WEEKLY HIGH-DOSAGE GLUCOCORTICOSTEROID TREATMENT OF LYMPHOCYTIC LEUKEMIAS AND LYMPHOMAS.
Topics: Anemia; Anemia, Hemolytic; Betamethasone; Chlorambucil; Dexamethasone; Geriatrics; Humans; Leukemia; | 1964 |
SPINAL-CORD COMPRESSION IN THE MALIGNANT LYMPHOMAS.
Topics: Chlorambucil; Hematopoiesis; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Mercaptopurin | 1964 |
[EXPERIENCES IN THE TREATMENT OF MALIGNANT DISEASES OF THE RETICULOENDOTHELIAL SYSTEM AND LEUKEMIAS. (I)].
Topics: Antineoplastic Agents; Cortisone; Hodgkin Disease; Leukemia; Lung Neoplasms; Lymphoma; Lymphoma, Lar | 1964 |
NONSURGICAL TREATMENT OF PULMONARY CANCER.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adrenal Cortex Hormones; Alkylating Agents; Antineoplastic Agen | 1964 |
[THE SIGNIFICANCE OF RETICULOSES IN THE AREA OF MALIGNANT HEMATOLOGICAL DISEASES IN CHILDHOOD].
Topics: Child; Cyclophosphamide; Genetic Diseases, X-Linked; Hematologic Diseases; Histiocytosis, Langerhans | 1963 |
[THE RETICULO-ENDOTHELIAL SYSTEM AND LYMPHOSARCOMAS].
Topics: Adolescent; Adrenal Cortex Hormones; Geriatrics; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Follic | 1964 |
METABOLIC RELATIONSHIPS BETWEEN TUMOR AND HOST DURING MASSIVE DOSES OF PREDNISONE IN HUMAN NEOPLASTIC DISEASE.
Topics: 17-Ketosteroids; Adenocarcinoma; Biomedical Research; Blood; Calcium; Chlorides; Creatine; Creatinin | 1964 |
RETICULUM CELL SARCOMA OF THE SMALL BOWEL AND STEATORRHOEA.
Topics: Ascorbic Acid; Blood Transfusion; Body Weight; Bone Marrow Examination; Celiac Disease; Diet; Diet T | 1964 |
THE SUPERIOR MEDIASTINAL SYNDROME IN CHILDREN WITH CANCER.
Topics: Adolescent; Child; Hodgkin Disease; Humans; Leukemia; Lymphoma; Lymphoma, Non-Hodgkin; Mediastinal N | 1965 |
Calcification in splenic lymphoma before chemotherapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Calcinosis; Causality; Cyclophos | 2003 |
Primary gastrointestinal non-Hodgkin's lymphoma: treatment outcome.
Topics: Adenocarcinoma, Follicular; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkyl | 2003 |
Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Cohort St | 2004 |
Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Cyclop | 2003 |
[Simultaneous detection of both non-Hodgkin's lymphoma cells and breast cancer cells in pleural effusion--a case report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; | 2003 |
Synchronous triple lung cancers after treatment for non-Hodgkin's lymphoma: metachronous quadruple cancers.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Squamous Cel | 2003 |
18FDG positron emission tomography versus 67Ga scintigraphy as prognostic test during chemotherapy for non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; | 2003 |
Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2003 |
Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2003 |
[Clinical analysis of 282 patients with non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; C | 2003 |
[Principles of treatment and military medical examination of the patients with indolent Non-Hodgkin's lymphomas].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cohort Studies; Combined Modalit | 2003 |
Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Filgrastim; G | 2003 |
Long-term follow-up of patients with intermediate or high-grade non-Hodgkin lymphoma treated with a combination of cyclophosphamide, epirubicin, vincristine, and prednisone.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Cyclophosphami | 2004 |
Long-term follow-up of patients with intermediate or high-grade non-Hodgkin lymphoma treated with a combination of cyclophosphamide, epirubicin, vincristine, and prednisone.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Cyclophosphami | 2004 |
Long-term follow-up of patients with intermediate or high-grade non-Hodgkin lymphoma treated with a combination of cyclophosphamide, epirubicin, vincristine, and prednisone.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Cyclophosphami | 2004 |
Long-term follow-up of patients with intermediate or high-grade non-Hodgkin lymphoma treated with a combination of cyclophosphamide, epirubicin, vincristine, and prednisone.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Cyclophosphami | 2004 |
[Survival of patients with aggressive non-hodgkin's lymphoma: no difference between first line treatment in a prospective randomised phase III clinical trial and first line treatment according to routine clinical practice].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Pha | 2004 |
Breast cancer after curative chemotherapy in non-Hodgkin's lymphoma: examination of the role of drug resistance and retrospective comparison to the outcome of de novo breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; | 2004 |
[Bilateral primary non-Hodgkin's lymphomas of the adrenals].
Topics: Adrenal Gland Neoplasms; Adrenal Glands; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyc | 2003 |
Multiple clinical manifestation of HTLV1 infection in a single patient.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dermatitis, Seborrheic; Dia | 2003 |
Remitting seronegative symmetrical synovitis with pitting edema syndrome associated with non-Hodgkin's lymphoma: a case report.
Topics: Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Edema; F | 2004 |
Intracellular IL-4/IFN-gamma producing peripheral T lymphocyte subsets in B cell non-Hodgkin's lymphoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; CD4-Posit | 2004 |
[Primary non-Hodgkin's lymphoma of bone].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Regeneration; Cyclophosphamide; | 2004 |
Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide | 2004 |
[Alveolar hypoxemic interstitial pneumonia related to rituximab therapy].
Topics: Acute Disease; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murin | 2004 |
[Primary central nervous system lymphoma: a report of 28 patients].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neop | 2004 |
[Chemotherapy and radiotherapy for non-Hodgkin's lymphomas of the nasal cavity].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Co | 2004 |
[Clinical features, treatment and prognosis of 136 patients with primary non-Hodgkin's lymphoma of the nasopharynx].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 2004 |
Cyclooxygenase-2 (Cox-2) expression in lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclooxygenase 2; Cyclophosp | 2004 |
Adrenal insufficiency due to primary bilateral adrenal non-Hodgkin's lymphoma.
Topics: Adrenal Gland Neoplasms; Adrenal Insufficiency; Antineoplastic Combined Chemotherapy Protocols; Cycl | 2004 |
Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2004 |
Pilot study of modified version of CHOP plus radiotherapy for early-stage aggressive non-Hodgkin's lymphoma of the head and neck.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2004 |
Primary mammary (non-Hodgkin) lymphoma presenting as locally advanced breast cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2004 |
Tositumomab/I-131 tositumomab following chemotherapy effective as first-line treatment of NHL.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclo | 2004 |
[Primary study of relationship between serum level of VEGF and non-Hodgkin's lymphoma in children and adolescent patients].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; C | 2004 |
[Clinical analysis of liver non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Aspar | 2004 |
Plasma glutathione S-Transferase P1-1 as a prognostic factor in patients with advanced non-Hodgkin's lymphoma (stages III and IV).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; | 2004 |
The effects of IL-2, IL-6 and IL-10 levels on prognosis in patients with aggressive Non-Hodgkin's Lymphoma (NHL).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Disea | 2004 |
[Clinical analysis of 68 patients with primary gastric lymphoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2004 |
[A three-year experience with use of mabthera (rituximab) in treatment of indolent non-Hodgkin's disease refractory to standard chemotherapy].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2004 |
A case of facial swelling and proptosis.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2004 |
Precore mutant hepatitis B reactivation after treatment with CHOP-rituximab.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2005 |
Cyclophosphamide, pegylated liposomal doxorubicin, vincristine and prednisone (CDOP) plus rituximab is effective and well tolerated in poor performance status elderly patients with non-Hodgkin's lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2005 |
[The choice of second-line chemotherapy for malignant lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Administration S | 2005 |
[A case of secondary non-Hodgkin's lymphoma of the colon after the treatment for Hodgkin's disease].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; | 2005 |
Marked telomere shortening in mobilized peripheral blood progenitor cells (PBPC) following two tightly spaced high-dose chemotherapy courses with G-CSF.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antigens, CD34; Antimetabolites, Antineoplastic; Ant | 2005 |
Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cross-Over Studies; Cycloph | 2005 |
Defining the stages of aggressive non-Hodgkin's lymphoma--a work in progress.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphami | 2005 |
Primary stage I-IIE non-Hodgkin's lymphoma of uterine cervix and upper vagina: evidence for a conservative approach in a study on three patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Fem | 2005 |
Neoadjuvant combined chemotherapy followed by external whole pelvic irradiation in two cases of primary extranodal non-Hodgkin's lymphoma of the uterine cervix.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans | 2005 |
Nephrotic syndrome in patients with peripheral blood stem cell transplant.
Topics: Acute Kidney Injury; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineop | 2005 |
Dysphagia revealing esophageal involvement by non-Hodgkin's lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Deglutition Disorders; Doxor | 2005 |
[Clinical analysis of 59 cases of primary gastric non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2005 |
Endothelin-1 and cardiac function in anthracycline-treated patients: a 1-year follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dacarbazin | 2004 |
Primary breast lymphoma cytologic diagnosis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy, Fine-Needle; Breas | 2005 |
Chemoradiotherapy for localized non-Hodgkin's lymphoma: lessons from old studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 2005 |
Stage I and II non-Hodgkin's lymphoma: results of combined of THP-COP chemotherapy and radiotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; | 2005 |
Treatment of localized lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Hum | 2005 |
Treatment of localized lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphami | 2005 |
Treatment of localized lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphami | 2005 |
Epstein-Barr virus DNA in serum in a HIV-infected patient during development and treatment of non-Hodgkin's lymphoma.
Topics: Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; DNA, Viral; Doxor | 2005 |
Non-Hodgkin's lymphoma after kidney transplantation: a single institution study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; | 2006 |
Long-term follow-up high-dose chemotherapy (drug-only program) followed by autologous stem cell transplantation for aggressive non-Hodgkin's lymphomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; | 2005 |
Treatment of a clinically determined lower-risk stage III non-lymphoblastic Non-Hodgkin lymphoma with less intensive therapy does not impact negatively on outcome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin | 2006 |
CHOP versus CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 2005 |
[Expression of glycoprotein 90K in non-Hodgkin's lymphoma and its clinical significance].
Topics: Adolescent; Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomark | 2005 |
Adapted CHOP plus rituximab in non-Hodgkin's lymphoma in patients over 80 years old.
Topics: Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Co | 2005 |
Relapsed non-Hodgkin lymphoma in fraternal twins managed successfully with rituximab maintenance therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2005 |
The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, | 2005 |
[Efficacy of different chemotherapy programs, indications for surgery and radiotherapy in primary mediastinal B-cell lymphosarcoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphami | 2005 |
Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non-Hodgkin's lymphomas.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Lymphoma, Non-Hodgkin; Pr | 2006 |
Cyclophosphamide, epirubicin, vincristine, and prednisone (CEOP) in the treatment of advanced stage non-Hodgkin's lymphomas with poor histology.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophospham | 1989 |
Results of three polychemotherapy programs in non-Hodgkin's lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1989 |
A Bayesian approach to a patient with a residual mass after treatment for non-Hodgkin's lymphoma of the thyroid.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2005 |
Primary non-Hodgkin's lymphoma of the spleen presenting as space occupying lesion: a case report and review of literature.
Topics: Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Human | 2006 |
Complete regression of cardiac non-Hodgkin lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineo | 2006 |
Model-based design of chemotherapeutic regimens that account for heterogeneity in leucopoenia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide | 2006 |
[Malignant non-Hodgkin diffuse lymphoma with extranodal orbital involvement--a clinical case].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Differential; Female; H | 2005 |
Cardiac function and cardiopulmonary performance in patients after treatment for non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphami | 2006 |
[Clinical analysis of reactive thymic hyperplasia following chemotherapy for childhood malignant lymphoma].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Child, Preschool; Daca | 2006 |
[Prognostic factors of primary non-Hodgkin's lymphoma of the nasal cavity--a report of 129 cases].
Topics: Adolescent; Adult; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; Combine | 2006 |
[Clinical features of 89 patients with primary non-Hodgkin's lymphoma of the tonsil].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Th | 2006 |
[Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2006 |
A case of non-hodgkin's lymphoma of the ovary: usefulness of 18F-FDG PET for staging and assessment of the therapeutic response.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Fluoro | 2006 |
Retroperitoneal fibrosis after chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Doxor | 2007 |
Primary bone lymphoma: a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Doxor | 2006 |
Fertility status among women treated for aggressive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cyclo | 2006 |
Treatment results of chemoradiation therapy for localized aggressive lymphomas: A retrospective 20-year study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2006 |
[Effect of high-dose chemotherapy with subsequent transplantation of blood-forming cells on left ventricle function in patients with malignant lymphomas treated with doxorubicin in primary chemotherapy].
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols | 2006 |
New concepts in treatment approaches and prognostic factors in aggressive NHL.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2006 |
Psoriasis occurring after myeloablative therapy and autologous stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lympho | 2006 |
[Treatment option and outcome for patients with primary non-Hodgkin's lymphoma of the nasal cavity].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; | 2006 |
[Clinical analysis of 32 primary intestinal non-Hodgkin's lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Follow | 2006 |
[Late cardiotoxicity in patients with malignant lymphoma treated with doxorubicin chemotherapy].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; | 2006 |
False-positive restaging PET scans involving the spleen in two patients with aggressive non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2006 |
[Clinical study of shenqi fuzheng injection and chemotherapy in CHOP protocol in treating malignant lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; CD4-CD8 Ratio; Cyclophosphamide; Doxorubicin; | 2006 |
Defining the cost of cure: infertility among female survivors of lymphoma.
Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxo | 2006 |
Something old, something new....
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Gemc | 2006 |
Rituximab plus CHOP for treatment of diffuse large B-cell lymphoma during second trimester of pregnancy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2006 |
Same day Pegfilgrastim and CHOP chemotherapy for non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2006 |
Hybrid cytogenetics of chronic lymphocytic leukemia and follicular cell lymphoma in a case of non-Hodgkin's lymphoma.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 14; Chromosom | 2006 |
Primary retroperitoneal non-Hodgkin lymphoma presenting with torturous generalized pruritus in an elderly.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Fema | 2007 |
Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protoc | 2006 |
Conservative management in primary genital lymphomas: the role of chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 2007 |
Avascular necrosis--an antineoplastic-treatment-related toxicity: the experiences of two institutions.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; Cytarabi | 2006 |
Lichenoid paraneoplastic pemphigus in the absence of detectable antibodies.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody Formation; Antineopla | 2007 |
[Primary non-Hodgkin's lymphoma of the nasal cavity at early stage: long-term treatment outcomes and prognostic analyses of 108 cases].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined | 2006 |
[Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; C | 2006 |
Primary gastric lymphoma.
Topics: Abdominal Pain; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2007 |
Sudden onset of herpes zoster following chemotherapy for orbital lymphoma in a HIV positive patient.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Cyclop | 2007 |
Influence of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone on serologic parameters and clinical course in lymphoma patients with autoimmune diseases.
Topics: Aged; Aged, 80 and over; Antibodies, Antinuclear; Antibodies, Monoclonal; Antibodies, Monoclonal, Mu | 2007 |
[Concurrent chemo-radiotherapy for localized refractory non-Hodgkin's lymphoma--report of two cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; D | 2007 |
Primary large B-cell lymphoma of the bone marrow.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2007 |
[Long term results for intermediate and high grade localized non Hodgkin lymphoma, treated with chemotherapy and radiotherapy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2006 |
Do cytogenetic abnormalities precede morphologic abnormalities in a developing malignant condition?
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2007 |
The effect of short-term intensive chemotherapy on reactivation of tuberculosis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Doxo | 2007 |
Rapid leukaemic evolution in a cutaneous blastic NK-cell lymphoma initially diagnosed as pseudolymphoma.
Topics: Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bleomycin; CD | 2007 |
Aggressive primary thyroid non Hodgkin's lymphoma with pregnancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans | 2007 |
[A case of primary malignant lymphoma of thyroid in young man].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Chemotherapy, Adjuvant; | 2006 |
[Primary non-Hodgkin's lymphoma of the adrenals. A case report].
Topics: Adrenal Gland Neoplasms; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Do | 2007 |
False-positive FDG-PET findings due to bone metastasis from prostate cancer in staging of non-Hodgkin's lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2007 |
[Hypercalcaemia and malignant lymphoma. One case report].
Topics: Aged, 80 and over; Bone Density Conservation Agents; Calcitriol; Diphosphonates; Glucocorticoids; Hu | 2007 |
Guillain-Barré syndrome after combined CHOP and rituximab therapy in non-Hodgkin lymphoma.
Topics: Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Ant | 2007 |
Early response assessment using 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2007 |
Sarcoid-like reaction in the spleen following chemotherapy for non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2007 |
The use of G-CSF during first line chemotherapy adversely affects the yield of PBSC mobilization in non-Hodgkin's lymphoma patients.
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; | 2002 |
How can we determine the role of radiotherapy in the treatment of localized aggressive non-Hodgkin's lymphoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; | 2007 |
Complete remission by chemotherapy in stage IE-IIE primary gastric lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Fema | 2007 |
[Genitourinary manifestations of lymphoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Diagnosis, Different | 2007 |
Prospective study of bone marrow infiltration in aggressive lymphoma by three independent methods: whole-body MRI, PET/CT and bone marrow biopsy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Neoplasms; Cyclopho | 2008 |
A 57-year-old man who developed arthritis during R-CHOP chemotherapy for non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2008 |
Successful rituximab-CHOP treatment of systemic lupus erythematosus associated with diffuse large B-cell non-Hodgkin lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2007 |
A case of primary cardiac lymphoma: analysis of the role of echocardiography in early diagnosis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2007 |
[Primary diffuse large B-cell lymphosarcoma of the spleen].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 2007 |
[CEOP regimen in the treatment for non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Child; Combined M | 2007 |
[Therapeutic results and evolution of Black African patients with follicular lymphoma: Ivory Coast experience].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cote d'Ivoire; C | 2007 |
[Prognostic factors of invasive non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined | 2007 |
Primary testicular lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; | 2007 |
Prognostic factors for hematotoxicity of chemotherapy in aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophospham | 2008 |
Diffuse lymphomatous infiltration of kidney presenting as renal tubular acidosis and hypokalemic paralysis: case report.
Topics: Acid-Base Equilibrium; Acidosis, Renal Tubular; Adult; Antigens, CD19; Antigens, CD20; Antineoplasti | 2007 |
Successful pregnancy in stage IE primary non-Hodgkin's lymphoma of uterine cervix treated with neoadjuvant chemotherapy and conservative surgery.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans | 2007 |
Non-Hodgkin lymphoma: retrospective study on the cost-effectiveness of early treatment response assessment by FDG-PET.
Topics: Antineoplastic Combined Chemotherapy Protocols; Belgium; Cost-Benefit Analysis; Cyclophosphamide; Do | 2008 |
Combined therapy with rituximab plus cyclophosphamide/vincristine/prednisone for Sjogren's syndrome-associated B-cell non-Hodgkin's lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineo | 2008 |
Expression of PLK1 and survivin in non-Hodgkin's lymphoma treated with CHOP.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Cyc | 2008 |
Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Belgium; Cyclophosphamide; Dose-Respons | 2008 |
[Clinical outcomes of different regimens for non-Hodgkin's lymphoma with bone marrow involvement: analysis of 148 cases].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Child, | 2008 |
Necrotizing leukoencephalopathy following CHOP chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Cerebral Cortex; Combined Mod | 2008 |
[Intravascular lymphoma revealed by generalized arborescent telangiectasia and repeated venous thrombosis].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineo | 2008 |
Erythema elevatum diutinum with rare distribution as a first clinical sign of non-Hodgkin's lymphoma: a novel association?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Differential; Dox | 2008 |
Comment on: 'Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome'.
Topics: Administration, Oral; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Ble | 2008 |
Complete remission in chronic lymphocytic leukemia and leukolymphosarcoma.
Topics: Aged; Chlorambucil; Female; Humans; Leukemia; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin; Male; Middl | 1967 |
Toxic epidermal necrolysis and malignant lymphoma.
Topics: Adult; Aged; Bendroflumethiazide; Chloramphenicol; Cyclizine; Female; Hodgkin Disease; Humans; Lymph | 1967 |
Management of the indolent non-Hodgkin's lymphomas.
Topics: Antineoplastic Agents; Bleomycin; Carmustine; Cyclophosphamide; Doxorubicin; Drug Therapy, Combinati | 1980 |
[Lymphomas. Treatment of malignant lymphomas. Current observations and future prospects].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; | 1982 |
Clinical and histological staging as prognostic determinants in advanced cutaneous T cell lymphomas treated by sequential polychemotherapy with bleomycin, vinblastine and prednisone. Preliminary results.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Drug Therapy, Combination; Female; | 1982 |
Combination chemotherapy ("MABOP") in advanced refractory lymphocytic lymphoma with unfavorable histology.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Doxor | 1982 |
Chronic lymphocytic leukemia in the elderly.
Topics: Aged; B-Lymphocytes; Chlorambucil; Diagnosis, Differential; Glucosephosphate Dehydrogenase; Humans; | 1982 |
Malignant lymphocytic lymphoma. Demonstration of a serum inhibitor of myelopoiesis and response to combination chemotherapy.
Topics: Antineoplastic Agents; Colony-Forming Units Assay; Cyclophosphamide; Drug Therapy, Combination; Hema | 1983 |
Composite lymphoma: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Hodgkin Disease; Humans; Lymph Nodes; Lymphoma | 1984 |
Myeloproliferative disorder with profound hypereosinophilia associated with chemotherapy for breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Eos | 1984 |
Combination of vindesine and prednisone in malignant lymphoma and acute leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Drug Therapy, Combination; Female; Humans; Leukem | 1983 |
Systemic lupus erythematosus and lymphoma. A family study.
Topics: Adult; Autoimmune Diseases; Azathioprine; Child; Drug Therapy, Combination; Female; Humans; Killer C | 1983 |
[Results of combined chemotherapy of lymphosarcoma with cyclophosphamide, vincristine and prednisolone].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Therapy, Combination; Humans; | 1983 |
Long-term results of the APO protocol (vincristine, doxorubicin [adriamycin], and prednisone) for treatment of mediastinal lymphoblastic lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Doxorubi | 1983 |
Reversal of red cell aplasia and marrow fibrosis in non-Hodgkin's lymphoma.
Topics: Adult; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; L | 1983 |
Dexamethasone binding to chromatin, inhibition of in vitro RNA synthesis, and therapeutic effect on human lymphosarcoma.
Topics: Child; Chromatin; Dexamethasone; Humans; Lymphoma, Non-Hodgkin; Male; Mediastinal Neoplasms; Prednis | 1980 |
[Non-Hodgkin's lymphoma and pregnancy treated with chemotherapy. Report of a case].
Topics: Adult; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Infant, N | 1981 |
Malignant pheochromocytoma. Severe clinical exacerbation and release of stored catecholamines during lymphoma chemotherapy.
Topics: Adrenal Gland Neoplasms; Catecholamines; Cyclophosphamide; Drug Therapy, Combination; Humans; Hypert | 1982 |
Chemotherapeutic responses in dogs with lymphosarcoma and hypercalcemia.
Topics: Animals; Asparaginase; Cyclophosphamide; Cytarabine; Dog Diseases; Dogs; Drug Therapy, Combination; | 1982 |
Chemotherapy of advanced non-Hodgkin lymphomas: a report of 35 cases.
Topics: Antineoplastic Agents; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Humans; Lym | 1982 |
Primary lymphoblastic lymphoma of the breast.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 1982 |
An intensive care chemo- or chemoimmunotherapy regimen for patients with intermediate and poor-prognosis acute lymphatic leukemia and leukemic lymphoblastic lymphosarcoma: preliminary results with 14-month median follow-up.
Topics: Adolescent; Asparaginase; Doxorubicin; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; | 1982 |
Lymphoblastic lymphoma in adults: results of a pilot protocol.
Topics: Adolescent; Adult; Asparaginase; Central Nervous System Diseases; Cyclophosphamide; Doxorubicin; Fem | 1981 |
[T-cell lymphoblastic lymphomas. Clinico-pathological study of 17 cases and short- and long-term therapeutic responses].
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Chi | 1982 |
Moderate versus intensive chemotherapy of prognostically favorable non-Hodgkin's lymphoma: a progress report.
Topics: Cyclophosphamide; Drug Therapy, Combination; Humans; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymp | 1980 |
[Results of chemotherapy with cyclophosphamide, vincristine, methotrexate and prednisone in recurring or disseminated non-Hodgkin lymphomas in the University of Kiel Radiology Clinic].
Topics: Cyclophosphamide; Drug Therapy, Combination; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Methotrexate; | 1981 |
Deferral of initial therapy for advanced indolent lymphomas.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Therap | 1982 |
Non-Hodgkin's lymphoma in Manitoba, 1968-77: the impact of chemotherapy.
Topics: Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Follow-Up Studies; Histiocytes; | 1982 |
Mesna/ifosfamide, mitoxantrone, etoposide, bleomycin, vincristine, prednisone (MINE-BOP) combination chemotherapy in the treatment of refractory and relapsed non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cytar | 1995 |
Bone marrow transplantation versus chemotherapy in non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Thera | 1995 |
[Effect of combination chemotherapy for elderly patients with malignant lymphoma].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1993 |
Prevention of chemotherapy-induced neutropenia using G-CSF with VACOP-B--a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; | 1993 |
Oculomotor nerve palsy associated with vincristine treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dexamethasone; Doxorubi | 1993 |
Postoperative chemotherapy increases the disease-free survival rate in primary gastric lymphomas stage IE and IIE.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; C | 1994 |
Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin- vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; beta 2-M | 1994 |
Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy.
Topics: Age Factors; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cost- | 1994 |
High-dose therapy and autologous bone marrow transplantation in first complete remission for adult patients with high-grade non-Hodgkin's lymphoma: the EBMT experience. Lymphoma Working Party of the European Group for Bone Marrow Transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Purging; B | 1994 |
Comparable prognostic factors and survival in elderly patients with aggressive non-Hodgkin's lymphoma treated with standard-dose adriamycin-based regimens.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 1994 |
Localized, late-onset, high-grade lymphoma following bone marrow transplantation: response to combination chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modalit | 1994 |
A cooperative study on ProMACE-CytaBOM in aggressive non-Hodgkin's lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Cyclophos | 1994 |
The response of diffuse large cell and other intermediate grade non-Hodgkin's lymphomas to adriamycin containing combination chemotherapy.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosp | 1994 |
Long-term results with MACOP-B in the treatment of aggressive non-Hodgkin's lymphomas. The experience in Brazil.
Topics: Actuarial Analysis; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomyc | 1994 |
Serious pulmonary complications in patients receiving recombinant granulocyte colony-stimulating factor during BACOP chemotherapy for aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubici | 1994 |
[Clinical analysis of 126 cases with NHL in extra-node of head and neck patients in stage I and II].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Child, Pr | 1994 |
[Type III procollagen N-terminal peptide and type IV collagen-7S level in the serum and BALF of patients with non-Hodgkin's lymphoma before and after chemotherapy].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bronchoalveolar | 1994 |
[Evaluation of pulmonary function and bronchoalveolar lavage fluid in elderly non-Hodgkin's lymphoma before and after COP-BLAM III therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bronchoalveolar Lavage Fluid; Cyclo | 1994 |
Non-Hodgkin's lymphomas in Turkey: eighteen years' experience at the Hacettepe University.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Anemia; Antineoplastic Agents; Ant | 1994 |
Intrapleural bleomycin in the treatment of chylothorax.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chylothorax; Cyclo | 1994 |
Influence of molecular characteristics on clinical outcome in human immunodeficiency virus-associated non-Hodgkin's lymphoma: identification of a subgroup with favorable clinical outcome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blotting, Southern; CD4 Lymphocyte Count; | 1995 |
Effects of rhG-CSF on infection complications and impaired function of neutrophils secondary to chemotherapy for non-Hodgkin's lymphoma. Hokkaido Study Group of Malignant Lymphoma, and rhG-CSF, Japan.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cell Adhesion Molecules; Cyclophos | 1995 |
Acute myocardial infarction in man treated with epirubicin for non-Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Epirubicin; Humans; Lymphom | 1995 |
Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Cells; Bone Marr | 1995 |
Primary lymphoma of the mandible: report of a case.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Differential; Do | 1995 |
Non-Hodgkin's lymphoma in the old old.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 1995 |
Bone marrow transplantation versus chemotherapy in non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Thera | 1995 |
Bone marrow transplantation versus chemotherapy in non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Thera | 1995 |
Bone marrow transplantation versus chemotherapy in non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cyclophosphamide; Doxor | 1995 |
Control theory as a conceptual framework for intensive care monitoring.
Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Artificial Intell | 1995 |
[Daily oral low-dose etoposide therapy for aged patients with relapsed aggressive lymphoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Administra | 1995 |
CHOP versus m-BACOD in non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dexamethasone; Doxorubi | 1993 |
Primary chemotherapy for obstructive jaundice caused by intermediate-grade non-Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cholestasis; Cyclophosphamid | 1993 |
CHOP-Bleo plus interferon for stage IV low-grade lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined | 1993 |
Brief induction chemotherapy followed by involved-field irradiation for the treatment of localized intermediate- and high-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; C | 1993 |
Results of treatment of small non-cleaved cell lymphoma in patients without positive HIV serology.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cause of Death; Cyclophospha | 1993 |
Clinical trials referral resource. AIDS-related non-Hodgkin's lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Doxorubi | 1993 |
[Thyroid lymphoma in a 51-year-old woman].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bleomycin; Combined Modality Therapy | 1993 |
Successful treatment of non-Hodgkin's lymphoma in a patient with common variable immunodeficiency.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Common Variable Immunodeficiency; | 1993 |
[Treatment of high risk non-Hodgkin's lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Protocols; Cyclophosphamide; Dox | 1993 |
Stevens-Johnson syndrome associated with methotrexate treatment for non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Humans; Le | 1993 |
[High dose chemoradiotherapy and autologous bone marrow transplantation (ABMT) as a first line therapy to treat advanced adult high-grade malignant T-cell non-Hodgkin's lymphoma--a pilot clinical study].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplant | 1993 |
CHOP versus intensive regimens in non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Doxorubicin | 1993 |
Pulmonary toxicity in patients with non-Hodgkin's lymphoma treated with bleomycin-containing combination chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chi-Square Distr | 1993 |
Hodgkin's disease and non-Hodgkin's lymphoma in an HIV positive patient.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Cyclophosphamide; Dexametha | 1993 |
Gonadal function after MACOP-B or VACOP-B with or without dose intensification and ABMT in young patients with aggressive non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dose-Response Relations | 1993 |
[Treatment with ACVP-16 for relapsed and refractory non-Hodgkin's lymphoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplat | 1993 |
Treatment of poor prognosis non-Hodgkin's lymphoma with intensive, inpatient combination chemotherapy of brief duration: long-term followup.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1993 |
[COP-BLAM III regimen for elderly non-Hodgkin's lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubici | 1993 |
HIV-associated lymphoma of the gastrointestinal tract: the University of Toronto AIDS-Lymphoma Study Group experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Gastro | 1995 |
Testicular lymphoma: late relapses and poor outcome despite doxorubicin-based therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; | 1995 |
Primary non-Hodgkin's lymphoma of the mediastinum: a clinicopathological report of six cases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; | 1995 |
Recurrent lymphoma in a cardiac allograft recipient.
Topics: Azathioprine; Cyclosporine; Follow-Up Studies; Graft Rejection; Heart Transplantation; Humans; Lung | 1994 |
CHOP chemotherapy of intermediate and high-grade non-Hodgkin's lymphoma.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; F | 1994 |
[Evaluation of the method of treating non-Hodgkin's lymphoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclop | 1994 |
Low power and striking results--a surprise but not a paradox.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Confidence Intervals; C | 1995 |
[Non-hodgkin's malignant lymphoma in the uterine cervix].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 1993 |
Myelodysplastic syndrome after autologous transplant for lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Hematopoietic Stem Cell Transplantation; Hodgkin Dis | 1994 |
Scintigraphic flare in skeletal lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Doxorubicin | 1994 |
Aggressive non-Hodgkin's lymphoma in elderly patients: where to go from here?
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Su | 1994 |
Intermediate and high grade malignant non-Hodgkin's lymphomas: preliminary results using a new combination regimen (EVE-COPEM).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Epirubicin; Eto | 1993 |
Excretion of Ascaris lumbricoides during total body irradiation.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Ascariasis; Ascaris lumbricoides; Bo | 1994 |
Primary colonic lymphoma. Clinical presentation, histopathologic features, and outcome with combination chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 1994 |
Relapsing chickenpox in a young man with non-Hodgkin's lymphoma.
Topics: Acyclovir; Adult; Antineoplastic Combined Chemotherapy Protocols; Chickenpox; Cyclophosphamide; Doxo | 1994 |
Teniposide plus cytarabine as intensification therapy and in continuation therapy for advanced nonlymphoblastic lymphomas of childhood.
Topics: Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschool; Cyclophos | 1994 |
Long-term gonadal toxicity after therapy for Hodgkin's and non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclop | 1994 |
Interferon alfa plus chemotherapy for non-Hodgkin's lymphoma: five-year follow-up.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Follow-Up Studies; Hu | 1993 |
Pentostatin increases the acute toxicity of high dose cyclophosphamide.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carmustine; Cis | 1993 |
Stage IA non-Hodgkin's lymphoma of the Waldeyer's ring. Limited chemotherapy and radiation therapy versus radiation therapy alone.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyclophosphamid | 1993 |
[Effect of THP-CVP regimen for elderly patients with malignant lymphoma].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 1993 |
Early response monitoring in malignant lymphoma using fluorine-18 fluorodeoxyglucose single-photon emission tomography.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Deoxyglucose; Doxorubicin; | 1993 |
[Case histories of extranodal non-Hodgkin's lymphomas with primary gastrointestinal appearance].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modali | 1993 |
Primary malignant lymphoma of the uterus: localization in a cervical polyp.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cervix Uteri; Cyclophosphamide; Doxorubicin; | 1993 |
CHOP versus intensive regimens in non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Diseases; Cyclophosphamide; D | 1993 |
[Successful oral administration of etoposide therapy for refractory malignant lymphoma treated with frequent combination chemotherapy].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxoru | 1993 |
Long-term effects of vincristine on the peripheral nervous system.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; | 1993 |
Combination chemotherapy for intermediate and high grade non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 1993 |
Lomustine, etoposide, methotrexate and prednisone (LEMP) therapy for relapsed and refractory non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Lomustine; L | 1993 |
Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin's lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 1993 |
Primary peripheral nodal lymphoma in children.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Cyclophosphamide; Cytarabine; D | 1993 |
[Severe bleeding in a case of factor VIII inhibitor associated with intravascular lymphomatosis].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxor | 1993 |
[Spontaneous splenic rupture in a case of non-Hodgkin's lymphoma].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascites; Cyclophosphamide; Do | 1993 |
[Manifestation of malignant lymphomatous polyposis of the nasopharynx].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Endoscopy; Huma | 1993 |
High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Response Relatio | 1995 |
[Dysfunction of the blood-brain barrier in patients with acute leukemias or lymphomas of high grade malignancy].
Topics: Adolescent; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood- | 1995 |
[Non-Hodgkin's lymphoma in a patient after many years of remission of Hodgkin's disease].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Hodgkin Disease; Humans; Lymphoma, No | 1995 |
[Non-Hodgkin's lymphoma of the uterine cervix].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Lymph | 1995 |
Alpha-interferon and corticosteroids as initial treatment in small cleaved-cell lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Interferon Type I; Lymphoma, F | 1995 |
Is the small non-cleaved-cell lymphoma histologic subtype a poor prognostic factor in adult patients? A case-controlled analysis. The Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Case-Control Studies; | 1996 |
Combined therapy for primary central nervous system lymphoma in immunocompetent patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; | 1995 |
Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkin's lymphoma.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Contraindications; Cyclophosphamide; Cyta | 1996 |
VACOP-B chemotherapy for high grade non-Hodgkin's lymphoma in pregnancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Eto | 1995 |
Primary lymphoma of the esophagus in a patient with AIDS.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Doxorubicin; Esophageal Di | 1995 |
VAPEC-B chemotherapy in the treatment of aggressive non-Hodgkin's lymphoma: a retrospective analysis of 45 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubici | 1995 |
[Sarcoidosis-lymphoma syndrome in a woman with acromegaly].
Topics: Acromegaly; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; | 1995 |
Aggressive non-Hodgkin's lymphoma: long-term results of full dose CHOP chemotherapy, and analysis of prognostic determinant.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphami | 1996 |
Assessment of potential doubling time (Tpot), argyrophilic nucleolar organizer regions (AgNOR), and proliferating cell nuclear antigen (PCNA) as predictors of therapy response in canine non-Hodgkin's lymphoma.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Chloramb | 1996 |
Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors--Part one. Model projections for cost based on charges.
Topics: Antibiotics, Antineoplastic; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alky | 1996 |
Comparison of costs for infusion versus bolus chemotherapy administration--Part two. Use of charges versus reimbursement for cost basis.
Topics: Antibiotics, Antineoplastic; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alky | 1996 |
[Semen preservation and gonadal toxicity in the treatment of non Hodgkin lymphoma. Experience at the Gustave-Roussy Institute from 1980 to 1993].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Ther | 1996 |
[Assessment of cardiac toxicity by 123I-MIBG myocardial SPECT in elderly non-Hodgkin lymphoma patients treated with COP-BLAM and G-CSF].
Topics: 3-Iodobenzylguanidine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophospha | 1995 |
Effects of chemotherapy in patients with dental implants.
Topics: Abdominal Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dental | 1995 |
Prognosis of orbital lymphoid hyperplasia.
Topics: Anti-Inflammatory Agents; Chemotherapy, Adjuvant; Follow-Up Studies; Humans; Hyperplasia; Incidence; | 1996 |
Primary ovarian lymphoma with liver metastases: report of one case.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; | 1996 |
[Effect of granulocyte colony-stimulating factor after chemotherapy with CHOP in patients with non-Hodgkin's lymphoma and HIV infection].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Granul | 1996 |
Therapy-related leukemia with a novel 21q22 rearrangement.
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chromosomes, Human, Pair 21; | 1996 |
Chemotherapy-induced non-Hodgkin's lymphoma in a patient with Hodgkin's disease--a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bleomycin; Cyclophosphamide; D | 1996 |
Value of the determination of TNF-alpha in the plasma of patients with non-Hodgkins lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers, Tumor; Cyclo | 1996 |
[Low-grade non-Hodgkin's lymphoma: intensive combined chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubici | 1996 |
Chemotherapy with MECOP-B for intermediate-grade and high-grade non-Hodgkin's lymphoma in Saudi Arabia: clinical results and analysis of prognostic factors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Humans; Le | 1996 |
Cervical spontaneous epidural hematoma as a complication of non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Hematoma, | 1996 |
Exacerbation of hepatitis in hepatitis B carriers following chemotherapy for haematological malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carrier State; Chronic Disea | 1996 |
EBV-positive non-Hodgkin's lymphoma developing after phenytoin therapy.
Topics: Anticonvulsants; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 1996 |
[Treatment of aggressive non Hodgkin's lymphoma: the experience of a general hospital].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Cyclophos | 1996 |
The effects of antineoplastic chemotherapy on HIV disease.
Topics: Antineoplastic Agents; CD4 Lymphocyte Count; CD8 Antigens; Clinical Trials, Phase III as Topic; Cycl | 1996 |
Acute hepatic injury after discontinuation of chemotherapy in a patient with non-Hodgkin's lymphoma and chronic hepatitis B virus infection.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cyclophosphamide; H | 1996 |
Granulocyte-colony stimulating factor fails to prevent leucopenia caused by CEMP in elderly patients with aggressive lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide | 1996 |
[Diagnosis and therapeutic management of gastric lymphomas].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 1996 |
Treatment for non-Hodgkin's lymphoma (stage I, II) of the elderly: usefulness of local and regional irradiation and reduced dose chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modalit | 1997 |
Resolution of HIV-associated cystic benign lymphoepithelial lesion of the parotid gland in a patient undergoing chemotherapy for non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cyclophosphamide; Cysts; Didanosin | 1996 |
A pilot study on the use of the ProMACE-CytaBOM regimen as a first-line treatment of advanced follicular non-Hodgkin's lymphoma. Gruppo Italiano per lo Studio dei Linfomi.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Doxo | 1997 |
Tumour inhomogeneities on magnetic resonance imaging, a new factor with prognostic information in non-Hodgkin's lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphami | 1997 |
[Gastrointestinal lymphomas: results of multimodal therapy in 57 patients of one center].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; C | 1996 |
Caecocystoplasty and bilateral oophorectomy followed by chemotherapy for diffuse, non-Hodgkins lymphoma of the ovary involving the bladder. Case report.
Topics: Anastomosis, Surgical; Antineoplastic Combined Chemotherapy Protocols; Cecum; Chemotherapy, Adjuvant | 1997 |
CD3- CD56+ non-Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette T | 1997 |
Combination of chemotherapy and antiviral therapy for Epstein-Barr virus-associated non-Hodgkin's lymphoma of high grade malignancy in cases of HIV infection.
Topics: Acyclovir; Adult; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Bleomycin; Burki | 1997 |
Five-year follow-up of saliva in patients treated for lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Amylases; Analysis of Variance; Antineoplastic Combined Ch | 1997 |
Non-Hodgkin's lymphoma presenting as thyroid and adrenal gland involvement.
Topics: Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cyclophosph | 1997 |
[Primary non-Hodgkin's lymphoma of the prostate].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Differe | 1996 |
Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma.
Topics: Adult; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; C | 1997 |
Late relapse in patients with diffuse large-cell lymphoma treated with MACOP-B.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bleomycin; Cyclophosphamid | 1997 |
Primary non-Hodgkin's lymphoma of the maxillary sinus.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 1997 |
Mobilization of peripheral blood progenitor cells following CHOP treatment combined with delayed granulocyte colony-stimulating factor administration in patients with non-Hodgkin's lymphoma.
Topics: Adolescent; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Movement; Colony | 1996 |
Combination of etoposide, idarubicin, cyclophosphamide, vincristine, prednisone and bleomycin (VICOP-B) in the treatment of advanced cutaneous T-cell lymphoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Al | 1997 |
Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Gallium Radioisotopes | 1997 |
[Treatment results and prognostic significance of selected clinical and laboratory features in children diagnosed with malignant lymphoma].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bleomycin; Child; Child, P | 1996 |
[Tumor lysis syndrome after treatment for mediastinal non-Hodgkin's lymphoma].
Topics: Acute Disease; Acute Kidney Injury; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cycl | 1997 |
Acute renal failure due to lymphomatous infiltration of the kidneys.
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Creatinine; Cyclophosphamide; D | 1997 |
High incidence of secondary myelodysplastic syndromes following PROMACE-MOPP and involved field radiotherapy for localized gastric non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Doxorubi | 1996 |
[Malignant lymphoma of the testis: report of two cases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Administration S | 1997 |
Acute exacerbation of hepatitis due to reactivation of hepatitis B virus with mutations in the core region after chemotherapy for malignant lymphoma.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; DNA | 1997 |
THP-COPBLM (pirarubicin, cyclophosphamide, vincristine, prednisone, bleomycin and procarbazine) regimen combined with granulocyte colony-stimulating factor (G-CSF) for non-Hodgkin's lymphoma in elderly patients: a prospective study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1997 |
A new effective treatment for indolent lymphoma: a pilot study with fludarabine, idarubicin and prednisone combination (FLIDA).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Idarubicin; | 1997 |
[Cutaneous B-cell lymphoma with aggressive clinical presentation: apropos of a case].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 1997 |
[Etoposide combination chemotherapy for malignant lymphoma: a report of 91 cases].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Cyclophos | 1996 |
Primary hepatic high-grade non-Hodgkin's lymphoma and chronic hepatitis C infection.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cyclophosp | 1997 |
Side effects of CHOP in the treatment of non-hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 1997 |
High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; | 1998 |
Non-Hodgkin's lymphoma trials in elderly look beyond CHOP.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Hu | 1998 |
[Interstitial pneumonia in patients treated with VACOP-B therapy for malignant lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubici | 1998 |
Fatal leukoencephalopathy in a patient with non-Hodgkin's lymphoma treated with CHOP chemotherapy and high-dose steroids.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Cyclophosphamide; Doxorubicin; Fatal | 1998 |
[Long term results of treatment of highly-malignant non-Hodgkin lymphoma in the elderly (70 years and older)].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chemotherapy, Ad | 1998 |
[Surgical therapy of non-Hodgkin lymphoma of the stomach].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Chemotherapy, Adjuvant; Combine | 1998 |
Fatal CMV pneumonia associated with steroid therapy after autologous transplantation in patients previously treated with fludarabine.
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; C | 1998 |
Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome.
Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cohort Studies; Cyc | 1998 |
Levels of proteins C and S do not decline subsequent to first line chemotherapy in lymphoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; alpha-2-Antiplasmin; Antineoplastic Combined Chemotherap | 1997 |
Alkalinization and the tumor lysis syndrome.
Topics: Adolescent; Bicarbonates; Fluid Therapy; Furosemide; Humans; Hypocalcemia; Lymphoma, Non-Hodgkin; Ma | 1998 |
Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphami | 1998 |
Expression of p53 predicts treatment failure in aggressive non-Hodgkin's lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Gene Expressi | 1998 |
High incidence of chemotherapy-induced acral erythema in female patients with non-Hodgkin's lymphoma treated with the VACOP-B regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dose-Response Relations | 1998 |
Intravascular lymphomatosis--an indolent or aggressive entity?
Topics: Aged; Arthritis, Rheumatoid; Asthma; Blood Sedimentation; Bone Marrow; Brain Neoplasms; Disease Prog | 1998 |
Chemoradiotherapy for localized non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease | 1998 |
Diagnosis and treatment of malignant lymphoma of the parotid gland.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclopho | 1998 |
Peripheral blood stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Doxo | 1998 |
Prolonged disease-free survival in relapsed/refractory low-grade lymphoma treated with fludarabine: a report of four cases.
Topics: Adult; Anthracyclines; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 1998 |
[Urinary enzymes during some antiblastic chemotherapy protocols].
Topics: alpha-Glucosidases; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers | 1983 |
Pirarubicin-induced myocardial damage in elderly patients with non-Hodgkin's lymphoma.
Topics: 3-Iodobenzylguanidine; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined | 1998 |
Biweekly THP-COPBLM (pirarubicin, cyclophosphamide, vincristine, prednisone, bleomycin and procarbazine) regimen combined with granulocyte colony-stimulating factor (G-CSF) for intermediate- and high-grade non-Hodgkins's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubici | 1998 |
[Prognostic factors in low-grade lymphoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; B | 1998 |
[Non-Hodgkin malignant lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 1998 |
Long-term follow-up of non-Hodgkin's lymphoma patients treated with ProMACE-CytaBOM: an effective regimen for the intermediate grade subtype.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine | 1998 |
Fludarabine-related hemolytic anemia in chronic lymphocytic leukemia and lymphoproliferative disorders.
Topics: Aged; Anemia, Hemolytic; Antimetabolites, Antineoplastic; Humans; Immunosuppressive Agents; Incidenc | 1998 |
Treatment of intermediate-grade and high-grade non-Hodgkin's lymphoma.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 1998 |
Treatment of intermediate-grade and high-grade non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 1998 |
Treatment of intermediate-grade and high-grade non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Confounding Factors, Epid | 1998 |
Treatment of intermediate-grade and high-grade non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 1998 |
[A case of primary hepatic lymphoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; | 1998 |
Fatal myelofibrosis following fludarabine administration in a patient with indolent lymphoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; D | 1998 |
Central retinal vein occlusion in a patient with IgG lambda monoclonal gammopathy.
Topics: Aged; Bone Marrow; Chlorambucil; Drug Therapy, Combination; Fluorescein Angiography; Humans; Hyperga | 1999 |
Paraneoplastic pemphigus as the presenting symptom of a lymphoma of the tongue.
Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Azathioprine; Cyclop | 1998 |
Primary epidural non-Hodgkin lymphoma: spinal cord compression syndrome as the initial form of presentation in childhood non-Hodgkin lymphoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Daunorubicin; D | 1999 |
Combined radiation and chemotherapy in posttransplant lymphoproliferative disorder.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 1998 |
Simultaneous occurrence of chronic myelogenous leukemia and non-Hodgkin lymphoma at diagnosis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Doxorubicin; F | 1999 |
[Clinical outcomes in low grade follicular lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; C | 1999 |
Cutaneous and subcutaneous necrosis following dexrazoxane-CHOP therapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Agents; Cyclophosphamide; Doxo | 1999 |
High-grade non-Hodgkin's lymphoma treated in northern Norway--treatment, outcome, and prognostic factors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined | 1999 |
Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 1999 |
Non-surgical CHOP cures right ventricular outflow obstruction.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Echocardiograp | 1999 |
Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cyclophosphamid | 1999 |
Synovial presentation of non-Hodgkin's lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Differential; Dox | 1998 |
Non-Hodgkin's lymphoma of the lacrimal sac and concomitant pansinusitis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 1998 |
Non-Hodgkin's lymphoma of the maxillary sinus in a patient with acquired immunodeficiency syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiprotozoal Agents; Cyclophosphamide; Doxorubicin; | 1998 |
[Dose reduction is not recommended for elderly patients undergoing chemotherapy for non-Hodgkin lymphoma].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Protocols; Cycloph | 1999 |
Small noncleaved, non-Burkitt's (Burkit-Like) lymphoma: cytogenetics predict outcome and reflect clinical presentation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 1999 |
Second lung adenocarcinoma after combination chemotherapy in two patients with primary non-Hodgkin's lymphoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclopho | 1999 |
[Exacerbation of hepatitis B and the expression of M proteinemia during the treatment of malignant lymphoma: a case study].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carrier State; Cyclophosphamide; Doxorubicin; | 1999 |
The impact of radiotherapy dose and other treatment-related and clinical factors on in-field control in stage I and II non-Hodgkin's lymphoma.
Topics: Actuarial Analysis; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combine | 1999 |
Hypophyseal non-Hodgkin's lymphoma presenting with diabetes insipidus: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Diabetes Insipidus; Dox | 1999 |
Unique alterations of thyroid function parameters after i.v. administration of alkylating drugs (cyclophosphamide and ifosfamide).
Topics: Adult; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexameth | 1999 |
[Statistical analysis of localized non-Hodgkin's lymphomas of the head and neck--multivariate analysis of prognostic factors and evaluation of therapeutic modalities].
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protoc | 1999 |
The usefulness of in vivo gene expression investigations from peripheral white blood cells: a preliminary study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cyclophosphamide; Doxorubicin; | 1999 |
Delivery of full dose CHOP chemotherapy to elderly patients with aggressive non-Hodgkin's lymphoma without G-CSF support.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disea | 1999 |
[Malignant lymphoma: magnetic resonance tomography findings in residual supradiaphragmatic space-occupying lesions].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; | 1999 |
Adult head and neck lymphomas in Papua New Guinea: a retrospective study of 70 cases.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Combined Modali | 1999 |
Response and adverse drug reactions to combination chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma: comparison of CHOP, COP-BLAM, COP-BLAM III, and THP-COPBLM.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1999 |
Primary non-Hodgkin's lymphoma of bone: a clinicopathological investigation of 60 cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neo | 1999 |
Non-Hodgkin's lymphoma: present status and future prospects.
Topics: Adult; Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Ag | 1999 |
High-dose therapy with autologous stem-cell transplantation in aggressive non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Consensus Development Conferences as Topic; Cyclopho | 1999 |
Stem cell transplantations in patients with malignant lymphoma: costs in a Dutch university hospital in the period 1984-1995.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Transfusion; Bone Marrow Tra | 1999 |
Non-Hodgkin's lymphoma following untreated essential thrombocythemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans | 2000 |
DNA flow cytometry of non-Hodgkin's lymphomas: correlation with cytologic grade and clinical relapse.
Topics: Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cyclophosphamide; DNA, N | 2000 |
When is hilar uptake of 67Ga-citrate indicative of residual disease after CHOP chemotherapy?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Citrates; Cyclophosphamide; Doxorubicin; Fema | 2000 |
[A case of non-Hodgkin lymphoma in the central nervous system, developing during treatment of galactorrhea amenorrhea syndrome].
Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; | 1999 |
[Two cases of orbital non-Hodgkin's lymphoma presenting with hemophagocytic syndrome].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Histiocytosis, | 2000 |
Translocation (1;11)(q23;p15), a novel simple variant of translocation (7;11)(p15;p15), in a patient with AML (M2) accompanied by non-Hodgkin lymphoma and gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chromosomes, Human, Pair 1; Chromosomes, | 2000 |
A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclopho | 2000 |
[Characteristics of blood cells during peripheral blood stem cell mobilization following chemotherapy in patients with non-Hodgkin's lymphoma].
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxor | 2000 |
[The analysis of failures in the treatment of children with non-B non-Hodgkin's lymphoma. Polish pediatric leukemia/lymphoma study group report].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 1998 |
Intravascular lymphomatosis: contribution of cerebral MRI findings to diagnosis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Central Nervous System Neoplasms; Cyclo | 2000 |
Predictive factors for central nervous system involvement in non-Hodgkin's lymphoma: significance of very high serum LDH concentrations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bleomycin; Central Nervous System | 2000 |
Secondary cutaneous infiltration in B cell chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Doxorubicin; Histidi | 2000 |
Human immunodeficiency virus-associated malignant lymphoma in eastern Denmark diagnosed from 1990-1996: clinical features, histopathology, and association with Epstein-Barr virus and human herpesvirus-8.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Denmark; DNA, Viral; Doxoru | 2000 |
[Ten-case report on primary cervical lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Cyclophosphamide; Doxoru | 1997 |
[Comparison of CHEP and CHOP chemotherapy in the management of non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Do | 1997 |
[Multivariate analysis on prognostic factors of non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Do | 1997 |
Pseudomembranous colitis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonoscopy; Cyclophosphamide; Enterocolitis, | 2000 |
Tumor bulk as a prognostic factor for the management of localized aggressive non-Hodgkin's lymphoma: a survey of the Japan Lymphoma Radiation Therapy Group.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 2000 |
In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antine | 2000 |
Clinical significance of simultaneous determination of serum soluble transferrin receptor, soluble Fas, soluble Fas ligand, hepatocyte growth factor and interleukin 18 levels in a patient with hemophagocytic syndrome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; | 2000 |
Acute deterioration of Charcot-Marie-Tooth disease IA (CMT IA) following 2 mg of vincristine chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Charcot-Marie-Tooth Disease; Cyclophosphamide; Doxor | 2000 |
Follow-up of sperm concentration and motility in patients with lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cryopreservation; Daca | 2000 |
Intensive chemotherapy (LNHIV-91 regimen) and G-CSF for HIV associated non-Hodgkin's lymphoma.
Topics: Actuarial Analysis; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; CD4 Lymphocyte | 2000 |
Interferon does not prolong progression-free survival after ProMACE-MOPP.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Cyclophosphamid | 2000 |
[Treatment outcome in elderly patients with aggressive non-Hodgkin's lymphoma].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 2000 |
Impact of involved field radiotherapy after CHOP-based chemotherapy on stage III-IV, intermediate grade and large-cell immunoblastic lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2000 |
Dose-escalation study of CHOP with or without prophylactic G-CSF in aggressive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 2000 |
Autologous bone marrow transplantation for aggressive non-Hodgkin's lymphoma: lessons learned and challenges remaining.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chemotherapy, Adjuvant; | 2001 |
Dose-response analysis for radiotherapy delivered to patients with intermediate-grade and large-cell immunoblastic lymphomas that have completely responded to CHOP-based induction chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined | 2001 |
A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 2001 |
Primary central nervous system lymphoma in childhood presenting as progressive panhypopituitarism.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Cyta | 2001 |
Cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy and radiotherapy for stage I intermediate or high grade non-Hodgkin's lymphomas: results of a strategy that adapts radiotherapy dose to the response after chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2001 |
Bilateral testicular lymphoma treated with chemotherapy and radiation without orchiectomy: complete response relapsed at 52 months in the vitreous humor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 2001 |
Lenograstim and filgrastim effects on neutrophil motility in patients undergoing chemotherapy: evaluation by computer-assisted image analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; CD18 Antigens; Cell Movement; Chemotaxis, | 2001 |
Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Cyclop | 2001 |
HIV-associated non-Hodgkin lymphoma: incidence, presentation, and prognosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Biopsy, Needl | 2001 |
Hypopyon uveitis and iris nodules in non-Hodgkin's lymphoma: ocular relapse during systemic remission.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Eye Neoplasms; | 2000 |
Nasal natural killer-cell lymphoma: a disease with very poor prognosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Debride | 2000 |
Treatment of elderly patients with intermediate- and high-grade non-Hodgkin's lymphoma: a retrospective population-based study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; | 2001 |
Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amifostine; Antihypertensive Agents; Antineoplastic Com | 2001 |
Primary pelvic non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Fr | 2001 |
Chlorambucil/prednisone-induced seizures in a patient with non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Drug | 2001 |
Reduced-dose chop therapy for elderly patients with non-Hodgkin's lymphoma.
Topics: Actuarial Analysis; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Proto | 2001 |
Primary effusion lymphoma (PEL) in HIV-negative patients--a distinct clinical entity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chest Pain; Cyclophosphamide; DNA, Viral; Doxo | 2001 |
T-cell lymphoma in the parotid region after cardiac transplant: case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Heart Transpla | 2001 |
Synchronous colonic tumours of dual pathology.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cecal Neoplasms; Colectomy; Co | 2001 |
Magnetic resonance imaging detection of avascular necrosis of the bone in children receiving intensive prednisone therapy for acute lymphoblastic leukemia or non-Hodgkin lymphoma.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Arthroplasty, R | 2001 |
Non-Hodgkin's lymphoma of the ocular adnexa.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2001 |
Prognostic variables in canine multicentric lymphosarcoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Do | 2001 |
The effect of optimal treatment on elderly patients with aggressive non-Hodgkin's lymphoma: more patients treated with unaffected response rates.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 2001 |
Transformation of Hodgkin's disease to high-grade B-cell lymphoma: remission after Rituximab monotherapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2001 |
[Evaluation of non-surgical therapy for the malignant lymphomas located mainly in the stomach and duodenum].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2001 |
Primary malignant lymphoma of the prostate--a report of three cases.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 2001 |
Remarkable response to rituximab in a 72-year-old patient with refractory non-Hodgkin's lymphoma and marrow aplasia.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineo | 2001 |
Epstein-Barr virus associated diffuse large B-cell lymphoma complicated by autoimmune hemolytic anemia and pure red cell aplasia.
Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Combined Chemotherapy Protocols; Combined Modality The | 2001 |
Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-F | 2001 |
Non-Hodgkin's lymphoma affecting the testis: is it curable with doxorubicin-based therapy?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclo | 2001 |
The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Res | 2001 |
6th European Hematology Association Meeting. Frankfurt, Germany. June 21-24, 2001.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2001 |
Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cy | 2001 |
Lymphoma 2000. The First International Symposium on Biology and Treatment of Aggressive Lymphomas: The stagnation seems to be over.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2001 |
Hematological malignancies and pregnancy: a final report of 84 children who received chemotherapy in utero.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Behavior; Bleomyci | 2001 |
Results with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone followed by radiotherapy with or without prechemotherapy surgical debulking for patients with bulky, aggressive lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Clinical Trials as Topic | 2002 |
[Superior mesenteric venous thrombosis during treatment of malignant lymphoma and of pure red cell aplasia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Lymph | 2002 |
Non-Hodgkin's lymphoma with pure red cell aplasia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cyclophosphamide; Doxorubicin | 2001 |
Primary anorectal lymphoma presenting as a perianal abscess in an HIV-positive male.
Topics: Abscess; Adult; Antineoplastic Combined Chemotherapy Protocols; Anus Diseases; Biopsy, Needle; Cyclo | 2002 |
[Non-Hodgkin's lymphoma of the uterus: apropos of 4 cases and review of the literature].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cervix Uteri; Cyclophosphamide; Diagno | 2002 |
The role of molecular monitoring in autotransplantation for non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow; B | 2002 |
Bilateral peripheral facial palsy secondary to lymphoma in a patient with HIV/AIDS: a case report and literature review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Facial Paralys | 2002 |
Assessment of drug activity and proliferation ex vivo for prediction of outcome in aggressive non-Hodgkin's lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biopsy; Bleomycin; Cell Division; Cycl | 2002 |
Multi-modality therapy leads to longer survival in primary central nervous system lymphoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2002 |
Remitting seronegative symmetrical synovitis with pitting oedema: a study of 12 cases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Colectomy; Colorectal Neoplasms; Ede | 2002 |
Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosp | 2002 |
Neutrophil-rich Ki-1-positive anaplastic large cell lymphoma: a study by fine-needle aspiration biopsy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma; Cyclophosphamide; | 2002 |
Colovesical fistula an unusual complication of cytotoxic therapy in a case of non-Hodgkin's lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Epiglottis; Hum | 2001 |
Non-Hodgkin's malignant lymphomata in adults: chemo-radiotherapy in stages III and IV.
Topics: Adult; Antineoplastic Agents; Azirines; Bleomycin; Cyclophosphamide; Daunorubicin; Etoposide; Female | 1975 |
[Immunological aspects in the L-asparaginase treatment of children with lymphoproliferative diseases].
Topics: Adolescent; Anaphylaxis; Antibodies; Antibody Specificity; Asparaginase; Child; Child, Preschool; Hu | 1976 |
Cyclophosphamide, vincristine, and prednisone (CVP) versus adriamycin, bleomycin, and prednisone (ABP) in stage IV non-Hodgkin's lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bleomycin; Child; Cyclophosphamide; Doxorubicin; Dru | 1977 |
Imidazole carboxamide (DTIC) in the treatment of advanced lymphomas. Efficacy of DTIC in cases which fail to respond to conventional chemotherupetic combinations.
Topics: Adult; Bleomycin; Cyclophosphamide; Dacarbazine; Drug Evaluation; Drug Resistance; Drug Therapy, Com | 1977 |
[Chemotherapy in non-Hodgkin's lymphomas (author's transl)].
Topics: Antineoplastic Agents; Bleomycin; Burkitt Lymphoma; Chlorambucil; Cyclophosphamide; Doxorubicin; Dru | 1977 |
The Sézary syndrome. A case with fetal-type glycogen and lymphocytic lymphoma.
Topics: Chlorambucil; Cytoplasmic Granules; Dermatitis, Exfoliative; Glycogen; Humans; Lymphoma, Non-Hodgkin | 1978 |
[A case of infiltrating type of lymphosarcoma with remission of 3 and a half years' duration].
Topics: Adrenocorticotropic Hormone; Brain Neoplasms; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Peni | 1975 |
Combination of cyclophosphamide, vincristine, and prednisone, followed by maintenance chemotherapy, with and without radiotherapy, in the management of patients with non-Hodgkin's lymphomas.
Topics: Adolescent; Adult; Aged; Cyclophosphamide; Drug Therapy, Combination; Humans; Lymphoma, Large B-Cell | 1977 |
Intraocular reticulum cell sarcoma: its dramatic response to systemic chemotherapy and its angiogenic potential.
Topics: Aged; Ciliary Body; Cyclophosphamide; Drug Therapy, Combination; Eye Neoplasms; Female; Glaucoma; Hu | 1977 |
Histiocytic lymphoma of B cell origin.
Topics: B-Lymphocytes; Cell Membrane; Humans; Immunoglobulins; Lymphoma, Large B-Cell, Diffuse; Lymphoma, No | 1977 |
[Combination of adriamycin, VM 26, cyclophosphamide and prednisone in the treatment of hematosarcomas].
Topics: Adolescent; Adult; Aged; Cyclophosphamide; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; | 1977 |
[Therapy of non-Hodgkin lymphomas with COP and COPP regimens (author's transl)].
Topics: Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Humans; Lymphoma; Lymphoma, Larg | 1977 |
Non-Hodgkin's lymphoma in children.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Cyclophosphamide; Drug Therapy, Combinat | 1978 |
Combined modality therapy for advanced, diffuse lymphocytic and histiocytic lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow; Cyclophosphamide; Doxorubicin; Drug The | 1978 |
Improvement in complete response rate, duration of response and survival with adriamycin combination chemotherapy for non-Hodgkin lymphoma: a prognostic factor comparison of two regimens.
Topics: Antineoplastic Agents; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Humans; Lym | 1978 |
Steroid-induced femoral head necrosis.
Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Female; Femur Head Necrosis; Humans; Lymphoma, Non-H | 1977 |
Development of a lymphocytic lymphoma during immunosuppressive therapy with azathioprine for systemic lupus erythematosus with renal involvement induced by phenylbutazone.
Topics: Azathioprine; Female; Humans; Kidney Diseases; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin; | 1977 |
Lymphocele. A complication of cancer chemotherapy.
Topics: Aged; Antineoplastic Agents; Cyclophosphamide; Cysts; Drug Therapy, Combination; Female; Humans; Lym | 1978 |
Leukocyte migration inhibition responses in canine lymphosarcoma.
Topics: Animals; Antigens, Neoplasm; BCG Vaccine; Cell Migration Inhibition; Cyclophosphamide; Dogs; Immuniz | 1978 |
Diffuse well-differentiated lymphocytic lymphoma (DLWD): response and survival.
Topics: Aged; Antineoplastic Agents; Carmustine; Cell Differentiation; Chlorambucil; Cyclophosphamide; Drug | 1978 |
Improved prognosis for patients with mediastinal lymphoblastic lymphoma.
Topics: Adolescent; Adult; Child; Child, Preschool; Doxorubicin; Drug Therapy, Combination; Female; Humans; | 1979 |
Total body irradiation and cyclophosphamide, vincristine, prednisone in the treatment of favorable prognosis non-Hodgkin's lymphomas.
Topics: Adult; Antineoplastic Agents; Bone Marrow; Cyclophosphamide; Drug Therapy, Combination; Female; Huma | 1979 |
[Adriamycin, VM 26, cyclophosphamide and prednisone (AVmCP) combination in the therapy of disseminated lymphoreticulosarcoma (Stages or topographical forms III and IV].
Topics: Adolescent; Adult; Aged; Child; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Drug Toler | 1975 |
Non-Hodgkin's lymphomas-present status of chemotherapy.
Topics: Adult; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Humans; Lymphoma; Lymphoma, Large B | 1975 |
[Combination chemotherapy and synchronization therapy in lymphogranulomatosis and non-Hodgkin's lymphomas].
Topics: Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Hodgkin Disease; Humans; Lymphom | 1976 |
[Cyclophosphamide-vincristine-prednisone combination in the treatment of lympho- and reticulosarcomas in adults (60 cases)].
Topics: Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Lymphoma, Large B-Cell | 1976 |
Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma.
Topics: Cyclophosphamide; Cytarabine; Doxorubicin; Drug Therapy, Combination; Female; Humans; Lymphoma; Lymp | 1976 |
Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma.
Topics: Cyclophosphamide; Cytarabine; Doxorubicin; Drug Therapy, Combination; Female; Humans; Lymphoma; Lymp | 1976 |
Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma.
Topics: Cyclophosphamide; Cytarabine; Doxorubicin; Drug Therapy, Combination; Female; Humans; Lymphoma; Lymp | 1976 |
Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma.
Topics: Cyclophosphamide; Cytarabine; Doxorubicin; Drug Therapy, Combination; Female; Humans; Lymphoma; Lymp | 1976 |
Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma.
Topics: Cyclophosphamide; Cytarabine; Doxorubicin; Drug Therapy, Combination; Female; Humans; Lymphoma; Lymp | 1976 |
Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma.
Topics: Cyclophosphamide; Cytarabine; Doxorubicin; Drug Therapy, Combination; Female; Humans; Lymphoma; Lymp | 1976 |
Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma.
Topics: Cyclophosphamide; Cytarabine; Doxorubicin; Drug Therapy, Combination; Female; Humans; Lymphoma; Lymp | 1976 |
Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma.
Topics: Cyclophosphamide; Cytarabine; Doxorubicin; Drug Therapy, Combination; Female; Humans; Lymphoma; Lymp | 1976 |
Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma.
Topics: Cyclophosphamide; Cytarabine; Doxorubicin; Drug Therapy, Combination; Female; Humans; Lymphoma; Lymp | 1976 |
Malignant lymphoma presenting as unilateral exophtalmos and thyroid nodule (author's transl)
Topics: Axilla; Exophthalmos; Heart Neoplasms; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Male; Mechlorethamin | 1975 |
Comparison of intensive versus moderate chemotherapy of lymphocytic lymphomas: a progress report.
Topics: Adult; Aged; Chlorambucil; Cyclophosphamide; Drug Combinations; Ethylnitrosourea; Evaluation Studies | 1976 |
Early responses to chemotherapy detected by pulse cytophotometry.
Topics: Adult; Antineoplastic Agents; Asparaginase; Bone Marrow; Bone Marrow Cells; Cell Division; Child; Cy | 1976 |
A comparison of cyclophosphamide, vincristine, and prednisone (COP) with nitrogen mustard, vincristine, procarbazine, and prednisone (MOPP) in the treatment of nodular, poorly differentiated, lymphocytic lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Female; Humans; Lymphoma, Non-Hodgkin; Male; M | 1976 |
Cyclophosphamide therapy and interstitial pulmonary fibrosis.
Topics: Adult; Aged; Child, Preschool; Cyclophosphamide; Drug Therapy, Combination; Female; Hodgkin Disease; | 1976 |
Pancreatic carcinoma as a sequel to therapy of lymphoma.
Topics: Adenocarcinoma; Adolescent; Adult; Antineoplastic Agents; Carmustine; Cyclophosphamide; Female; Hodg | 1976 |
Non-Hodgkin's lymphoma: patterns of relapse from complete remission after combination chemotherapy.
Topics: Antineoplastic Agents; Bone Marrow; Cyclophosphamide; Drug Therapy, Combination; Humans; Lymph Nodes | 1975 |
Reversible achalasia due to reticulum-cell sarcoma.
Topics: Aged; Deglutition Disorders; Esophageal Achalasia; Esophageal Neoplasms; Gallium Radioisotopes; Huma | 1975 |
Trichlortriethylamine (TS-160 Spofa) in combination chemotherapy of malignant lymphomas.
Topics: Adult; Aged; Antineoplastic Agents; Drug Therapy, Combination; Female; Hodgkin Disease; Humans; Lymp | 1975 |
Combined cyclophosphamide vincristine, procarbazine, and prednisone (COPP) therapy of malignant lymphoma. Evaluation of 190 patients.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cyclophosphamide; Drug Therapy, Combination; Femal | 1975 |
[Cytostatic therapy of primary lympho- and reticulosarcoma of the stomach].
Topics: Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Humans; Lymphoma, N | 1975 |
Results of combination chemotherapy of non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Humans; Lymphoma; Lymphoma, Larg | 1975 |
The influence of chemotherapy on the management of non-Hodgkin's lymphomata at the Princess Margaret Hospital. A comparison of the results from 1962-64 with 1967-69.
Topics: Adult; Aged; Cyclophosphamide; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgki | 1975 |
Letter: Reticulum-cell sarcoma and Sjögren's syndrome in a patient treated with azathioprine.
Topics: Azathioprine; Female; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Prednisone; Sjogren's Syndrome | 1976 |
Infiltrative retinopathy in systemic lymphoma.
Topics: Cobalt; Cyclophosphamide; Eye Neoplasms; Female; Fluorescein Angiography; Fundus Oculi; Humans; Ison | 1975 |
Protein-losing enteropathy in lymphoma of the small intestine.
Topics: Adult; Biopsy; Cyclophosphamide; Humans; Intestinal Neoplasms; Intestine, Small; Lymphocytes; Lympho | 1975 |
Subacute thyroiditis associated with lymphosarcoma of the thyroid.
Topics: Autopsy; Biopsy; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Precancerous Conditions; Predniso | 1975 |
Lymphosarcoma of the right atrium. Angiographic and hemodynamic documentation of response to chemotherapy.
Topics: Adult; Angiocardiography; Cardiac Catheterization; Coronary Circulation; Heart Atria; Heart Neoplasm | 1975 |
Hemodialysis for acute anuric uric acid nephropathy.
Topics: Abdominal Neoplasms; Acute Kidney Injury; Allopurinol; Child; Cyclophosphamide; Humans; Lymphoma, No | 1975 |
Hemolytic anemia with IgG and IgM autoantibodies and allontibodies.
Topics: Aged; Anemia, Hemolytic, Autoimmune; Autoantibodies; Blood Transfusion; Humans; Immunoglobulin G; Im | 1975 |
Orbital inflammatory pseudo-tumours: immunological aspects.
Topics: Aged; Diagnosis, Differential; Eye Diseases; Female; Humans; Immunoglobulin M; Inflammation; Lymphom | 1975 |
Chemotherapy with MACOP-B and VACOP-B for intermediate- and high-grade non-Hodgkin's lymphoma: clinical results and analysis of prognostic factors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1992 |
[Primary non-Hodgkin's lymphoma of paranasal sinuses. Review of the literature and a case report].
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyc | 1992 |
Right ventricular outflow tract obstruction due to extrinsic compression by non-Hodgkin's lymphoma: importance of echocardiographic diagnosis and follow up.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin | 1992 |
Impairment of peripheral nervous system in patients with non-Hodgkin's lymphomas treated with CBVPM/AVBP and CHOP schedules.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1992 |
The clinical use of RHG-CSF for malignant lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Administration S | 1992 |
Salivary flow and composition in lymphoma patients before, during and after treatment with cytostatic drugs.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 1992 |
[Vibrio cholerae can be encountered even at home].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Female; Hu | 1991 |
A combination of mitoxantrone, etoposide and prednisone in elderly patients with non-Hodgkin's lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; | 1992 |
[Non-Hodgkin lymphoma with Ki-1 antigen: a case report].
Topics: Aged; Aged, 80 and over; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Prot | 1992 |
Treatment and prognosis of orbital non-Hodgkin's lymphomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chlorambucil; Cyclophosphamide; Cyt | 1992 |
Constitutional translocation (8;13) in a patient with non-Hodgkin's lymphoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Chromosome Bandi | 1992 |
[Value of MACOP B polychemotherapy for malignant non-Hodgkin's lymphomas in AIDS infected patients].
Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin | 1992 |
[Progress in hematological malignancy of aged--therapy of malignant lymphoma in aged].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1992 |
Clinical and prognostic significance of monoclonal small cells in the peripheral blood and bone marrow of various B-cell lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Cyclophosphamide; Doxorubici | 1992 |
Successful treatment of primary gastric non-Hodgkin's lymphoma with chemotherapy and radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphami | 1992 |
Fulminant hepatic failure in non-Hodgkin lymphoma patients treated with chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chemical and Drug Induced Li | 1992 |
[Treatment of elderly patients with hematological malignancies].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modalit | 1992 |
Treatment of diffuse non-Hodgkin's lymphoma with combined chemotherapy using methotrexate, adriamycin, cyclophosphamide, vincristine, prednisolone and bleomycin (MACOP-B).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1992 |
Non-Hodgkin's lymphomas: a review of the M.D. Anderson experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin | 1992 |
Primary malignant lymphoma of the spleen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 1992 |
[Disparity of the bone marrow involvement in a 5-year-old boy with primary non-Hodgkin's malignant lymphoma of the bone].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Bone Neoplasms; Child, Pr | 1992 |
[The use of novantrone in combination with other preparations in hematosarcoma patients].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 1992 |
[The chemoradiation treatment of patients with aggressive non-Hodgkin's lymphomas in the III-IV stages of the disease].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1992 |
Left main coronary stenosis by a mediastinal lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Coronary Disease; Cyclophosphamide; Humans; Lymphoma | 1992 |
AgNORs predictive value of prognosis in non-Hodgkin's lymphoma: comparison with flow cytometric cell cycle analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cyclophosphamide; DNA, Neoplasm; Doxorub | 1992 |
Growth after radiotherapy and chemotherapy in children with leukemia or lymphoma.
Topics: Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparag | 1992 |
[Infiltration into the aqueous humor (uveitis) in a patient with malignant lymphoma].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aqueous Humor; Cyclophospha | 1992 |
[Low-grade non-Hodgkin's lymphomas. Study of 73 cases].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclop | 1992 |
Abnormal uptake of technetium-99m hexakis-2-methoxyisobutylisonitrile in a primary cardiac lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 1992 |
[2 patients with a non-Hodgkin lymphoma located in the pancreas].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphom | 1992 |
[Results of modified LSA2-L2 protocol with moderate-dose MTX therapy in children with untreated non-Hodgkin's lymphoma].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Cyclophosphamide; C | 1992 |
To CHOP or not to CHOP ... is that the question?
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Doxorubi | 1992 |
[Combination chemotherapy with mitoxantrone, etoposide, vindesine and prednisolone for relapsed or refractory malignant lymphoma: presence of cross-resistance to CHOP therapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Res | 1992 |
Stage I malignant lymphoma of Waldeyer's ring: frequent relapse after radiation therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 1992 |
Primary non-Hodgkin's lymphoma of the urinary bladder.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; D | 1992 |
MACOP-B chemotherapy for the treatment of high grade and intermediate grade non Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubici | 1990 |
Stomach conservation in stages IE and IIE gastric non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined | 1990 |
Long-term survival of patients with intermediate and high grade lymphoma treated with COMLA/ABP.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine | 1990 |
Treatment of an aggressive non-Hodgkin's lymphoma during pregnancy with MACOP-B chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Fem | 1990 |
Pure red cell aplasia associated with B cell lymphoma: demonstration of bone marrow colony inhibition by serum immunoglobulin.
Topics: Antibodies, Anti-Idiotypic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; | 1990 |
Mediastinal large-B-cell lymphoma with sclerosis: a clinical study of 21 patients.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bleom | 1990 |
Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group.
Topics: Actuarial Analysis; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy | 1990 |
Palmar-plantar erythema associated with combination chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Ery | 1990 |
[Intraparenchymal non-neoplastic residual masses after treatment of large-cell non-Hodgkin's lymphoma with intensive chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Fibrosis; | 1990 |
Multifocal extranodal lymphomas: an expression of homing phenomenon.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cell Movement; Child, | 1990 |
[Kinetics of circulating hematopoietic stem cells following chemotherapy in patients with hematopoietic malignancies].
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; C | 1990 |
Nursing care of the patient with non-Hodgkin's lymphoma. A case study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Hum | 1990 |
[The COP-BLAM therapy for non-Hodgkin's lymphoma in elderly patients].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Drug | 1990 |
Primary non-Hodgkin's lymphoma of liver with humoral hypercalcaemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Hum | 1990 |
[Acute pneumocystosis during polychemotherapy following the MACOP-B protocol].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bleomycin; Bronchi; Bronchoalveolar Lavage F | 1990 |
[Expansion of peripheral blood progenitors by recombinant human granulocyte colony-stimulating factor].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Combined Modality The | 1990 |
[Assessment of the antitumor effect after remission induction therapy for non-Hodgkin's lymphoma--an approach to a response-adapted therapy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophos | 1990 |
A brief-duration combination chemotherapy for elderly patients with poor-prognosis non-Hodgkin's lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modalit | 1991 |
Growth and development of children of mothers treated with chemotherapy during pregnancy: current status of 43 children.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Behavior; Bleomyci | 1991 |
A clinical phase II study of ProMACE-CytaBOM.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Cyclophosphamid | 1991 |
Effective treatment of small-noncleaved-cell lymphoma with high-intensity, brief-duration chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubici | 1991 |
Results of treatment with high intensity, brief duration chemotherapy in poor prognosis non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine | 1991 |
Drug-related pulmonary toxicity in non-Hodgkin's lymphoma. Comparative results with three different treatment regimens.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Calcium; Cyclophosphamide; Dexamet | 1991 |
Influence of cytostatic treatment on the coagulation system and fibrinolysis in patients with non-Hodgkin's lymphomas and acute leukemias.
Topics: Acute Disease; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antithrombin I | 1991 |
Central nervous system involvement in patients with diffuse aggressive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 1991 |
Intensive weekly combination chemotherapy for patients with intermediate-grade and high-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Central Nervous System Neopl | 1991 |
[A comparative study of CHOP therapy and COP-BLAM therapy for non-Hodgkin's lymphoma in elderly patients].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1991 |
[The COP-BLAM III therapy of non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 1991 |
Malignant lymphomas in HIV-seropositive patients. Frequency, features, and prognosis. Report on 31 cases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Central Nervous System Neoplasms; | 1991 |
[Indicators of nonspecific immunity in patients with non-Hodgkin's lymphoma of high grade malignancy in the remission phase of the disease].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bleomycin; C | 1991 |
[Malignant lymphomas. Preliminary report of the National Protocol of Antineoplastic Drugs].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1991 |
[Malignant lymphomatous polyposis of the gastrointestinal tract].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Cyclophosphamide; Doxorubic | 1992 |
Renal insufficiency due to bilateral primary renal lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Doxorubicin; Female; Human | 1992 |
All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Bone Marrow; Bone Marrow Transplantat | 1991 |
The natural history of low grade non-Hodgkin's lymphoma and the impact of a no initial treatment policy on survival.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophospha | 1991 |
[Hodgkin's disease associated with LDH-M subunit deficiency].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Isoenzymes; L-Lactate Dehy | 1991 |
Risk factors in intermediate and high-grade non-Hodgkin's lymphomas of adults: a need for a new staging system.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 1991 |
Clinicopathological features and prognostic factors in extranodal non-Hodgkin lymphomas. Danish LYFO Study Group.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protoc | 1991 |
The F-MACHOP regimen in advanced diffuse aggressive lymphomas: summary of ten years' experience at a single institution.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Fluoroura | 1991 |
Clinical and pathological restaging in aggressive non-Hodgkin's lymphomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Fe | 1991 |
Sinonasal non-Hodgkin's lymphomas and Wegener's granulomatosis: a clinicopathological study.
Topics: Adult; Antibodies, Neoplasm; Cyclophosphamide; Female; Follow-Up Studies; Granulomatosis with Polyan | 1991 |
[Limited chemotherapy and radiotherapy for stage I-II intermediate or high grade lymphoma of nodal sites or Waldeyer's ring].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; | 1991 |
Mitoxantrone, etoposide, cytarabine and prednisone as salvage therapy for refractory non-Hodgkin lymphoma (NHL) and alternated with CHOP in previously untreated patients with NHL.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubic | 1991 |
Salvage therapy with PROMACE in relapsed non-Hodgkin malignant lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposid | 1991 |
Late relapse with nodular lymphoma after treatment for diffuse non-Hodgkin's lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cyclophospham | 1991 |
[Modified CHOP therapy in patients with non-Hodgkin's lymphoma].
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphami | 1991 |
[Similar efficacy of less than 6 and 7-10 courses of therapy with anthracycline-based combination chemotherapy for localized non-Hodgkin's lymphoma of extranodal type].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Do | 1991 |
Successful chemotherapy on a pregnant non-Hodgkin's lymphoma patient.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans | 1990 |
[A case of B-cell non-Hodgkin's lymphoma with prominent splenomegaly and high serum titer of cold agglutinin].
Topics: Adult; Agglutinins; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Combined Modality | 1990 |
Excessive chemotherapy-related granulocytopenia in a child with non-Hodgkin's lymphoma and a congenital abnormality of purine salvage.
Topics: Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cyclophosphamide; | 1990 |
ECAPP chemotherapy for lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Fema | 1990 |
Prognostic value of lymphocyte homing receptor and S phase fraction in non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Adhesion Molecu | 1990 |
Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphami | 1990 |
Interleukin-2 receptor levels in non-Hodgkin's lymphoma. Correlation to histological degree of malignancy and presence of constitutional symptoms.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopho | 1990 |
CEPP(B): an effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Et | 1990 |
[Radiotherapy and chemotherapy in stages I and II non-Hodgkin's lymphomas of Waldeyer's ring].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 1990 |
Primary non-Hodgkin's lymphoma of the larynx treated only by chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Epirubicin; Humans; Laryngeal Neop | 1990 |
Phase II study of lomustine, cytarabine, mitoxantrone, and prednisone (CAMP) combination chemotherapy for doxorubicin-resistant intermediate- and high-grade malignant non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Doxorubicin; | 1990 |
[Non-Hodgkin's lymphoma of the Waldeyer's ring: the treatment results of the past 22 years and the significance of CHOP].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; C | 1990 |
[Regression of cerebral post-transplantation lymphoma under cyclosporin A reduction].
Topics: Adult; Biopsy; Brain Neoplasms; Cyclosporins; Humans; Kidney Transplantation; Lymphoma, Non-Hodgkin; | 1990 |
Acute hepatic injury after the withdrawal of immunosuppressive chemotherapy in patients with hepatitis B.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Female; Hepatitis B; Hepatit | 1990 |
Long-term follow-up of CHOP-treated non-Hodgkin lymphoma of high-grade malignancy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Follow- | 1990 |
Continuous cyclophosphamide, doxorubicin, vincristine, and prednisolone. A new, innovative protocol for diffuse aggressive lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Chi | 1990 |
Erythema nodosum and non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Erythema Nodos | 1990 |
UKALL X--an effective treatment for stage III mediastinal non-Hodgkin's lymphoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 1990 |
Primary non-Hodgkin's lymphoma of the esophagus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Esophageal Neop | 1990 |
[Disseminated, highly malignant non-Hodgkin's lymphoma and pregnancy: polychemotherapy in the 2d and 3d trimester].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; | 1990 |
[Non-Hodgkin's lymphoma of the parotid gland].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; F | 1990 |
Non-Hodgkin lymphoma: a rare primary vulvar localization.
Topics: Brain Neoplasms; Drug Therapy, Combination; Female; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Pred | 1990 |
Lymphoblastic lymphoma in a female with chronic granulocytic leukaemia.
Topics: Adolescent; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cell Transformat | 1985 |
[Lactic acidosis in non-Hodgkin's lymphoma].
Topics: Acidosis, Lactic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Cyclophosp | 1985 |
Fatal pulmonary fibrosis from low-dose bleomycin therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Huma | 1987 |
Updated clinical experience with MACOP-B.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubici | 1987 |
Advances in chemotherapy for large cell lymphoma.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubici | 1987 |
Minimizing toxicity of MACOP-B.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Humans; Le | 1987 |
Failure of conventional chemotherapy in aggressive lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubici | 1987 |
Non-Hodgkin's lymphoma in children. Results of therapy.
Topics: Abdominal Neoplasms; Actuarial Analysis; Adolescent; Antineoplastic Combined Chemotherapy Protocols; | 1987 |
Retrospective analysis of stage I and II indolent lymphomas at the National Cancer Institute.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modalit | 1988 |
Low O6-alkylguanine DNA alkyltransferase activity in the peripheral blood lymphocytes of patients with therapy-related acute nonlymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Doxorubicin; Hodgkin Disease | 1988 |
Results of treating stage III and IV malignant non-Hodgkin's lymphomas (NHL).
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chlorambucil; Cyclophosphamide; Doxorubic | 1988 |
Response-oriented therapy with CHOP and VIM-Bleo in high-grade malignant non-Hodgkin's lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Drug Evalu | 1988 |
Non-Hodgkin's lymphoma in Saudi Arabia: prognostic factors and an analysis of the outcome of combination chemotherapy only, for both localized and advanced disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1988 |
Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Dexamethaso | 1988 |
The COP-BLAM programs: evolving chemotherapy concepts in large cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Drug Evalu | 1988 |
MACOP-B chemotherapy for malignant lymphomas and related conditions: 1987 update and additional observations.
Topics: Acquired Immunodeficiency Syndrome; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protoco | 1988 |
HOAP-Bleo as salvage therapy for diffuse aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cytarabine; Doxorubicin; Fem | 1988 |
Pulmonary emboli in patients receiving chemotherapy for non-Hodgkin's lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Diagnosis, Differential; | 1988 |
Non-Hodgkin's lymphoma in the elderly: a retrospective evaluation of toxicity related to aggressive vs. conservative treatments.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1988 |
The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protoc | 1988 |
Allogeneic bone marrow transplantation in patients with lymphoma relapsing after autologous marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplant | 1989 |
Bone marrow and blood involvement by non-Hodgkin's lymphoma: a study of clinicopathologic correlations and prognostic significance in relationship to the Working Formulation.
Topics: Actuarial Analysis; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomyc | 1989 |
[Effective evaluation of combination chemotherapy in stage I-II of non-Hodgkin's lymphoma--a comparison of treatment with multivariate analysis].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemothera | 1989 |
Severe chemotherapy-induced recall of radiation mucositis in a patient with non-Hodgkin's lymphoma of Waldeyer's ring.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Humans; Le | 1989 |
Sequential combination chemotherapy (CABOPP/VIM) for the treatment of high-grade malignant non-Hodgkin lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1989 |
B-cell lymphoma associated with eosinophilia.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bleomycin; Cyclophosphamide; Doxorubi | 1989 |
[Results of the treatment of non-Hodgkin's lymphoma with 6 cytostatic drug combination].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1989 |
[Treatment of medium and highly malignant non-Hodgkin's lymphoma with combined chemotherapy using methotrexate, adriamycin, cyclophosphamide, vincristine, prednisone and bleomycin (protocol MACOP-B)].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Fem | 1989 |
[Chemoradiation treatment of patients with aggressive non-Hodgkin's lymphomas in stages I to II of the disease].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1989 |
Monoclonal B-cells in blood in non-Hodgkin lymphoma. Correlation with clinical features and prognoses.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bone Marrow Diseases; Cyclophosphamid | 1989 |
[Clinical, anatomo-pathologic aspects and therapeutic results in 63 malignant ORL non-Hodgkin's lymphomas in children].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 1989 |
[Long-term results in the treatment of lymphomas using polychemotherapy (CHOP)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Non | 1989 |
[Treatment of large cell lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Israe | 1989 |
The malignant lymphomas in Benin City, Nigeria.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Fe | 1989 |
[Evaluation of the response of advanced diffuse large cell lymphomas (LSG classification) to weekly CHOP therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Administration S | 1989 |
[Combined (poly-chemo-radio) therapy of non-Hodgkin's lymphomas].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; | 1989 |
[Indirect endolymphatic chemotherapy of patients with lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Hodgkin Disease; Humans; Injection | 1989 |
Intraocular non-Hodgkin's lymphoma treated with systemic and intrathecal chemotherapy and radiotherapy. A case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Cytarabine; Doxorubicin; E | 1989 |
Multilobated non-Hodgkin lymphoma of B-cell type: leukemization and multiorganic involvement.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bone Marrow; Cell Nucleus; Cyclophosp | 1989 |
Poor-risk non-lymphoblastic lymphoma of childhood: results of an intensive pilot study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Pr | 1989 |
B-immunoblastic lymphoma arising in angioimmunoblastic lymphadenopathy.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cells, Cultured; Cyclophosphamide; Dr | 1986 |
Chemotherapy followed by consolidation radiation therapy for the treatment of clinical stage II aggressive histologic type non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 1988 |
High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Cytarabin | 1987 |
High-dose methotrexate and continuous infusion Ara-C in children's non-Hodgkin's lymphoma: phase II studies and their use in further protocols.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Diseases; Child; Cyclophos | 1986 |
Childhood non-Hodgkin's lymphoma and "leukemia-lymphoma syndrome": long-term results with the modified LSA2-L2 protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Cranial Irradiatio | 1986 |
Adjusting survival curves for imbalances in prognostic factors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Hemoglobins; Humans; | 1988 |
[A comparative trial of C-novantrone OP(CNOP) vs C-adriamycin OP(CHOP) in the treatment of stage II-IV malignant lymphoma--the preliminary report].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 1988 |
[Advanced abdominal non-Hodgkin's lymphoma in the child. Features and response to treatment].
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Pre | 1988 |
Prognostic factors of stage I and II non-Hodgkin's lymphomas of the head and neck: the value of the working formulation and need for chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; C | 1988 |
[Studies of patients with non-Hodgkin's lymphoma unresponsive to C-MOPP].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance; Fema | 1988 |
[Non-Hodgkin's lymphomas in childhood. Evaluation of therapeutic results according to histopathologic criteria (Catalan Interhospital Group of Pediatric Oncology)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschool; Cyclophos | 1988 |
Improved treatment results for lymphoblastic lymphoma in adolescents and adults using a doxorubicin-based (APO) protocol.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Doxorubicin; Drug A | 1988 |
Treatment of diffuse histiocytic and diffuse mixed non-Hodgkin lymphomas with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 1988 |
The effects of four drug regimens on sister chromatid exchange frequency in patients with lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; DNA Damage; Doxorubicin; Hodgkin D | 1988 |
Short-term intensive treatment (V.A.A.P.) of adult acute lymphoblastic leukemia and lymphoblastic lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytara | 1988 |
Non-Hodgkin's lymphoma in children; diffuse lymphoblastic histology; diffuse non-lymphoblastic histology; LSA2-L2 experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Daunorubi | 1988 |
[Non-Hodgkin's lymphoma. Results of a therapeutic protocol].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 1988 |
[Results of the treatment of 46 non-Hodgkin's lymphomas in children].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 1988 |
[THP-COP, BHAC-VMP alternating chemotherapy in patients with non-Hodgkin's lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubic | 1988 |
Methylprednisolone, etoposide, vindesine, and chlorambucil (PEEC) alone or alternating with CHOP as initial or salvage therapy for non-Hodgkin's lymphoma.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamid | 1988 |
[Evaluation of the results of treatment of non-Hodgkin's lymphoma in children by the Wollner method].
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Daunorubicin; Humans; Lymph | 1988 |
[A case of lymphoma of a higher stage of malignancy treated with cytostatics and interferon].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans | 1988 |
Pancreatic lymphoma, diagnosis and management.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Comb | 1987 |
Treatment of malignant non-Hodgkin's lymphoma in elderly patients.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphami | 1988 |
Clinical and pathological evolution of alpha chain disease to immunoblastic lymphoma and response to COMP chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Humans; Immunoproliferative | 1988 |
High grade nonHodgkin's lymphoma: management with moderate dose combination chemotherapy.
Topics: Aged; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Humans; Lymphoma, Non-Hodgki | 1988 |
Factors of prognostic importance in childhood non-Hodgkin's lymphoma treated with two modified LSA2-L2 protocols. A multivariate analysis approach.
Topics: Abdominal Neoplasms; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; C | 1988 |
Rapid transient reversal of anemia and long-term effects of maintenance intravenous immunoglobulin for autoimmune hemolytic anemia in patients with lymphoproliferative disorders.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Autoantibodies; Combined Modality The | 1988 |
[Second tumors in patients treated for Hodgkin's disease].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modali | 1988 |
Cyclophosphamide, mitoxantrone, vincristine and prednisone in the treatment of non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lymphoma, Non-Hodg | 1988 |
[Results of treatment in children with diffuse large cell lymphoma].
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphami | 1987 |
[A case of mantle-zone lymphoma with salivary gland swelling as the initial manifestation].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Differential; Dox | 1987 |
[Treatment of malignant lymphoma: 12 years' experience with 109 patients. 2). Treatment of non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1987 |
Epirubicin in combination chemotherapy in the treatment of advanced stage non-Hodgkin's lymphomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathies; Cyclophosphamide; Doxorubic | 1987 |
Short-term high-dose treatment in bad-risk ALL and lymphoblastic NHL.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia, Lymphoid; L | 1987 |
Intermediate and high-dose cytosine arabinoside-containing regimens for induction and consolidation therapy for patients with acute lymphoblastic leukemia and lymphoblastic non-Hodgkin's lymphoma: the Leyden experience and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; Cytarabine; D | 1987 |
[Clinical efficacy of combined treatment in a late-stage malignant tumor of the head and neck].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 1987 |
[non-Hodgkin's lymphoma treated with modified LSA2-L2 protocol--a clinical experience and case report].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospham | 1987 |
[Treatment of non-Hodgkin's lymphoma with CHOP therapy: analysis of lymphocyte subsets and interleukin 2 activity during CHOP therapy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Do | 1986 |
[A case of non-Hodgkin's lymphoma manifesting an eyelid tumor as a major symptom].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cyclophosphamide; Doxorubicin; | 1987 |
Pulmonary complications of cytosine-arabinoside therapy: radiographic findings.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Humans; Leukemia, | 1987 |
Age as the main prognostic factor in adult aggressive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protoc | 1987 |
Intensive chemotherapy regimen in high-grade non Hodgkin's lymphomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclop | 1987 |
Combination chemotherapy for the treatment of diffuse aggressive lymphomas: F-MACHOP update.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dox | 1987 |
Failure of combination chemotherapy of advanced follicular (low-grade) non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Adm | 1987 |
[Analysis of the course and treatment of primary non-Hodgkin's lymphoma of the gastrointestinal tract].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 1987 |
Radiotherapy versus radiotherapy plus chemotherapy in stages I and II non-Hodgkin's lymphoma of the upper digestive and respiratory tract.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 1987 |
Chemotherapy in patients who fail radiotherapy for diffuse aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Do | 1987 |
Sequential combination chemotherapy of high-grade non-Hodgkin's lymphoma with 5-fluorouracil, methotrexate, cytosine-arabinoside, cyclophosphamide, doxorubicin, vincristine, and prednisone (F-MACHOP).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cyclo | 1987 |
[Short-term result of non-Hodgkin's lymphoma treated by the COMP regimen].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; H | 1987 |
Progressive loss of vision in patients with high-grade non-Hodgkin's lymphoma.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined | 1987 |
[C-MOPP therapy in advanced diffuse lymphoma, large cell type (LSG)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lymph | 1987 |
Activation of haemostasis by combined chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Hemostasis; Humans; Lymphoma, Non- | 1987 |
Staging and treatment of non-Hodgkin's lymphoma of intermediate-grade malignancy: a retrospective study of 102 cases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Do | 1987 |
Uric acid and phosphorus excretion in dogs with lymphosarcoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Dog Diseases; Dogs; Female; L | 1986 |
[Clinical picture, diagnosis and treatment of the brain lesions in lymphosarcomas].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined M | 1986 |
Methotrexate kinetics in myeloid bone marrow cells and peripheral neutrophils.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Separation; Cyclophosphamide; Doxo | 1987 |
[Combined CHOP and radiotherapy in non-Hodgkin's lymphoma of unfavorable histology].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1986 |
[Non-Hodgkinś lymphoma in childhood, preliminary results of the LSA2 L2 protocol modified by high-dose methotrexate].
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Daunorubi | 1987 |
An alternating chemotherapy and radiotherapy combination for non-Hodgkin's lymphomas of unfavourable histologies: feasibility and preliminary results.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1985 |
Effectiveness of a six-drug regimen (APO) without local irradiation for treatment of mediastinal lymphoblastic lymphoma in children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 1985 |
Progress in the management of high risk non-Hodgkin's lymphomas. 10 years of experience of the 3rd Medical Department of Hanusch Hospital, Vienna.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1985 |
[Results of the treatment of lymphosarcoma of the large intestine].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cecal Neoplasms; Cecum; Colectomy; Colonic Neoplasms | 1985 |
[Experience treating 30 cases of oromaxillofacial non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Th | 1985 |
The nitroblue tetrazolium test in lymphoma.
Topics: Adult; Diagnosis, Differential; Hodgkin Disease; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, | 1973 |
Generalized herpes simplex complicating lymphoma.
Topics: Aged; Chloramphenicol; Culture Techniques; Cyclophosphamide; gamma-Globulins; Herpes Simplex; Humans | 1969 |
Biclonal gammopathy in a patient with a lymphoproliferative disease.
Topics: Aged; Blood Protein Electrophoresis; Bone Marrow Cells; Female; gamma-Globulins; Humans; Leukemia, L | 1968 |
Symptomatic control of fever in lymphoma and leukemia.
Topics: Adolescent; Adult; Aged; Aminopyrine; Analgesics; Aspirin; Female; Fever; Hodgkin Disease; Humans; I | 1969 |
Hypercalcemia associated with chronic lymphocytic leukemia. Treatment with mithramycin.
Topics: Bone Neoplasms; Diuretics; Humans; Hypercalcemia; Kidney; Leukemia, Lymphoid; Lung; Lymphoma, Non-Ho | 1973 |
[Rheumatoid polyarthritis and chronic lymphoid leukemia. Studies of 7 cases of association of these 2 diseases].
Topics: Adult; Age Factors; Aged; Animals; Antibodies; Arthritis, Rheumatoid; Autoimmune Diseases; Chlorambu | 1969 |
Chronic immunosuppression and occult lymphoma: a case report.
Topics: Adult; Azathioprine; Bone Neoplasms; Cadaver; Carcinoma, Squamous Cell; Cytomegalovirus Infections; | 1972 |
Pemphigus vulgaris and internal malignancy.
Topics: Adenocarcinoma, Scirrhous; Adult; Aged; Breast Neoplasms; Carcinoma, Squamous Cell; Dexamethasone; F | 1974 |
Childhood non-Hodgkin's lymphoma--a study of 17 cases in Israel.
Topics: Abdominal Neoplasms; Adolescent; Age Factors; Allopurinol; Antigens, Viral; Arabia; Bone Marrow Dise | 1974 |
[Therapy and course of malignant diseases of the lymphoreticular system in infancy and early childhood].
Topics: Age Factors; Antineoplastic Agents; Child, Preschool; Hodgkin Disease; Humans; Infant; Infant, Newbo | 1973 |
Polymyalgia rheumatica: a not so benign syndrome.
Topics: Adrenocorticotropic Hormone; Aged; Arrhythmias, Cardiac; Blood Protein Electrophoresis; Diagnosis, D | 1969 |
The place of the L-asparaginase in the treatment of acute leukemias.
Topics: Acute Disease; Adolescent; Adult; Animals; Asparaginase; Child; Child, Preschool; Chronic Disease; D | 1970 |
Lymphosarcomatous arthropathy.
Topics: Arthritis; Biopsy; Cyclophosphamide; Female; Foot; Hand; Hematocrit; Humans; Lymphoma, Non-Hodgkin; | 1974 |
Malignant lymphoma invading the facial nerve.
Topics: Child; Cochlear Nerve; Colon; Electric Stimulation; Facial Nerve; Facial Paralysis; Female; Humans; | 1974 |
[IgM paraproteinaemia in lymphoblastic lymphosarcoma in a child (author's transl)].
Topics: Blood Protein Disorders; Blood Protein Electrophoresis; Chromatography, Gel; Humans; Immunoelectroph | 1974 |
Effect of chemotherapy with cyclophosphamide on the buoyant density separation and volume distributions of lymphocytes in chronic lymphocytic leukemia and lymphosarcoma.
Topics: Centrifugation, Density Gradient; Chromatin; Cyclophosphamide; Electronics, Medical; Humans; Leukemi | 1974 |
[The treatment of lymphosarcoma in childhood (author's transl)].
Topics: Age Factors; Antineoplastic Agents; Asparaginase; Child; Cyclophosphamide; Cytarabine; Daunorubicin; | 1974 |
Conversion of Hodgkin's disease to lymphoblastic lymphosarcoma.
Topics: Aged; Cyclophosphamide; Doxorubicin; Female; Hodgkin Disease; Humans; Liver; Lymph Node Excision; Ly | 1974 |
[L-asparaginase in combined treatment of lymphosarcoma in children].
Topics: Adolescent; Age Factors; Asparaginase; Child; Child, Preschool; Drug Therapy, Combination; Humans; L | 1974 |
Development of acute leukaemia in a patient with lymphosarcoma.
Topics: Autopsy; Bone Marrow; Bone Marrow Cells; Chlorambucil; Humans; Immunoglobulins; Karyotyping; Leukemi | 1973 |
[Chemotherapy of malignant tumors and acute leukoses. New developments and results].
Topics: Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Hodgkin Disease; Humans; Leukemi | 1972 |
Evidence for a specific seminiferous tubular factor affecting follicle-stimulating hormone secretion in man.
Topics: Adult; Biopsy; Cell Count; Clomiphene; Cyclophosphamide; Follicle Stimulating Hormone; Hodgkin Disea | 1972 |
Reticulum cell sarcoma. A review of radiotherapeutic experience.
Topics: Adolescent; Adult; Aged; Chlorambucil; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Mal | 1972 |
[Hodgkin's disease and other malignant lymphomas].
Topics: Hodgkin Disease; Humans; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Prednison | 1972 |
[Multiple drug therapy in Hodgkin's disease, lymphosarcoma and reticulosarcoma].
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Female; Hodg | 1972 |
[Chylous effusion during reticulosarcoma].
Topics: Abdominal Neoplasms; Chylothorax; Humans; Hydrazines; Inguinal Canal; Lumbosacral Region; Lymphatic | 1973 |
Management of patients with non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents; Burkitt Lymphoma; Cyclophosphamide; Hodgkin Disease; Humans; Lymphography; Ly | 1973 |
Updated Hodgkin's disease. C. Advanced disease and special problems. Comment: the non-Hodgkin's lymphomas.
Topics: Burkitt Lymphoma; Cyclophosphamide; Hodgkin Disease; Humans; Leukemia; Lymphoma; Lymphoma, Large B-C | 1973 |
Pulmonary nocardiosis complicating malignant lymphoma successfully treated with chemotherapy.
Topics: Agammaglobulinemia; Antineoplastic Agents; Chlorambucil; Cyclophosphamide; Humans; Lung Diseases; Ly | 1973 |
Effect of drug treatment for lymphoma on male reproductive capacity. Studies of men in remission after therapy.
Topics: Adolescent; Adult; Antineoplastic Agents; Biopsy; Burkitt Lymphoma; Cyclophosphamide; Germ Cells; Ho | 1973 |
The appearance of reticulum cell sarcoma at the site of antilymphocyte globulin injection.
Topics: Amphotericin B; Antibodies; Antilymphocyte Serum; Azathioprine; Buttocks; Cadaver; Cryptococcosis; C | 1973 |
Combination chemotherapy with cyclophosphamide, vinblastine, procarbazine and prednisone in the treatment of malignant lymphomas.
Topics: Administration, Oral; Cyclophosphamide; Drug Therapy, Combination; Hodgkin Disease; Humans; Injectio | 1973 |
Potential for prolonged disease-free survival following combination chemotherapy of non-Hodgkin's lymphoma.
Topics: Cyclophosphamide; Drug Therapy, Combination; Humans; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymp | 1974 |
Treatment of Hodgkin's disease and other malignant lymphomas.
Topics: Alkylating Agents; Antineoplastic Agents; Carmustine; Chlorambucil; Cyclohexanes; Cyclophosphamide; | 1973 |
The therapy of canine and feline lymphosarcoma.
Topics: Ampicillin; Animals; BCG Vaccine; Cat Diseases; Cats; Chloramphenicol; Cyclophosphamide; Dog Disease | 1973 |
Cerebral reticulum cell sarcoma after multiple renal transplants.
Topics: Adult; Azathioprine; Brain Neoplasms; Dactinomycin; Glomerulonephritis; Humans; Immunosuppression Th | 1974 |
[Primary lymphosarcoma of the stomach].
Topics: Diagnosis, Differential; Drug Therapy, Combination; Histological Techniques; Humans; Lymphoma, Non-H | 1974 |
A clinical study of the natural history of lymphosarcoma and reticulum cell sarcoma.
Topics: Adult; Aged; Chlorambucil; Cyclophosphamide; Female; Humans; Lymph Nodes; Lymphoma, Non-Hodgkin; Mal | 1974 |
Status and perspectives in chemotherapy of Hodgkin's disease.
Topics: Animals; Antineoplastic Agents; Benzoates; Breast Neoplasms; Burkitt Lymphoma; Cyclophosphamide; Cyt | 1973 |
Lymphosarcoma presenting as Löffler's syndrome.
Topics: Asparaginase; Biopsy; Blood Cell Count; Bone Marrow; Child, Preschool; Diagnosis, Differential; Hepa | 1973 |
Multiple lymphomatous polyposis of the gastrointestinal tract.
Topics: Autopsy; Biopsy; Celiac Disease; Chlorambucil; Gastrointestinal Neoplasms; Humans; Intestinal Polyps | 1973 |
[Polychemotherapy using prednisone, cyclophosphamide, and vincristine in stage IV lymphosarcoma].
Topics: Adult; Aged; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Lymphoma, Non-Hodgkin; Mal | 1973 |
Chemotherapy of the lymphomas.
Topics: Adult; Burkitt Lymphoma; Child; Chlorambucil; Cyclophosphamide; Doxorubicin; Drug Therapy, Combinati | 1974 |
[Treatment of lymphosarcoma by the triple combination vincristine-rubidomycin-prednisone].
Topics: Antibiotics, Antineoplastic; Child; Humans; Lymphoma, Non-Hodgkin; Mercaptopurine; Methotrexate; Pre | 1967 |
Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults.
Topics: Adolescent; Adult; Aged; Blood Cell Count; Blood Platelets; Blood Transfusion; Bone Marrow Examinati | 1968 |
Reticulum cell sarcoma after renal homotransplantation and azathioprine and prednisone therapy.
Topics: Adult; Azathioprine; Brain Neoplasms; Female; Herpes Simplex; Humans; Kidney Transplantation; Liver | 1968 |
[Association of nitrogen mustard, vincristine, methylhydrazine and prednisone in treatment of diffuse forms of Hodgkin's disease and ganglionic sarcomas].
Topics: Adolescent; Adult; Child; Child, Preschool; Drug Synergism; Female; Hodgkin Disease; Humans; Hydrazi | 1968 |
Combination chemotherapy in lymphosarcoma and reticulum cell sarcoma.
Topics: Adolescent; Adult; Aged; Body Weight; Cyclophosphamide; Drug Synergism; Hemoglobinometry; Humans; Ly | 1969 |
Corticosteroid therapy for lymphomas and chronic lymphocytic leukemia.
Topics: Cortisone; Glucocorticoids; Hodgkin Disease; Hydrocortisone; Leukemia, Lymphoid; Lymphoma, Large B-C | 1969 |
[The role of vinblastine in the treatment of malignant lymphomas].
Topics: Adolescent; Adult; Aged; Cyclophosphamide; Female; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Larg | 1968 |
Combination chemotherapy with nitrogen mustard, vincristine, procarbazine, and prednisone in lymphosarcoma and reticulum cell sarcoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzoates; Bone Marrow; Female; Follow-Up Studies; Humans; Leuko | 1970 |
The use of etiocholanolone for the measurement of marrow granulocyte reserves.
Topics: Acute Kidney Injury; Adolescent; Adult; Agranulocytosis; Blood Urea Nitrogen; Bone Marrow; Bone Marr | 1970 |
L-asparaginase and human malignant disease.
Topics: Animals; Antineoplastic Agents; Asparaginase; Blood Coagulation; Central Nervous System; Drug Hypers | 1971 |
Transformation of reticulum cell sarcoma to acute leukemia.
Topics: Acute Disease; Biopsy; Bone Marrow; Central Nervous System; Humans; Jaw Neoplasms; Leukemia; Lymph N | 1971 |
Combined chemotherapy and radiotherapy for advanced Hodgkin's disease and reticulum cell sarcoma: a preliminary report.
Topics: Adolescent; Adult; Aged; Blood Cell Count; Cyclophosphamide; Female; Hodgkin Disease; Humans; Lympho | 1971 |
Pneumocystitis carinii pneumonia: percutaneous lung biopsy and review of literature.
Topics: Adolescent; Adult; Agammaglobulinemia; Amphotericin B; Anuria; Azathioprine; Biopsy; Bis-Trimethylam | 1971 |
[Prolonged remission of reticulum cell sarcoma].
Topics: Cyclophosphamide; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Mechlorethamine; Middle Ag | 1971 |
Cyclic chemotherapy in lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzoates; Cyclophosphamide; Evaluation Studies as Topic; Female | 1971 |
Malignant lymphomas in transplantation patients.
Topics: Adolescent; Adult; Antilymphocyte Serum; Azathioprine; Brain Neoplasms; Female; Humans; Immunosuppre | 1969 |
Disseminated extrapulmonary nocardiosis presenting as a renal abscess.
Topics: Abscess; Adult; Anemia, Hemolytic, Autoimmune; Autopsy; Brain Diseases; Chlorambucil; Diagnosis, Dif | 1970 |
[Effectiveness of polychemotherapeutic treatments of lymphoproliferative diseases].
Topics: Adult; Antineoplastic Agents; Cyclophosphamide; Drug Synergism; Hodgkin Disease; Humans; Leukemia; L | 1970 |
Advanced lymphosarcoma: intensive cyclical combination chemotherapy with cyclophosphamide, vincristine, and prednisone.
Topics: Adult; Aged; Blood Cell Count; Blood Platelets; Cyclophosphamide; Drug Synergism; Female; Hematologi | 1972 |
Combination chemotherapy of advanced lymphomas.
Topics: Adult; Age Factors; Benzoates; Blood Cell Count; Blood Platelets; Cyclophosphamide; Drug Combination | 1972 |
Daunorubicin therapy in adult acute lymphatic leukemia.
Topics: Adolescent; Adult; Bone Marrow; Daunorubicin; Female; Humans; Leukemia, Lymphoid; Lymphoma, Non-Hodg | 1972 |
[Case of thyroid lymphosarcoma].
Topics: Aged; Female; Humans; Lymphoma, Non-Hodgkin; Neoplasm Metastasis; Prednisone; Radiography, Thoracic; | 1971 |
Comments on treatment of leukemia in the cat.
Topics: Animals; Cat Diseases; Cats; Cyclophosphamide; Dog Diseases; Dogs; Leukemia; Lymphoma; Lymphoma, Non | 1971 |
Therapy of localized and regional lymphosarcoma of childhood.
Topics: Adolescent; Child; Child, Preschool; Cobalt Isotopes; Cyclophosphamide; Head and Neck Neoplasms; Hum | 1971 |
Some problems in the management of leukaemia and lymphoma.
Topics: Antineoplastic Agents; Busulfan; Cyclophosphamide; Female; Humans; Leukemia; Leukemia, Lymphoid; Leu | 1966 |
Chemotherapy of the leukemic transformation of lymphosarcoma.
Topics: Adolescent; Bone Marrow Examination; Child; Child, Preschool; Humans; Leukemia; Leukemia, Lymphoid; | 1967 |
Prediction of in vivo cytotoxicity of chemotherapeutic agents by their effect on malignant leukocytes in vitro.
Topics: Blood Cell Count; Cytarabine; DNA; Humans; In Vitro Techniques; Injections, Intravenous; Leukemia; L | 1967 |
Hyperuricemic nephropathy. Report of a case of lymphoblastic lymphosarcoma.
Topics: Acetazolamide; Acute Kidney Injury; Allopurinol; Bicarbonates; Biopsy; Child; Humans; Leukemia, Lymp | 1970 |
Leukemia and lymphoma.
Topics: Antineoplastic Agents; BCG Vaccine; Burkitt Lymphoma; Busulfan; Chlorambucil; Cyclophosphamide; Cyta | 1970 |
The successful treatment of pneumocystis carinii pneumonitis in an adult with lymphosarcoma. A comment on pentamidine isethionate nephrotoxicity.
Topics: Amidines; Animals; Anuria; Biopsy; Blood Urea Nitrogen; Creatinine; Cyclophosphamide; Female; Humans | 1969 |
[Multiple plasmocytoma with immature cells with transition into reticulosarcoma].
Topics: Aged; Blood Protein Electrophoresis; Bone Neoplasms; Female; Humans; Lymphoma, Non-Hodgkin; Plasmacy | 1965 |
High-dose corticoid therapy in Hodgkin's disease and other lymphomas.
Topics: Adolescent; Adult; Aged; Cortisone; Diabetes Mellitus; Female; Gastrointestinal Diseases; Hodgkin Di | 1967 |
Disseminated lymphocytoma cutis. Case reports of miliarial and nodular types.
Topics: Adult; Biopsy; Diagnosis, Differential; Female; Humans; Lymphoma, Non-Hodgkin; Prednisone; Skin Dise | 1969 |
Nephrotic syndrome: a prodrome to lymphoma.
Topics: Adolescent; Aged; Biopsy; Hodgkin Disease; Humans; Kidney; Lymphoma, Non-Hodgkin; Male; Microscopy, | 1970 |
Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol.
Topics: Adult; Allopurinol; Autopsy; Cyclophosphamide; Humans; Kidney Calculi; Kidney Pelvis; Lymphoma, Non- | 1970 |
[Long-term survivals in lymphomas and generalized lymphosarcomas treated by chemo- and hormonal therapy].
Topics: Antineoplastic Agents; Cyclophosphamide; Drug Synergism; Hodgkin Disease; Humans; Hydrazines; Longev | 1967 |
Vaccination of a patient receiving immunosuppressive therapy for lymphosarcoma.
Topics: Agammaglobulinemia; Aged; Animals; Autoimmune Diseases; Body Weight; Female; Globulins; Guinea Pigs; | 1966 |